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Summary 
Colorectal cancer (CRC) is among the most frequently diagnosed cancers worldwide. Recent 
research focused on the association of CRC with an altered microbiome. More specifically, 
two bacteria, Fusobacterium nucleatum (F. nucleatum) and Streptococcus gallolyticus 
subspecies gallolyticus (S. gallolyticus) were individually brought in context with CRC. F. 
nucleatum is predominantly present in oral plaques and was found to be abundant in stool and 
tumor tissue of CRC patients. S. gallolyticus is a rare commensal in the human intestine and 
inducer of infective endocarditis that is associated with presence of CRC.  
The aim of this thesis was to explore potential serological associations of F. nucleatum and S. 
gallolyticus with CRC using multiplex serology, a high-throughput technology that allows the 
analysis of large seroepidemiological studies. Multiplex serology was to be developed for F. 
nucleatum and S. gallolyticus and applied in a retrospective case-control study to analyze 
potential serological associations with CRC. Prospective studies were to be analyzed to give 
information on temporality of the association: if serological associations are present prior to 
diagnosis, these antibodies might serve as early marker for risk of developing CRC. 
Eleven proteins for each, F. nucleatum and S. gallolyticus, were selected, recombinantly 
expressed and applied in multiplex serology. Serological validation of the assays was possible 
only to a limited extent due to a lack of a gold standard assay for comparison. Cut-offs for 
antibody-positivity to the individual proteins were arbitrarily defined to allow for 10% of 
controls as positive. Antibody responses to F. nucleatum and S. gallolyticus were analyzed in 
a retrospective case-control study conducted in Germany and two independent case-control 
studies nested within multi-center prospective cohorts from Europe and southern United 
States. Positivity to any of the F. nucleatum proteins was not associated with CRC, neither 
retro- nor prospectively. In contrast, odds for prevalent and incident CRC in the German case-
control study as well as the European prospective study were significantly 2-fold increased 
with positivity to two or more proteins of a S. gallolyticus 6-marker panel. However, this 
association was not found in the southern United States study.  
In conclusion, antibody responses to S. gallolyticus, but not F. nucleatum, were significantly 
associated with CRC prior to diagnosis and might serve as marker for CRC development. A 
causal relationship of S. gallolyticus with CRC cannot be inferred from the generated data, 
however, results of this thesis might stimulate research on the involvement of S. gallolyticus 
in CRC development as well as risk factors leading to S. gallolyticus colonization. 
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Zusammenfassung 
Dickdarmkrebs ist eine der am häufigsten diagnostizierten Krebsarten weltweit. Aktuelle 
Studien untersuchen die Assoziation von Dickdarmkrebs mit einer Veränderung des 
bakteriellen Mikrobioms. Zwei bakterielle Spezies, Fusobakterium nucleatum (F. nucleatum) 
und Streptokokkus gallolyticus subspezies gallolyticus (S. gallolyticus), sind dabei besonders 
im Zusammenhang mit Dickdarmkrebs aufgefallen. F. nucleatum wird im Menschen 
hauptsächlich in Zahnbelägen gefunden, ist aber auch in Stuhl- und Tumorgewebe-Proben 
von Dickdarmkrebspatienten identifiziert worden. S. gallolyticus ist ein seltener Kommensal 
im menschlichen Gastrointestinaltrakt, aber auch ein Auslöser der infektiösen Endokarditis, 
welche wiederum assoziiert mit Dickdarmkrebs auftritt. 
Das Ziel der vorliegenden Arbeit war die Untersuchung der serologischen Assoziation von  
F. nucleatum und S. gallolyticus mit Dickdarmkrebs. Dafür wurden pro Bakterium jeweils elf 
Antigene entwickelt und mittels Multiplex-Serologie zur Antikörper-Analyse in einer 
deutschen retrospektiven Fall-Kontroll-Studie eingesetzt. Des Weiteren wurden zwei 
unabhängige prospektive Studien, eine multinationale europäische und eine US-
amerikanische Kohorte, auf Antikörper gegen F. nucleatum und S. gallolyticus untersucht, um 
den zeitlichen Zusammenhang der Assoziation zu analysieren. Wenn serologische 
Assoziationen vor der Dickdarmkrebs-Diagnose messbar sind, wären die Antikörper 
potentielle Marker für ein erhöhtes Dickdarmkrebs-Risiko. 
Da keine serologischen Goldstandard-Testverfahren für F. nucleatum und S. gallolyticus 
verfügbar sind, wurde der Cut-Off für Antikörper-Positivität arbiträr festgelegt und definiert 
10% der Kontrollen als Antikörper-positiv. Antikörper-Positivität für F. nucleatum war nicht 
assoziiert mit Dickdarmkrebs, weder retro- noch prospektiv. Im Gegensatz dazu waren die 
Antikörper-Antworten gegen S. gallolyticus in der deutschen Fall-Kontroll-Studie und der 
prospektiven europäischen, aber nicht der US-amerikanischen, Kohorte mit einem 2-fach 
erhöhten Risiko für Dickdarmkrebs assoziiert.  
Zusammenfassend waren Antikörper-Antworten gegen S. gallolyticus, aber nicht  
F. nucleatum, assoziiert mit einem erhöhten Dickdarmkrebs-Risiko und sind potentielle 
Marker für die Erkrankung. Ein kausaler Zusammenhang einer S. gallolyticus Infektion mit 
Dickdarmkrebs kann aus den präsentierten Analysen nicht hergeleitet werden, jedoch sind die 
Ergebnisse der Arbeit ein möglicher Anknüpfungspunkt für zukünftige Forschung zum 
Einfluss einer S. gallolyticus Infektion auf die Tumor-Entwicklung im Dickdarm. 
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1. Introduction 
1.1. Colorectal cancer (CRC) 
1.1.1. Epidemiology and risk factors 
Colorectal cancer (CRC) is among the most frequently diagnosed cancers. According to the 
World Health Organization (WHO) it accounted for the third most common cancer worldwide 
with 1.36 million newly diagnosed cases in 2012. Mortality was lower with 693,933 deaths 
worldwide in 2012. The incidence was higher in men (746,000 new cases in 2012) than in 
women (614,000 new cases in 2012) (Figure 1) [1] and CRC risk increases with older age [2]. 
CRC incidence varied strongly between developed (737,000 new cases in 2012) and 
developing regions (624,000 new cases in 2012) in the world. Thereby, age-standardized 
incidence rates (ASR) were highest in Australia and New Zealand (44.8 and 32.3 per 100,000 
in men and women) and lowest in Western Africa (4.5 and 3.8 per 100,000) (Figure 1) [1]. 
The higher incidence in more developed regions has been attributed to risk factors associated 
with a more „Western“ lifestyle, including changes in diet and other lifestyle factors. Indeed, 
smoking [3], excessive alcohol consumption [4], high consumption of processed red meat [5], 
lowered physical activity [6] and associated morbidities like obesity and diabetes [7, 8] were 
identified as risk factors for CRC. Interestingly, also inflammatory diseases of the bowel were 
found to increase CRC risk [9], which is emphasized by the finding that long-term use of non-
steroidal anti-inflammatory drugs (NSAID) like Aspirin has protective effects [10]. Apart 
from these environmental risk factors, family history of CRC was identified as another strong 
risk factor indicating a hereditary component of the disease [11]. Approximately 5% of all 
CRC cases have been even attributed to hereditary syndromes. The most frequent is the so-
called Lynch-syndrome or hereditary non-polyposis CRC [12], followed by familial 
adenomatous polyposis coli [13].  
Introduction 
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Figure 1: Estimated age-standardized incidence and mortality rate (new cases per 
100,000 and year) for CRC, by sex and region [1]. 
 
1.1.2. CRC development 
The majority of CRC cases (~70%), however, develop sporadically with a multistep process 
of genetic and morphological changes over a long period of time. Two pathways were 
described: the conventional adenomatous and the serrated pathway [14, 15]. The majority of 
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sporadic CRC (85-90%) follow the conventional adenomatous pathway [14]. Chromosomal 
instability leads to mutations, classically in the APC (adenomatous polyposis coli) gene, 
which results in hyperproliferation of the tissue and development of polyps [16]. Acquisition 
of additional mutations, mostly in the KRAS (Kirsten rat sarcoma) and tumor suppressor p53 
genes, then further promotes progression from adenoma to CRC [16]. The histology and 
morphology are thereby indicators for the risk of CRC development out of adenomatous 
polyps: Adenomatous polyps larger than 1 cm, those with high-grade dysplasia as well as 
those consistent of mainly villous, in contrast to tubular architecture, are often termed 
advanced adenoma and considered to have a faster progression [14].  
Approximately 10-15% of sporadic CRC cases are attributed to the serrated pathway [14]. 
This pathway is characterized by initial activating mutations in the BRAF oncogene but also 
by the CpG island methylator phenotype (CIMP) resulting in hypermethylation and thus 
deactivation of relevant promotors [17]. A frequent epiphenomenon in the serrated pathway is 
a high degree of microsatellite instability (MSI-H) resulting from an inactivation of mismatch 
repair genes. MSI-H adenomas have an increased susceptibility to the acquisition of 
additional cancer-relevant mutations [17]. Based on their morphology serrated adenomas can 
be further subdivided into three different types: most serrated adenomas (70-95%) are 
considered hyperplastic polyps, which are small (< 5 mm) and most frequently occur in the 
rectosigmoid colon; traditional serrated adenomas are rare (< 1%), often pedunculated and 
most frequently occur in the distal colon or rectum; sessile serrated adenomas, which account 
for 5-25% of serrated adenomas, are flat and mostly found in the proximal colon [17]. 
Whether adenomas of the serrated pathway have a similar risk of progression to CRC as the 
conventional adenomatous pathway is unclear [17]. 
1.1.3. CRC screening 
Early identification of colorectal neoplasm has led to a decrease in incidence but also 
mortality of CRC in the recent years [18]. Several countries introduced screening programs 
based on mainly two diagnostic methodologies: highly sensitive but invasive 
colonoscopy/sigmoidoscopy and less invasive but also less sensitive blood in stool tests [15]. 
In Germany, for example, blood in stool test by guaiac-based fecal occult blood test (gFOBT) 
is covered by health insurances for all individuals above 50 years in 2 years intervals [19]. 
Colonoscopy is recommended every 10 years for individuals between age 55 and 74. Other 
European countries like Denmark or Netherlands have not introduced a CRC screening 
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program by 2008, others like France based their screening programs only on gFOBT [19]. 
Colonoscopy offers a very sensitive method with the major advantage that identified 
precancerous lesions can be removed directly during the procedure [15]. However, it is also 
more unpleasant for the patient and more cost- and time-intensive for the health system than 
testing for blood in stool. Blood in stool tests, especially fecal immunochemical test (FIT), 
provide a good sensitivity in detecting CRC [15]. A German study compared gFOBT and FIT 
and found sensitivities of 33.3% and 73.3% in detecting CRC at a specificity of 95%. 
Sensitivity for advanced adenomas, however, was low with 8.6% and 23.4% [20]. A meta-
analysis by Niedermaier et al. showed the same with sensitivities for detecting CRC by FIT 
ranging from 48% to 95% at specificities above 90% and lowered sensitivities for detecting 
advanced adenomas ranging from 21% to 63% [21]. A more detailed analysis by type of 
adenoma revealed that the likelihood of detecting small adenomas (< 1 cm) was two-fold 
lower compared to adenomas larger than 1 cm. In addition, pedunculated adenomas were 
more likely to be detected than sessile adenomas. Apart from the morphology, also the 
localization influenced the diagnostic potential with proximal adenomas being less likely 
detected than distal adenomas [22]. Different approaches were addressed trying to identify a 
screening test that is effective, inexpensive and succeeds in a high compliance in patients. 
They are mostly based on the identification of biomarkers in either blood or fecal samples and 
try to measure aberrant genetics, epigenetics, protein expression, or bacterial composition [21, 
23, 24]. None of the approaches have been shown to outcompete blood in stool tests in test-
performance but also cost-effectiveness so far. However, it could be attempted to combine 
different blood- or fecal-based tests to increase sensitivity in detection of colorectal neoplasm, 
especially at the early stage. 
1.2. Gastrointestinal Bacteria in Health and Disease 
The gut microbiome has raised increasing interest in the recent years with regard to hosts 
health and disease. The human colon harbors an enormous number of microorganisms 
including up to 1012 bacterial cells per 1 g of feces. The most predominant phyla in the colon 
are Firmicutes and Bacteroidetes. Differences in the ratio between both phyla but also in 
abundance of more specific bacterial species have been related to disease. Obesity-related 
diseases, inflammatory bowel diseases (IBD) and CRC are thereby of special interest [25].  
The gut is colonized with bacteria shortly after birth and the resulting microbiome is in an 
important symbiosis with the host [26]. The microbiome contributes to the host by digestion 
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of food and consequently liberation of essential nutrients such as the degradation of complex 
polysaccharides into short chain fatty acids [27]. It also protects the host from pathogenic 
bacteria by outcompeting them. The intestinal barrier, given by a mucous layer, a tight 
epithelium and a sophisticated immune system, retains the microbiome in the intestinal 
lumen, however, also enables tolerance of the commensal bacteria by the host immune system 
[28, 29]. Disturbances in this equilibrium may correlate with disease, e.g. IBD, obesity-related 
disease or CRC [25]. These disturbances might result from host factors, including genetics or 
hormonal status, as well as from the environment, including diet, drug use (antibiotics, 
NSAIDs) or lifestyle [25].  
Several metagenomic attempts have been made to identify microbial compositions that are 
associated with CRC [29]. For example, a study by Zeller et al. found especially high 
abundance of Fusobacterial species associated with CRC [30]. Another study by Flemer et al. 
tried to generate CRC-associated microbiota profiles [31]. These metagenomic studies are 
overall very comprehensive since they regard the complete microbiome, however, 
consequently they are also highly complex and cost-intensive. This thesis focuses on two 
specific bacterial species that have been brought into context with CRC by different means 
that will be described below. So far it is unclear if and how bacteria might influence 
tumorigenesis. The alpha-bug theory hypothesizes that certain pro-oncogenic bacteria, e.g. 
Bacteroides fragilis, are able to induce changes in the microbiome, in the immune response of 
the host and finally in the colonic epithelium resulting in CRC [32]. A second theory, the so-
called bacterial driver-passenger model (Figure 2), involves bacterial drivers that initiate 
tumor formation by DNA damage followed by passenger bacteria that benefit from the 
changes in the epithelium and are enabled to invade the tissue and potentially promote 
tumorigenesis [33]. However, so far it is unclear whether bacteria can be causally related to 
CRC or whether presence of an altered composition of the microbiome simply is a 
consequence of changes in the epithelial tissue. 
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Figure 2: Bacterial driver-passenger model [33]. Driver bacteria initiate tumor formation 
and passenger bacteria later colonize the tumor tissue. 
 
1.2.1. Fusobacterium nucleatum and CRC  
Fusobacterium nucleatum (F. nucleatum) is an anaerobic gram-negative bacterium that 
belongs to the phylum Fusobacteria and the family of Fusobacteriaceae. F. nucleatum can be 
further subdivided into four subspecies (subsp.): F. nucleatum subsp. nucleatum, subsp. 
polymorphum, subsp. vincentii and subsp. animalis [34]. For simplicity I will restrict the 
designation to F. nucleatum. It is a predominant species in oral plaques and was found in 
about 80% of periodontal samples in a study by Moore et al., and supposed to be involved in 
the initiation of periodontitis [35]. It thereby not only acts pro-inflammatory with the ability to 
invade host cells but also functions as a bridging bacterium binding other potentially 
pathogenic bacterium to the oral cells [36]. Besides its presence in the oral cavity  
F. nucleatum was identified in several other entities including lung and urinary tract 
infections, sinusitis and abscesses in the brain, liver and skin but also in context with CRC 
[36]. Zeller et al., for example, found F. nucleatum among those bacteria with higher 
abundance in fecal samples of CRC patients compared to that of healthy controls [30]. Other 
studies focused more specifically on the detection of F. nucleatum instead of the composition 
of the whole microbiome (Table 1). Application of mostly 16S rDNA or nusG based PCR in 
fecal or rectal mucosal samples identified a higher abundance of F. nucleatum DNA in 
adenoma and CRC cases compared to controls [37-42].  
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Table 1: Case-control studies on the association of F. nucleatum with CRC 
First 
Author 
Year Country  Sample size  Method Result 
McCoy 
[39] 
2013 USA 
Controls
1
 (n=67) 
Adenoma (n=48) 
16S rDNA qPCR  
rectal mucosal 
samples 
F. nucleatum DNA more 
abundant in rectal mucosal 
samples of adenoma cases 
compared to controls 
Mira-
Pascual 
[40] 
2015 Spain 
Controls
1
 (n=10) 
Adenoma (n=11) 
CRC (n=7) 
16S rDNA qPCR  
Fecal samples 
F. nucleatum DNA more 
abundant in fecal samples 
of CRC cases compared to 
controls 
Fukugaiti 
[37] 
2015 Brasil 
Controls
1
 (n=10) 
CRC (n=7) 
16S rDNA qPCR  
Fecal samples 
F. nucleatum DNA more 
abundant in fecal samples 
of CRC cases compared to 
controls 
Yu 
[42] 
2015  China 
Controls
2
 (n=109) 
CRC (n=47) 
Butyryl-CoA 
dehydrogenase 
qPCR  
Fecal samples 
F. nucleatum DNA more 
abundant in fecal samples 
of CRC cases compared to 
controls 
Wong 
[41] 
2016 China 
Controls
1
 (n=102) 
Adenoma (n=103) 
CRC (n=104) 
nusG qPCR 
Fecal samples 
F. nucleatum DNA more 
abundant in fecal samples 
of adenoma and CRC cases 
compared to controls 
Liang 
[38] 
2016 China 
Controls
2
 (n=236) 
CRC (n=203) 
nusG qPCR 
Fecal samples 
F. nucleatum DNA more 
abundant in fecal samples 
of CRC cases compared to 
controls 
1
colonoscopy-negative; 
2
Healthy controls 
 
Distinct studies compared the abundance of F. nucleatum DNA directly in tumor tissue and 
adjacent normal tissue of the same patient (Table 2) [43-46]. They all found significantly 
higher levels of F. nucleatum DNA specifically in the tumor tissue. These findings led to 
further studies assessing a potential causal role of F. nucleatum in CRC development. Studies 
by Flanagan et al., Mima et al. and Wei et al. found that a higher amount of F. nucleatum 
DNA in tumor tissue was associated with worse clinical outcome and larger tumor size [44, 
47, 48]. Moreover they found that higher amount of F. nucleatum DNA associates with MSI-
H tumors. These findings were confirmed by Nosho et al. and Ito et al. in independent studies 
and extended by the finding that high F. nucleatum DNA levels are significantly less frequent 
in premalignant lesions compared to CRC and more frequent in tumors expressing the BRAF 
mutant and those of the serrated pathway [49, 50].  
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Table 2: Studies comparing F. nucleatum DNA abundance in CRC tumor and normal 
adjacent tissue. 
First 
Author 
Year Country  Sample size  Method Result 
Kostic 
[45] 
2012 Spain CRC (n=95) 16S rDNA qPCR 
F. nucleatum DNA 
more abundant in tumor 
than adjacent normal 
tissue 
Castellarin 
[43] 
2013 USA  CRC (n=99)  nusG qPCR 
F. nucleatum DNA 
more abundant in tumor 
than adjacent normal 
tissue 
Flanagan 
[44] 
2014 
Czech Republic CRC (n=49) 
nusG qPCR 
F. nucleatum DNA 
more abundant in tumor 
than adjacent normal 
tissue in CRC cases 
Germany CRC (n=45) 
Ireland CRC (n=28) 
Adenoma (n=52) 
Li 
[46] 
2016 China CRC (n=101) 16S rDNA qPCR 
F. nucleatum DNA more 
abundant in tumor than 
adjacent normal tissue 
 
More mechanistic studies addressed a potential mode of action of the bacterium in tumor 
progression and found that F. nucleatum might interact with and inhibit the adaptive immune 
system in the tumor. High abundance of F. nucleatum DNA was found to be inversely 
associated with presence of CD3+ T-cells [51]. In vitro studies showed that outer membrane 
proteins Fap2 (systematic name: Fn1449) and RadD (Fn1526) induced cell death in human 
lymphocyte cell lines [52] and that Fap2 binds to inhibitory receptors of Natural killer cells 
[53]. In the contrary, a study in mice showed that tumors confronted with F. nucleatum 
infection exhibited a pro-inflammatory microenvironment [54]. Wei et al. found an 
association of high abundance of F. nucleatum with NFκB (nuclear factor κB) expression 
[48]. In addition it was found that infection of CRC cell lines with F. nucleatum enhanced 
their proliferation by the induction of NFκB [55]. These findings indicate an inhibitory effect 
on the adaptive immune system and a pro-inflammatory and pro-proliferative effect on the 
tissue. However, these studies should be further confirmed to gain a comprehensive evidence 
for an immunity modulating influence of F. nucleatum. Apart from a potential influence on 
the immune system an adhesion protein FadA (Fn0264) was identified [56] to be important in 
invasion of the bacterium but also promotion of tumorigenesis by binding to E-cadherin and 
activation of β-catenin signaling [57]. RadD and Fap2 belong to a type V secretion system 
with potential virulence properties [58]: Fap2 was shown to adhere to D-galactose-β(1-3)-N-
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acetyl-D-galactosamine, which is highly expressed by tumor cells [59] and RadD was shown 
to be important for biofilm formation [60]. Altogether recent research found several 
indications for a potential causal involvement of F. nucleatum in CRC development and 
progression, however, clear evidence is not given so far. 
1.2.2. Streptococcus gallolyticus subsp. gallolyticus and CRC 
Streptococcus gallolyticus subsp. gallolyticus (S. gallolyticus) is a gram-positive bacterium 
that belongs to the S. bovis/S. equinus complex and the family of Streptococcaceae in the 
phylum Firmicutes. The S. bovis/S. equinus complex is a diverse group of human and animal 
commensals but also pathogens and comprises besides S. gallolyticus also S. gallolyticus 
subsp. pasteurianus (S. pasteurianus), S. gallolyticus subsp. macedonicus (S. macedonicus), 
S. infantarius subsp. infantarius (S. infantarius), S. lutetiensis, S. alactolyticus and strains 
originally and not further subdifferentiated as S. equinus and S. bovis. As the name of the 
complex indicates, these bacteria, also S. gallolyticus, are frequently identified from sources 
of animal origin, including ruminants, especially cattle, chickens, pigeons and pigs indicating 
a potential for zoonotic transmission [61-65]. The taxonomy and nomenclature shown above 
was proposed by Schlegel et al. in 2003 [66]. Prior to that the classification was based on the 
ability of the bacteria to ferment mannitol and subdivided the S. bovis species into biotype I 
(now S. gallolyticus), biotype II/1 (now S. infantarius and S. lutetiensis), biotype II/2 (now  
S. pasteurianus) as well as S. macedonicus and S. equinus [67]. The nomenclature is still 
under debate but for consistency I will use the nomenclature proposed by Schlegel et al. [66]. 
Early before species of the complex were further subclassified, studies linked an infective 
endocarditis inducing bacterium named S. bovis to CRC [68-71]. Ruoff et al. in 1989 were the 
first to describe that bacteremia induced specifically by S. gallolyticus was highly correlated 
with colorectal neoplasm [72]. Table 3 summarizes studies that compare the presence of 
adenoma and/or CRC in patients with bacteremia induced by S. gallolyticus compared to 
those induced by other bacteria.  
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Table 3: Cohorts of bacteremia patients and association with CRC. 
First 
Author 
Year Country Bacteremia induced by Method Result 
Corredoira
[73] 
2005 Spain  
S. gallolyticus (n=42) 
S. pasteurianus/  
S. infantarius (n=20) 
S. salivarius (n=17) 
Microbial 
typing 
Presence of adenoma/CRC 
significantly more frequent in 
patients with S. gallolyticus 
bacteremia (57% vs. 15% and 
0%, respectively) 
Corredoira
[74] 
2012 Spain 
S. gallolyticus (n=98) 
No bacteremia (n=196) 
Microbial 
typing 
Presence of advanced 
adenoma/CRC significantly more 
frequent in patients with S. 
gallolyticus bacteremia (70% vs. 
32%, respectively) 
Corredoira
[75] 
2014 Spain 
S. gallolyticus (n=99) 
S. pasteurianus/  
S. infantarius (n=36) 
Microbial 
typing 
Presence of adenoma/CRC 
significantly more frequent in 
patients with S. gallolyticus 
bacteremia (70% vs 22%, 
respectively) 
Sheng 
[76] 
2014  Taiwan 
S. gallolyticus (n=31) 
S. pasteurianus (n=126)  
S. infantarius (n=15) 
Microbial 
typing 
Presence of adenoma/CRC was 
not significantly more frequent in 
patients with S. gallolyticus 
bacteremia (16% vs 15% and 0%, 
respectively) 
Corredoira
[77] 
2015 Spain 
S. gallolyticus (n=224) 
S. pasteurianus/  
S. infantarius (n=270) 
Microbial 
typing 
Presence of adenoma/CRC 
significantly more frequent in 
patients with S. gallolyticus 
bacteremia (51% vs 16%, 
respectively) 
1
colonsocopy-negative 
 
Four of the five studies were conducted by Corredoira et al. in Spain and showed a 
significantly higher fraction of adenoma/CRC cases among S. gallolyticus bacteremia patients 
(51-70%) than among patients with bacteremia induced by other bacteria (0-32%) [73-75, 77]. 
The fifth study by Sheng et al. from Taiwan, however, did not see this difference in 
adenoma/CRC presence between patients with bacteremia induced by S. gallolyticus, S. 
pasteurianus and S. infantarius [76].  
The association of S. gallolyticus presence in fecal or tumor tissue with CRC was only rarely 
described in the current literature, as compared to the F. nucleatum studies. Fecal carriage 
rates were assessed by PCR or bacterial isolation of S. gallolyticus DNA and overall fecal 
carriage rates in healthy individuals were low (1-11%) [78, 79]. Chirouze et al. could not 
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identify a significant difference in the fecal carriage rate between controls and CRC cases 
[78]. Abdulamir et al. isolated species of the so-called S. gallolyticus member bacteria 
(SGMB), not differentiating between the different subspecies gallolyticus, pasteurianus and 
macedonicus, from fecal, mucosal and tissue samples of CRC patients and controls [80]. 
There was no difference between CRC cases and controls in the number of isolates from fecal 
and mucosal samples but in the number of isolates from tissue samples. Other studies 
addressed the association of S. gallolyticus with CRC and premalignant lesions with 
serological methods (Table 4). Independent of the detection method they all found 
significantly more S. gallolyticus positive CRC cases than controls. A study performed in our 
laboratory applied multiplex serology (1.4) using four S. gallolyticus pilus proteins [81], two 
of them, Gallo2178 and Gallo2179, being further elucidated in this thesis. All of these studies 
were in a retrospective case-control design and although Abdulamir et al. [82] and Garza-
Gonzalez et al. [83] regarded also polyps in addition to CRC cases there was no prospective 
study conducted so far addressing whether S. gallolyticus infection is present in the same 
individual prior to CRC diagnosis. This could be on the one hand of diagnostic value and on 
the other hand indicative for a causal relationship. 
Table 4: Case-control studies on the association of S. gallolyticus with CRC 
First 
Author 
Year Country  Sample size  Method Result 
Abdulamir 
[82] 
2009 Malaysia  
Controls
1,2
 (n=60) 
CRC (n=50) 
Adenoma (n=14) 
S. gallyticus cell 
wall protein 
ELISA 
Significantly more S. 
gallolyticus positive 
adenoma/CRC cases 
Boleij 
[84] 
2010 
Netherlands 
Controls
1
 (n=127) 
Early stage CRC (n=48) 
Advanced CRC (n=34) 
S. gallolyticus 
ribosomal protein 
RpL7/L12 ELISA 
Higher antibody titers 
among early stage 
CRC cases compared 
to controls USA 
Controls
1
 (n=48) 
Early stage CRC (n=35) 
Advanced CRC (n=22) 
Garza-
Gonzalez 
[83] 
2012 USA 
Controls
2 
(n=54) 
Polyps (n=133) 
S. gallolyticus 
whole cell protein 
Western blot 
Significantly more S. 
gallolyticus positive 
polyp cases 
Butt 
[81] 
2016 Spain 
Controls
1
 (n=576) 
CRC (n=576) 
Multiplex 
serology with S. 
gallolyticus pilus 
proteins 
Significantly more S. 
gallolyticus positive 
CRC cases 
1
Healthy controls; 
2
colonoscopy-negative 
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The bacterial driver-passenger model developed by Tjalsma et al. [33] (1.2) describes  
S. gallolyticus as a potential passenger bacterium: a commensal that invades tissue and blood 
stream to finally cause a bacteremia or endocarditis specifically through the presence of CRC 
or a precursor. Several studies found that S. gallolyticus is able to bind to collagen I rich 
surfaces [85, 86], a collagen type that is expressed in heart valves as well as CRC tissue  
[87, 88] indicating a niche for S. gallolyticus adherence to CRC tissue in contrast to normal 
tissue. Pilus-structures, appendages of gram-positive bacteria, especially those composed of 
proteins Gallo2178 and Gallo2179, are assumed to be mediators of this adherence [89, 90]. 
Furthermore S. gallolyticus was shown to adhere to collagen type IV, fibrinogen and mucus 
[85, 86, 91-93]. Boleij et al. even showed that S. gallolyticus has a growth advantage in spent 
medium of malignant colonocytes [94]. Additionally, cytokine expression profiles in human 
CRC tissue positive for S. gallolyticus DNA indicate a pro-inflammatory and thus pro-
carcinogenic potential [80, 82]. However, further studies are needed to confirm a role of S. 
gallolyticus in CRC carcinogenesis going beyond the possibility of a simple “passenger” in 
this process. 
1.3. Seroepidemiology of Infection-Associated Cancers 
1.3.1. Epidemiological study designs and measures of association 
Epidemiology is “the study of the occurrence and distribution of health-related events, states, 
and processes in specified populations, including the study of determinants influencing such 
processes, and the application of this study to the control of health problems.” [95]. With 
respect to this thesis this implies the study of an exposure to bacterial infections as potential 
determinant for the event/outcome CRC. The application of different epidemiological study 
designs thereby allows assessing whether exposures are related to outcomes. A relatively 
convenient study design in terms of cost- and time-effectiveness is given by retrospective 
case-control studies: individuals are chosen based on the outcome (and cases and controls are 
often matched by important confounders such as age and sex), and then the prevalence of the 
exposure is assessed retrospectively (Figure 3A). Consequently, the odds for the outcome at 
presence of exposure can be compared to the odds for the outcome in the absence of the 
exposure resulting in an odds ratio (OR) as a measure of association for the relationship 
between outcome and exposure (Figure 3A) [96].  
Prospective cohorts, in contrast, provide incidences (number of newly identified cases per 
person-time at risk) for the outcome. In this study design the presence of the exposure in a 
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cohort of individuals is determined at baseline and then the individuals are followed-up over 
time for the occurrence of the outcome (Figure 3B). Incidences for the outcome among those 
individuals with the exposure at baseline are compared to those without the exposure to 
estimate the relative risk (RR) for the outcome in the exposed in relation to the unexposed 
(Figure 3B) [97].  
 
 
Figure 3: Principle and measures of association of different epidemiological study 
designs. A) retrospective case-control studies, B) prospective cohorts. 
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Prospective cohorts imply a temporality of the association since exposure happens prior to 
outcome detection. Temporality is one out of the nine Bradford Hill criteria and a first 
indicator for causation [98]. In contrast, retrospective case-control studies can only show an 
association between exposure and outcome. Prospective studies, however, are also cost- and 
time-intensive especially for rare outcomes and exposures, since study groups have to be large 
enough to guarantee statistical power, analyses of resulting large numbers of biological 
specimens are costly, and often the follow-up time lasts several years for the outcome to 
occur. An often applied design is therefore a case-control study nested within a prospective 
cohort. Frequency of exposure is assessed in either all or a selection of individuals with 
incident outcome under comparison to a respective group of controls. This subset analyses 
offers the advantage of a prospective setting, and consequently temporality of the association 
as well as data analyses in a minimal number of samples. However, also here the strength of 
the association is estimated as OR and not as relative risk [99].  
In both study designs, retrospective case-control and case-control studies nested within a 
prospective cohort, the strength of an association between categorical exposure and outcome 
is given by the OR. In a simple univariate approach the OR can be calculated from a 2 by 2 
table as depicted in Figure 3B. However, in the majority of cases exposure and outcome do 
not depend exclusively on each other. Other factors, so-called confounders, might influence 
the relation and have to be considered when estimating the strength of an association. Logistic 
regression models enable such multivariate modelling of the association [100]. 
The significance of the estimated OR is assessed by the 95% confidence interval (95% CI). 
This interval gives the upper and lower limits among which the true parameter (OR) will 
range in an unlimited repetition of the analysis at least as frequent as given by the confidence 
level (95%) [101].  
As mentioned above other factors, confounders, might influence the association between 
exposure and outcome and it should be adjusted for confounding variables to minimize bias. 
Confounders are associated with both, the outcome and exposure of interest, and cannot be an 
intermediary step in the causal pathway [102]. Bias through confounding can be minimized 
already during study design: the selection of controls can be matched to cases by important 
and potentially confounding variables [103]. In contrast, if there is indication for effect 
modification, i.e. a biological assumption why one group of individuals should differ to 
another in the strength and/or direction of the association, the association should be estimated 
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stratified by the two groups of individuals [104]. In case of CRC potential associations are 
often assessed separately for males and females since males are more likely to develop CRC 
than females and may also differ in their association with risk factors for the outcome [105].  
1.3.2. Infection-associated cancers and serology 
Valid ascertainment of the exposure, in this case a bacterial infection, is crucial for assessing a 
potential association with the outcome. Acute bacterial infections can be diagnosed directly 
by bacterial culture, microscopic analysis or based on detection of species-specific DNA by 
PCR or sequencing [106]. However, these methodologies, especially the gold standard 
bacterial culture, are time-consuming and costly and do not provide the possibility to measure 
also past infections. A different, easy-to-apply method is serology, the measurement of 
antibodies against antigenic structures. The detected antibody responses serve as biomarkers 
for the indirect detection of acute and past infections [106]. Seroepidemiological studies 
provide the possibility to identify associations of this biomarker with the outcome. As 
described above serum collections of retrospective case-control studies are analyzed to assess 
associations, however, cannot be used to analyze causal inference. Serum collections of case-
control studies nested within prospective cohorts, in contrast, provide the possibility to assess 
the temporality of an association. This knowledge may be the basis for further molecular 
analyses of a potential causal relationship of the infection with the outcome. Independent of a 
potential causality the identified antibody markers might be applicable in early diagnostics of 
the outcome. 
Coherently, serological associations of infectious agents with cancer have been frequently 
identified and appeared in different ways: 
i) Infection was more frequent in tumor patients leading to a higher seroprevalence, 
i.e. Hepatitis C infection and liver cancer [107] 
ii) The infectious load was higher in tumor patients leading to higher antibody titers 
and perhaps also higher seroprevalence, i.e. Helicobacter pylori (H. pylori) 
infection and gastric cancer [108] or Epstein-Barr-virus infection and 
nasopharyngeal cancer [109] 
iii)  Specific antigens were mainly expressed in tumor development or in the 
established tumor and antibodies to them might serve as tumor markers, i.e. 
antibodies to human papillomavirus 16 E6 and E7 proteins in cervical [110] and 
oropharyngeal cancer [111], Merkel cell polyomavirus T-antigen in Merkel cell 
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carcinoma [112] or to H. pylori Cytotoxin-associated antigen A (CagA) and 
Vacuolating toxin A (VacA) [113]. 
1.4. Multiplex Serology 
Conventional serology often uses the enzyme-linked immunosorbent assay (ELISA) or 
Western blot to detect antibody responses to antigens of infectious agents. Whole cell lysates, 
or purified endogenously or recombinantly expressed antigens are immobilized on microtiter 
plates or blotted on a membrane, respectively. These methods are limited to one antigen or 
one antigen pool analyzed per well/lane and analysis of large seroepidemiological studies is 
time- and material-consuming. A technique called multiplex serology, developed in our 
laboratory by Waterboer et al. [114] allows the analysis of approximately up to 2000 sera per 
day for up to 100 antigens. Polystyrene beads filled with two fluorescent dyes in various 
ratios provide an array of 100 different bead sets, each with its internal specific color. Mixing 
of the differently loaded bead sets results in a suspension array. The technique developed by 
Waterboer et al. [114] uses recombinantly expressed proteins (X) as antigens flanked by an N-
terminal Glutathione-S-transferase (GST) and a C-terminal peptide including the seven C-
terminal amino acids of SV40 large T antigen (tag). Glutathione-casein is crosslinked to the 
beads and binds to GST, which allows for in-situ affinity purification of the GST-X-tag fusion 
proteins. Antibodies in serum samples binding to the antigens can be detected by a biotin-
labeled secondary antibody and streptavidin-R-phycoerythrin (strep-PE) as fluorescent 
reporter dye (Figure 4). A Luminex xMAP device, which is comparable to a flow cytometer, 
has two lasers: the red laser excites the internal fluorescence of the bead set and consequently 
identifies the loaded antigen and the green laser excites the reporter fluorescence (strep-PE), 
which is then quantified. The antibody reactivity is given as median fluorescent intensity 
(MFI) -value of at least 100 beads per set. Altogether, multiplex serology allows for 
quantification of antibody responses in large sets of sera against several pathogens 
simultaneously.  
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Figure 4: Principle of multiplex serology. (modified from [114]) 
1.5. Objectives 
The aim of this thesis was to elucidate the potential serological association of F. nucleatum 
and S. gallolyticus with CRC. More specifically it was aimed at first developing a fluorescent 
bead-based multiplex serology assay for the detection of antibody responses against  
F. nucleatum and S. gallolyticus proteins. Second, using this assay it was aimed to assess 
whether published associations of F. nucleatum and S. gallolyticus with prevalent CRC can be 
reproduced on a serological basis in a retrospective CRC case-control study and whether 
specific bacterial antibody marker for CRC can be identified. At last, it was to be addressed 
whether antibody responses to the bacteria can be detected specifically prior to CRC diagnosis 
in two independent case-control studies nested within prospective cohorts. The prospective 
analyses thereby might give further insight into the temporality of the association and whether 
specific detection of such antibody markers prior to diagnosis might be of diagnostic potential 
in the identification of individuals at increased risk of (pre-) cancerous colorectal lesions. 
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2. Materials and Methods 
2.1. Materials 
2.1.1. Chemicals 
Acrylamide/Bisacrylamide-solutions Carl Roth (Karlsruhe) 
Agarose Sigma-Aldrich (Steinheim) 
Ammoniumperoxodisulfate (APS) Carl Roth (Karlsruhe) 
Ampicillin Roche (Mannheim) 
β-Mercaptoethanol Merck (Darmstadt) 
Bacto agar DIFCO Becton Dickinson (Sparks, MD, USA) 
Bacto tryptone DIFCO Becton Dickinson (Sparks, MD, USA) 
Bacto yeast extract GIBCO, Invitrogen (Karlsruhe) 
Bradford reagent (Roti-Quant) Carl Roth (Karlsruhe) 
Bromphenol blue Merck (Darmstadt) 
Casein Sigma-Aldrich (Steinheim) 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich (Schnelldorf) 
DNA marker (Smart ladder) Eurogentec (Seraing, Belgium) 
1,4-Dithiothreitol (DTT) Carl Roth (Karlsruhe) 
Ethanol Riedel-de Häen (Seelze) 
Ethylendiamintetraacetat (EDTA) GIBCO, Invitrogen (Karlsruhe) 
Glutathione Sigma-Aldrich (Taufkirchen) 
Glycerol (100%) Carl Roth (Karlsruhe) 
Glycine Gerbu (Gaiberg) 
H2O, DNase/RNase-free GIBCO, Invitrogen (Karlsruhe) 
Hydrochloric acid (HCl) Riedel-de-Häen (Seelze) 
Isopropanol J.T. Baker (Deventer, Niederlande) 
Isopropyl-β-D-thiogalactosid (IPTG) Carl Roth (Karlsruhe) 
Methanol DKFZ (Heidelberg) 
Milk powder Carl Roth (Karlsruhe) 
N,N,N’,N’-Tetramethylethylendiamin 
(TEMED) 
Merck (Darmstadt) 
peqGreen peqLab, VWR (Erlangen) 
Polyvinylalcohol (PVA) Sigma-Aldrich (Steinheim) 
Polyvinylpyrrolidon (PVP) Sigma-Aldrich (Steinheim) 
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Potassiumdihydrogenphosphate 
(KH2PO4) 
Merck (Darmstadt) 
Prestained protein ladder (Broad range) Biolabs (Munich) 
Protease Inhibitor Complete (1 tablet/ml) Roche (Mannheim) 
Smart ladder Eurogentec (Cologne) 
Sodium-acetate (NaAc) Thomas Chemikalien (Heidelberg) 
Sodium-azide (NaN3) Merck (Darmstadt) 
Sodium-carbonate (Na2CO3) Carl Roth (Karlsruhe) 
Sodium-chloride (NaCl) Sigma-Aldrich (Steinheim) 
Sodium-dodecyl-sulfate (SDS) Gerbu (Gaiberg) 
di-Sodiumhydrogenphosphate 
(Na2HPO4) 
Merck (Darmstadt) 
Streptavidin-R-Phycoerythrin (strep-PE) Moss Inc. (Pasadena, Maryland, USA) 
Sucrose Merck (Darmstadt) 
Sulfuric acid (H2SO4), 95-97 % AppliChem (Darmstadt) 
Superchemiblock (CBS-K) Chemicon (Temecula, CA, USA) 
Tetramethylbencidine (TMB) Sigma-Aldrich (Taufkirchen) 
Tris(hydroxymethyl)-aminoethan (Tris) Sigma-Aldrich (Steinheim) 
Tween®-20 Gerbu (Gaiberg) 
xMAPTM Sheath fluid Luminex Corp. (Austin, Tx, USA) 
2.1.2. Buffers 
Agarose gel electrophoresis buffer, 50x 2 M Tris, pH 7.8, 0.25 M NaAc water free, 
0.05 M EDTA 
DNA sample buffer, 6x 0.25% (w/v) Bromphenol blue, 40% (w/v) 
sucrose in H2O 
ELISA blocking buffer 0.2% (w/v) casein in PBS-T 
ELISA coating buffer 2 ng/µl glutathione-casein in 50 mM carbonate 
buffer (50 mM Na2CO3, 50 mM NaHCO3 1:4, 
pH 9.6) 
ELISA stop solution 1 M H2SO4 
ELISA substrate solution 100 µg/ml TMB in 100 mM NaAc, pH 6.0, 
0.015% H2O2 
EMBL transfer buffer 48 mM Tris, 39 mM glycine, 0.0345% SDS, 20% 
methanol 
LB medium 1% (w/v)) Bacto tryptone, 0.5% (w/v) Bacto 
yeast extract, 1% (w/v) NaCl; pH 7.5 
LBamp medium LB medium, 10 µl/ml ampicillin 
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LBamp agar LBamp medium, 1.5% (w/v) Bacto agar 
Phosphate-buffered saline (PBS), 10x 124 mM NaCl, 22 mM Na2HPO4, 10 mM 
KH2PO4, pH 7.4 
PBS-T 0.05% (v/v) Tween 20 in 1x PBS 
SDS sample buffer, 4x 160 mM Tris, pH 6.8; 10% (v/v) glycerol; 2% 
(w/v) SDS; 5% (v/v) β-mercaptoethanol; 0.25% 
(w/v) bromphenol blue 
SDS-PAGE running buffer, 10x 250 mM Tris, 14.4% (w/v) Glycine, 1% (w/v) 
SDS 
Multiplex serology blocking buffer  1 mg/ml Casein in PBS 
Serum pre-incubation buffer 2 mg/ml GST-tag lysate, 0.5% (w/v) polyvinyl 
alcohol, 0.8% (w/v) Polyvinyl pyrrolidone, 2.5% 
(v/v) CBS-K super chemiblock in multiplex 
serology blocking buffer 
Storage buffer  0.05% (w/v) NaN3 in multiplex serology 
blocking buffer 
Western blot blocking buffer 10% milk in PBS-T 
2.1.3. Consumables 
Beside the general consumables, i.e. tips, gloves, tubes, the following specific consumables 
were applied: 
96-well microtiter plates Nunc (Wiesbaden) 
96-well polystyrene flat-bottom plates Greiner bio-one (Frickenhausen) 
96-well filter plates Millipore (Bredford, MA, USA) 
ECLTM Western blotting Detection reagents GE Healthcare (Freiburg) 
Electroporation cuvettes 10 mm, Invitrogen (Karlsruhe) 
Nitrocellulose membrane PROTRAN Schleicher & Schuell (Dassel) 
QiaPrep Spin MidiPrep kit Qiagen (Hilden) 
QiaPrep Spin MiniPrep kit Qiagen (Hilden) 
Qiagen Multiplex PCR kit Qiagen (Hilden) 
QiaQuick PCR purification kit Qiagen (Hilden) 
SeroMAPTM Microspheres (Fluorescent 
polysterene beads) 
Luminex Corp. (Austin, TX, USA) 
Whatman 3MM paper Schleicher & Schuell (Dassel) 
X-ray films X-OmatTM Blue XB-1 Kodak (Rochester, NY, USA) 
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2.1.4. Laboratory equipment 
Beside the general laboratory equipment, i.e. shaker, vortex, heater and water baths, the 
following specific tools were used: 
Agarose gel electrophorese system Renner GmbH (Darmstadt) 
Benchtop centrifuge (5415D) Eppendorf (Hamburg) 
Centrifuge RC-5C, Sorvall Thermo Scientific (DuPont, DE, USA) 
Developer Curix 60 Agfa (Cologne) 
Gel Doc EZ Imager BioRad (Munich) 
Gene pulser BioRad (Munich) 
Luminex 100 analyzer Luminex Corp. (Austin, TX, USA) 
Luminex 200 analyzer Luminex Corp. (Austin, TX, USA) 
Luminex SD sheath fluid delivery system Luminex Corp. (Austin, TX, USA) 
Luminex XYP plate handler Luminex Corp. (Austin, TX, USA) 
Mini Trans-Blot Electrophoretic Transfer 
Cell 
BioRad (Munich) 
Multiskan PLUS MKII Titertek (Pforzheim) 
NanoDrop ND-1000 Thermo Scientific (DuPont, DE, USA) 
PCR cycler (Eppendorf Mastercycler) Eppendorf (Hamburg) 
Power Pac 300 BioRad (Munich) 
Pressure homogenizer EmulsiFlex-C5 Avestin (Mannheim) 
Pulse controller BioRad (Munich) 
Rotor ThermoScientific F12-6x500 LEX Thermo Scientific (DuPont, DE, USA) 
Rotor Sorvall SA-600 Thermo Scientific (DuPont, DE, USA) 
SDS-PAGE electrophoresis chamber (Mini-
PROTEAN II) 
BioRad (Munich) 
Ultrasonic bath Bandelin Sonorex (Berlin) 
Underbench centrifuge (Varifuge RF) Heraeus (Hanau) 
Vacuum manifold Millipore (Bredford, MA, USA) 
Vacuum pump (Millivac ®) Millipore (Bredford, MA, USA) 
 
2.1.5. Antibodies 
Biotinylated goat anti-human IgA, IgM, IgG Dianova (Hamburg) 
Biotinylated goat anti-mouse IgG Dianova (Hamburg) 
Biotinylated goat anti-bovine IgA, IgM, IgG Dianova (Hamburg) 
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Biotinylated mouse anti-tag from KT3 
hybridoma cell supernatant 
[115], purified and biotinylated by Tim 
Waterboer 
Goat anti-mouse IgG horseradish peroxidase 
(HRP) conjugate 
Dianova (Hamburg) 
Goat anti-mouse IgG (HRP) conjugate Dianova (Hamburg) 
Mouse anti-tag from KT3 hybridoma cell 
supernatant 
[115], purified by Tim Waterboer 
Rabbit anti-GST Sigma-Aldrich 
2.1.6. Bacterial strains 
Escherichia coli (E. coli) BL21 wildtype bacteria were purchased from GE Healthcare 
(Freiburg). 
2.1.7. Enzymes and reaction buffers 
All restriction enzymes and respective reaction buffers were purchased from NEB (Frankfurt). 
2.1.8. Antigens 
The bacterial lysates containing recombinantly expressed GST-tag (without insert) and 
Polyomavirus JC VP1 as GST-X-tag fusion protein were prepared in the laboratory of 
Michael Pawlita (DKFZ, Heidelberg) by Ute Koch. 
2.1.9. Sera and respective study data 
S. gallolyticus reference sera from mice were kindly provided by Annemarie Boleij (Radboud 
University Medical Centre, Nijmegen, Netherlands). Mice had been inoculated with 4.5*106 
S. gallolyticus UCN34 cells (positive control) or PBS (negative control). Serum samples had 
been taken weekly for up to 7 weeks. Data on colonization status of the mice with  
S. gallolyticus were also kindly provided by Annemarie Boleij. S. gallolyticus DNA status in 
colon tissue and fecal samples was kindly provided by Indra-Jasmin Gierse (DKFZ, 
Heidelberg). 
S. gallolyticus reference sera from cattle and respective fecal samples were collected by Indra-
Jasmin Gierse in 10 farms located in Eastern Germany. S. gallolyticus DNA status in fecal 
samples was kindly provided by Indra-Jasmin Gierse. 
S. gallolyticus reference sera from three individuals with diagnosed S. gallolyticus bacteremia 
and three healthy controls were kindly provided by Harold Tjalsma (Radboud Medical 
University Center Nijmegen, Netherlands). 
Materials and Methods 
23 
 
Serum samples and study data of the BliTz and DACHSplus study were kindly provided by 
Hermann Brenner (DKFZ, Heidelberg). 
Serum samples and study data of the SCCS were kindly provided by Meira Epplein 
(Vanderbilt University, Nashville, TN, USA). 
Serum samples and study data of the EPIC study were kindly provided by Mazda Jenab 
(International Agency for Research on Cancer (IARC), Lyon, France). 
Serum samples and study data of the Irish CRC case-control study were kindly provided by 
David Hughes (Royal College of Surgeons in Ireland (RCSI), Dublin, Ireland). For 52 
participants colon tissue samples were analyzed for the presence of fusobacterial DNA by 
qPCR. Data were kindly provided by David Hughes as reference for F. nucleatum multiplex 
serology results. 
2.1.10. Software and websites 
BlastP https://blast.ncbi.nlm.nih.gov/Blast.cgi 
Clustal Omega https://www.ebi.ac.uk/Tools/msa/clustalo/ 
GraphPad Prism 6 GraphPad Software (La Jolla, USA) 
Luminex 100 IS 2.2 SP1 Software Luminex Corp. (Austin, TX, USA) 
Microsoft Windows 7  Microsoft Corp. (Unterschleißheim) 
Microsoft Office 2010 Microsoft Corp. (Unterschleißheim) 
PubMed https://www.ncbi.nlm.nih.gov/pubmed 
Reverse Complement http://www.bioinformatics.org/sms/rev_comp.html 
SAS 9.4 SAS Institute Inc. (Cary, NC, USA) 
SignalP 4.1 http://www.cbs.dtu.dk/services/SignalP/ 
TMpred http://www.ch.embnet.org/software/TMPRED_form.html 
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2.2. Methods 
2.2.1. Selection and cloning of proteins for F. nucleatum and S. gallolyticus 
multiplex serology 
Extensive literature search (“PubMed”) identified only few known immunogenic proteins for 
S. gallolyticus (pilus proteins Gallo1569, Gallo2178, Gallo2179 and Gallo2039) [116] and  
F. nucleatum (adhesin Fn0264 (FadA) [117] and porin Fn1859 (FomA) [118]). Both  
F. nucleatum proteins were included in the antigen selection. Based on the findings in Butt et 
al. [81] only Gallo2178 and Gallo2179 were included for S. gallolyticus.  
Sequence data was available for the genomes of different strains of both, S. gallolyticus and 
F. nucleatum. Genomes of S. gallolyticus strain UCN34 [119] and F. nucleatum strain 
ATCC25586 [120] served as reference to select additional potential antigens for each 
bacterium (Table 5). Predictions of protein function and localization (cell wall/outer 
membrane or secretion) thereby served as major criterion for protein selection [119-122]. 
Based on these predictions I chose 18 additional proteins resulting in a total number of eleven 
proteins per bacterium (Table 5). Ten out of eleven S. gallolyticus proteins were predicted to 
be located at the cell wall and Gallo0933 as a putative enzyme degrading tannins was 
predicted to be secreted. Gallo0272, Gallo0577, Gallo1570, Gallo2178 and Gallo2179 were 
predicted to be involved in adhesion of the bacterium. Especially Gallo2178 and Gallo2179 
were well described as parts of pilus structures that enable S. gallolyticus to adhere to 
collagen rich surfaces [89]. Gallo0112, Gallo0748 and Gallo2018 were predicted to have 
enzymatic function. The function of Gallo1675 was unknown. Proteins selected for F. 
nucleatum were mainly localized at the outer membrane. Two fragments of a putative 
hemolysin were predicted to be secreted (Fn1817_1 and Fn1817_2). Others were predicted to 
be important for adhesion (Fn0264), to be outer membrane proteins (Fn0253, Fn1859) or act 
as secretion system in the outer membrane (FN0131, Fn0387, Fn1426, Fn1449, Fn1526 and 
Fn1893). 
Amino acid sequences for predicted signal peptides (“SignalP 4.1”) or predicted 
transmembrane domains (“TMpred”) were excluded from the final sequence to facilitate 
expression. If the full-length proteins were bigger than 100 kD they were either split up (e.g. 
Gallo0112) or only domains with a predicted function were selected (e.g. autotransporter 
domains in Fn0387, Fn1526, Fn0387 and Fn1893). 
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Table 5: Selected antigens and their characteristics for F. nucleatum and S. gallolyticus multiplex serology 
Strain Antigen Putative function
1
 Predicted 
localization
1
 
Protein 
accession no.
2
 
Selected 
region (AA) 
Protein size incl. 
GST-tag (kD)
4
 
Fusobacterium 
nucleatum subsp. 
nucleatum 
(ATCC25586; 
Accession no.: 
NC_003454) 
Fn0131 Hemolysin activator OM NP_603038 17-566 86 
Fn0253 Outer membrane protein A OM NP_603160 37-132 37 
Fn0264
3
 Adhesin (FadA) OM NP_603171 19-129 38 
Fn0387 Outer membrane protein, Type Va secretion 
system, autotransporter domain 
OM/EC NP_603291 1442-1714 56 
Fn1426 Outer membrane protein, Type Va secretion 
system, serine peptidase domain 
OM/EC NP_604320 25-374 65 
Fn1449 Outer membrane protein, Type Va secretion 
system, autotransporter domain 
OM/EC NP_604343 2884-3155 56 
Fn1526 Outer membrane protein, Type Va secretion 
system, autotransporter domain 
OM/EC NP_602353 1857-2135 57 
Fn1817_1 Hemolysin, filamentous haemagglutinin repeat EC NP_602617 205-276 34 
Fn1817_2 Hemolysin, filamentous haemagglutinin repeat EC NP_602617 839-909 34 
Fn1859
3
 Major outer membrane protein (FomA) OM NP_602659 21-368 64 
Fn1893 Outer membrane protein, Type Va secretion 
system, autotransporter domain 
OM/EC NP_602692 1079-1351 56 
Streptococcus 
gallolyticus subsp. 
gallolyticus 
(UCN34; 
Accession no.: 
NC_013798) 
Gallo0112A Fructan hydrolase N-Terminus CW WP_012961337 44-816 111 
Gallo0112B Fructan hydrolase C-Terminus CW WP_012961337 784-1275 80 
Gallo0272 Glucan binding protein C domain CW WP_012961389 500-997 81 
Gallo0577 CnaB domain CW WP_012961602 27-715 102 
Gallo0748 Cell-envelope proteinase A CW WP_012961731 36-800 110 
Gallo0933 Tannase EC WP_012961863 21-596 90 
Gallo1570 Pil2 pilus subunit CW WP_012962246 24-605 90 
Gallo1675 Unknown function CW WP_012962333 40-724 102 
Gallo2018 Involved in bacteriocin synthesis CW WP_009855005 27-311 58 
Gallo2178
3
 Pil1 pilus subunit (major pilin) CW WP_009855153 26-448 73 
Gallo2179
3
 Pil1 pilus subunit (collagen-binding domain) CW WP_009855154 35-628 92 
1
[52, 56, 58, 60, 119-123]; 
2
NCBI Reference Sequence; 
3
previously shown to be immunogenic [116-118]; 
4
Molecular weight GST-tag 27.4 kD 
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Amino acid sequences of the selected antigens were analyzed for homologues in other 
bacterial species with “BLASTp” to assess specificity. The reference strain for F. nucleatum 
belonged to the F. nucleatum subsp. nucleatum. Proteins of other F. nucleatum subspecies 
were closely related to the selected proteins (> 74% identity) impeding a subspecies specific 
detection of antibody responses (Table 6). In 2015, after protein selection had been 
performed, a new fusobacterial species had been identified, F. hwasookii [124]. The selected 
proteins shared high sequence identity to proteins of this bacterium (up to 97%) and a 
serological distinction between F. hwasookii and F. nucleatum could not be guaranteed based 
on the antigen selection. However, the impact of F. hwasookii in human infection is unknown 
so far. F. periodonticum is the next bacterial relative and except for Fn0264 the selected 
proteins shared a sequence identity of less than 80% with proteins of this bacterium. Other, 
none fusobacterial species did not exceed an identity of 56%.  
Several S. gallolyticus proteins shared high sequence identity with proteins of S. equinus (up 
to 97%) (Table 7). However, this bacterium is a frequent isolate of horses and only rarely 
identified in humans [66]. Other closely related species of S. gallolyticus were S. pasteurianus 
and S. infantarius. S. infantarius has a homologous protein to Gallo0748 (67% sequence 
identity). A protein of S. pasteurianus identified recently [125] shares a high sequence 
identity with Gallo1675 (99%). The sequence identity was below 75% for all other selected S. 
gallolyticus proteins to proteins of species of the S. equinus/S. bovis complex, the family of 
Streptococcacae or none streptococcal species.  
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Table 6: Amino acid sequence homologies of selected F. nucleatum subsp. nucleatum 
antigens to proteins of other bacteria 
 Amino acid sequence homology (% query; % identity) to closest other 
Antigen F. nucleatum subspecies Fusobacteriaceae bacterial species 
Fn0131 F. nucleatum subsp. vincentii 
(99%; 94%) 
F. periodonticum 
(99%; 73%); 
F. hwasookii
1
 
(99%; 92%) 
Klebsiella michiganensis 
(93%; 28%) 
Fn0253 F. nucleatum subsp. vincentii 
(100%; 99%) 
F. periodonticum 
(100%; 79%); 
F. hwasookii
1
 
(100%; 97%) 
Bordetella ansorpii 
(98%; 55%) 
Fn0264 F. nucleatum subsp. 
polymorphum 
(100%; 98%) 
F. periodonticum 
(100%; 96%); 
F. hwasookii
1
 
(100%; 97%) 
- 
Fn0387 F. nucleatum subsp. fusiforme 
(100%; 96%) 
F. periodonticum 
(100%; 73%); 
F. hwasookii
1
 
(100%; 72%) 
Campylobacter 
ureolyticus 
(98%, 33%) 
Fn1426 F. nucleatum subsp. vincentii 
(100%; 95%) 
F. necrophorum 
(99%; 44%); 
F. hwasookii
1
 
(100%; 47%) 
Haemophilus ducreyi 
 (97%; 28%) 
Fn1449 F. nucleatum subsp. 
polymorphum 
(100%; 93%) 
F. periodonticum 
(100%; 85%); 
F. hwasookii
1
 
(100%; 89%) 
Campylobacter 
ureolyticus 
(88%, 33%) 
Fn1526 F. nucleatum subsp. vincentii 
(100%; 93%) 
F. russii 
(100%; 63%) 
Campylobacter hominis 
(89%, 31%) 
Fn1817_1 F. nucleatum subsp. animalis 
(100%; 74%) 
F. periodonticum 
(100%; 68%) 
Proteus mirabilis 
(70%; 56%) 
Fn1817_2 F. nucleatum subsp. animalis 
(100%; 99%) 
F. necrophorum 
(100%; 75%) 
Bordetella bronchiseptica 
(97%; 39%) 
Fn1859 F. nucleatum subsp. vincentii 
(100%; 87%) 
F. periodonticum 
(100%; 70%); 
F. hwasookii
1
 
(100%; 74%) 
Bordetella trematum 
(92%; 26%) 
Fn1893 F. nucleatum subsp. fusiforme 
(100%; 99%) 
F. periodonticum 
(100%; 75%) 
 
Campylobacter 
ureolyticus 
(98%, 33%) 
1
identified 2015 [124]; % query: percentage of query coverage that overlaps the subject sequence; % 
identity: percentage identity between the query and subject sequences over the coverage area 
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Table 7: Amino acid sequence homologies of selected S. gallolyticus antigens to proteins 
of other bacteria 
 Amino acid sequence homology (% query; % identity) to closest other 
Antigen species of the 
 S. equinus/bovis complex Streptococcaceae bacterial species 
Gallo0112A S. equinus
1
 
(100%; 90%) 
S. uberis 
(97%; 75%) 
Atopobium parvulum 
(94%; 60%) 
Gallo0112B S. equinus
1
 
(100%; 91%) 
S. uberis 
(96%; 71%) 
Lactobacillus equi 
(96%; 50%) 
Gallo0272 - S. suis 
(73%; 38%) 
Atopobium parvulum 
(74%; 33%) 
Gallo0577 - S. parasanguinis 
(95%; 42%) 
Lactobacillus fermentum 
(97%; 56%) 
Gallo0748 S. equinus
1
 
(100%; 86%) 
S. infantarius  
(100%; 67%) 
S. suis 
(95%; 61%) 
Enterococcus cecorum 
(97%; 56%) 
Gallo0933 S. equinus
1
 
(100%; 97%) 
S. oralis 
(99%; 69%) 
Butyrivibrio sp. NC2007 
(99%; 57%) 
Gallo1570 S. equinus
1
 
(94%; 48%) 
S. iniae 
(64%; 51%) 
Lactobacillus apodemi 
(65%; 51%) 
Gallo1675 S. pasteurianus
2
 
(100%; 99%) 
S. equinus
1
 
(97%; 68%) 
S. dysgalactiae 
(67%; 27%) 
Parascardovia denticolens 
(88%; 31%) 
Gallo2018 S. equinus
1
 
(100%; 93%) 
S. lutetiensis 
(72%; 33%) 
S. cristatus 
(43%; 64%) 
Lactobacillus acidophilus 
(49%; 46%) 
Gallo2178 S. equinus
1
 
(100%; 73%) 
 
S. anginosus 
(100%; 58%) 
Lachnospiraceae AC2014 
(100%; 49%) 
Gallo2179 S. lutetiensis 
(49%; 62%) 
S. equi 
(99%; 55%) 
S. agalactiae 
(94%; 38%) 
Parascardovia denticolens 
(97%; 45%) 
% query: percentage of query coverage that overlaps the subject sequence; % identity: percentage 
identity between the query and subject sequences over the coverage area;
 1
predominantly isolated from 
horses, rarely isolated from humans [66];
 2
strain HC-2909-2, sequence (RefSeq: WP_041973257) 
identified in whole genome shotgun sequencing (NCBI RefSeq: CDEY01000010), query 51% and 
identity 37% to homologue in reference strain S. pasteurianus ATCC43144 
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DNA sequences for selected amino acid sequences of S. gallolyticus and F. nucleatum 
proteins were synthesized by eurofins genomics (Ebersberg, Germany) after codon adaption 
for expression in E. coli. Synthesized genes were subcloned via 5’-end BamH1 and 3’-end 
SalI restriction sites into the pGEX4T3tag [126] vector (eurofins genomics (Ebersberg, 
Germany)). The resulting constructs encoded N-terminal GST, the protein of interest and C-
terminal tag sequence (eleven C-terminal amino acids from the large T antigen of simian virus 
40) (GST-X-tag fusion protein) (Figure 5). All resulting vector maps can be found in 
Appendix I. 
 
Figure 5: GST-X-tag fusion protein as present on the plasmid and resulting recombinant 
protein (modified from Lena-Mareen Kranz) 
 
2.2.2. Recombinant expression of selected F. nucleatum and S. gallolyticus 
proteins in E. coli BL21 
Recombinant expression of selected proteins was performed in E. coli BL21. 
Electrocompetent E. coli BL21 were grown in LB medium and stored at -80°C (provided by 
Ute Koch). Plasmids encoding the GST-X-tag fusion proteins were delivered by eurofins 
genomics (Ebersberg, Germany) in amounts of up to 8 µg of lyophilized plasmids. DNA was 
dissolved in 20 µl ddH2O. One µl of a further 1:20 dilution was combined with 50 µl of 
electrocompetent E. coli BL21 that were thawed on ice. Bacteria were transformed in 
precooled electroporation cuvettes with the electroporation devices Gene Pulser and Pulse 
Controller with the following settings: voltage of 2.3 kV, resistance of 200 Ω and capacity of 
960 µF (Controller) and 25 µF (Gene Pulser). Two hundred µl of LB medium were added and 
transformed bacteria were incubated for 1 hour at 37°C on a shaker. Twenty µl of the 
incubated bacteria were plated on LBamp agar plates and incubated overnight at 37°C. One 
colony was picked and combined with 5 ml LBamp medium and incubated for 6 hours at 37°C 
on a shaker. The 5 ml cultures were transferred to 250 ml LBamp medium and incubated 
overnight at 37°C on a shaker. After the incubation 50 ml of the 250 ml overnight culture 
were centrifuged (15 min at 5,000 rpm) and the pellet was used for plasmid purification and 
subsequent analytical digestion (2.2.5). Seven hundred µl of bacterial culture were added to 
Materials and Methods 
30 
 
700 µl 50% glycerol to obtain a glycerol stock of transformed bacteria that was stored at  
-80°C. The remaining bacterial culture was transferred to 1 l LBamp. Protein expression was 
induced with 0.5 mM IPTG at an optical density of 0.5 measured at 600 nm. After 6 hours of 
incubation at room temperature cultures were centrifuged at 6,000 rpm for 10 min at 4°C 
(rotor ThermoScientic F12-6x500 LEX) and pellets were stored in 10 ml PBS at -20°C until 
bacterial lysis (2.2.3).  
2.2.3. Bacterial lysis 
Frozen pellets (2.2.2) were thawed in a water bath at 37°C. Thawed pellets were kept on ice 
and 20 µl per 10 ml resuspended bacterial pellet of 1 M DTT (final concentration 2 mM) as 
well as 0.5 ml protease inhibitor per 1 l of original expression culture were added. Bacterial 
lysis was performed with a precooled high pressure homogenizer according to the 
manufacturer’s protocol. Pressure of 1,000-1,500 bar was applied once for 2 min to ensure 
disruption of bacterial cells. One hundred µl aliquots of the total lysate were taken for 
subsequent Western blot analyses (2.2.8). Lysates were cleared by centrifugation at 14,000 
rpm for 1 hour at 4°C (rotor Sorvall SA-600). A second aliquot (100 µl) was taken for 
subsequent Western blot analyses (2.2.8). Cleared lysates were combined with 100% glycerol 
1+1 to obtain the final lysate and stored at -20°C. 
2.2.4. Quantification of lysate protein concentration by Bradford assay 
Total lysate protein concentration was determined using the Bradford reagent. Eight hundred 
µl ddH2O, 200 µl Bradford reagent and 0.5 µl of cleared lysate were mixed and incubated for 
5 min. Absorption was measured at OD595. A sample containing water instead of lysate 
thereby served as reference. The protein concentration was calculated as follows based on a 
calibration curve prepared with BSA: 
cprotein (µg/µl) = OD595 * 44 µg/µl lysate 
2.2.5. Analytical DNA digestion 
Plasmid DNA was isolated from bacterial pellets harvested just before induction (2.2.2) using 
the QIAprep Spin Midiprep Kit according to the manufacturer’s instructions. The 
concentration of plasmid DNA was determined with the NanoDrop ND-100 and adjusted to a 
final concentration of 0.5 µg/µl. One µl plasmid DNA (500 ng), 1 µl or 2 µl of restriction 
buffer (1x or 2x), 0.3 µl of each enzyme and ddH2O up to a total volume of 10 µl were 
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incubated for 1.5 hours at 37°C. The digests were analyzed by agarose gel electrophoresis 
(2.2.6).  
Table 8: Enzymes used for asymmetric analytical digestions 
Antigen Enzyme 1 Enzyme 2 
F. nucleatum 
Fn0131 NdeI BsaA1 
Fn0253 MfeI PstI 
Fn0264 XhoI PstI 
Fn0387 NsiI PstI 
Fn1426 EcoRI PstI 
Fn1449 NdeI AlwNI 
Fn1526 MluI  
Fn1817_1 MluI  
Fn1817_2 PvuII  
Fn1859 BsmI PstI 
Fn1893 EcoRV  
S. gallolyticus 
Gallo0112A NsiI SalI 
Gallo0112B SphI SalI 
Gallo0272 BsmI SalI 
Gallo0577 BsmI SalI 
Gallo0748 EcoRI SalI 
Gallo0933 KpnI SalI 
Gallo1570 KpnI SalI 
Gallo1675 HindIII SalI 
Gallo2018 BsmI SalI 
Gallo2178 KpnI SalI 
Gallo2179 HindIII SalI 
 
2.2.6. Agarose gel electrophoresis 
Agarose gel electrophoresis was applied to verify the correct lengths of digested DNA. 1.5 g 
agarose was dissolved in 150 ml 1x electrophoresis buffer by heating it up in a microwave 
oven. Five µl peqGreen DNA dye were added. The polymerized gel was run in an 
electrophoresis chamber filled with 1x electrophoresis buffer. Ten µl of sample were mixed 
with 2 µl of 6x sample buffer and loaded onto the gel. 5 µl of DNA marker (smart ladder) 
served as reference to determine the size of fragments. Gel electrophoresis was performed for 
1 hour at a voltage of 100 V. Gel documentation was done with the Gel DocTM EZ Imager.  
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2.2.7. Polymerase chain reaction with subsequent sequencing 
Plasmid DNA was purified from 200 µl of cleared lysate (2.2.3) by QIAprep Spin Miniprep 
Kit according to the manufacturer’s instructions. PCR was performed using the QIAGEN 
multiplex PCR kit. Fifty ng of purified DNA were mixed with 12.5 µl QIAGEN Multiplex 
PCR master mix, 0.25 µl sense primer (pGEXs+T3, final concentration 0.1 µM), 0.25 µl 
antisense primer (pGEXas+T7, final concentration 0.1 µM), 2.5 µl Q-solution and 
DNase/RNase free H2O in a total volume of 25 µl. One µl DNase/RNase free H2O instead of 
template was used as negative control. The PCR-program was as follows: 
1. 95°C – 15 min: initial denaturation 
2. 94°C – 30 sec: denaturation 
3. 68 °C – 90 sec: annealing 
4. 72 °C – 1 min/ 1000 base pairs (bp): elongation 
45 cycles of step 2. – 4. 
5. 72 °C – 10 min: final elongation 
Ten µl of PCR product were mixed with 2 µl of 6x DNA sample buffer and analyzed by 
agarose gel electrophoresis (1% agarose gel, separation at 100 V for 1 hour) (2.2.6).  
The primers (sense: pGEXs+T7 and antisense: pGEXas+T3) used for PCR and their location 
are shown in Figure 6. Due to primer length and location the product size is 98 bp larger than 
the respective insert size.  
If the PCR product was identified at the expected size in the agarose gel the remaining 15 µl 
of PCR product were purified using the QiaQuick PCR purification kit according to 
manufacturer’s instructions. The purified product was sent for sequencing to eurofins 
genomics (Ebersberg, Germany) and sequencing was performed via the T3 and T7 primer 
sequences attached to the PCR product. If sequencing via T3 and T7 primers was 
unsuccessful purified plasmids were sent for sequencing with primers pGEXfor and pGEXrev 
with the disadvantage of lower quality of the sequencing results. Obtained sequences were 
compared to the expected DNA sequences using “Clustal Omega” to verify presence of the 
expected insert in the respective lysate. 
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A 
841  ccagcaagta tatagcatgg cctttgcagg gctggcaagc cacgtttggt ggtggcgacc atcctccaaa 
     ggtcgttcat atatcgtacc ggaaacgtcc cgaccgttcg gtgcaaacca ccaccgctgg taggaggttt 
     >...................................GST....................................> 
                                               
                           BamHI              SalI 
                         --+----             -+----- 
911  atcggatctg gttccgcgtg gatccccgaa ttcccgggtc gacaaacctc ccacacctcc ccctgaacct 
     tagcctagac caaggcgcac ctaggggctt aagggcccag ctgtttggag ggtgtggagg gggacttgga 
     >.........GST.........>> 
                                                    >>...........tag............> 
               
981  gaaacataag cggccgcatc gtgactgact gacgatctgc ctcgcgcgtt tcggtgatga cggtgaaaac 
     ctttgtattc gccggcgtag cactgactga ctgctagacg gagcgcgcaa agccactact gccacttttg 
     >...>> tag 
 
1051  ctctgacaca tgcagctccc ggagacggtc acagcttgtc tgtaagcgga tgccgggagc agacaagccc 
      gagactgtgt acgtcgaggg cctctgccag tgtcgaacag acattcgcct acggccctcg tctgttcggg 
 
B 
 
pGEXs+T7: 5’TAATACGACTCACTATAGGGtccaaaatcggatctggttccgcgtgga3‘ 
pGEXas+T3: 5’AATTAACCCTCACTAAAGGGgatgcggccgcttatgtttcaggttcaggg3‘ 
 
Figure 6: Location of primers for quality control PCR and sequencing. A) Sequence 
details of the primer binding region. Highlighted in green are pGEXs and pGEXas. 
Highlighted in yellow are primer pGEXfor and pGEXrev for sequencing of mini-Prep DNA 
without preceding PCR. B) pGEXs and pGEXas primer with attached T3 and T7 primer 
(capital letters) sequences. Adapted from Martina Willhauck-Fleckenstein. 
 
2.2.8. Western blot 
SDS-PAGE using the Mini-PROTEAN II system was performed for Western blot analyses. 
SDS-polyacrylamide gels were prepared as depicted in Table 9. Samples from total and 
cleared lysates (2.2.3) were adjusted to 1 µg/µl total protein concentration with ddH2O in a 
total volume of 100 µl including 25 µl 4x SDS sample buffer. Samples were heated at 95°C 
for 5 min before loading. GST-tag lysate served as positive control and was treated the same 
way. SDS-gels were placed into the gel chamber and covered with 1x SDS running buffer. 
Ten µl of samples and 5 µl of pre-stained protein ladder were loaded onto the gels and the gel 
was run at 200 V for 50 min. 
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Table 9: Protocol for two SDS-polyacrylamide gels. The resolving gel is poured first 
followed by the stacking gel. 
Reagent Resolving gel (13.5%) Stacking gel (5%) 
H2O 1.6 ml 3.675 ml 
30% (w/v) acrylamid) 3.75 ml 0.625 ml 
1 M Tris-HCl (pH 8.8)/1 M Tris-HCl (pH 6.8) 4.5 ml 0.665 ml 
10% (w/v) SDS 0.1 ml 0.05 ml 
TEMED 0.005 ml 0.005 ml 
10% (w/v) APS 0.05 ml 0.025 ml 
 
A nitrocellulose membrane, two Whatman papers and two pads per gel were soaked in EMBL 
transfer buffer. Proteins were blotted onto the membrane with the Mini Trans-Blot 
Electrophoretic Transfer Cell in a “sandwich” format: pad, Whatman paper, membrane, gel, 
Whatman paper and pad were layered into the transfer cartridge. The transfer chamber was 
supplied with an ice block and filled with EMBL transfer buffer. The transfer was performed 
at 100 V for 1 hour.  
After transfer, membranes were blocked with 10% Western blot blocking buffer for 1 hour on 
a shaker at room temperature. Membranes were washed three times for 10 min with PBS-T 
and subsequently incubated with primary antibodies diluted in 25 ml 5% Western blot 
blocking buffer. Primary antibodies were directed either against the N-terminal GST 
(polyclonal rabbit anti-GST antibody, 1:10,000) or against the C-terminal tag (monoclonal 
mouse anti-tag antibody, 1:5,000). Incubation with primary antibody was done at 4°C 
overnight on a shaker. Membranes were washed three times for 10 min with PBS-T. 
Secondary antibodies (goat anti-rabbit IgG HRP conjugate and goat anti-mouse IgG HRP 
conjugate) were diluted 1:10,000 in 5% Western blot blocking buffer and incubated with the 
membranes for 1 hour at room temperature on a shaker. Membranes were washed three times 
for 10 min with PBS-T and incubated with ECLTM Western Blotting Detection reagents. 
Enhanced luminescence signals were visualized with x-ray films. Exposure time varied 
between 30 sec and 2 min. 
2.2.9. Anti-tag ELISA 
96-well microtiter plates were coated with 100 µl ELISA coating buffer per well and 
incubated overnight. Lysates were diluted in polystyrene plates with a 1:3 dilution series in 
ELISA blocking buffer starting at a concentration of 2 µg/µl in 300 µl volume. Lysate 
dilution series were prepared in duplicates. GST-tag lysate served as a reference and was 
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diluted the same way. ELISA coating buffer was discarded and coated 96-well microtiter 
plates were incubated with 180 µl ELISA blocking buffer for 1 hour at 37°C. Hundred µl of 
lysate dilution were added to the blocked plates after discarding the ELISA blocking buffer 
and incubated for 1 hour at room temperature on a shaker. Antigen dilutions were discarded 
and plates were washed five times with PBS-T. Plates were dried by knocking them on paper 
towels and 100 µl of antibody directed against the C-terminal tag were added (mouse anti-tag 
antibody, 1:5,000 in ELISA blocking buffer). After incubation for 1 hour at room temperature 
on a shaker, plates were washed 5 times with PBS-T and dried as described above. Plates 
were incubated with 100 µl of goat anti-mouse IgG HRP conjugate per well (1:10,000 in 
ELISA blocking buffer) for 1 hour at room temperature. Plates were washed five times with 
PBS-T and dried. Hundred µl of ELISA substrate solution were added per well and incubated 
for 2-8 min until the reaction was stopped with 50 µl of ELISA stop solution. Absorption was 
measured at 450 nm with the Multiskan PLUS MKII.  
2.2.10. Multiplex serology 
Recombinantly expressed GST-X-tag fusion proteins were affinity-purified on fluorescent 
polystyrene beads with coupled glutathione-casein (provided by Monika Oppenländer, [114]). 
Bacterial lysates were diluted to 1 mg/ml total protein with multiplex serology blocking buffer 
in a volume of 1 ml. Beads were added, mixed thoroughly and incubated for 1 hour at room 
temperature in the dark on a shaker. Beads were washed three times by intermitting 
centrifugation at 13,000 rpm for 2 min, discarding the supernatant and adding 1 ml of 
multiplex serology blocking buffer. Loaded beads were stored in storage buffer until further 
use. 
Serum samples were diluted in polystyrene flat-bottom plates as indicated for the individual 
experiments in a total volume of 100 µl with serum pre-incubation buffer. The pre-incubation 
buffer contained 1 mg/ml casein and 2 mg/ml of GST-tag lysate to block unspecific binding 
of antibodies directed against residual bacterial proteins, and the N-terminal GST and C-
terminal tag. Further, PVX was added mimicking the bead surface to suppress unspecific 
binding of antibodies to the beads [127]. Sera were incubated for 1 hour at room temperature 
on a shaker. 
The multiplex serology assay was performed as described in [114]. Beads loaded with antigen 
were resuspended by four times intermitting sonification for 30 sec and vortexing. 96-well 
filter plates were incubated with ddH2O for 10 min and dried using a vacuum manifold at 10 
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inHg of negative pressure and subsequent knocking on the lid with a hammer to mobilize 
residual liquid at the membrane. Beads were mixed and 50 µl of the bead mix were incubated 
with 50 µl of pre-incubated sera in filter plates for 1 hour at room temperature on a shaker in 
the dark. Serum was removed from the plates and plates were washed three times with 100 µl 
per well of multiplex serology blocking buffer and then dried as described above. 100 µl of 
biotinylated secondary antibody (goat anti-human IgA, IgM and IgG or goat anti-mouse IgG 
(1:1,000 in multiplex serology blocking buffer) or goat anti-bovine IgA, IgM and IgG 
(1:2,000 in multiplex serology blocking buffer)) were added to each well and incubated for 1 
hour at room temperature on a shaker in the dark. One well containing beads but no serum 
was incubated with biotinylated mouse anti-tag (1:100 in multiplex serology blocking buffer) 
as a bead-loading control. Plates were washed and dried as described above and 100 µl of 
Strep-PE (1:750 in blocking buffer) was added to each well. Plates were incubated on a 
shaker for 30 min at room temperature in the dark. After washing 100 µl of storage buffer 
were added per well and plates were stored at 4°C overnight. 
Serum antibodies bound to affinity-purified antigens on beads were quantified using the 
Luminex 100 or 200 analyzer. The output was given as the median fluorescence intensity 
(MFI) of at least 100 beads per bead set measured. Net MFI values were generated by 
subtraction of bead-background (one well per plate without serum but beads and secondary 
reagents) and GST-background (one bead set loaded with GST-tag lysate). Net values below 
one were set to one. Sera with GST-background higher than 150 MFI were excluded from 
analyses. Plate controls, standard sera pipetted on each plate within one assay, served for 
control of technical inter-plate variation. Bead-loading was controlled with the biotinylated 
mouse anti-tag antibody directed against the C-terminal tag of recombinantly expressed 
proteins. A positive pipetting control was given by the highly seroprevalent antigen VP1 of 
Polyomavirus JC [128] loaded onto one bead-type. 
Cut-offs for antibody positivity were set arbitrarily as indicated.  
2.2.11. Study designs 
2.2.11.1. BliTz and DACHSplus 
Study samples and study data were kindly provided by Hermann Brenner. A detailed 
description of the design of this case-control study was described elsewhere [129]. Briefly, 
serum samples included were part of the BliTz study (“Begleitende Evaluierung innovativer 
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Testverfahren zur Darmkrebsfrüherkennung”) or DACHSplus study, a substudy of the 
DACHS study (“Darmkrebs: Chancen der Verhütung durch Screening”) [130-132]. BliTz 
participants were recruited at screening colonoscopy in gastroenterology practices in southern 
Germany between 2005 and 2013. A random sample of 228 subjects with no colorectal 
neoplasm identified during colonoscopy served as controls. DACHSplus CRC cases were 
recruited after diagnosis but before treatment at four hospitals in Southern Germany. The 
subset analyzed here included 318 prevalent CRC cases (International Classification of 
Diseases (ICD-) codes C18.0-C18.7, C18.9, C19 and C20 as by the 10th Revision of the 
International Statistical Classification of Diseases, Injury and Causes of Death). Since the 
initial design aimed to resemble a true screening setting, DACHSplus CRC cases were not 
matched to BliTz controls [129]. Thus, DACHSplus CRC cases differed significantly from 
BliTz controls with cases being more frequently males, older and ever smokers (Table 10). A 
slight majority of DACHSplus CRC cases presented with UICC stages I and II (55%) 
compared to 45% with UICC stage III and IV.  
I further analyzed a set of gastric cancer (GC) cases that was compared to BliTz controls to 
assess whether potentially observed associations were specific for CRC. These gastric cancer 
cases were also part of the DACHSplus study [133] and compared to BliTz controls 
significantly more often males, older and ever smokers (Table 10). 
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Table 10: Baseline Characteristics of BliTz controls and DACHSplus CRC and GC cases 
  
BliTz 
Controls 
(n=228) 
DACHSplus 
CRC 
(n=318) 
DACHSplus 
GC 
(n=129)     
  n (%) n (%) p-value* n (%) p-value* 
Sex female 124 (54) 133 (42)  44 (34)  
male 104 (46) 185 (58) 0.004 85 (66) 0.0002 
Age (years) 31-59 96 (42) 74 (23)  41 (32)  
60-65 66 (29) 56 (18)  19 (15)  
66-94 66 (29) 187 (59) <0.0001 69 (53) <0.0001 
 missing 0 1  0  
 mean (range) 62 (40-85) 68 (31-94)  64 (30-89)  
School education < 10 years 125 (56) 197 (64)  57 (50)  
≥ 10 years 98 (44) 111 (36) 0.066 57 (50) 0.291 
missing 5 10  15  
Smoking status never 132 (58) 152 (49)  72 (62)  
 ever 95 (42) 158 (51) 0.037 45 (38) 0.0005 
 missing 1 8  12  
BMI < 25 89 (40) 118 (38)  50 (43)  
25-29.9 95 (42) 134 (44)  52 (45)  
≥ 30 40 (18) 56 (18) 0.946 13 (11) 0.265 
missing 4 10  14  
Family history of 
CRC 
no 200 (88) 274 (89)  105 (90)  
yes 28 (12) 35 (11) 0.734 12 (10) 0.578 
 missing 0 9  12  
*Pearson’s Chi-Square-test as compared to controls; significant associations are marked in bold font 
Apart from colonoscopy-negative individuals (controls) there were also colorectal neoplasms 
identified in the BliTz study that were sub-grouped in non-advanced adenoma, advanced 
adenoma (high-grade dysplasia, villous architecture without high-grade dysplasia or large 
adenoma (> 10 mm)) and CRC. A separate approach of analyses included samples of these 
three groups (non-advanced adenoma n=30, advanced adenoma n=100, and CRC n=50) that 
were compared to the BliTz controls described above (n=228). BliTz CRC cases were 
significantly more males, older and ever smokers. BliTz advanced adenoma cases had a lower 
educational level than BliTz controls. BliTz non-advanced adenoma cases did not differ 
significantly from BliTz controls (Table 11). 
All studies had been approved by the ethics committees of the University of Heidelberg and 
of the respective state medical boards. Informed consent had been obtained from each 
participant.  
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Table 11: Baseline Characteristics of BliTz controls, precursors and CRC cases 
  
Controls 
(n=228) 
Non-advanced 
adenoma
1
 
(n=30) 
Advanced adenoma
2
 
(n=100) 
CRC 
(n=50) 
    
  n (%) n (%) p-value
3
 n (%) p-value
3
 n (%) p-value
3
 
Sex female 124 (54) 13 (43)  50 (50)  16 (32)  
male 104 (46) 17 (57) 0.254 50 (50) 0.464 34 (68) 0.004 
Age (years) 31-59 96 (42) 11 (37)  30 (30)  9 (18)  
60-65 66 (29) 7 (23)  31 (31)  15 (30)  
66-94 66 (29) 12 (40) 0.459 39 (39) 0.084 26 (52) 0.002 
 mean (range) 62 (40-85) 64 (55-78)  63 (50-86)  67 (55-81)  
School education < 10 years 125 (56) 16 (53)  67 (68)  30 (63)  
≥ 10 years 98 (44) 14 (47) 0.778 32 (32) 0.050 18 (37) 0.413 
missing 5 0  1  2  
Smoking status never 132 (58) 16 (53)  48 (48)  20 (40)  
 ever 95 (42) 14 (47) 0.616 52 (52) 0.089 30 (60) 0.020 
 missing 1 0  0  0  
BMI < 25 89 (40) 8 (27)  37 (38)  12 (24)  
25-29.9 95 (42) 15 (50)  40 (41)  25 (52)  
≥ 30 40 (18) 7 (23) 0.375 20 (21) 0.843 12 (24) 0.127 
missing 4 0  3  1  
Family history of 
colorectal cancer 
no 200 (88) 26 (87)  82 (82)  41 (82)  
yes 28 (12) 4 (13) 0.869 18 (18) 0.170 9 (18) 0.281 
 missing 0 0  0  0  
1
tubular adenoma, adenoma <10mm; 
2
High grade dysplasia, villous adenoma with high-grade dysplasia, large adenoma 
(>10mm) with neither high-grade dysplasia nor villous architecture; 
3Pearson’s Chi-square test in comparison to controls; 
significant associations are marked in bold font 
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2.2.11.2. Southern community cohort study (SCCS) 
Study samples and study data were kindly provided by Meira Epplein. The nested case-
control design presented here has been published elsewhere [134]. Briefly, study samples 
included were part of the SCCS, which is a large prospective cohort that enrolled 
approximately 86,000 men and women, aged 40-79, between 2002 and 2009 from 12 
southeastern US states [135]. Participants were recruited from community health care centers 
(CHC) (86%) or via mail (14%) and represent a low-income and mainly uninsured population 
of Caucasian-Americans and a substantial number of African-Americans [135]. Participants 
completed a questionnaire (in-person, comprehensive computer-assisted for CHC recruited 
individuals or paper version for individuals recruited via mail) that addressed information 
about demographic and lifestyle factors including regular diet, personal and family medical 
history and health services utilization. Participants recruited at CHC provided a venous blood 
sample [134].  
Briefly, among participants that donated a blood sample 188 incident CRC cases 
(International Classification of Diseases for Oncology, Third Edition (ICD-O-3) codes C18.0-
C18.9, C19.9, C20.9) were identified via state cancer registries and/or the National Death 
Index mortality records until the end of 2011. For the nested case-control design each case 
was matched with two controls on age (± 2 years), ethnicity (African-American, Caucasian-
American, or other), sex, menopausal status (women), CHC site and date of sample collection 
(± 6 months) [134]. Due to missing baseline data, lack of serum sample, duplicates, laboratory 
reasons and the missing matched counterparts 7 cases and 28 controls had to be excluded 
resulting in a final number of 181 cases and 348 controls. 
At baseline incident CRC cases differed significantly from SCCS controls in smoking status 
with more cases being never smokers (Table 12). None of the other characteristics analyzed 
here was significantly different. The incident CRC cases were predominantly females (54%) 
and of African-American ethnicity (82%). The average age at diagnosis was 59 years with a 
range of 40 to 81 years. The average time between blood draw and diagnosis was 3.2 years 
ranging from 0.4 to 8.1 years. Tumor stages according to SEER staging [136] were 
predominantly localized (39%) followed by metastatic (36%) and distant (25%). The majority 
of incident CRC cases were located in the colon (75%) (Table 13).  
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The SCCS had been reviewed and approved by the institutional review boards at Vanderbilt 
University and Meharry Medical College. Written informed consent had been obtained from 
all participants.  
Table 12: Baseline characteristics of the CRC case-control study nested within SCCS 
  
Controls 
(n=348) 
Cases 
(n=181) 
 
    n (%) n (%) p-value* 
Sex female 191 (55) 98 (54)  
male 157 (45) 83 (46) 0.871 
Age at blood draw (years) 40-55 164 (47) 86 (48)  
56-60 76 (22) 37 (20)  
61-77 108 (31) 58 (32) 0.927 
 mean (range) 56 (40-77) 57 (40-77)  
Ethnicity Caucasian-American 60 (18) 32 (18)  
African-American 276 (82) 142 (82) 0.882 
 missing 12 7  
Education < high school 135 (40) 78 (44)  
≥ high school 206 (60) 100 (56) 0.352 
missing 7 3  
Smoking never 95 (28) 68 (38)  
 former 108 (32) 58 (33)  
 current 138 (40) 52 (29) 0.018 
 missing 7 3  
BMI < 25 84 (25) 35 (20)  
25-29.9 96 (28) 62 (36)  
≥ 30 160 (47) 76 (44) 0.184 
 missing 8 8  
Family history of CRC no 127 (86) 55 (77)  
 yes 20 (14) 16 (23) 0.096 
 missing 201 110  
*Pearson’s Chi-Square-test; significant associations are marked in bold font 
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Table 13: Characteristics of cases in the CRC case-control study nested within SCCS at 
time of diagnosis 
  
Cases (n=181) 
    n (%) 
Age at diagnosis (years) 38-59 93 (51) 
 60-65 40 (22) 
 66-81 48 (27) 
 mean (range) 59 (40-81) 
Time between blood draw 
and diagnosis (years) 
< 2 57 (31) 
2-4 61 (34) 
 > 4 63 (35) 
 mean (range) 3.2 (0.5-8.3) 
SEER Stage localized 64 (39) 
regional 59 (36) 
distant 41 (25) 
missing 17 
Site colon 129 (75) 
rectum 44 (25) 
 missing 8 
 
2.2.11.3. European prospective investigation into nutrition and cancer (EPIC) 
The case-control study presented here is nested within EPIC [137], a large multi-national 
prospective cohort with 23 centers in 10 Western European countries (Denmark, France, 
Greece, Germany, Italy, Netherlands, Norway, Spain, Sweden, United Kingdom). Access to 
biological samples and data from the EPIC cohort was authorized by the EPIC steering 
Committee. A detailed description of the EPIC study design is published elsewhere [138]. 
Briefly, 521,468 participants, aged 35 to 70 years, were enrolled between 1992 and 2000. 
Dietary and lifestyle data as well as biological samples, including blood, were collected at 
enrollment.  
The nested CRC case-control study analyzed here included pre-diagnostic serum samples of 
485 incident CRC cases (primary tumors, ICD codes C18.0-C18.9, C19 and C20 as by the 
10th Revision of the International Statistical Classification of Diseases, Injury and Causes of 
Death). These cases were a random subset of the larger total CRC cases accrued within the 
cohort, identified until 2004 and with existing sufficient volume of serum for the laboratory 
analyses [139]. The average age at diagnosis was 63 years (range 38 to 81 years) and the 
average time between blood draw and diagnosis was 3.4 years (range 0.4 to 8.5 years). The 
majority of cases (89%) were diagnosed with cancer in the colon and 49% of cases were of 
localized stage according to the EPIC staging classification [140] (Table 15).  
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485 controls were matched by age at blood collection (± 6 month to ± 2 years), sex, study 
center, time of the day at blood collection (± 2 to 4 hours interval), fasting status at blood 
collection (< 3/3-6/6 hours); among women by menopausal status, and among premenopausal 
women, by phase of menstrual cycle and hormone replacement therapy use at time of blood 
collection. Controls were free of cancer by time of matching (except for non-melanoma skin 
cancer). There was no significant difference between controls and cases in the baseline 
characteristics assessed here (Table 14). 
Table 14: Baseline characteristics of the CRC case-control study nested within EPIC 
  
Controls 
(n=485) 
Cases 
(n=485) 
 
    n (%) n (%) p-value* 
Sex female 247 (51) 247 (51)  
male 238 (49) 238 (49) 1.000 
Age at blood 
draw (years) 
37-55 120 (25) 121 (25)  
56-60 124 (25) 122 (25)  
 61-77 241 (50) 242 (50) 0.989 
 mean (range) 60 (37-77) 59 (37-77)  
Country Italy/Greece 112 (23) 112 (23)  
France/Spain 93 (19) 93 (19)  
 UK 134 (28) 134 (28)  
 Germany/Netherlands 146 (30) 146 (30) 1.000 
Education none/primary school completed 212 (45) 215 (46)  
technical/professional 115 (25) 95 (21)  
secondary school/longer education  142 (30) 153 (33) 0.317 
 missing 16 22  
Smoking status never 234 (48) 202 (42)  
 former 154 (32) 183 (38)  
 current 95 (20) 96 (20) 0.089 
 missing 2 4  
Alcohol intake never 48 (10) 28 (6)  
 former 40 (9) 39 (9)  
 current 0-6 g/day 133 (29) 141 (31)  
 6.01-20 g/day 130 (28) 126 (28)  
 > 20 g/day 109 (24) 120 (26) 0.195 
 missing 25 31  
BMI < 25 167 (34) 160 (33)  
25-29.9 238 (49) 220 (45)  
≥ 30 80 (16) 105 (22) 0.120 
Family history 
of CRC 
no 176 (93) 173 (90)  
yes 13 (7) 19 (10) 0.288 
missing 296 293  
*Pearson’s Chi-Square-test  
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Table 15: Characteristics of cases in the CRC case-control study nested within EPIC at 
time of diagnosis 
  
Cases (n=485) 
    n (%) 
Age at diagnosis (years) 38-59 158 (33) 
 60-65 123 (25) 
 66-81 204 (42) 
 mean (range) 63 (38-81) 
Time between blood draw 
and diagnosis (years) 
< 2 130 (27) 
2-< 3.5 127 (26) 
 3.5-< 5 119 (25) 
 ≥ 5 109 (22) 
 mean (range) 3.4 (0.01-8.5) 
EPIC Stage localized 154 (49) 
metastasic 162 (51) 
missing 169 
Site colon 432 (89) 
rectum 53 (11) 
 
2.2.11.4. Irish CRC case-control study 
Study samples and study data were kindly provided by David Hughes. Participants of the Irish 
CRC case-control study were recruited at the Departments of Gastroenterology and Surgery at 
the Adelaide and Meath Hospital (AMNCH) in Dublin, Ireland between 2008 and 2011. The 
majority (n=235, 80%) of the in total 292 participants in this sub-study were part of the 
AMNCH immunochemical FOBT CRC screening pilot program [141]. In this screening 
program approximately 10,000 individuals aged between 50 and 75 years in the AMNCH 
catchment area were invited to have an immunochemical fecal occult blood test (FIT) 
performed. FIT-positive individuals were further invited for colonoscopy. The remaining 57 
participants were recruited at the gastroenterology and surgery department of AMNCH and 
presented with positive FIT, rectal bleeding, control colonoscopy or other reasons. Of the in 
total 292 participants 37 were found in colonoscopy to be normal (controls) and 63 were 
found with minor diagnoses including 39 participants with hemorrhoids, 27 with 
diverticulosis, 2 with mucosal inflammation/ulceration, 2 with erythema, and each 1 
participant with melanosis coli, menorrhagia/disordered proliferative endometrium, mild 
active colitis and diarrhea. 192 participants were diagnosed with colorectal neoplasm 
including polyps (n=85, hyperplastic polyps and small adenoma less than 10 mm in diameter), 
adenoma (n=60, more than 10 mm in diameter, including tubular, villous or tubulovillous 
adenoma), adenoma with high-grade dysplasia (n=22) and CRC (n=25). Lifestyle information 
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was limited for these patients, however, information on age and sex revealed that individuals 
with minor diagnoses and colorectal neoplasm were more frequently of male sex and that 
especially CRC cases were of older age compared to controls.  
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Table 16: Baseline characteristics of the Irish CRC case-control study 
  
Controls  
(n=37) 
Minor 
diagnoses
1
  
(n=63) 
p-
value
4
 
Polyp
2
 
(n=85) 
p-
value
4
 
Adenoma
3
 
(n=60) 
p-
value
4
 
High 
grade 
dysplasia 
(n=22) 
p-
value
4
 
CRC 
(n=25) 
p-
value
4
 
Sex female 23 (62) 30 (48)  34 (40)  28 (47)  8 (36)  13 (52)  
 male 14 (38) 33 (52) 0.160 51 (60) 0.024 32 (53) 0.138 14 (64) 0.055 12 (48) 0.426 
Age at 
blood draw 
(years) 
36-59 18 (49) 29 (46)  32 (38)  17 (28)  8 (36)  10 (40)  
60-65 11 (30) 16 (30)  26 (31)  20 (33)  7 (32)  2 (8)  
66-109 8 (22) 8 (22) 0.730 27 (32) 0.429 23 (38) 0.095 7 (32) 0.590 13 (52) 0.022 
 mean (range) 59 (42-71) 61 (51-71)  62 (44-75)  64 (50-109)  62 (44-84)  66 (36-89)  
1
includes hemorrhoids, diverticulosis, mucosal ulceration/inflammation, melanosis coli, menorrhagia/disordered proliferative endometrium, mild active colitis, 
diarrhea, erythema; 
2
hyperplastic polyp or small tubular adenoma (< 10mm); 
3
tubular adenoma, tubulovillous adenoma, villous adenoma; 
4Pearson’s Chi-
square test in comparison to controls;
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2.2.12. Statistical analyses 
Differences between cases and controls in baseline characteristics as well as risk factors for  
F. nucleatum and S. gallolyticus positivity were analyzed by Pearson’s Chi-Square test. 
Correlations between positivity to individual proteins in F. nucleatum or S. gallolyticus 
multiplex serology were also analyzed by Pearson’s Chi-Square test. 
Association of antibody responses to F. nucleatum and S. gallolyticus with prevalent CRC in 
the BliTz-DACHSplus study were assessed by logistic regression models to compute OR and 
95% CI. The respective associations with CRC risk in the SCCS and EPIC studies were 
assessed by conditional logistic regression models, since cases were matched to controls. The 
following variables were considered to potentially confound the associations: age and sex 
(only in case of BliTz-DACHSplus), BMI, education, smoking and alcohol status (data only 
available in EPIC). In BliTz-DACHSplus sex was identified as significantly related to the 
outcome CRC as well as to F. nucleatum and S. gallolyticus positivity and was therefore 
considered as important confounder in the model. None of the other potential confounders 
was identified in any other study as being simultaneously related to the outcome (CRC) and 
the exposure (F. nucleatum / S. gallolyticus positivity) and would therefore not be considered 
to substantially influence the estimate. Indeed comparison of unadjusted models to models 
adjusting for age and sex (BliTz-DACHSplus only), BMI, education, smoking and alcohol 
status (EPIC only) did not alter the estimate by more than 15%, which is only slightly higher 
than the often in epidemiology applied 10% change mark as criterion for adjustment 
(Appendices V and VI). Although adjustment for potential confounders BMI, education, 
smoking and alcohol status did not alter the estimate substantially, it was decided in personal 
communication with David Hughes and Mazda Jenab to include these variables in the final 
model for the EPIC study in order to be consistent with statistical analyses models applied to 
EPIC data and with known information about CRC confounders. To make the individual 
studies more comparable, models in BliTz-DACHSplus and SCCS were also applied under 
adjustment for BMI, education and smoking status (data on alcohol not available). Missings in 
the individual variables thereby decreased the final number of samples included in the 
estimate calculation and were therefore included as individual categories to save statistical 
power. Sensitivity analyses comparing both, exclusion of missings and inclusion as individual 
category, did not exhibit substantial differences in the estimates (Appendices V and VI).  
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A sensitivity analyses was carried out in the EPIC and SCCS studies to exclude reverse 
causation in the potential prospective associations. Associations were estimated under 
exclusion of cases diagnosed within 2 years after blood draw and their respective matched 
controls.  
Sex, age and country of residence are considered major risk factors for CRC [142]. To assess 
whether these variables affect the association of antibody responses to F. nucleatum and  
S. gallolyticus proteins with CRC I further estimated the association stratified by the baseline 
characteristics age at blood draw, sex, country of residence (EPIC) or ethnicity (SCCS). To 
potentially identify subgroups at increased risk for developing CRC with antibody responses 
to S. gallolyticus and F. nucleatum I estimated the association for certain case subgroups, i.e. 
tumor stage, tumor site and age at diagnosis in separate (conditional) logistic regression 
models under adjustment for above mentioned confounders. 
The sample numbers for precancerous lesions and CRC in the BliTz and Irish case-control 
study were rather small (n <100) and important baseline data in the Irish case-control study 
was missing. Therefore analyses of associations of antibody responses to S. gallolyticus 
proteins and precancerous lesions in these two studies should be regarded as exploratory and 
were carried out in a crude model comparing the frequencies of antibody positivity between 
the groups by Pearson’s Chi-Square test.  
Significance of the associations was further assessed with Bonferroni corrections to address 
multiple testing. The p-value indicating significance thereby decreased to 0.004 with 12 
possibilities for F. nucleatum positivity (eleven individual proteins and positivity to any F. 
nucleatum protein) and to 0.0036 with 14 possibilities for S. gallolyticus positivity (eleven 
individual proteins, positivity to any S. gallolyticus protein, double-positivity to Gallo2178 
and Gallo2179 and positivity to two or more proteins of the 6-marker panel). 
All statistical analyses were carried out using the SAS 9.4 software, all graphical 
representations using GraphPad Prism 6. 
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3. Results 
3.1. Expression and quality control of F. nucleatum and S. gallolyticus proteins 
3.1.1. Cloning and expression 
DNA sequences coding for selected F. nucleatum and S. gallolyticus proteins (2.2.1) were 
codon optimized for expression in E. coli and resulting genes were synthesized by eurofins 
genomics (Ebersberg). Synthesized genes were subcloned into the pGEX4T3tag vector 
resulting in a construct encoding the protein of interest flanked by an N-Terminal GST and a 
C-terminal tag (GST-X-tag fusion proteins).  
Electrocompetent E. coli BL21 were transformed with plasmids encoding the recombinant  
F. nucleatum and S. gallolyticus GST-X-tag fusion proteins. Expression of proteins was 
induced with IPTG and bacterial cells were mechanically lysed after 6 hours of induction. 
Protein concentrations of cleared lysates were determined and ranged from 8.8 to 33.5 mg/ml 
(Table 17).   
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Table 17: Total protein concentration of F. nucleatum and S. gallolyticus fusion protein 
containing bacterial lysates 
Antigen Concentration (mg/ml) 
F. nucleatum  
Fn0131 21.0 
Fn0253 11.8 
Fn0264 13.2 
Fn0387 12.3 
Fn1426 11.4 
Fn1449 11.4 
Fn1526 15.8 
Fn1817_1 23.8 
Fn1817_2 25.1 
Fn1859 10.1 
Fn1893 17.2 
S. gallolyticus   
Gallo0112A 9.3 
Gallo0112B 17.1 
Gallo0272 33.5 
Gallo0577 18.3 
Gallo0748 24.6 
Gallo0933 28.1 
Gallo1570 26.9 
Gallo1675 11.5 
Gallo2018 8.8 
Gallo2178 11.1 
Gallo2179 19.4 
 
3.1.2. Verification of the expression constructs by analytical digestion and PCR 
with subsequent sequencing 
The expression constructs were verified at an intermediate step (by analytical plasmid DNA 
digestion) and in the final lysate (by PCR and subsequent sequencing of inserted DNA). 
Before induction, plasmids were isolated from a sample of the transformed bacterial culture 
and analyzed for the correct insert by analytical restriction digestion. The plasmids were 
linearized, digested symmetrically at the restriction sites used for cloning (BamHI and SalI) as 
well as digested asymmetrically using a restriction site inside the insert (Figure 7). Small 
fragments (< 230 nt) expected in the symmetric digest of Fn1817_1 and Fn1817_2 as well as 
the asymmetric digest of Fn1817_2 could not be detected with the applied gel electrophoresis. 
All other digests showed fragments with the expected sizes. Extra bands visible in digestions 
of Gallo0112A, Gallo1570, Gallo1675 and Gallo2179 most probably resulted from an excess 
amount of DNA loaded on the gel. 
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Figure 7: Analytical restriction digests of plasmids isolated from transformed E. coli 
BL21. A) Analytical digests of F. nucleatum constructs. B) Analytical digests of S. 
gallolyticus constructs. Plasmids were purified from bacterial cultures before induction and 
linearized (1), digested symmetrically (2) and digested asymmetrically (3). Fragments were 
separated by agarose gel electrophoresis. Expected fragment sizes (in base pairs, bp) are given 
below the respective lanes. M = marker. 
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Plasmids were isolated from the final lysate and analyzed for the presence of the correct insert 
via PCR and sequencing of the PCR products. Applied primers were located 5’ and 3’ outside 
the insert and attached sequences for T7 and T3 were used for subsequent sequencing of the 
PCR product. Gel electrophoresis showed all amplicon fragments with the expected sizes 
(Figure 8). Sequencing of the PCR products, either reversely by T3 primer alone or 
additionally with forward T7 primer, was successful for all amplicons except Fn0131, 
Gallo0112A, Gallo0577, Gallo0748, Gallo1570, Gallo1675 and Gallo2179 (Table 18). 
Amplicons of Gallo0577, Gallo0748, Gallo1570 and Gallo1675 were too long to be 
sequenced completely, however, partially sequenced fragments clearly showed the presence 
of the expected insert sequence. 
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Figure 8: Amplification of insert sequence in plasmids isolated from final lysate. A) PCR 
of F. nucleatum constructs. B) PCR of S. gallolyticus constructs. 50 ng of purified plasmid 
DNA were applied to PCR with primer pGEXs+T3 and pGEXas+T7 and products were 
separated by agarose gel electrophoresis. Expected amplicon sizes in base pairs (bp) are given 
below the respective lanes. M = marker. 
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Table 18: Summary of sequencing results for amplified inserts or expression plasmids in 
final lysates 
Antigen Sequencing primer Result 
F. nucleatum   
Fn0131 Forward: pGEXfor
2
; 
reverse: T3
1
 
Incomplete sequencing of the insert;  
nt 1-610 and 742-1641 100% match to ref  
Fn0253 Reverse: T3
1
 Complete sequencing of insert; 100% match to ref 
Fn0264 Reverse: T3
1
 Complete sequencing of insert; 100% match to ref 
Fn0387 Reverse: T3
1
 Complete sequencing of insert; 100% match to ref 
Fn1426 Forward: T7; reverse: T3
1
 Complete sequencing of insert; 100% match to ref 
Fn1449 Reverse: T3
1
 Complete sequencing of insert; 100% match to ref 
Fn1526 Reverse: T3
1
 Complete sequencing of insert; 100% match to ref 
Fn1817_1 Reverse: T3
1
 Complete sequencing of insert; 100% match to ref 
Fn1817_2 Reverse: T3
1
 Complete sequencing of insert; 100% match to ref 
Fn1859 Forward: T7; reverse: T3
1
 Complete sequencing of insert; 100% match to ref 
Fn1893 Forward: T7; reverse: T3
1
 Complete sequencing of insert; 100% match to ref 
S. gallolyticus   
Gallo0112A Forward: pGEXfor
2
; 
reverse: T3
1
 
Incomplete sequencing of the insert;  
nt 1-545 and 1373-2319 100% match to ref  
Gallo0112B Forward: T7; reverse: T3
1
 Complete sequencing of insert; 100% match to ref 
Gallo0272 Forward: T7; reverse: T3
1
 Complete sequencing of insert; 100% match to ref 
Gallo0577 Forward: T7; reverse: T3
1
 Incomplete sequencing of the insert;  
nt 1-941 and 1060-2067 100% match to ref 
Gallo0748 Forward: T7; reverse: T3
1
 Incomplete sequencing of the insert;  
nt 1-982 and 1377-2295 100% match to ref 
Gallo0933 Forward: T7; reverse: T3
1
 Complete sequencing of insert; 100% match to ref 
Gallo1570 Forward: pGEXfor
2
; 
reverse: T3
1
 
Incomplete sequencing of the insert;  
nt 1-432 and 763-1746 100% match to ref  
Gallo1675 Forward: T7; reverse: T3
1
 Incomplete sequencing of the insert;  
nt 1-1011 and 1079-2055 100% match to ref 
Gallo2018 Forward: T7; reverse: T3
1
 Complete sequencing of insert; 100% match to ref 
Gallo2178 Forward: T7; reverse: T3
1
 Complete sequencing of insert; 100% match to ref 
Gallo2179 Forward: pGEXfor
2
; 
reverse: pGEXrev
2
;  
Incomplete sequencing of the insert;  
nt 1-398 and 1440-1782 100% match to ref  
1
Preceding PCR performed with pGEXs+T7 and pGEXas+T3 primer; 
2
Sequencing of plasmid DNA 
without preceding PCR; nt = nucleotide; ref = reference. 
 
Forward sequencing of Fn0131 and Gallo0112A as well as forward and reverse sequencing of 
Gallo2179 was not possible with the T3 and T7 primers. Therefore extracted plasmids were 
directly sent for sequencing without preceding PCR and sequenced using primers located 
further upstream and downstream of the insert. Although the lower quality of DNA compared 
to the purified PCR products led to shorter sequence read, the expected insert sequence could 
be identified. Thus, the presence of the expected insert could be verified for all expression 
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constructs before induction as well as in the final lysates. Complete alignments are presented 
in Appendix II. 
3.1.3. Verification of full-length expression by Western blot and anti-tag ELISA 
Expression of the selected proteins was characterized by Western blot and semi-quantitative 
anti-tag ELISA.  
In Western blot analyses antibodies were applied that can detect either the N-terminal GST or 
the C-terminal tag-peptide of the GST-X-tag fusion protein sequence. This allowed detecting 
full-length proteins as well as N-terminal and/or C-terminal fusion protein fragments. Total 
and cleared lysates were compared to address the solubility of the proteins. Lysate containing 
GST-tag served as positive control for antibody reactivity as well as indicator of unspecific 
binding.  
In general, with both, anti-GST and anti-tag blot, in addition to full-length protein of the 
expected size minor bands were also detectable (Figure 9) that mostly migrated faster than the 
full-length protein indicating protein degradation or premature abortion of translation. The 
anti-GST antibody is polyclonal and therefore more sensitive than the monoclonal anti-tag 
antibody. The detection of several epitopes in the N-terminal GST-tag might explain the 
higher frequency of unexpected bands in the anti-GST blot. Furthermore, there were faint 
bands appearing in the GST-tag lane with the anti-GST antibody at approximately 20 kD and 
50 kD indicating unspecific binding of the antibody to endogenous E. coli proteins. The 
monoclonal anti-tag antibody specific for the C-terminal tag sequence detects only proteins 
and their N-terminally degraded fragments with full- length expression.  
For all S. gallolyticus proteins as well as F. nucleatum proteins Fn0253, Fn0264, Fn0387, 
Fn1449, Fn1817_1, Fn1817_2 and Fn1893 proteins of expected sizes were detected with anti-
tag antibody in the cleared lysate indicating the presence of full-length proteins of these 
constructs in the final lysates. Total lysates of Fn0131, Fn1426 and Fn1526 showed signals in 
the anti-GST and the anti-tag blots, however, signals were weaker or even absent in the 
cleared lysates, indicating strong insolubility of these proteins. For Fn1859 there is a faint 
band in the anti-tag blot of the cleared lysate detectable, however, at a smaller size than 
expected (approximately 56kD instead of 64kD). To exclude that this was due to a gel artifact 
the Western blots were repeated three times and gave the same result. Since PCR control of 
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the final lysate verified the presence of the correct plasmid in the lysate this might indicate N-
terminal degradation of Fn1859. 
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Figure 9: Quality control of protein expression by anti-GST and anti-tag Western blot of 
(A) F. nucleatum and (B) S. gallolyticus lysates. E. coli BL21 expressing recombinant F. 
nucleatum and S. gallolyticus proteins were lysed and 10 µg of total (T) and cleared (C) lysate 
proteins were analyzed in Western blot. Upper panel anti- (α-) GST antibody, lower panel 
anti-tag antibody. M = marker. 
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Anti-tag ELISA allowed relative quantitation of full-length fusion protein compared to the 
reference GST-tag lysate. Fusion proteins in bacterial lysates were bound to the glutathione-
casein coated ELISA plate via the N-terminal GST and full length protein was detected with 
the anti-tag antibody directed against the C-terminal tag. Bacterial lysates were titrated in a 
1:3 dilution series and OD was plotted against the total lysate protein concentration (Figure 
10).  
Total protein concentrations in GST-X-tag lysates necessary to reach half maximal absorption 
of GST-tag (OD50(GST-tag)) were set in relation to the total protein concentration of the GST-
tag lysate at OD50(GST-tag) (Table 19). S. gallolyticus proteins Gallo0112A, Gallo0112B, 
Gallo0933, Gallo2018 and Gallo2178 as well as F. nucleatum proteins Fn0253, Fn0264, 
Fn0387, Fn1449, Fn1817_1, Fn1817_2 and Fn1893 reached OD50(GST-tag) with concentrations 
less than 30-fold compared to the GST-tag lysate itself. For all other lysates the concentration 
necessary to reach OD50(GST-tag) ranged from 33- to 143-fold indicating lower relative full-
length protein concentration in the lysates. Saturation levels of Gallo0577 were found to be 
even below OD50(GST-tag). However, all lysates reached saturation at or below 1 mg/ml total 
lysate protein concentration. 
Anti-tag ELISA results were concordant to Western blot results for F. nucleatum proteins and 
indicated in summary lower quantities of full-length expressed protein in the lysates of 
Fn0131, Fn1426, Fn1526 and Fn1859.  
Most of the S. gallolyticus proteins showed lower relative full-length protein concentration in 
anti-tag ELISA, while all proteins had bands at the expected sizes in the anti-tag blot of 
cleared lysate. A major difference in the two assays is the linearization of the proteins in the 
Western blot while proteins in anti-tag ELISA should keep their conformation. The anti-tag 
epitope might be hidden in the folded protein and therefore not accessible for anti-tag 
antibody in the ELISA leading to lower quantities relative to GST-tag lysate alone.  
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Figure 10: Relative quantitation of full-length protein in cleared lysates by anti-tag 
ELISA. A) F. nucleatum fusion proteins. B) S. gallolyticus fusion proteins. Absorption at 
450 nm (OD(450nm)) was plotted against total lysate protein concentration. Full-length 
fusion proteins were detected by mouse anti-tag antibody. The dashed line indicates the half-
maximum absorption reached by GST-tag lysate (OD50(GST-tag)).  
 
Adjustment of the protein lysate volume applied in bead-loading to achieve higher 
concentrations of full-length protein bound to the beads is undesirable since increasing 
glycerol content would interfere with bead sedimentation and the washing procedure of the 
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beads. All recombinantly expressed F. nucleatum and S. gallolyticus proteins, despite lower 
relative full-length protein concentration for some of the proteins, were applied in multiplex 
serology at 1 mg/ml total protein concentration. Immunogenic epitopes might be found also 
on non-full length expressed proteins. However, results from Western blot and anti-tag 
ELISA should be kept in mind for interpretation of observed findings.  
Table 19: Total lysate protein concentrations at half-maximum OD of GST-tag (OD50). 
Fusion protein Total lysate protein concentration 
at OD50(GST-tag) (mg/ml) 
x-fold to GST-tag lysate 
concentration at OD50 
F. nucleatum   
Fn0131 0.03 60 
Fn0253 0.001 2 
Fn0264 0.0006 1 
Fn0387 0.02 29 
Fn1426 0.09 129 
Fn1449 0.01 14 
Fn1526 0.1 143 
Fn1817_1 0.003 4 
Fn1817_2 0.0015 2 
Fn1859 0.06 86 
Fn1893 0.02 29 
S. gallolyticus   
Gallo0112A 0.008 5 
Gallo0112B 0.009 6 
Gallo0272 0.05 33 
Gallo0577* - - 
Gallo0748 0.08 44 
Gallo0933 0.02 8 
Gallo1570 0.1 67 
Gallo1675 0.1 67 
Gallo2018 0.03 20 
Gallo2178 0.03 20 
Gallo2179 0.06 40 
*OD of respective lysate did not reach OD50(GST-tag) 
 
3.1.4. Loading of GST-X-tag fusion proteins onto beads 
GST-X-tag fusion proteins from bacterial lysates were affinity-purified in situ by binding onto 
glutathione-casein coated beads. A biotinylated antibody directed against the C-terminal tag 
was applied as a technical bead-loading control for presence of full-length protein on the 
beads. Anti-tag antibody bound to all F. nucleatum and S. gallolyticus proteins as well as 
GST-tag as a reference was quantified (MFI) in three independent bead-loadings and mean, 
standard deviation and the coefficient of variation in percent (%CV) were calculated (Table 
20). In general, there was little variation observable between the three bead-loadings. The 
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%CV was below 25% for 20 out of the 23 proteins indicating a good reproducibility and 
slightly higher but still acceptable for Fn1859, Fn1893 and Gallo2179 (32%, 29.6% and 
31.3%, respectively). The mean MFI to none of the GST-X-tag fusion proteins was more than 
1.5-fold lower, e.g. 2846 MFI to Fn1526, compared to the GST-tag lysate (3652 MFI). This 
indicated a comparable amount of full-length proteins loaded onto the beads relative to GST-
tag. In addition, mean anti-tag signals from three independent bead-loading reactions 
correlated only weakly (R2 = 0.2204) with the total protein lysate concentration necessary to 
reach OD50(GST-tag) in anti-tag ELISA (3.1.3) (Figure 11). Thus, although Western blot and 
anti-tag ELISA results showed lower concentrations of full-length protein for some of the 
lysates, sufficient amounts of full-length protein loaded onto the beads were detected probably 
resulting from an excess of protein applied in the bead-loading. In conclusion, even lowly 
concentrated full-length fusion proteins were at saturating levels when beads were loaded 
with GST-X-tag fusion proteins at 1 mg/ml total lysate concentration. 
Table 20: Anti-tag signal (MFI) on antigen-loaded beads in three independent bead-
loading reactions 
 MFI (anti-tag)  
Antigen 
Load 1 Load 2 Load 3 Mean 
Standard 
deviation 
%CV 
F. nucleatum  
Fn0131 4881 4184 2951 4005 977 24.40 
Fn0253 5754 5349 4545 5216 615 11.80 
Fn0264 6163 5188 4870 5407 674 12.46 
Fn0387 4919 3662 3698 4093 715 17.48 
Fn1426 5475 5945 4444 5288 768 14.52 
Fn1449 4027 5182 3774 4328 751 17.35 
Fn1526 3005 2831 2701 2846 153 5.36 
Fn1817_1 3401 3747 3899 3682 255 6.93 
Fn1817_2 5132 4967 4428 4842 368 7.60 
Fn1859 3337 4511 2340 3396 1087 32.00 
Fn1893 4785 5544 2986 4438 1314 29.60 
S. gallolyticus      
Gallo0112A 3826 3790 3761 3792 33 0.86 
Gallo0112B 4091 2945 4135 3724 675 18.12 
Gallo0272 3306 2629 3652 3196 520 16.28 
Gallo0577 3539 3682 3195 3472 250 7.21 
Gallo0748 3567 3037 3464 3356 281 8.37 
Gallo0933 3270 3598 3548 3472 177 5.09 
Gallo1570 3839 3539 4046 3808 255 6.69 
Gallo1675 2802 2926 3018 2915 108 3.72 
Gallo2018 4113 3174 3665 3651 470 12.87 
Gallo2178 3526 3936 3637 3700 212 5.73 
Gallo2179 2424 3200 4513 3379 1056 31.26 
GST-tag 3283 4162 3512 3652 456 12.49 
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Figure 11: Comparison of mean anti-tag signal (MFI) from three independent bead-
loading reactions to total protein lysate concentration at OD50(GST-tag) in anti-tag ELISA 
(3.1.3). 
 
3.2. Validation of F. nucleatum and S. gallolyticus multiplex serology 
There is no serological gold standard test available for F. nucleatum and S. gallolyticus 
antibody detection making a proper antibody-based validation of the multiplex assays 
difficult. However, to validate the assays by alternative means I explored whether positive 
serological results are correlated with presence of F. nucleatum DNA in normal or tumorous 
colonic tissue, with experimental S. gallolyticus infection in mice, with presence of S. 
gallolyticus DNA in feces of cattle and with S. gallolyticus bacteremia in human individuals. 
3.2.1. Antibody responses to F. nucleatum in comparison to F. nucleatum DNA 
in colon tissue 
Tumor and adjacent normal colon tissues of participants in the Irish CRC case-control study 
had been analyzed with qPCR for F. nucleatum DNA [44]. Corresponding sera (n=52) and 
data on F. nucleatum DNA status were kindly provided by David Hughes. Sera were analyzed 
with F. nucleatum multiplex serology in a 1:100 and 1:1000 dilution. For each individual  
F. nucleatum antigen MFI values were plotted and compared between DNA-negative and  
-positive individuals (Figure 12).  
Results 
61 
 
F n 0 1 3 1
F . n u c le a tu m D N A
in  c o lo n  tis s u e
A
n
ti
b
o
d
y
 r
e
a
c
ti
v
it
y
 (
M
F
I)
n
e
g
 (
n
=
2
2
)
p
o
s
 (
n
=
3
0
)
1
1 0
1 0 0
1 0 0 0
1 0 0 0 0
F n 0 2 5 3
F . n u c le a tu m D N A
in  c o lo n  tis s u e
A
n
ti
b
o
d
y
 r
e
a
c
ti
v
it
y
 (
M
F
I)
n
e
g
 (
n
=
2
2
)
p
o
s
 (
n
=
3
0
)
1
1 0
1 0 0
1 0 0 0
1 0 0 0 0
F n 0 2 6 4
F . n u c le a tu m D N A
in  c o lo n  tis s u e
A
n
ti
b
o
d
y
 r
e
a
c
ti
v
it
y
 (
M
F
I)
n
e
g
 (
n
=
2
2
)
p
o
s
 (
n
=
3
0
)
1
1 0
1 0 0
1 0 0 0
1 0 0 0 0
F n 0 3 8 7
F . n u c le a tu m D N A
in  c o lo n  tis s u e
A
n
ti
b
o
d
y
 r
e
a
c
ti
v
it
y
 (
M
F
I)
n
e
g
 (
n
=
2
2
)
p
o
s
 (
n
=
3
0
)
1
1 0
1 0 0
1 0 0 0
1 0 0 0 0
F n 1 4 2 6
F . n u c le a tu m D N A
in  c o lo n  tis s u e
A
n
ti
b
o
d
y
 r
e
a
c
ti
v
it
y
 (
M
F
I)
n
e
g
 (
n
=
2
2
)
p
o
s
 (
n
=
3
0
)
1
1 0
1 0 0
1 0 0 0
1 0 0 0 0
F n 1 4 4 9
F . n u c le a tu m D N A
in  c o lo n  tis s u e
A
n
ti
b
o
d
y
 r
e
a
c
ti
v
it
y
 (
M
F
I)
n
e
g
 (
n
=
2
2
)
p
o
s
 (
n
=
3
0
)
1
1 0
1 0 0
1 0 0 0
1 0 0 0 0
F n 1 5 2 6
F . n u c le a tu m D N A
in  c o lo n  tis s u e
A
n
ti
b
o
d
y
 r
e
a
c
ti
v
it
y
 (
M
F
I)
n
e
g
 (
n
=
2
2
)
p
o
s
 (
n
=
3
0
)
1
1 0
1 0 0
1 0 0 0
1 0 0 0 0
F n 1 8 1 7 _ 1
F . n u c le a tu m D N A
in  c o lo n  tis s u e
A
n
ti
b
o
d
y
 r
e
a
c
ti
v
it
y
 (
M
F
I)
n
e
g
 (
n
=
2
2
)
p
o
s
 (
n
=
3
0
)
1
1 0
1 0 0
1 0 0 0
1 0 0 0 0
F n 1 8 1 7 _ 2
F . n u c le a tu m D N A
in  c o lo n  tis s u e
A
n
ti
b
o
d
y
 r
e
a
c
ti
v
it
y
 (
M
F
I)
n
e
g
 (
n
=
2
2
)
p
o
s
 (
n
=
3
0
)
0 .1
1
1 0
1 0 0
1 0 0 0
1 0 0 0 0
F n 1 8 5 9
F . n u c le a tu m D N A
in  c o lo n  tis s u e
A
n
ti
b
o
d
y
 r
e
a
c
ti
v
it
y
 (
M
F
I)
n
e
g
 (
n
=
2
2
)
p
o
s
 (
n
=
3
0
)
1
1 0
1 0 0
1 0 0 0
1 0 0 0 0
F n 1 8 9 3
F . n u c le a tu m D N A
in  c o lo n  tis s u e
A
n
ti
b
o
d
y
 r
e
a
c
ti
v
it
y
 (
M
F
I)
n
e
g
 (
n
=
2
2
)
p
o
s
 (
n
=
3
0
)
1
1 0
1 0 0
1 0 0 0
1 0 0 0 0
A
Results 
62 
 
F n 0 1 3 1
F . n u c le a tu m D N A
in  c o lo n  tis s u e
A
n
ti
b
o
d
y
 r
e
a
c
ti
v
it
y
 (
M
F
I)
n
e
g
 (
n
=
2
2
)
p
o
s
 (
n
=
3
0
)
1
1 0
1 0 0
1 0 0 0
1 0 0 0 0
F n 0 2 5 3
F . n u c le a tu m D N A
in  c o lo n  tis s u e
A
n
ti
b
o
d
y
 r
e
a
c
ti
v
it
y
 (
M
F
I)
n
e
g
 (
n
=
2
2
)
p
o
s
 (
n
=
3
0
)
1
1 0
1 0 0
1 0 0 0
1 0 0 0 0
F n 0 2 6 4
F . n u c le a tu m D N A
in  c o lo n  tis s u e
A
n
ti
b
o
d
y
 r
e
a
c
ti
v
it
y
 (
M
F
I)
n
e
g
 (
n
=
2
2
)
p
o
s
 (
n
=
3
0
)
1
1 0
1 0 0
1 0 0 0
1 0 0 0 0
F n 0 3 8 7
F . n u c le a tu m D N A
in  c o lo n  tis s u e
A
n
ti
b
o
d
y
 r
e
a
c
ti
v
it
y
 (
M
F
I)
n
e
g
 (
n
=
2
2
)
p
o
s
 (
n
=
3
0
)
1
1 0
1 0 0
1 0 0 0
1 0 0 0 0
F n 1 4 2 6
F . n u c le a tu m D N A
in  c o lo n  tis s u e
A
n
ti
b
o
d
y
 r
e
a
c
ti
v
it
y
 (
M
F
I)
n
e
g
 (
n
=
2
2
)
p
o
s
 (
n
=
3
0
)
1
1 0
1 0 0
1 0 0 0
1 0 0 0 0
F n 1 4 4 9
F . n u c le a tu m D N A
in  c o lo n  tis s u e
A
n
ti
b
o
d
y
 r
e
a
c
ti
v
it
y
 (
M
F
I)
n
e
g
 (
n
=
2
2
)
p
o
s
 (
n
=
3
0
)
1
1 0
1 0 0
1 0 0 0
1 0 0 0 0
F n 1 5 2 6
F . n u c le a tu m D N A
in  c o lo n  tis s u e
A
n
ti
b
o
d
y
 r
e
a
c
ti
v
it
y
 (
M
F
I)
n
e
g
 (
n
=
2
2
)
p
o
s
 (
n
=
3
0
)
1
1 0
1 0 0
1 0 0 0
1 0 0 0 0
F n 1 8 1 7 _ 1
F . n u c le a tu m D N A
in  c o lo n  tis s u e
A
n
ti
b
o
d
y
 r
e
a
c
ti
v
it
y
 (
M
F
I)
n
e
g
 (
n
=
2
2
)
p
o
s
 (
n
=
3
0
)
1
1 0
1 0 0
1 0 0 0
1 0 0 0 0
F n 1 8 1 7 _ 2
F . n u c le a tu m D N A
in  c o lo n  tis s u e
A
n
ti
b
o
d
y
 r
e
a
c
ti
v
it
y
 (
M
F
I)
n
e
g
 (
n
=
2
2
)
p
o
s
 (
n
=
3
0
)
1
1 0
1 0 0
1 0 0 0
1 0 0 0 0
F n 1 8 5 9
F . n u c le a tu m D N A
in  c o lo n  tis s u e
A
n
ti
b
o
d
y
 r
e
a
c
ti
v
it
y
 (
M
F
I)
n
e
g
 (
n
=
2
2
)
p
o
s
 (
n
=
3
0
)
1
1 0
1 0 0
1 0 0 0
1 0 0 0 0
F n 1 8 9 3
F . n u c le a tu m D N A
in  c o lo n  tis s u e
A
n
ti
b
o
d
y
 r
e
a
c
ti
v
it
y
 (
M
F
I)
n
e
g
 (
n
=
2
2
)
p
o
s
 (
n
=
3
0
)
1
1 0
1 0 0
1 0 0 0
1 0 0 0 0
B
 
Figure 12: Antibody responses to individual F. nucleatum proteins in colon tissue DNA-
negative and –positive individuals. Sera of 52 individuals (kindly provided by David 
Hughes) were analyzed in F. nucleatum multiplex serology in A) 1:100 and B) 1:1000 
dilution. Antibody reactivity to individual F. nucleatum proteins is given in MFI. Horizontal 
bars represent the 25th, 50th and 75th percentile. The dashed line indicates antigen-specific cut-
offs derived from mean MFI in controls + 3 * standard deviation excluding outliers. neg = 
DNA-negative, pos = DNA-positive. 
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Overall, responses to all F. nucleatum proteins were low in both reference groups. The 
maximum MFI value achieved in the 1:100 dilution was with Fn1449 (4763 MFI). However, 
such high MFI values were rare. The median MFI to any of the antigens in the two groups 
ranged from 11 (Fn1817_1) to 257 MFI (Fn0131).  
In the 1:1000 dilution the median antibody responses were approximately 10-fold lower and 
ranged from 1 MFI (Fn0253, Fn0264, Fn0387 and Fn1817_1) to 20 MFI (Fn0131). Maximum 
MFI values were approximately 3-fold lower and with 1464 MFI highest again to Fn1449. 
There was no significant difference between F. nucleatum DNA-negative and -positive 
individuals in median antibody response to any of the eleven F. nucleatum antigens given by 
Wilcoxon rank-sum test, neither in the 1:100 nor in the 1:1000 dilution. 
Application of a cut-off derived from the mean MFI plus three times the standard deviation 
among controls under exclusion of outliers was used to analyze whether positivity to 
individual and multiple proteins was more frequent in F. nucleatum DNA- positive compared 
to –negative individuals (Table 21). Positivity to proteins Fn0131, Fn0387, Fn1426, Fn1449, 
Fn1817_1, Fn1817_2 as well as positivity to any and to more than one of the proteins was 
consistently more frequent in both dilutions in DNA-positives compared to DNA-negatives. 
However, due to the small sample size there was no significant difference.  
Table 21: Percentage antibody-positives to individual and multiple F. nucleatum 
proteins in colon tissue DNA-negative and –positive individuals 
 n (%) antibody-positives
1
 
in serum dilution 1:100 
n (%) antibody-positives
1
 
in serum dilution 1:1000 
Antigen  
(-combination) 
DNA-
negative
2
 
DNA-
positive
2
 
p-value
3
 DNA-
negative
2
 
DNA-
positive
2
 
p-value
3
 
Fn0131 0 (0) 2 (7) 0.217 1 (5) 2 (9) 0.746 
Fn0253 1 (5) 3 (10) 0.466 0 (0) 0 (0) 1.000 
Fn0264 1 (5) 1 (3) 0.822 1 (5) 0 (0) 0.238 
Fn0387 3 (14) 6 (20) 0.549 3 (14) 5 (23) 0.764 
Fn1426 3 (14) 8 (27) 0.256 2 (9) 4 (18) 0.695 
Fn1449 3 (14) 7 (23) 0.381 3 (14) 6 (27) 0.549 
Fn1526 3 (14) 1 (3) 0.168 1 (5) 0 (0) 0.238 
Fn1859 1 (5) 1 (3) 0.822 0 (0) 2 (9) 0.217 
Fn1817_1 0 (0) 4 (13) 0.075 1 (5) 4 (18) 0.081 
Fn1817_2 1 (5) 6 (20) 0.107 0 (0) 2 (9) 0.217 
Fn1893 5 (23) 6 (20) 0.812 4 (18) 2 (9) 0.199 
= 1 protein 11 (50) 21 (70) 0.143 8 (36) 16 (53) 0.225 
> 1 protein 5 (23) 13 (43) 0.123 4 (18) 7 (23) 0.653 
> 2 proteins 4 (18) 7 (23) 0.653 4 (18) 3 (10) 0.393 
> 3 proteins 1 (5) 3 (10) 0.465 0 (0) 1 (3) 0.387 
1
cut-off was determined by the mean MFI + 3 * standard deviation in controls under 
exclusion of outliers; 
2
DNA status in colon tissue was kindly provided by David Hughes 
[44], n(DNA-negative) = 22, n(DNA-positive) = 30; 
3Pearson’s Chi-square test 
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In summary, there was no correlation between F. nucleatum DNA-positivity in colonic tissue 
and continuous antibody responses in F. nucleatum multiplex serology. However, application 
of a cut-off found a trend for a higher number of antibody-positives among DNA-positives as 
compared to DNA-negative individuals. This finding was independent of the serum dilution. 
3.2.2. S. gallolyticus multiplex serology in sera from experimentally infected mice 
Serum samples of three mice, two inoculated by gavage with 4.5*108 cells of S. gallolyticus 
UCN34 (mice 91 and 98) and the third (mouse 68) with PBS, were kindly provided by 
Annemarie Boleij. Starting two weeks post inoculation blood was taken every week up to 
week seven and serum samples were analyzed by S. gallolyticus multiplex serology in 1:100 
serum dilution (Figure 13). The PBS-inoculated mouse constantly showed antibody responses 
below 100 MFI for all antigens except for a slight increase with Gallo0272 to up to 316 MFI 
in week 6. At this time point the mouse had to be sacrificed due to an unidentified illness. 
Mouse 91 showed seroconversion to two S. gallolyticus antigens. Beginning in week 3 
antibody response to Gallo2179 increased, and reached 4335 MFI at week 4 and declined to 
2244 MFI in week 6. Antibody response to Gallo0577 also increased in week 3 reaching a 
maximum of 527 MFI in week 5. Mouse 98 also showed seroconversion but only weakly and 
to a single and different protein (Gallo0272) reaching 814 MFI in week 7. 
These results corresponded to data obtained with a newly developed PCR (Indra-Jasmin 
Gierse and Daniela Höfler, unpublished data): S. gallolyticus DNA was found in feces of mice 
sampled at week 7 post inoculation in mouse 91 but not 68 and 98. Similar to that Annemarie 
Boleij measured colonization of the bacteria and found mouse 91 still colonized with  
S. gallolyticus at week 7 while mouse 98 lost colonization with S. gallolyticus already at week 
3 post inoculation. 
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Figure 13: Antibody responses to S. gallolyticus proteins in experimentally infected mice. 
Antibody reactivity (MFI) against individual S. gallolyticus proteins is plotted over time. Two 
mice had been inoculated by gavage with S. gallolyticus UCN34 and one negative control 
mouse with PBS. Blood samples were taken weekly after inoculation up to week 7. Sera were 
analyzed in a 1:100 dilution. Sera were provided by Annemarie Boleij.  
 
3.2.3. S. gallolyticus multiplex serology in bovine sera 
S. gallolyticus is highly prevalent in the rumen of cattle [62]. Serum and fecal samples had 
been collected from 51 dairy cows (kindly provided by Indra-Jasmin Gierse) and analyzed for 
S. gallolyticus DNA in fecal samples by S. gallolyticus PCR (Indra-Jasmin Gierse et al., 
unpublished data). Twenty-eight of the 51 cows were positive for S. gallolyticus DNA in their 
feces, 13 were negative and 10 had invalid PCR results, since neither S. gallolyticus DNA nor 
DNA of a bovine housekeeping gene could be identified. Antibody responses to all eleven  
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S. gallolyticus proteins in S. gallolyticus fecal-DNA-negative cows were compared to those of 
–positive cows (Figure 14). Overall, antibody responses to S. gallolyticus proteins were low. 
At 1:100 dilution the majority of serum samples showed an antibody response higher than 
1000 MFI only with Gallo0748. With Gallo1570, Gallo2018 and Gallo2178 only few serum 
samples exceeded 1000 MFI. Lowest median MFI were achieved with Gallo0112B, 
Gallo1675 and Gallo0933 (14, 26 and 19 MFI, respectively) followed by Gallo0577 and 
Gallo0272 (38 and 40 MFI). For the remaining antigens the median MFI ranged around 100 
MFI with the exception of Gallo0748 that achieved a median MFI of above 1000 MFI in both 
groups. There was no significant difference between S. gallolyticus DNA-negative and  
-positive individuals in median antibody response to any of the eleven S. gallolyticus antigens 
given by Wilcoxon rank-sum test. 
Application of a cut-off derived from controls as the mean MFI plus three times the standard 
deviation under exclusion of positive outliers allowed analyzing further whether positivity to 
individual and multiple proteins differed between the two groups. Indeed positivity to 
Gallo0112A, Gallo0272, Gallo0933, Gallo1570, Gallo1675, Gallo2018, Gallo2179, any of the 
proteins and multiple proteins was more frequent among DNA-positive compared to  
-negative cows. Positivity to any of the eleven proteins among DNA-negative cows (23%) 
was significantly less frequent than among DNA-positive cows (71%). None of the DNA-
negative cows was positive to more than two proteins compared to 18% of the DNA-positive 
cows indicating that correlation of the proteins strengthens the specificity of S. gallolyticus 
antibody detection in comparison to PCR.  
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Figure 14: Antibody responses to individual S. gallolyticus proteins in cows. Sera of 41 
cows with known fecal S. gallolyticus DNA status (DNA data and serum samples provided by 
Indra-Jasmin Gierse) were analyzed with S. gallolyticus multiplex serology in 1:100 dilution. 
Antibody reactivity to individual S. gallolyticus proteins is given in MFI. Horizontal bars 
represent the 25th, 50th and 75th percentile. The dashed line indicates antigen-specific cut-offs 
derived from mean MFI in controls + 3 * standard deviation excluding positive outliers. neg = 
DNA-negative, pos = DNA-positive.  
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Table 22: Percentage antibody-positives to individual and multiple S. gallolyticus 
proteins in fecal DNA-negative and -positive cows 
 n (%) antibody-positives
1
 
in serum dilution 1:100 
Antigen  
(-combination) 
DNA-negative
2
 DNA-positive
2
 p-value
3
 
Gallo0112A 0 (0) 3 (11) 0.220 
Gallo0112B 1 (8) 2 (7) 0.950 
Gallo0272 0 (0) 2 (7) 0.323 
Gallo0577 1 (8) 14 (4) 0.548 
Gallo0748 0 (0) 0 (0) 1.000 
Gallo0933 1 (8) 6 (21) 0.276 
Gallo1570 2 (15) 10 (36) 0.183 
Gallo1675 0 (0) 2 (7) 0.323 
Gallo2018 0 (0) 3 (11) 0.220 
Gallo2178 0 (0) 0 (0) 1.000 
Gallo2179 0 (0) 4 (14) 0.151 
= 1 protein 3 (23) 20 (71) 0.004 
> 1 protein 2 (15) 10 (36) 0.183 
> 2 proteins 0 (0) 5 (18) 0.104 
> 3 proteins 0 (0) 1 (4) 0.490 
1
cut-off was determined by the mean MFI + 3* standard deviation in controls 
under exclusion of outliers; 
2
DNA status in feces was kindly provided by 
Indra-Jasmin Gierse, n(DNA-negative) = 13, n(DNA-positive) = 28; 
3Pearson’s Chi-square test, significant associations are marked in bold font. 
 
3.2.4. S. gallolyticus multiplex serology in humans with S. gallolyticus bacteremia 
In a previous study we directly had coupled four pilus proteins, including Gallo2178 and 
Gallo2179, as recombinantly expressed and affinity-purified his-tagged proteins to Luminex 
beads [81]. In the attempt to validate these proteins we had analyzed in total six sera, three 
from healthy controls (HC 1-3) and three from patients diagnosed with S. gallolyticus 
bacteremia (SGG-pos 1-3) for antibody responses to the his-tagged pilus proteins (both, 
proteins and sera had been provided by Harold Tjalsma) (Figure 15B). Antibody responses to 
his-tagged Gallo2178 had been higher in all positive serum controls compared to healthy 
controls (SGG-pos1: 15039, SGG-pos2: 12297 and Sgg-pos3: 1907 MFI versus HC: 188 and 
1 MFI in 1:100 dilution, respectively). Antibody responses to his-tagged Gallo2179 were 
higher in two out of three positive serum controls (SGG-pos1: 8413, SGG-pos2:8053 vs HC1: 
889 MFI in 1:100 dilution).  
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Figure 15: Antibody responses to S. gallolyticus proteins in individuals with S. 
gallolyticus bacteremia and healthy controls. A) Multiplex serology with S. gallolyticus 
GST-X-tag fusion proteins and B) with his-tagged Gallo2178 and Gallo2179 directly coupled 
to beads [81]. Antibody reactivity (MFI) to individual S. gallolyticus proteins was measured 
in a 1:2 dilution series of serum samples from three S. gallolyticus bacteremia patients (SGG-
pos 1-3) and healthy controls (HC 1-3). Serum samples and his-tagged Gallo2178 and 
Gallo2179 had been kindly provided by Harold Tjalsma. 
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These serum samples were analyzed with the newly developed S. gallolyticus proteins in a 
similar multiplex serology setup with the exception that two of the healthy controls were 
analyzed at 1:100 serum dilution only (Figure 15A). First of all, I was able to replicate results 
from his-tagged Gallo2178 and Gallo2179 with the GST-X-tag fusion proteins. SGG-pos1 
(5821 MFI) and SGG-pos2 (4835 MFI) reacted strongly with GST-tagged Gallo2178 
followed by SGG-pos3 (242 MFI) still having higher responses than the highest healthy 
control (16 MFI at 1:100 dilution). The increase in MFI at higher dilutions as seen with 
Gallo2178 in dilution 1:800 (9456 MFI) compared to dilution 1:100 (5821 MFI) can be 
explained by a so-called “hook-effect”: Saturation with serum antibody in lower dilution 
blocks binding of secondary antibodies/reagents, which is enabled in higher serum dilutions 
by the liberation of more potential binding sites. SGG-pos1 (2529 MFI) and SGG-pos2 (2111) 
also reacted strongly to GST-tagged Gallo2179, whereas SGG-pos3 (27 MFI) did not exceed 
the antibody response of HC1 (78 MFI). 
Overall, in these human serum samples lowest antibody responses were present with 
Gallo0112A (6-55 MFI in 1:100 dilution), Gallo0112B (1-36 MFI), Gallo1675 (1-77 MFI) 
and Gallo0933 (1-207 MFI) irrespective of serum type. There was also no difference in 
response to these proteins between positive serum controls and healthy controls. Positive 
serum controls had higher MFI compared to healthy controls to the remaining antigens, 
however, in different patterns (Table 23):  
SGG-pos1 to Gallo0577, Gallo0748, Gallo1570, Gallo2178 and Gallo2179; 
SGG-pos2 to Gallo0577, Gallo2018, Gallo2178 and Gallo2179; 
SGG-pos3 to Gallo0272, Gallo0748, Gallo2018 and Gallo2178. 
Table 23: Antibody responses (MFI) to S. gallolyticus proteins in individuals with  
S. gallolyticus bacteremia and healthy controls analyzed at 1:100 serum dilution. 
Antigen HC-1 HC-2 HC-3 SGG-pos1 SGG-pos2 SGG-pos3 
Gallo0112A 30 12 6 55 10 19 
Gallo0112B 4 4 1 36 4 1 
Gallo0272 188 5 1 10 11 1943 
Gallo0577 166 11 1 3458 2780 27 
Gallo0748 20 6 5 236 17 383 
Gallo0933 64 166 1 207 47 1 
Gallo1570 129 7 3 458 117 75 
Gallo1675 61 5 1 77 16 4 
Gallo2018 114 13 3 3 3584 2648 
Gallo2178 16 3 1 5821 4835 242 
Gallo2179 78 3 1 2529 2111 27 
MFI > 100 and at least 2-fold higher than in HC are marked in bold font; SGG-pos = S. gallolyticus 
bacteremia patients 1 to 3; HC = Healthy controls 1 to 3. 
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In summary, I observed similar patterns of antibody responses to S. gallolyticus in three 
different hosts. One out of two experimentally infected mice was successfully colonized with 
S. gallolyticus for 7 weeks and showed strong antibody responses to Gallo2179 and 
Gallo0577 only. The second mouse inoculated with S. gallolyticus raised antibody responses 
only to Gallo0272. The PBS-inoculated mouse for unidentified reasons also developed two-
fold lower antibody responses to Gallo0272. In bovine serum samples, application of a cut-off 
derived from the mean plus three times the standard deviation of MFI in controls showed that 
fecal S. gallolyticus DNA-positive cows were more frequently antibody-positive than DNA–
negative cows also to Gallo0272 and Gallo2179 and additionally to Gallo0112A, Gallo0933, 
Gallo1570, Gallo1675, Gallo2018, any of the proteins and multiple proteins. Due to the small 
sample sizes none of the differences was significant except for positivity to any of the 
proteins. Gallo0272 and Gallo2179 were consistently distinguishing defined negatives from 
positives among all three types of hosts, also humans. Additionally, in human samples, which 
will be the type of samples analyzed for an association with CRC, I observed that Gallo2178 
is recognized specifically by sera of patients diagnosed with S. gallolyticus bacteremia 
together with Gallo0272 and Gallo2179 but also Gallo0577, Gallo0748, Gallo1570 and 
Gallo2018. Also these proteins mostly overlap with the proteins that best distinguished S. 
gallolyticus DNA-positive from -negative cows as well as experimentally infected from non-
infected mice (Table 24). In addition, the finding that patients with S. gallolyticus bacteremia 
raised antibody responses to several proteins simultaneously was concordant to the 
observation in bovine sera, where positivity to several proteins strengthened the specificity in 
comparison to DNA. 
Table 24: Proteins distinguishing S. gallolyticus infected from non-infected individuals in 
three different host species 
Antigen Murine
1
 Bovine
2
 Human
1
 
Gallo0112A  x  
Gallo0112B    
Gallo0272 x x x 
Gallo0577 x  x 
Gallo0748   x 
Gallo0933  x  
Gallo1570  x x 
Gallo1675  x  
Gallo2018  x x 
Gallo2178   x 
Gallo2179 x x x 
1
x = MFI at least 2-fold higher in defined positives compared to negatives; 
2
x = % 
antibody-positives at least 2-fold higher in DNA-negatives compared to -positives 
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An ideal agreement of different assays, e.g. PCR and serology, would imply a high sensitivity 
and high specificity. However, here both were only moderate. Serology is a cumulative 
measure of systemic past and present infections, whereas DNA detection only measures 
present infection at the sampled site. I could not exclude that DNA-negative cows never had a 
S. gallolyticus infection neither could I exclude that S. gallolyticus DNA is under the 
detection limit of the PCR nor that seroconversion could have occurred in the past and/or 
from infection of sites not resulting in S. gallolyticus DNA-positive feces. The number of 
artificially infected mice and human individuals with known S. gallolyticus infection was not 
sufficient to define robust cut-offs for individual proteins neither to define an algorithm for S. 
gallolyticus overall positivity.  
Thus, also the S. gallolyticus multiplex serology could not be completely validated. However, 
the different attempts indicated that S. gallolyticus multiplex serology developed here is able 
to measure antibody responses to S. gallolyticus but sensitivity and specificity remain to be 
determined further. 
3.3. Search for serological  associations of F. nucleatum with CRC by multiplex 
serology in a retrospective case-control study and prospective nested case- 
control studies  
3.3.1. Cut-off definition 
Since infection-based validation of F. nucleatum multiplex serology by DNA-status in the 
intestine failed I had to arbitrarily define cut-offs for F. nucleatum antibody positivity. The 
BliTz study included samples from colonoscopy negative individuals that served as control 
group. The distribution of antibody responses in these CRC- and precursor lesion- free study 
participants was overall skewed towards low MFI for all eleven F. nucleatum antigens (Figure 
16). Fn1426 showed strongest responses but still with only 12% of sera reaching > 500 MFI, 
while with Fn1526 only 1% reached this antibody level. For each F. nucleatum antigen a cut-
off defining 10% of controls as antibody-positive was close to the approximate point of 
inflection in the antibody distribution curve. Visual inspection of these percentile plots was 
previously used in our laboratory to define cut-offs in the absence of gold-standard references 
since it is assumed that a sudden rise in the antibody response over percentile of serum 
indicates the cut-off for antibody-positivity ([128] and personal communication with Michael 
Pawlita). Therefore, I arbitrarily defined cut-offs for antibody-positivity to F. nucleatum 
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proteins allowing 10% of positive control individuals (Figure 17). The technical minimum 
cut-off was 30 MFI. This definition will be applied separately for the individual studies, i.e. 
cut-offs will be based on the distribution of MFI among the respective control population.  
BliTz and SCCS samples were analyzed in the same experimental setup and could therefore 
be directly compared. Cut-off values in the two studies were similar for the majority of 
antigens. An exception, however, was Fn1817_1, for which the cut-off in BliTz was 133 MFI 
compared to 2039 MFI in the SCCS indicating a strong difference in the antibody response to 
this protein among the two study populations. EPIC samples were analyzed in a different 
experimental setup and in a higher serum dilution (1:1000 compared to 1:100 in BliTz and 
SCCS) and absolute MFI values could not be directly compared to those in BliTz and SCCS. 
However, in EPIC 10% of controls exceeded only a rather low MFI of 42 to Fn1817_1 similar 
to the low cut-off in BliTz. Antibody positivity to Fn1817_1 strongly correlated with being 
African-American in SCCS controls (data not shown). The difference between ethnicities will 
be elucidated later also in the context of S. gallolyticus. 
In summary, I had to arbitrarily define cut-offs for positivity to F. nucleatum proteins due to a 
lack of a serological gold standard assay. This cut-off was based on the antibody distribution 
among control subjects in the separate studies and defined 10% of controls as being positive 
to the individual proteins. Overall F. nucleatum positivity will be arbitrarily defined in a first 
step as being positive to any of the eleven proteins allowing for inter-individual differences in 
the immune response but also infection with different bacterial strains. 
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Figure 16: Distribution of antibody responses to F. nucleatum proteins in BliTz controls. 
Antibody reactivity (MFI) is plotted against the percentile of sera. The red line indicates 
arbitrary antigen-specific cut-offs defining 10% of controls as sero-positive. 
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Figure 17: Distribution of antibody responses to individual F. nucleatum proteins and 
antigen-specific cut-offs in (A) BliTz, (B) SCCS and (C) EPIC controls. Boxes represent 
the 25th to 75th percentile and the solid line represents the median. Whiskers include the 10th to 
90th percentile. The red line indicates the arbitrary antigen-specific cut-offs defining 10% of 
controls as antibody-positive. The technical minimum cut-off was 30 MFI applied in A) for 
Fn1526 and in C) for Fn0253, Fn0264, Fn0387, Fn1526, Fn1893. 
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3.3.2. Risk factors for antibody-positivity to any F. nucleatum protein among 
controls 
I first assessed whether controls positive to any F. nucleatum protein differed from negative 
control individuals in any of the given baseline characteristics to assess potential risk factors 
for antibody responses to F. nucleatum. These risk factors might affect and/or confound a 
potential association with CRC.  
Significantly more males were positive to any F. nucleatum protein among BliTz controls 
(Table 25). This difference was less pronounced and consequently non-significant in SCCS 
(Table 26) and EPIC controls (Table 27). None of the other variables was significantly 
associated with positivity to any F. nucleatum protein in BliTz, SCCS and EPIC controls. 
Table 25: Comparison of individuals antibody-positive or -negative to any F. nucleatum 
protein for demographic and other risk factors among BliTz controls. 
  
Any F. nucleatum protein 
  
neg (n=99) pos (n=129)  
    n (%) n (%) p-value* 
Sex female 62 (63) 62 (48)  
male 37 (37) 67 (52) 0.029 
Age (years) 40-59 42 (42) 54 (42)  
60-65 28 (28) 38 (29)  
66-85 29 (29) 37 (27) 0.981 
 mean (range) 62 (40-85) 62 (50-80)  
School education < 10 years 55 (57) 70 (55)  
≥ 10 years 41 (43) 57 (45) 0.746 
missing 3 2  
Smoking status never 56 (57) 76 (59)  
 ever 43 (43) 52 (41) 0.671 
 missing 0 1  
BMI < 25 42 (43) 47 (37)  
25-29.9 39 (40) 56 (44)  
≥ 30 17 (17) 23 (18) 0.693 
missing 1 3  
Family history of CRC no 86 (87) 114 (88)  
yes 13 (13) 15 (12) 0.732 
*Pearson’s Chi-square-test; significant associations are marked in bold font 
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Table 26: Comparison of individuals antibody-positive or -negative to any F. nucleatum 
protein for demographic and other risk factors among SCCS controls 
  Any F. nucleatum protein 
  
neg (n=134) neg (n=205) p-value* 
Sex female 85 (59) 106 (52)  
male 58 (41) 99 (48) 0.154 
Age at blood draw 
(years) 
40-55 67 (47) 97 (47)  
56-60 28 (20) 48 (23)  
 61-77 48 (34) 60 (29) 0.585 
 mean (range) 57 (40-77) 56 (40-76)  
Ethnicity Caucasian-American 31 (23) 29 (15)  
 African-American 106 (77) 170 (85) 0.058 
 missing 6 6  
Education < high school 60 (44) 75 (37)  
 ≥ high school 77 (56) 129 (63) 0.193 
 missing 6 1  
Smoking never 41 (30) 54 (26)  
 former 40 (29) 68 (33)  
 current 56 (41) 82 (40) 0.669 
 missing 6 1  
BMI < 25 31 (23) 53 (26)  
 25-29.9 39 (28) 57 (28)  
 ≥ 30 67 (49) 93 (46) 0.751 
 missing 6 2  
Family history of CRC no 54 (87) 73 (86)  
 yes 8 (13) 12 (14) 0.832 
 Missing 81 120  
*Pearson’s Chi-square-test 
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Table 27: Comparison of individuals antibody-positive or -negative to any F. nucleatum 
protein for demographic and other risk factors among EPIC controls. 
  Any F. nucleatum protein 
  
neg (n=230) pos (n=255) p-value* 
Sex female 122 (53) 125 (49)  
male 108 (47) 130 (51) 0.376 
Age at blood draw, 
years 
37-55 61 (27) 59 (23)  
56-60 56 (24) 68 (27)  
61-77 113 (49) 128 (50) 0.657 
 mean (range) 60 (37-76) 60 (37-76)  
Country Italy/Greece 43 (19) 69 (27)  
France/Spain 42 (18) 51 (20)  
UK 64 (28) 70 (27)  
 Germany/Netherlands 81 (35) 65 (25) 0.054 
Education ≤ primary school 98 (45) 114 (46)  
technical/professional  63 (29) 52 (21)  
≥ secondary school 58 (26) 84 (34) 0.082 
 missing 11 5  
Smoking status never 106 (46) 128 (51)  
 former 73 (32) 81 (32)  
 current 51 (22) 44 (17) 0.385 
 missing 0 2  
Alcohol never 27 (13) 21 (9)  
 former 21 (10) 19 (8)  
 current > 0-6 g/day 61 (28) 72 (30)  
            6.01-20 g/day 58 (27) 72 (30)  
            > 20 g/day 49 (23) 60 (25) 0.612 
 missing 14 11  
BMI < 25 79 (34) 88 (35)  
25-29.9 112 (49) 126 (49)  
≥ 30 39 (17) 41 (16) 0.966 
Family history of 
CRC 
no 82 (94) 94 (92)  
yes 5 (6) 8 (8) 0.570 
missing 143 153  
*Pearson’s Chi-Square-test 
 
3.3.3. Antibody responses to F. nucleatum and prevalent CRC in the BliTz-
DACHSplus study 
The association of antibody responses to F. nucleatum was first assessed in prevalent CRC 
cases from the DACHSplus study compared to BliTz controls as reference. Overall, I neither 
identified a positive association of CRC with positivity to any of the eleven F. nucleatum 
proteins nor with positivity to individual F. nucleatum proteins (Figure 18). Odds for CRC 
were even decreased with positivity to Fn1859 though this was borderline not significant (OR: 
0.53, 95% CI: 0.27-1.04).  
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Figure 18: Antibody-positivity to individual F. nucleatum proteins and to any F. 
nucleatum protein in relation to CRC in DACHSplus. BliTz controls (n=228) served as 
reference. OR and 95% CI were estimated using logistic regression models with adjustment 
for age, sex, smoking, BMI and education. The dashed line indicates null association. pos = 
antibody-positive.  
It was shown in H. pylori multiplex serology that correlation among antibody responses to 
several bacterial proteins increased specificity for detection of the infection [143]. I analyzed 
whether there were correlations between positivity to individual F. nucleatum proteins and 
whether positivity to two or more proteins occurred preferentially among cases compared to 
controls and thus in a disease-specific manner (Table 28). I indeed found several protein pairs, 
where positivity significantly correlated. Strongest pairwise correlations were seen among 
three proteins: Fn0387, Fn1449 and Fn1893. The fraction of double-positive individuals was 
thereby similar for controls and cases. However, these three proteins share an 80% amino acid 
homology (Appendix IV) and the observed correlations most probably represent cross-
reactions. Only one pair of sequence-unrelated proteins was significantly correlated and had a 
more than 2-fold higher fraction of double-positives among cases than among controls: 
Fn0264-Fn1859. However, double-positivity was present only in 1.6% of cases compared to 
0.4% of controls leading to very small group sizes. For most of the other correlated protein 
pairs, correlation was preferentially among controls and the fraction of double-positives was 
even lower among cases than among controls, for some even equal to or more than 0.5-fold: 
Fn0264-Fn1426 (0.5-fold), Fn0264-Fn1817_1 (0.5-fold), Fn1426-Fn1526 (0.4-fold), Fn1526-
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FN1817_1 (0.4-fold), Fn1817_1-Fn1893 (0.5-fold) indicating an overall inconsistent and 
possibly even an opposite trend to what was hypothesized.  
In summary, positivity to F. nucleatum proteins generally correlated, however, not 
preferentially among cases. Thus, I was not able to identify a panel of protein pairs that 
correlated in a higher fraction among cases than among controls.  
Since age and sex are main risk factors for CRC development I assessed whether any of the 
two characteristics might affect the estimate for positivity to any F. nucleatum protein with 
CRC (Figure 19A). As already seen with the risk factor analyses positivity to any F. 
nucleatum protein was more frequent in male controls compared to female controls. This 
relation was also seen with CRC cases: The fraction of cases positive to any F. nucleatum 
protein and being of female sex was 44% compared to 64% in males. The resulting estimate 
was an inverse, even significant association of positivity to any F. nucleatum protein with 
CRC cases among women (OR: 0.59 95% CI: 0.37-0.95) in contrast to a null association in 
men (OR: 1.30, 95% CI: 0.84-1.99). There was no effect of age observed on the estimate.  
It was previously reported that F. nucleatum abundance was higher in cases with advanced 
stage compared to lower tumor stage [47]. I here analyzed the association of positivity to any 
F. nucleatum protein separately for UICC stages I/II and III/IV and did not observe a strong 
difference in the estimate between the two groups. The estimate for higher stages (OR: 0.69, 
95% CI: 0.44-1.09) was even lower than that for lower stages (OR: 1.11, 95% CI: 0.71-1.74) 
(Figure 19B). 
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Table 28: Percentage F. nucleatum antibody double-positives (DP) among BliTz controls (n=228) and DACHSplus cases (n=318) 
 0131 0253 0264 0387 1426 1449 1526 1817_1 1817_2 1859 1893 
0131  1.3 1.8 2.2 0.4 1.3 1.3 0.9 1.3 1.3 1.8 
 1.9 (1.5x)
1
 2.2 (1.2x) 1.3 (0.6x) 0.9 (2.3x) 1.3 (1x) 2.5 (1.9x) 1.3 (1.4x) 1.6 (1.2x) 1.6 (1.2x) 1.3 (0.7x) 
0253   0.9 2.6 1.3 3.1 1.8 1.8 0.9 1.8 2.2 
  1.6 (1.8x) 1.6 (0.6x) 1.6 (1.2x) 1.9 (0.6x) 2.2 (1.2x) 0.9 (0.5x) 1.6 (1.8x) 1.6 (0.9x) 1.9 (0.9x) 
0264    0.4 1.8 0.4 1.8 1.8 1.3 0.4 0.4 
   0.6 (1.5x) 0.9 (0.5x) 0.9 (2.3x) 1.6 (0.9x) 0.9 (0.5x) 0.9 (0.7x) 1.6 (4x) 0.6 (1.25x) 
0387     1.3 6.6 0.4 2.2 0.4 1.3 7.0 
    0.9 (0.7x) 6.3 (0.9x) 1.3 (3.3x) 1.3 (0.6x) 0.9 (2.3x) 0.3 (0.2x) 6.3 (0.9x) 
1426      2.2 2.2 0.4 0 0.4 1.3 
     1.3 (0.6x) 0.9 (0.4x) 0.3 (0.8x) 0.6 (>999x) 0.6 (1.5x) 1.6 (1.2x) 
1449       0.9 1.8 0.4 0.9 6.6 
      1.9 (2.1x) 1.3 (0.7x) 0.3 (0.8x) 0.6 (0.7x) 6.3 (0.9x) 
1526        2.2 0.4 0.9 0.4 
       0.9 (0.4x) 0.6 (1.5x) 1.3 (1.4x) 1.3 (3.3x) 
1817_1         1.3 0.9 2.6 
        0.6 (0.5x) 0 (0) 1.3 (0.5x) 
1817_2          0.4 0.9 
         0.6 (1.5x) 0.3 (0.3x) 
1859           0.9 
          0.3 (0.3x) 
1893            
           
Grey: % DP among controls; red: % DP among cases; Significant correlations (Pearson’s Chi-square test, p-value <0.05) are marked in bold font; 1%DP among 
cases relative to %DP among controls; blue field: %DP cases >2-fold than %DP controls and correlation significant 
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Figure 19: OR and 95% CI for antibody-positivity to any F. nucleatum protein in 
relation to CRC in BliTz-DACHSplus, overall and in separate logistic regression models 
for (A) sex and age at diagnosis and (B) UICC stage under adjustment for age, sex, BMI, 
education, and smoking where applicable. The dashed line indicates null association. pos = 
antibody-positive. 
 
3.3.4. Antibody responses to F. nucleatum and incident CRC in the SCCS study 
I did not observe any positive association of antibody positivity to individual proteins or any 
F. nucleatum protein with prevalent CRC in BliTz-DACHSplus. A potential association with 
risk of developing CRC was analyzed with a case-control study nested within SCCS. Overall, 
there was also no positive association of antibody responses to F. nucleatum with CRC risk 
(Figure 20). However, positivity to Fn1426 individually showed a significant association with 
CRC (OR: 1.85, 95%CI: 1.04-3.29) with 17% of cases positive compared to 10% of controls. 
This association was not significant anymore (p-value 0.035) after Bonferroni-correction (p-
value < 0.004). In a sensitivity analysis excluding samples with CRC diagnosed within 2 
years after blood draw the association with Fn1426 positivity was not significant anymore as 
well.  
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Figure 20: Antibody-positivity to individual F. nucleatum proteins and to any F. 
nucleatum protein in relation to CRC risk in SCCS. A) Analyses with all individuals. B) 
Analyses of individuals diagnosed more than two years after blood draw. OR and 95% CI 
were estimated using conditional logistic regression models with adjustment for smoking, 
BMI and education. The dashed line indicates null association. pos = antibody-positive. 
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Analyses stratified by sex showed a lower OR for males (OR: 0.60, 95% CI: 0.32-1.13) 
compared to females (OR: 1.02, 95% CI: 0.63-1.66) opposite to what was observed in BliTz-
DACHSplus (Figure 21A). However, similar to BliTz-DACHSplus there were more male 
controls being positive to any F. nucleatum protein (63%) compared to female controls 
(56%). The fraction of positive cases was similar between males and females (53% and 56%, 
respectively). Stratification by age and ethnicity did not reveal differences in the estimate 
between the different groups. 
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Figure 21: OR and 95% CI for antibody-positivity to any F. nucleatum protein in 
relation to CRC risk in SCCS, overall and in separate conditional logistic regression 
models for (A) sex, age at blood draw and ethnicity as well as (B) for age at diagnosis, 
SEER stage and tumor site under adjustment for BMI, education, and smoking. The 
dashed line indicates null association. pos = antibody-positive. 
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Analyses separated by case characteristics age at diagnosis, stage and tumor site revealed a 
significant inverse association of positivity to any F. nucleatum protein with rectal cancer 
only (OR: 0.33, 95% CI: 0.13-0.84) (Figure 21B). 
3.3.5. Antibody responses to F. nucleatum and incident CRC in the EPIC study 
The association of antibody responses to F. nucleatum proteins with risk of developing CRC 
was finally assessed in a second case-control study nested within the prospective study EPIC. 
Also in this study I did not observe a positive association of positivity to any F. nucleatum 
protein nor with individual F. nucleatum proteins with CRC risk. Positivity to Fn0131 was 
even significantly inversely associated (OR: 0.59, 95% CI: 0.36-0.95) with CRC risk. 
However, this inverse association (p-value 0.030) was not significant after Bonferroni-
correction (p-value < 0.004) and also not in samples that were diagnosed more than two years 
after blood draw. 
Analyses stratified by baseline characteristics showed a difference in the estimate between 
male and female sex. The difference observed in EPIC was similar but less pronounced to that 
observed in BliTz-DACHSplus with females having an inverse and even significant 
association of positivity to any F. nucleatum protein with CRC (OR: 0.64, 95% CI: 0.43-
0.96). In EPIC there was also a difference between the age groups observable with a 
significant inverse association for age 56-60 (OR: 0.43, 95% CI: 0.22-0.85) compared to 
younger and older individuals. Also I observed a difference in the association with CRC risk 
between the different countries of residence with individuals from Italy/Greece being 
significantly inversely associated (OR: 0.55, 95% CI: 0.31-0.98) and individuals from 
Germany/Netherlands having non-significantly increased odds (OR: 1.21, 95%CI: 0.70-2.11). 
There was no difference observable with separate analyses by age at diagnosis, stage or tumor 
site. 
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Figure 22: Antibody-positivity to individual F. nucleatum proteins and to any F. 
nucleatum protein in relation to CRC risk in EPIC. A) Analyses with all individuals. B) 
Analyses of individuals diagnosed more than two years after blood draw. OR and 95% CI 
were estimated using conditional logistic regression models with adjustment for smoking, 
alcohol status, BMI and education. The dashed line indicates null association. pos = antibody-
positive. 
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Figure 23: OR and 95% CI for antibody-positivity to any F. nucleatum protein in 
relation to CRC risk in EPIC, overall and in separate conditional logistic regression 
models for (A) sex, age at blood draw and country of residence as well as (B) for age at 
diagnosis, EPIC stage and tumor site under adjustment for BMI, education, alcohol and 
smoking status. The dashed line indicates null association. pos = antibody-positive. 
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3.4. Search for serological associations of S. gallolyticus with CRC by 
multiplex serology in a retrospective case-control study and prospective 
nested case-control studies  
3.4.1. Cut-off definition 
The different attempts to validate S. gallolyticus multiplex serology based on S. gallolyticus 
positivity in animal but also human samples were not sufficient to define cut-offs for 
individual proteins as well as an algorithm for S. gallolyticus antibody-positivity. Therefore, I 
arbitrarily defined cut-off values for each individual S. gallolyticus protein that allowed 10% 
of controls to be antibody-positive to this protein. The distribution of antibody responses in 
BliTz controls to the individual S. gallolyticus antigens is shown in Figure 24. The arbitrarily 
defined cut-offs were mostly more stringent than cut-offs that would have been defined by the 
inflection points of the curves identified by visual inspection of the percentile plots. For 
example the cut-off for Gallo0272 was 1780 MFI, whereas the approximate inflection point of 
the curve was at 750 MFI and corresponding to the 20th percentile. In the attempt for higher 
specificity I opted for the more stringent cut-off. The cut-off values were defined separately 
for each individual study based on the respective control population. The technical minimum 
cut-off was 30 MFI. 
The cut-offs defined for each S. gallolyticus antigen in the different studies are shown in 
Figure 25. BliTz and SCCS samples were analyzed in the same experiment and can therefore 
be directly compared. 10% of controls achieved slightly higher MFI in SCCS compared to 
colonoscopy-negative individuals in BliTz. The strongest differences were seen with 
Gallo0272 (cut-off BliTz: 1780 MFI vs. SCCS: 2272 MFI), Gallo0933 (cut-off BliTz: 1640 
MFI vs. SCCS: 2566 MFI), Gallo2018 (cut-off BliTz: 984 MFI vs. SCCS: 1475 MFI), 
Gallo2178 (cut-off BliTz: 30 MFI (technical minimum cut-off, reached by only 5%) vs. 
SCCS: 140 MFI) and Gallo2179 (cut-off BliTz: 919 MFI vs. SCCS: 1425 MFI). This 
indicates a difference in the antibody response S. gallolyticus proteins among the two control 
groups. The analysis of EPIC serum samples was performed in a different experiment and 
also in a higher serum dilution (1:1000 compared to 1:100 in BliTz and SCCS) and was 
therefore not directly comparable to BliTz and SCCS for the absolute MFI.  
In summary, I arbitrarily defined cut-off values for antibody-positivity to individual  
S. gallolyticus proteins based on the assumption that colonization with and seroconversion 
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against S. gallolyticus are rare (10%) events in healthy individuals. This cut-off was based on 
the antibody distribution among control subjects in the separate studies and defined 10% of 
controls as being positive to the individual proteins. An algorithm for overall S. gallolyticus 
antibody-positivity will be arbitrarily defined in a first step as being positive to any of the 
eleven proteins allowing for inter-individual differences in the immune response but also 
infection with different bacterial strains potentially expressing different sets of proteins. 
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Figure 24: Distribution of antibody responses to S. gallolyticus proteins in BliTz 
controls. Antibody reactivity (MFI) is plotted over the percentile of sera. The red line 
indicates the arbitrarily chosen antigen-specific cut-offs defining 10% of controls as antibody-
positive.  
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Figure 25: Distribution of antibody responses to individual S. gallolyticus proteins and 
antigen-specific cut-offs in (A) BliTz, (B) SCCS and (C) EPIC controls. Boxes represent 
the 25th to 75th percentile and the solid line represents the median. Whiskers include the 10th to 
90th percentile. The red line indicates the arbitrary antigen-specific cut-offs defining 10% of 
controls as antibody-positive. The technical minimum cut-off was 30 MFI applied in A) for 
Gallo2178 and in C) for Gallo0112A, Gallo0112B and Gallo2178. 
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3.4.2. Risk factors for antibody-positivity to any S. gallolyticus protein among 
controls 
I first addressed whether controls antibody-positive to any S. gallolyticus protein differed 
from negative controls in any of the given baseline characteristics to assess potential risk 
factors for antibody responses to S. gallolyticus. These risk factors might affect and/or 
confound a potential association with CRC. However, none of the variables was significantly 
associated with positivity to any S. gallolyticus protein in BliTz (Table 29), SCCS (Table 30) 
and EPIC controls (Table 31).  
Table 29: Comparison of individuals antibody-positive or -negative to any S. gallolyticus 
protein for demographic and other risk factors among BliTz controls. 
  
Any S. gallolyticus protein 
  
neg (n=97) pos (n=131)  
    n (%) n (%) p-value* 
Sex female 60 (62) 64 (49)  
male 37 (38) 67 (51) 0.051 
Age (years) 40-60 39 (40) 57 (44)  
60-65 31 (32) 35 (27)  
66-85 27 (28) 39 (30) 0.689 
 mean (range) 62 (40-79) 62 (48-85)  
School education < 10 years 58 (61) 67 (52)  
≥ 10 years 37 (39) 61 (48) 0.195 
missing 2 3  
Smoking status never 55 (57) 77 (59)  
 ever 41 (43) 54 (41) 0.929 
 missing 1 0  
BMI < 25 44 (45) 45 (35)  
25-29.9 37 (38) 58 (46)  
≥ 30 16 (16) 24 (19) 0.320 
missing 0 4  
Family history of CRC no 82 (85) 118 (90)  
yes 15 (15) 13 (10) 0.208 
*Pearson’s Chi-square-test  
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Table 30: Comparison of individuals antibody-positive or -negative to any S. gallolyticus 
protein for demographic and other risk factors among SCCS controls 
  Any S. gallolyticus protein 
  
neg (n=142) pos (n=206) p-value* 
Sex female 80 (56) 111 (54)  
male 62 (44) 95 (46) 0.651 
Age at blood 
draw (years) 
40-55 61 (43) 103 (50)  
56-60 34 (24) 42 (20)  
 61-77 47 (33) 61 (30) 0.427 
 mean (range) 57 (40-76) 56 (40-77)  
Ethnicity Caucasian-American 28 (20) 32 (16)  
 African-American 111 (80) 165 (84) 0.358 
 missing 3 9  
Education < high school 48 (35) 87 (43)  
 ≥ high school 91 (65) 115 (57) 0.113 
 missing 3 4  
Smoking never 39 (28) 56 (28)  
 former 43 (31) 65 (32)  
 current 57 (41) 81 (40) 0.970 
 missing 3 4  
BMI < 25 36 (26) 48 (24)  
 25-29.9 42 (30) 54 (27)  
 ≥ 30 61 (44) 99 (49) 0.617 
 missing 3 5  
Family history 
of CRC 
no 52 (91) 75 (83)  
yes 5 (9) 15 (17) 0.174 
 Missing 85 116  
*Pearson’s Chi-square-test 
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Table 31: Comparison of individuals antibody-positive or -negative to any S. gallolyticus 
protein for demographic and other risk factors among EPIC controls. 
  Any S. gallolyticus protein 
  
neg 
(n=212) 
pos 
(n=273) p-value* 
Sex female 103 (49) 144 (53)  
male 109 (51) 129 (47) 0.363 
Age at blood 
draw, years 
37-55 44 (21) 76 (28)  
56-60 55 (26) 69 (25)  
61-77 113 (53) 128 (47) 0.180 
 mean (range) 60 (39-77) 59 (37-75)  
Country Italy/Greece 50 (24) 62 (23)  
France/Spain 41 (19) 52 (19)  
UK 60 (28) 74 (27)  
 Germany/Netherlands 61 (29) 85 (31) 0.955 
Education none/primary school completed 92 (45) 120 (46)  
technical/professional 54 (26) 61 (23)  
secondary school/longer education  60 (29) 82 (31) 0.736 
 missing 6 10  
Smoking status never 94 (45) 140 (51)  
 former 73 (35) 81 (30)  
 current 44 (21) 51 (19) 0.316 
 missing 1 1  
Alcohol intake never 20 (10) 28 (11)  
 former 17 (8) 23 (9)  
 current > 0-6 g/day 49 (24) 84 (33)  
 6.01-20 g/day 63 (31) 67 (26)  
 > 20 g/day 53 (26) 56 (22) 0.230 
 missing 10 15  
BMI < 25 76 (36) 91 (33)  
25-29.9 95 (45) 143 (52)  
≥ 30 41 (19) 39 (14) 0.177 
Family history 
CRC 
no 83 (95) 93 (91)  
yes 4 (5) 9 (9) 0.253 
missing 125 171  
*Pearson’s Chi-Square-test  
 
3.4.3. Antibody responses to S. gallolyticus and prevalent CRC in the BliTz-
DACHSplus study 
The association of antibody responses to S. gallolyticus was first assessed with prevalent CRC 
in samples of the BliTz-DACHSplus study.  
In a previous independent CRC case-control study conducted in Spain using different protein 
sources we had found a significant association of antibodies to Gallo2178 and Gallo2179, 
individually but also in combination, with prevalent CRC [81]. Therefore, I first aimed to 
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replicate this finding in the BliTz-DACHSplus study (Figure 26). Indeed, also in this study 
positivity to Gallo2178 was significantly associated with CRC (OR: 4.50, 95%CI: 2.22-9.11) 
with 17% positive cases compared to 5% positive controls. The association was even 
significant (p-value < 0.0001) after Bonferroni-correction (p-value < 0.0036). Gallo2179 
alone was not significantly associated with CRC here (OR: 1.35, 95%CI: 0.73-2.51), 
however, double-positivity to Gallo2178-Gallo2179 showed a significant association with 
CRC. Since none of the controls was double-positive to Gallo2178-Gallo2179, it was not 
possible to calculate an estimate for the strength of the association, a crude analyses, however, 
showed a strong association (p-value 0.001) with 4% of DACHSplus cases being double-
positive.  
O R
0
.1 1 1
0
G a llo 2 1 7 8 -G a llo 2 1 7 9  D P
An y  S . g a llo ly t ic u s   p r o te in
G a llo 2 1 7 9
G a llo 2 1 7 8
G a llo 2 0 1 8
G a llo 1 6 7 5
G a llo 1 5 7 0
G a llo 0 9 3 3
G a llo 0 7 4 8
G a llo 0 5 7 7
G a llo 0 2 7 2
G a llo 0 1 1 2 B
G a llo 0 1 1 2 A
p o s
c o n tro ls
n  (% )
2 2  (1 0 )
2 2  (1 0 )
2 2  (1 0 )
2 2  (1 0 )
2 2  (1 0 )
2 2  (1 0 )
2 2  (1 0 )
2 2  (1 0 )
2 2  (1 0 )
1 1  (5 )
2 2  (1 0 )
1 3 1  (5 7 )
p o s
c a s e s
n  (% )
3 1  (1 0 )
2 8  (9 )
3 9  (1 2 )
3 2  (1 0 )
3 7  (1 2 )
4 0  (1 3 )
1 6  (5 )
3 3  (1 0 )
3 8  (1 2 )
5 5  (1 7 )
3 4  (1 1 )
2 1 3  (6 7 )
0  (0 ) 1 4  (4 )
p -v a lu e
0 .702
0 .583
0 .686
0 .602
0 .373
0 .148
0 .069
0 .725
0 .491
< 0 .0 0 0 1
0 .342
0 .010
0 .0 0 1 *
 
Figure 26: Antibody-positivity to individual S. gallolyticus proteins, double-positivity to 
Gallo2178 and Gallo2179 as well as positivity to any S. gallolyticus protein in relation to 
CRC in DACHSplus. BliTz controls (n=228) served as reference. OR and 95% CI were 
estimated using logistic regression models with adjustment for age, sex, smoking, BMI and 
education. The dashed line indicates null association. Significant associations after 
Bonferroni-correction (p-value < 0.0036) are underlined. *Crude analyses using Pearson’s 
Chi-square test. pos = antibody-positive. 
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After the replication for Gallo2178 and Gallo2179 I explored whether any of the newly 
developed proteins was individually associated with CRC. However, this was not the case for 
any of the additional nine proteins individually. Positivity to any of the in total eleven 
proteins, however, was significantly associated with CRC (OR: 1.65, 95% CI: 1.13-2.41) with 
67% positive cases compared to 57% positive controls. Considering multiple testing the 
association was not significant (p-value 0.01) (Figure 26). Sensitivity analyses with exclusion 
of the strongest individual marker Gallo2178 resulted in a non-significant OR (OR: 1.29; 95% 
CI: 0.89-1.87) indicating that the association with positivity to any S. gallolyticus protein was 
mostly driven by the strong impact of Gallo2178.  
The analyses of bovine sera as well as of sera from humans with S. gallolyticus bacteremia 
indicated that S. gallolyticus antibody-positive individuals could be positive to several of the 
eleven proteins simultaneously (3.2.3 and 3.2.4). Therefore, I assessed whether positivity to 
the different proteins correlated. Under the assumption that the presence of CRC or 
precancerous lesions is a prerequisite for S. gallolyticus infection, I expected this correlation 
to be stronger among cases than among controls. Several correlating protein pairs were 
identified (Table 32). Two of them (Gallo0577-Gallo1570 and Gallo0577-Gallo2179) 
correlated significantly among controls and cases. Sequence alignment of these three proteins 
(Appendix III) identified homologous stretches especially at the C-terminus of the proteins. 
This indicated that correlations seen among these proteins were probably due to antibodies 
reacting to conserved epitopes in the C-terminus of the three proteins. Apart from Gallo2178-
Gallo2179, which were correlating only among cases and where the double-positivity to both 
proteins was more than 2-fold higher among cases than among controls, three additional pairs 
with the same pattern were identified: Gallo0272-Gallo0748 (3.4-fold more double-positive 
cases compared to controls), Gallo0272-Gallo1675 (2.8-fold) and Gallo2018-Gallo2179 (2.2-
fold). The in total 6 proteins (Gallo0272, Gallo0748, Gallo1675, Gallo2018, Gallo2178 and 
Gallo2179) were combined in a 6-marker panel and positivity was defined as being positive to 
two or more proteins of this panel. 11% of controls were positive to two or more proteins of 
the 6-marker panel, compared to 19% of cases resulting in a significant association with CRC 
(OR: 1.99, 95%CI: 1.15-3.45) (Table 33). However, with Bonferroni-correction the 
association was not significant anymore (p-value 0.014).  
I further addressed whether the association of CRC with positivity to two or more proteins of 
the 6-marker panel was affected by baseline characteristics age and sex and whether the 
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association differed between different stages of the tumor (Figure 27). However, stratification 
by age or sex did not affect the estimate. Also the estimate of the association did not differ 
between different stages of the tumor. 
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Table 32: Percentage S. gallolyticus antibody double-positives (DP) among Blitz controls (n=228) and DACHSplus cases (n=318) 
 0112A 0112B 0272 0577 0748 0933 1570 1675 2018 2178 2179 
0112A  1.3 0.4 1.8 0.9 0 1.3 1.3 1.3 0.4 1.3 
 0.9 (0.7x)
1
 1.6 (4x) 1.3 (0.7x) 1.3 (1.4x) 1.6 (>999x) 0.3 (0.2x) 1.3 (1x) 1.9 (1.5x) 1.9 (4.8x) 0.9 (0.7x) 
0112B   0.4 2.2 1.3 2.2 0.9 0.4 1.8 1.3 0 
  1.9 (4.8x) 0.6 (0.3x) 0.9 (0.7x) 0.9 (0.4x) 1.6 (1.8x) 0.9 (2.3x) 1.6 (0.9x) 1.3 (1x) 0.6 (>999x) 
0272    1.3 0.9 0.9 1.3 0.9 0.4 0.4 1.3 
   1.3 (1x) 3.1 (3.4x) 1.3 (1.4x) 1.9 (1.5x) 2.5 (2.8x) 2.2 (5.5x) 2.5 (6.3x) 1.9 (1.5x) 
0577     1.8 1.3 4.0 1.3 1.3 0.4 3.5 
    1.6 (0.9x) 0.6 (0.5x) 2.2 (0.6x) 1.6 (1.2x) 1.9 (1.5x) 2.5 (6.3x) 4.4 (1.3x) 
0748      1.8 1.3 1.8 2.2 0.9 0.9 
     2.5 (1.4x) 1.6 (1.2x) 1.9 (1.1x) 1.3 (0.6x) 0.3 (0.3x) 0.9 (1x) 
0933       0.9 0.9 1.3 0 0.4 
      0.6 (0.7x) 0.9 (1x) 0.3 (0.2x) 1.3 (>999x) 0.6 (1.5x) 
1570        0.4 1.3 0.4 2.6 
       0.6 (1.5x) 0.3 (0.2x) 1.3 (3.3x) 1.3 (0.5x) 
1675         0.9 0.4 1.3 
        1.9 (2.1x) 1.9 (4.8x) 2.2 (1.7x) 
2018          0.4 1.3 
         3.1 (7.8x) 2.8 (2.2x) 
2178           0 
          4.4 (>999x) 
2179            
           
Grey: %DP among controls; red: %DP among cases; Significant correlations (Pearson’s Chi-square test, p-value <0.05) are marked in bold font; 1%DP among cases 
relative to %DP among controls; blue: %DP cases >2-fold than %DP controls and correlation significant 
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Table 33: Antibody responses to the S. gallolyticus 6-marker panel in relation to 
prevalence of CRC in the DACHSplus study compared to BliTz controls  
 Positive n (%)  
 Controls Cases    
 n=228 n=318 OR
1
 95% CI p-value 
≥2 of 6-marker panel 24 (11) 60 (19) 1.99 1.15-3.45 0.014 
6-marker panel includes Gallo0272, Gallo0748, Gallo1675, Gallo2018, Gallo2178 and 
Gallo2179; 
1
Logistic regression model with adjustment for age (continuous variable), sex, 
BMI, education and smoking; Significant associations are marked in bold font 
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Figure 27: OR and 95% CI for antibody-positivity to two or more proteins of the  
S. gallolyticus 6-marker panel in relation to CRC in BliTz-DACHSplus, overall and in 
separate logistic regression models for (A) sex, age at diagnosis and (B) UICC stage 
under adjustment for age, sex BMI, education, and smoking where applicable. The 
dashed line indicates null association. pos = antibody-positive. 
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A specificity analyses was carried out to assess whether observed associations of antibody 
responses to S. gallolyticus proteins with CRC were disease-specific. It was estimated 
whether positivity to individual S. gallolyticus proteins, any S. gallolyticus protein, to two or 
more proteins of the 6-marker panel or double-positivity to Gallo2178-Gallo2179 was 
associated with gastric cancer (GC) cases of the DACHSplus study in reference to BliTz 
controls (Figure 28). Odds for GC were not significantly increased with any of the above 
mentioned possibilities for S. gallolyticus positivity indicating a disease-specific association 
of antibody responses to S. gallolyticus with prevalent CRC in the BliTz-DACHSplus study. 
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Figure 28: Antibody-positivity to individual S. gallolyticus proteins and protein 
combinations in relation to gastric cancer cases (GC) in DACHSplus. BliTz controls 
(n=228) served as reference. OR and 95% CI were estimated using logistic regression models 
with adjustment for age, sex, smoking, BMI and education. The dashed line indicates null 
association. Significant associations after Bonferroni-correction are underlined. 6-marker 
panel includes Gallo0272, Gallo0748, Gallo1675, Gallo2018, Gallo2178 and Gallo2179 
*Crude analyses using Chi-square test. pos = antibody-positive. 
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3.4.4. Antibody responses to S. gallolyticus and incident CRC in SCCS 
The observed associations in the BliTz-DACHSplus CRC case-control studies were assessed 
in a prospective setting with the CRC case-control study nested within SCCS. However, none 
of the associations of antibody responses to S. gallolyticus with CRC in the BliTz-
DACHSplus study could be reproduced in the SCCS. OR for positivity to individual proteins, 
for positivity to any of the eleven proteins, double-positivity to Gallo2178-Gallo2179 as well 
as positivity to two or more proteins of the 6-marker panel with CRC risk ranged around the 
null in the SCCS (Figure 29A). Also exclusion of cases diagnosed within two years from the 
analyses did not alter the estimates (Figure 29B).  
Stratification of the study by baseline characteristics age at blood draw, sex and ethnicity did 
not reveal a certain group at specifically increased odds for CRC with positivity to two or 
more proteins of the 6-marker panel (Figure 30A). The very small group of Caucasian-
Americans included in this study showed an elevated odds ratio (OR: 3.94, 95% CI: 0.37-
41.54) compared to African-Americans (OR: 1.03, 95% CI: 0.56-1.89), however, due to the 
small sample size confidence intervals were widely overlapping. Subgroup analyses by age at 
diagnosis, stage or tumor site did not reveal any group at increased risk either (Figure 30B) 
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Figure 29: Antibody-positivity to individual S. gallolyticus proteins and combinations in 
relation to CRC risk in SCCS. A) Analyses with all individuals. B) Analyses of individuals 
diagnosed more than two years after blood draw. OR and 95% CI were estimated using 
conditional logistic regression models with adjustment for smoking, BMI and education. The 
dashed line indicates null association. 6-marker panel includes Gallo0272, Gallo0748, 
Gallo1675, Gallo2018, Gallo2178 and Gallo2179. pos = antibody-positive. 
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Figure 30: OR and 95% CI for antibody-positivity to two or more proteins of the  
S. gallolyticus 6-marker panel in relation to CRC risk in SCCS, overall and in separate 
conditional logistic regression models for (A) sex, age at blood draw and ethnicity as well 
as (B) for age at diagnosis, SEER stage and tumor site under adjustment for BMI, 
education, and smoking. The dashed line indicates null association. pos = antibody-positive. 
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3.4.5. Antibody responses to S. gallolyticus and incident CRC in the EPIC study 
A second prospective nested CRC case-control study was analyzed for an association of 
antibody responses to S. gallolyticus with CRC risk. In this study I was able to reproduce 
findings from BliTz-DACHSplus in a prospective setting: positivity to Gallo2178 individually 
(OR: 2.74, 95% CI: 1.39-5.40), double-positivity to Gallo2178-Gallo2179 (OR: 7.02, 95% CI: 
1.52-32.51), positivity to any of the eleven S. gallolyticus proteins (OR: 1.36, 95%CI: 1.05-
1.78) as well as to two or more proteins of the 6-maker panel (OR: 2.10, 95% CI: 1.40-3.14) 
were significantly associated with CRC risk (Figure 31A). Positivity to two or more proteins 
of the 6-marker panel even remained significant (p-value 0.0004) after Bonferroni-correction 
for multiple testing (p-value < 0.0036). In addition to the replicated findings also antibody 
responses to individual proteins Gallo0272 (OR: 1.52, 95% CI: 1.01-2.29) and Gallo0748 
(OR: 1.49, 95% CI: 1.02-2.17) were significantly associated with CRC, however, only 
without correction for multiple testing. Sensitivity analyses with exclusion of those 
participants diagnosed within 2 years after blood draw revealed similar associations as 
described above with the exception of Gallo0748, which was not significantly associated 
anymore (OR: 1.38, 95% CI: 0.89-2.15). In addition, the statistical power with the reduced 
sample size was not sufficient for positivity to two or more proteins of the 6-marker panel 
being significantly associated (p-value 0.006) after correction for multiple testing (Figure 
31B). Thus, I was able to reproduce findings of the BliTz-DACHSplus study in the 
prospective EPIC study setting showing that antibody responses to S. gallolyticus proteins 
were significantly associated with CRC more than two years prior to diagnosis.  
Interestingly, stratification by age at blood draw showed that CRC in the youngest age group 
(37-55 years) was not significantly associated with positivity to two or more proteins of the 6-
marker panel (OR: 1.12, 95% CI: 0.49-2.56) compared to the two other age groups examined 
(56-60 years (OR: 3.94, 95% CI: 1.27-12.25) and 61-77 years (OR: 2.41, 95% CI: 1.32-4.39)) 
(Figure 32A). Stratification by country of residence showed a slight difference in the 
estimates ranging from Germany/Netherlands with a non-significant OR of 1.73 to a 
significant association in Italy/Greece (OR: 3.48, 95% CI: 1.21-10.03). There was no 
difference in the estimate by stage, however, by tumor site: rectal cancer cases showed a 
stronger association with positivity to two or more proteins of the 6-marker panel (OR: 22.16, 
95% CI: 1.58-311.11) than colon cancer cases (OR: 1.92, 95% CI: 1.26-2.94). However, 
confidence intervals were strongly overlapping due to the small sample size of rectal cancers 
(Figure 32B).  
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Figure 31: Antibody-positivity to S. gallolyticus proteins and combinations in relation to 
CRC risk in EPIC. A) Analyses with all individuals. B) Analyses with individuals diagnosed 
more than two years after blood draw. OR and 95% CI were estimated using conditional 
logistic regression models with adjustment for smoking, alcohol status, BMI and education. 
The dashed line indicates null association. Significant associations after Bonferroni-correction 
(p-value < 0.0036) are underlined. 6-marker panel includes Gallo0272, Gallo0748, 
Gallo1675, Gallo2018, Gallo2178 and Gallo2179. pos = antibody-positive. 
 
Results 
106 
 
O R
0
.1 1 1
0
1
0
0
G e rm a n y /N e th e r la n d s
U K
F ra n c e /S p a in
Ita ly /G re e c e
6 1 -7 7
5 6 -6 0
3 7 -5 5
m a le
fe m a le
O v e ra ll
p o s
c a s e s
n  (% )
S e x
A g e  a t b lo o d
d ra w  (y e a rs )
8 3  (1 7 )
4 2  (1 7 )
4 1  (1 7 )
1 6  (1 3 )
2 3  (1 9 )
4 4  (1 8 )
p o s
c o n tro ls
n  (% )
4 5  (9 )
2 0  (8 )
2 2  (9 )
2 3  (1 0 )
1 4  (1 2 )
1 1  (9 )
C o u n try
1 8  (1 6 )
1 7  (1 8 )
2 5  (1 9 )
2 3   (1 6 )1 5  (1 0 )
6  (5 )
9  (1 0 )
1 5  (1 1 )
O R
0
.1 1 1
0
1
0
0
re c tu m
c o lo n
m e ta s ta t ic
lo c a liz e d
6 6 -8 1
6 0 -6 5
3 8 -5 9
O v e ra ll
p o s
c a s e s
n  (% )
E P IC  s ta g e
8 3  (1 7 )
2 5  (1 6 )
2 0  (1 6 )
p o s
c o n tro ls
n  (% )
 4 5  (9 )
1 6  (1 0 )
1 1  (9 )
A g e  a t d ia g n o s is
(y e a rs )
S ite
3 8  (1 9 )1 8  (9 )
6 9  (1 6 )4 0  (9 )
1 4  (2 6 )5  (9 )
2 6  (1 7 )1 4  (9 )
2 4  (1 5 )1 3  (8 )
A
B
 
Figure 32: OR and 95% CI for antibody-positivity to two or more proteins of the  
S. gallolyticus 6-marker panel in relation to CRC risk in EPIC, overall and in separate 
conditional logistic regression models for (A) sex, age at blood draw and country of 
residence as well as (B) for age at diagnosis, stage (EPIC classification) and tumor site 
under adjustment for BMI, education, alcohol and smoking status. The dashed line 
indicates null association. pos = antibody-positive. 
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3.4.6. Exploration of S. gallolyticus multiplex serology in precancerous colorectal 
lesions 
I found a significant association of antibody responses to S. gallolyticus proteins with 
prevalent CRC in the BliTz-DACHSplus study but also with the risk of developing CRC in 
the prospective EPIC study. I analyzed two studies, BliTz (1:100 serum dilution) and the Irish 
CRC case-control study (1:1000 serum dilution), for an association of antibody responses to 
S. gallolyticus proteins to assess the hypothesis that antibody responses can be detected prior 
to diagnosis and thus already in precancerous lesions. Both studies provided only small 
sample numbers of precancerous lesions (n < 100) and analyses should therefore be 
considered exploratory. Antibody responses to S. gallolyticus proteins in precancerous lesions 
and CRC cases in BliTz were compared to those in BliTz controls with the above described 
cut-offs (3.4.1). The Irish case-control study consisted of only 37 controls to generate antigen 
specific cut-offs (Table 34). Applied cut-offs were used to compare the fraction of positive 
individuals in Irish controls to those with minor diagnoses and colorectal neoplasm. 
The fraction of individuals positive to two or more proteins of the 6-marker panel was 11% in 
BliTz controls and 8% in Irish controls. These numbers were exceeded by all diagnosed 
colorectal neoplasms (14%-27% in BliTz and 18%-26% in the Irish study) and those 
individuals with minor diagnoses in the Irish study (25%) (Table 35 and Table 36, 
respectively). These differences were significant for non-advanced adenoma cases in the 
BliTz study and for minor diagnoses, polyp and adenoma cases in the Irish study. Positivity to 
any S. gallolyticus protein was significantly different between Irish controls and individuals 
with minor diagnoses as well as with polyps. Double-positivity to Gallo2178-Gallo2179 was 
a rare event and did not differ among groups in the Irish study, however, was significantly 
different between controls and non-advanced adenoma cases in the BliTz study, even after 
Bonferroni-correction for multiple testing. Positivity to individual proteins differed 
significantly for Gallo0272 between Irish controls and individuals with polyps, adenomas and 
high-grade dysplasia; for Gallo0748 between Irish controls and individuals with minor 
diagnoses as well as high-grade dysplasia; for Gallo0933 between Irish controls and 
individuals with polyps; for Gallo2178 between BliTz controls and CRC cases; and for 
Gallo2179 with BliTz controls and non-advanced adenoma cases as well as with Irish controls 
and CRC cases.  
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Thus, despite small sample numbers in the BliTz and Irish CRC case-control studies I 
observed an overall trend for a higher fraction of individuals antibody-positive to  
S. gallolyticus proteins and combinations in precancerous lesions and CRC cases compared to 
controls. However, both studies were rather inconsistent in their individual results, probably 
due to the statistical imprecision resulting from the small sample numbers in both studies.  
Table 34: S. gallolyticus antigen-specific cut-offs in the Irish CRC case-control study 
Antigen Cut-off (MFI) 
Gallo0112A 30 
Gallo0112B 30 
Gallo0272 91 
Gallo0577 193 
Gallo0748 73 
Gallo0933 108 
Gallo1570 162 
Gallo1675 109 
Gallo2018 111 
Gallo2178 14 
Gallo2179 132 
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Table 35: Fraction of S. gallolyticus antibody-positive individuals among controls in comparison to individuals with colorectal neoplasm 
identified during colonoscopy screening in the BliTz study 
 
Controls  
(n=228) 
Non-advanced 
adenoma
1
  
(n=30) 
p-value
3
 
Advanced 
adenoma
2
 
(n=100) 
p-value
3
 
CRC 
(n=50) 
p-value
3
 
Gallo0112A 22 (10) 2 (7) 0.597 5 (5) 0.159 3 (6) 0.414 
Gallo0112B 22 (10) 3 (10) 0.951 12 (12) 0.520 1 (2) 0.075 
Gallo0272 22 (10) 5 (17) 0.238 12 (12) 0.520 6 (12) 0.617 
Gallo0577 22 (10) 4 (13) 0.529 5 (5) 0.159 4 (8) 0.717 
Gallo0748 22 (10) 3 (10) 0.951 16 (16) 0.098 8 (16) 0.190 
Gallo0933 22 (10) 4 (13) 0.529 17 (17) 0.058 7 (14) 0.362 
Gallo1570 22 (10) 4 (13) 0.529 4 (4) 0.081 5 (10) 0.940 
Gallo1675 22 (10) 6 (20) 0.087 8 (8) 0.633 6 (12) 0.617 
Gallo2018 22 (10) 3 (10) 0.951 12 (12) 0.520 9 (18) 0.089 
Gallo2178 11 (5) 3 (10) 0.240 3 (3) 0.452 7 (14) 0.017 
Gallo2179 22 (10) 7 (23) 0.026 11 (11) 0.708 3 (6) 0.414 
Any S. gallolyticus protein 131 (57) 20 (67) 0.336 65 (65) 0.200 34 (68) 0.169 
Gallo2178-Gallo2179 DP 0 (0) 2 (7) <0.0001 2 (2) 0.032 0 (0)  
≥ 2 of 6-marker panel4 24 (11) 8 (27) 0.012 14 (14) 0.366 8 (16) 0.272 
1
tubular adenoma, adenoma <10mm; 
2
High grade dysplasia, villous adenoma with high-grade dysplasia, large adenoma (> 10 mm) with 
neither high-grade dysplasia nor villous architecture; 
3Pearson’s Chi-square test in comparison to controls; 46-marker panel includes: 
Gallo0272, Gallo0748, Gallo1675, Gallo2018, Gallo2178 and Gallo2179; Significant associations after Bonferroni-correction (p-value < 
0.0036) are underlined. DP = double-positivity 
   
Results 
110 
 
Table 36: Fraction of S. gallolyticus antibody-positive individuals among controls in comparison to individuals with minor diagnoses or 
individuals with colorectal neoplasm diagnosed with colonoscopy in the Irish CRC and precursors sample collection 
 
Controls  
(n=37) 
Minor 
diagnoses
1
  
(n=63) 
p-
value
4
 
Polyp
2
 
(n=85) 
p-
value
4
 
Adenoma
3
 
(n=60) 
p-
value
4
 
High grade 
dysplasia 
(n=22) 
p-
value
4
 
CRC 
(n=25) 
p-
value
4
 
Gallo0112A 2 (5) 4 (6) 0.848 7 (8) 0.583 4 (7) 0.802 2 (9) 0.586 3 (12) 0.350 
Gallo0112B 1 (3) 1 (2) 0.701 6 (7) 0.342 2 (3) 0.862 0 (0) 0.437 1 (4) 0.777 
Gallo0272 3 (8) 14 (22) 0.070 23 (27) 0.019 17 (28) 0.017 6 (27) 0.048 1 (4) 0.518 
Gallo0577 3 (8) 9 (14) 0.359 13 (15) 0.280 3 (5) 0.537 2 (9) 0.896 4 (16) 0.335 
Gallo0748 3 (8) 16 (25) 0.033 19 (22) 0.060 11 (18) 0.164 8 (36) 0.007 6 (24) 0.081 
Gallo0933 3 (8) 14 (22) 0.070 23 (27) 0.019 6 (10) 0.755 5 (23) 0.113 3 (12) 0.611 
Gallo1570 3 (8) 10 (16) 0.265 11 (13) 0.441 4 (7) 0.790 5 (23) 0.113 2 (8) 0.988 
Gallo1675 3 (8) 6 (10) 0.811 11 (13) 0.441 5 (8) 0.969 1 (5) 0.599 1 (4) 0.518 
Gallo2018 3 (8) 8 (13) 0.479 15 (18) 0.172 8 (13) 0.431 3 (14) 0.497 5 (20) 0.171 
Gallo2178 2 (5) 5 (8) 0.632 10 (12) 0.278 3 (5) 0.930 1 (5) 0.884 2 (8) 0.683 
Gallo2179 3 (8) 8 (13) 0.479 9 (11) 0.672 10 (17) 0.229 2 (9) 0.896 7 (28) 0.037 
Any S. gallolyticus protein 21 (57) 48 (76) 0.043 65 (76) 0.028 40 (67) 0.326 16 (73) 0.220 18 (72) 0.223 
Gallo2178-Gallo2179 DP 0 1 (2) 0.441 1 (1) 0.508 1 (2) 0.430 0  0  
≥2 of 6-marker panel5 3 (8) 16 (25) 0.033 22 (26) 0.025 15 (25) 0.038 4 (18) 0.247 6 (24) 0.081 
1
includes hemorrhoids, diverticulosis, mucosal ulceration/inflammation, melanosis coli, menorrhagia/disordered proliferative endometrium, mild active 
colitis, diarrhea, erythema; 
2
hyperplastic polyp or small tubular adenoma (< 10mm); 
3
tubular adenoma, tubulovillous adenoma, villous adenoma; 
4Pearson’s 
Chi-square test in comparison to controls; 
5
6-marker panel includes: Gallo0272, Gallo0748, Gallo1675, Gallo2018, Gallo2178 and Gallo2179; DP = double-
positivity
 
 
 
Discussion 
111 
 
4. Discussion 
CRC is the third most common type of cancer worldwide [1]. A connection of CRC with 
alterations in the gastrointestinal microbiome has gained increasing interest in recent years 
[25]. In particular, CRC prevalence was found to be associated with two bacterial species:  
F. nucleatum and S. gallolyticus [33]. However, it still remains unclear whether associated 
bacterial infections are a consequence of tumor development or whether they play a causal 
role in tumorigenesis or progression of the disease. The latter could have importance in 
prevention by eradication of the bacterium. Knowledge on the former, especially at which 
stage or precancerous lesion this association is present, might be of diagnostic value in the 
early detection of CRC. 
Serology is a time- and cost-effective methodology, especially compared to PCR- and 
sequencing-based methods, to analyze infection markers in epidemiological studies. Multiplex 
serology, developed by Tim Waterboer et al. allows the simultaneous analyses of up to 100 
antigens in one reaction and thus is a high-throughput serology application [114].  
In this thesis, I developed multiplex serology assays for the detection of antibodies directed 
against eleven proteins each of F. nucleatum and S. gallolyticus. These were applied in one 
retrospective case-control study as well as two independent case-control studies nested within 
prospective cohorts. Gold-standard assays for serological validation of F. nucleatum and S. 
gallolyticus multiplex serology assays were not available. Attempts to validate the assays by 
comparison to DNA status in colon or fecal samples indicated specific antibody responses to 
F. nucleatum and S. gallolyticus proteins, however, small sample sizes resulted in non-
significant differences. Experimentally infected mice and samples from humans with  
S. gallolyticus bacteremia further strengthened the observations, however, also here sample 
sizes were not sufficient to define robust cut-offs for antibody-positivity. Though, with 
arbitrary definitions for antibody-positivity I was able to identify repeatedly an association of 
prevalent and incident CRC cases with antibody responses to S. gallolyticus proteins in a 
German case-control study (BliTz-DACHSplus) and a prospective European study (EPIC) but 
interestingly not in an US-American study (SCCS). In contrast, I could not identify a 
serological association of F. nucleatum with CRC, neither retro- nor prospectively.  
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4.1. F. nucleatum multiplex serology and CRC 
4.1.1. Development of F. nucleatum multiplex serology 
Multiplex serology provides the possibility of the simultaneous analyses of several antigens in 
one reaction [114]. This is of great advantage especially in the seroepidemiological analysis 
of bacterial infections since bacteria express a large variety of potential immunogenic proteins 
that are presented to the immune system. H. pylori multiplex serology for example includes 
15 different immunogenic proteins giving a high sensitivity and specificity for detection of 
present and past H. pylori infection [143]. Previous studies on F. nucleatum serology used 
whole cell protein extracts [144-146]. This method is prone to lack specificity due to cross-
reacting antibody responses induced by proteins from other bacterial species, which share 
high homology to F. nucleatum proteins.  
Only few species-specific and immunogenic proteins of F. nucleatum have been identified so 
far. The adhesin FadA (Fn0264) was applied in ELISA to analyze antibody responses in 
saliva and plasma of periodontitis patients [117]. The outer membrane protein FomA 
(Fn1859) [118] was used to immunize mice, which developed plasma IgG and IgA antibody 
responses against FomA. A very recent study identified FomA also as immunogenic protein 
in CRC patients that were F. nucleatum DNA-positive in stool [147]. These two proteins have 
been included in the F. nucleatum multiplex serology assay. The selection of additional nine 
proteins was based on their localization and potential function in the bacterium since 
experience from H. pylori multiplex serology had revealed that proteins located at the outer 
membrane or secreted as well as those important in virulence are immunogenic and associated 
with disease [113, 143]. As described in 1.2.1 proteins Fap2 (Fn1449) and RadD (Fn1526) 
may have virulence functions, on the one hand by modulating the immune system and on the 
other in adhesion and biofilm formation [52, 53, 59, 60]. These two proteins are members of a 
type Va secretion pathway [58]. They represent autotransporters, polypeptides which possess 
three domains for translocating effectors (signal sequence) over the inner (passenger domain) 
and outer membrane (translocation unit) to be finally secreted. Such autotransporters were 
described in other bacteria to be of importance in virulence of the bacterium. A well-known 
autotransporter in H. pylori is the Vacuolating Cytotoxin A (VacA), which inserts into the 
host cell plasma membrane and induces vacuoles which lead to cell death [148]. VacA also 
induces antibody responses that are associated with gastric cancer [149]. Other F. nucleatum 
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proteins included in the multiplex serology and belonging to the Type Va secretion system 
were Fn0387, Fn1426 and Fn1893.  
Fn0131 and Fn1817, in contrast, belong to the type Vb secretion pathway, which is a two-
partner secretion pathway of a transporter (Fn0131) and a secreted protein (Fn1817) [58, 148]. 
Finally Fn0253 was identified as a protein located at the outer membrane and therefore prone 
to be detected by the host immune system [122].  
Specificity of selected proteins was addressed in silico. This approach is limited to genomes 
of sequenced bacteria and thus potentially misses sequences of yet unidentified and non-
sequenced bacterial species. Amino acid sequences were compared for percentage identity to 
homologous proteins in other bacteria. The reference strain ATCC 25586 belongs to the F. 
nucleatum subspecies nucleatum. Proteins of other F. nucleatum subspecies shared a more 
than 74% amino acid sequence identity with the selected proteins. Thus, detected antibody 
responses are probably not subspecies-specific. The selected proteins have a high amino acid 
identity (up to 97%) to proteins of a newly identified fusobacterial species, F. hwasookii 
[124]. A serological distinction between F. hwasookii and F. nucleatum cannot be guaranteed. 
F. hwasookii was first isolated from a human periodontitis lesion in 2015 [124], however, 
since then was not further reported in the literature. The epidemiology of this bacterium has 
not been assessed to date and the impact in human infections cannot be inferred from the 
available literature. The next known bacterial relative is F. periodonticum. Except for Fn0264, 
selected proteins shared a sequence identity of less than 80% with proteins of this bacterium. 
Other, none fusobacterial species did not exceed an identity of 56%. Thus, although cross-
reactive antibody responses to linear epitopes were unlikely, cross-reactive responses to 
conformational epitopes cannot be excluded. Homologous proteins could be generated to 
measure potential cross-reactive antibody responses, however, this was not possible within the 
scope of this thesis.  
The eleven selected F. nucleatum proteins were recombinantly expressed and underwent 
quality controls, both, on the DNA- and protein level to ascertain expression of the correct 
and functional full-length antigen in acceptable quantity. Quality controls on the DNA level 
included an analytical restriction digestion of plasmids isolated from an intermediate step 
during the expression procedure as well as PCR of the final lysate with subsequent 
sequencing. Both controls identified the presence of all expected expression constructs in the 
respective lysates. Quality control on the protein level included Western blot with antibodies 
directed against the N-terminal GST and, to detect full-length fusion protein, against the C-
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terminal tag. Additionally, an anti-tag ELISA was performed for the quantification of 
glutathione-binding full-length protein relative to GST-tag as reference. Seven out of eleven 
proteins could be detected in the anti-tag blot of the final lysate at the expected protein size. 
These proteins also needed less than 30-fold of the total protein concentration relative to 
GST-tag to reach the half-maximum OD of GST-tag. Low amounts of full-length fusion 
proteins were found for Fn0131, Fn1426, Fn1526 and Fn1859 in the final lysates indicating 
partial insolubility. All four proteins were predicted to be located in the cell membrane. 
Potential transmembrane domains that were not identified with the applied prediction 
programs might have led to hydrophobicity and consequently insolubility. Additionally, 
Fn1859 migrated like an approximately 10 kD smaller protein. The protein was most probably 
N-terminally degraded since the C-terminal tag was detectable. The polyclonal anti GST-
antibody, in contrast to monoclonal anti-tag antibody, recognizes several epitopes in GST 
explaining why bands in the anti-GST blot could be detected despite the presumed N-terminal 
degradation.  
A final quality control on the protein level was performed by loading of antigens onto 
glutathione-casein coupled beads at a lysate protein concentration of 1 mg/ml. Subsequent 
loading control with anti-tag antibody indicated similar amounts of full-length protein on the 
beads for all F. nucleatum proteins as compared to GST-tag lysate. Thus, all recombinantly 
expressed F. nucleatum proteins were finally applied in multiplex serology. 
In addition to the technical controls it was attempted to serologically validate F. nucleatum 
multiplex serology. A clear limitation thereby was the lack of a serological gold standard 
assay for comparison to the newly developed multiplex serology. In the attempt to 
nonetheless validate the assay I used serum samples of patients with adenoma or CRC in 
whom F. nucleatum DNA had been found in the tumor and/or surrounding normal tissue. 
Antibody levels (MFI values) to none of the F. nucleatum proteins were able to discriminate 
between F. nucleatum colon-tissue DNA-negative and –positive individuals. Experience from 
H. pylori multiplex serology had shown that positivity to several proteins simultaneously 
increased specificity for detection of the infection [143]. Application of a cut-off derived from 
the mean MFI plus three times standard deviation in controls revealed a trend of a higher 
frequency of F. nucleatum antibody-positives in DNA-positives compared to –negatives, with 
positivity to individual but also to more than one of the proteins. However, due to the small 
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sample size and the weakness of the differences there was no significant correlation 
observable.  
As described in 1.3.2 amplification of DNA of infectious agents only detects acute infections 
at the specific site analyzed. Serology, however, detects acute and past infections independent 
of the site of infection. F. nucleatum is most predominant in the oral cavity, another infection 
site possibly leading to antibody responses. This and the detection of antibody responses 
resulting from possible past infections may have led to the difficulties in discrimination 
between colonic-tissue DNA-negative and –positive individuals by multiplex serology.  
4.1.2. Antibody responses to F. nucleatum and CRC in a retrospective case-
control study and two independent case-control studies nested within 
prospective cohorts 
F. nucleatum multiplex serology was applied in one German CRC case-control study (BliTz-
DACHSplus) and two independent case-control studies nested within prospective cohorts: one 
multi-center cohort from southern US (SCCS) and one multi-national cohort conducted across 
Europe (EPIC). A clear limitation in the analyses was the lack of an infection-based cut-off 
for F. nucleatum antibody-positivity resulting from the above described absence of 
appropriate reference assay and samples. Therefore, the cut-off had to be defined arbitrarily 
and was set for individual F. nucleatum proteins to the MFI that defined 10% of control 
individuals as being positive. The distribution of MFI in BliTz controls supported this cut-off 
definition: The overall antibody responses to individual proteins were low and the cut-off was 
similar to the approximate point of inflection in the antibody distribution curve. Visual 
inspection of these so-called percentile plots was previously used in our laboratory to define 
cut-offs since it is assumed that a sudden rise in the antibody response over percentile of 
serum indicates the cut-off for antibody-positivity ([128] and Michael Pawlita, personal 
communication). Cut-offs were defined per study. The SCCS study was analyzed in the same 
experimental run as the BliTz-DACHSplus study and cut-offs can therefore directly be 
compared. Cut-offs were similar for the individual proteins among studies indicating 
robustness. However, for one protein, Fn1817_1, the cut-off defining 10% of controls as 
positive was 15-times higher in the SCCS (2039 MFI) than in the BliTz-DACHSplus study 
(133 MFI). The only baseline characteristic in SCCS controls significantly associated with 
antibody-positivity to Fn1817_1 was being African-American indicating a difference in 
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antibody response by ethnicity that will be discussed later in the context of S. gallolyticus 
multiplex serology.  
The arbitrarily defined cut-offs for individual proteins were applied to assess whether there is 
an association of antibody responses measured in F. nucleatum multiplex serology with 
prevalent and incident CRC. Overall F. nucleatum positivity was defined as being positive to 
any of the eleven proteins to allow inter-individual differences in the immune response but 
also infection with different bacterial strains. This algorithm resulted in similar fractions of F. 
nucleatum antibody-positive controls in all three studies (57% in BliTz-DACHSplus, 59% in 
SCCS and 53% in EPIC). These were compared to F. nucleatum antibody-negative controls in 
their baseline characteristics. The only significant difference between F. nucleatum negative 
and positive controls was identified in the BliTz-DACHSplus study with sex distribution. 
Here, more males were F. nucleatum antibody-positive than females. This trend was also 
observed in SCCS and EPIC, however, it was not significant. A review by Albandar identified 
studies showing that periodontitis, a disease associated with increased gingival levels of  
F. nucleatum was more frequent in adult males than in females independent of age [150]. 
However, a specific association of sex with F. nucleatum infection was not reported so far.  
I did not observe a significant association of positivity to any F. nucleatum protein or 
individual F. nucleatum proteins with neither prevalent nor incident CRC in any of the 
studies. Positivity to individual F. nucleatum proteins correlated, which was expected from 
proteins of the same organism, however, not specifically in CRC patients. These results are 
not concordant with the PCR-based studies presented in 1.2.1 that all found an association of 
F. nucleatum with CRC [37-42]. Recently, a study by Wang et al. was published where the 
authors used F. nucleatum whole cell protein ELISA to analyze serum samples of 200 healthy 
subjects, 50 benign colon disease patients and 258 CRC patients for differences in antibody 
responses to F. nucleatum [147]. They found significant differences in antibody responses 
between healthy controls and CRC patients. Application of a cut-off based on 96% specificity 
resulted in sensitivities of detecting overall CRC of 31% with a secondary antibody against 
IgA and 19% with anti-IgG. In addition they applied Western blot analyses with subsequent 
mass spectrometry analyses to identify specific immunogenic F. nucleatum proteins detected 
by anitbodies in serum from CRC patients with F. nucleatum DNA-positive stool. Fn1859, 
but none of the other F. nucleatum multiplex serology proteins, was among the identified 
proteins. However, also Fn1859 was neither associated with CRC nor with F. nucleatum 
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DNA-positivity in colon tissue (3.2.1) in the studies presented here. Different possible reasons 
for the discordance of the results presented here with the current literature can be inferred 
from the study by Wang et al. [147]:  
i) The selection of antigens. The only identified immunogenic protein by Wang et al. 
included in multiplex serology was Fn1859. However, in their association study 
with CRC they even used F. nucleatum whole cell protein instead of 
recombinantly expressed proteins [147]. Potentially, the proteins selected for 
multiplex serology are of low sensitivity in detecting antibody responses against F. 
nucleatum, which could be reflected by the overall low antibody responses in all 
three studies presented here.  
ii) The selection of secondary antibody. Wang et al. analyzed IgA and IgG antibody 
responses separately and found differing sensitivities in detection of antibody 
responses against F. nucleatum [147]. F. nucleatum was identified in CRC by 
detection of the DNA in tumor tissue, rather than by a secondary bacteremia as 
seen with S. gallolyticus. It is probable that F. nucleatum resides in the colonic 
epithelial/mucosal tissue, where the main isotype of antibodies secreted is IgA 
[151]. The secondary antibody applied in multiplex serology is directed against 
IgG, IgA and IgM simultaneously, however, a more specific detection of the three 
isotypes could be beneficial in F. nucleatum serology.  
iii)  The selection of study subjects. The association of F. nucleatum DNA with CRC 
was predominantly found in proximal tumors, higher stage tumors, tumors of 
larger size, MSI-H tumors, and those of the serrated pathway [47-50, 152]. 
Separate analyses by stage in the studies presented here did not reveal differences 
in the OR. The only significant differences observed between subgroups were an 
inverse association in females of the BliTz-DACHSplus and EPIC studies in 
contrast to a null association among males and an inverse association with rectal in 
contrast to colon cases in SCCS. These differences could not be reproduced over 
all studies and might result from an underlying sample characteristic that was not 
analyzable with the given data. However, the differences might also have occurred 
simply by chance. Wang et al. did not further specify the types of cases they 
included [147]. It would be interesting to further analyze studies with cases more 
specifically characterized by morphology and histology of the tumor to assess 
whether positivity with F. nucleatum multiplex serology is associated with a 
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certain subtype of CRC that may have been underrepresented in the studies 
analyzed in this thesis.  
4.2. S. gallolyticus multiplex serology and CRC 
4.2.1. Development of S. gallolyticus multiplex serology 
In a previous study I used recombinantly expressed and purified his-tagged S. gallolyticus 
pilus proteins (Gallo1569, Gallo2039, Gallo2178 and Gallo2179) in multiplex serology to 
analyze a Spanish multi-center CRC case-control study [81]. Two of these pilus proteins, 
Gallo2178 and Gallo2179 were individually associated with CRC (OR of 1.5) and double-
positivity to both significantly increased odds for CRC 3.6-fold. However, only 1% of 
controls were double-positive compared to 4%, and thus only a minor fraction, of cases.  
In the attempt to possibly increase sensitivity by the inclusion of several more S. gallolyticus 
proteins I further selected nine additional proteins for S. gallolyticus multiplex serology. 
Similar to F. nucleatum, selection of proteins was based on predicted function and 
localization of the proteins in the bacterium since information on immunogenic proteins in 
literature was rare. S. gallolyticus is a gram-positive bacterium possessing a cell wall as an 
outer shell. Sillanpää et al. and Hinse et al. listed several proteins potentially localized at the 
cell wall due to the presence of a LpxTG signal motif [121, 123]. These proteins included 
Gallo2178 and Gallo2179 as well as Gallo0112, a putative fructan hydrolase, Gallo0272, a 
putative agglutinin receptor, Gallo0577, a protein containing a cnaB domain, which is 
frequently found in pilus structures, Gallo0748, a putative proteinase, Gallo1570, also a 
subunit of a pilus structure, Gallo1675 with unknown function and Gallo2018, a protein 
putatively involved in bacteriocin synthesis. I additionally included an enzyme that is 
putatively secreted from the bacterium, Gallo0933, a potential tannase. Tannases degrade 
toxic tannins found in plants to gallic acid, which can be further used as carbon supply for the 
bacterium and may represent a survival advantage compared to other bacteria not expressing 
tannases [119].  
Comparison of amino acid sequences to proteins of other bacteria identified several S. 
gallolyticus proteins sharing a high sequence identity with proteins of S. equinus (up to 97%). 
However, this bacterium is rarely isolated from humans [66]. Other closely related species of 
S. gallolyticus, S. pasteurianus and S. infantarius have homologous proteins to Gallo1675 
(99% sequence identity) and Gallo0748 (67%), respectively. The sequence identity was below 
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75% for all other S. gallolyticus proteins to those of species of the S. equinus/S. bovis 
complex, the family of Streptococcacae or none streptococcal species indicating a high 
specificity of the assay. However, as described for F. nucleatum, also here antibodies cross-
reacting to conformational epitopes cannot be excluded.  
Most of the recombinantly expressed S. gallolyticus proteins showed lower relative full-length 
protein concentration in anti-tag ELISA, while all proteins were identified at the expected 
sizes in the anti-tag blot of cleared lysate. The anti-tag epitope might have been hidden in 
anti-tag ELISA, where proteins should keep their conformation. In the application in 
multiplex serology, however, proteins loaded onto beads were detected in comparable 
quantities to GST-tag indicating also for S. gallolyticus proteins that there is a saturating 
excess of full- length protein in the amount of lysate applied in bead-loading. 
There is no gold standard assay available for the serological validation of S. gallolyticus 
multiplex serology. However, I had three different possibilities to potentially address 
serological validation: i) A time-series of sera from mice after inoculation with S. gallolyticus 
UCN34 or PBS; ii) serum samples from dairy cows with additional information on S. 
gallolyticus DNA found in feces; iii) serum samples from three individuals with diagnosed S. 
gallolyticus bacteremia and three healthy controls. The three different attempts resulted in 
similar pattern of antibody responses to S. gallolyticus proteins. Antibody responses to 
Gallo0272 and Gallo2179 distinguished defined positives from negatives in all three hosts. 
Analysis of the human serum samples from individuals diagnosed with S. gallolyticus 
bacteremia probably resembles best the later application in serum collections of human origin. 
Gallo2178 was recognized specifically by sera of patients diagnosed with S. gallolyticus 
bacteremia together with Gallo0272 and Gallo2179 but also Gallo0577, Gallo0748, 
Gallo1570 and Gallo2018. Also these proteins mostly overlap with the proteins that best 
distinguished S. gallolyticus DNA-negative from -positive cows as well as experimentally 
infected from non-infected mice. In addition, the finding that patients with S. gallolyticus 
bacteremia raised antibody responses to several proteins simultaneously was concordant to the 
observation in bovine sera, where positivity to several proteins strengthened the specificity in 
comparison to DNA positivity. 
Comparison of serology with PCR-based data has two major pitfalls: Serology measures 
present and past systemic infections, whereas PCR measures present infection at a specific 
site. I cannot exclude that DNA-negative cows never had a past S. gallolyticus infection 
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neither can I assure that S. gallolyticus is excreted with feces. Unfortunately, the number of 
human samples with known systemic S. gallolyticus infection status was small with three 
individuals in each, healthy control and S. gallolyticus-bacteremia patient groups. Larger 
serum collections would have been needed to define robust cut-offs for individual proteins 
and an algorithm for S. gallolyticus overall positivity.  
4.2.2. Antibody responses to S. gallolyticus and CRC in a German case-control 
study and an independent case-control study nested within a European 
prospective cohort 
A limitation, also for S. gallolyticus, was the arbitrary cut-off definition for the analyses of 
seroepidemiological studies in BliTz, SCCS and EPIC. The fecal carriage rate of S. 
gallolyticus in healthy individuals was found to range between 1 and 11% [78, 79]. In a 
previous multiplex serology study, where four S. gallolyticus pilus proteins were applied as 
antigens in a Spanish multi-center CRC case-control study, the cut-offs were arbitrarily set to 
define 10% of controls being positive to each of the four S. gallolyticus proteins. The overall 
antibody responses to the newly developed eleven S. gallolyticus GST-X-tag fusion proteins 
in colonoscopy-negative BliTz controls was low, reflecting the expected low fecal carriage 
rate: A MFI of 500 was achieved by more than 30% of the serum samples only with antigens 
Gallo0272, Gallo0933, Gallo1570 and Gallo2018. Cut-offs defining 10% of the controls as 
being positive for the individual proteins ranged from 30 MFI as a technical minimum cut-off 
for Gallo2178 to above 1000 MFI for Gallo0272, Gallo0933, Gallo1570 and Gallo2018. 
Comparison with inflection points of percentile plots showed that the here arbitrarily defined 
cut-offs were more stringent. However, to make the results comparable to the previous 
already published CRC case-control study it was decided to further apply the 10% cut-off. In 
addition, a more stringent cut-off provides a higher specificity in detecting S. gallolyticus and, 
if associated, CRC-specific antibody responses.  
In a first attempt overall S. gallolyticus antibody-positivity was defined as being positive to 
any of the eleven proteins. This resulted in 57% positive BliTz controls, 59% positive SCCS 
controls and 56% positive EPIC controls. These fractions were much larger than the reported 
low fecal carriage rates (1-11%). However, to allow for inter-individual differences in the 
immune response but also infection with different bacterial strains, I applied this algorithm to 
assess potential risk factors for antibody responses to S. gallolyticus in controls of the three 
studies. None of the here assessed baseline characteristics was significantly associated with  
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S. gallolyticus among controls and thus considered as a potential risk factor in healthy 
individuals. Case-control studies by Abdulamir, Boleij and Garza-Gonzalez addressed age 
and sex as potential risk factors and did not identify a significant association with antibody-
positivity measured in ELISA or Western blot with whole cell protein [82-84]. In Butt et al., 
2016, I addressed the same risk factors as presented here, age, sex, BMI, smoking, education 
and family history of CRC and did not identify significant risk factors for antibody responses 
to the four S. gallolyticus pilus proteins either [81]. Whether other characteristics like diet, 
lifestyle or co-morbidities are associated, remains to be elucidated.  
In a first step in the analysis of an association of S. gallolyticus with CRC I attempted to 
reproduce findings from Butt et al. [81] with respect to an association of antibody responses 
to proteins Gallo2178 and Gallo2179 with CRC in the BliTz-DACHSplus case-control study. 
Indeed, positivity to Gallo2178, but not Gallo2179, was significantly associated with 
prevalent CRC with an OR of 4.5. This association even remained significant after 
Bonferroni-correction for multiple testing. Double-positivity to Gallo2178-Gallo2179 was a 
rare event, as seen in Butt et al. [81], with 0% double-positive controls compared to 4% 
double-positive cases. Since none of the controls was double-positive it was not possible to 
estimate the strength of the association, however, a crude p-value obtained by Chi-square test 
was even significant after correction for multiple testing.  
None of the other individual S. gallolyticus proteins was associated with prevalent CRC in the 
BliTz-DACHSplus study. Positivity to any of the proteins was significantly associated with 
1.6-fold increased odds for CRC, however, significance was not retained after correction for 
multiple testing. As discussed above analyses of serum samples from cattle and from  
S. gallolyticus bacteremia patients indicated a higher specificity for detecting S. gallolyticus 
specific antibodies when being positive to several S. gallolyticus proteins simultaneously. I 
assessed whether positivity to S. gallolyticus proteins significantly correlated similar to 
Gallo2178-Gallo2179. These analyses were done separately for BliTz controls and 
DACHSplus cases, since I hypothesized that correlations would occur preferentially in cases 
if S. gallolyticus infection was CRC specific. Positivity to three proteins, Gallo0577, 
Gallo1570 and Gallo2179, correlated strongly but independently of being a control or case. 
Amino acid sequence comparison identified long homologous stretches at the C-terminal part 
of the proteins that most probably led to cross-reacting antibodies mimicking a correlation in 
positivity between these proteins. In contrast, there were three antigen pairs, in addition to 
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Gallo2178-Gallo2179 that specifically correlated among CRC cases: Gallo0272-Gallo0748, 
Gallo0272-Gallo1675 and Gallo2018-Gallo2179. Except for Gallo1675 all of these proteins 
were among those best distinguishing serologically the bacteremia patients from healthy 
controls in the validation attempts. So far, functions of the newly identified proteins were only 
predicted by amino acid similarities to proteins of other bacterial species: i) Gallo0272 is a 
putative agglutinin receptor. The expressed domain resembles a glucan binding protein C 
domain. Agglutinin receptors in the oral bacterium Streptococcus gordinii mediate binding to 
host cell and bacterial receptors and may represent important virulence factors [153]. ii) 
Gallo0748 is supposed to have an endopeptidase function, which is important in protein 
turnover. iii) Gallo2018 is putatively involved in bacteriocin synthesis, inhibiting the growth 
of other bacteria in the surrounding and thereby mediating a growth advantage. iv) Gallo1675 
is a cell wall protein with unknown function [121]. The in total 6 proteins, Gallo0272, 
Gallo0748, Gallo1675, Galo2018, Gallo2178 and Gallo2179 were combined to a 6-marker 
panel. To reflect the correlation between these markers, positivity was defined as being 
positive to at least two proteins of the 6-marker panel. Eleven percent of controls were 
positive with this newly defined algorithm, reflecting again the fecal carriage rate in healthy 
individuals. Compared to 19% of positive prevalent CRC cases this resulted in significantly 2-
fold increased odds for CRC in the BliTz-DACHSplus study. Probably due to the relatively 
small sample size this association was not significant after correction for multiple testing. To 
further show that the observed association is CRC specific I compared BliTz controls to GC 
cases of the DACHSplus study for positivity to S. gallolyticus. Indeed, I did not observe an 
association of antibody responses to S. gallolyticus with GC undermining the specificity of 
the association seen with CRC. 
The findings of the CRC case-control study BliTz-DACHSplus were further elucidated in a 
prospective setting in two independent nested case-control studies to assess a temporality of 
the association. One of the studies, EPIC, was a multi-national study, conducted in several 
countries of Europe, including Spain, Italy, France, Greece, the Netherlands and also 
Germany. I was able to reproduce findings from prevalent CRC also with incident CRC cases 
in EPIC: Positivity to Gallo2178 (OR: 2.7), double-positivity to Gallo2178-Gallo2179 (OR: 
7), positivity to any S. gallolyticus protein (OR: 1.4) and positivity to two or more proteins of 
the 6-marker panel (OR: 2) were significantly associated. Additionally, positivity to 
Gallo0272 (OR: 1.5) and Gallo0748 (OR: 1.5), two proteins included in the 6-marker panel, 
were also individually associated with CRC risk. The positivity to two or more proteins of the 
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6-marker panel even remained significant after correction for multiple testing. A sensitivity 
analyses was carried out including only those cases diagnosed after two years from blood 
draw to exclude that observed associations are attributed to those cases most probably already 
having advanced colorectal tumors at time of blood draw. All associations seen with the 
complete dataset remained significant except for Gallo0748, which was not associated 
anymore with CRC diagnosed more than two years from blood draw. Also with correction for 
multiple testing the association of positivity to two or more proteins of the 6-marker panel 
with these cases becomes insignificant, however, also the sample size was reduced leading to 
reduced statistical power.  
Thus, I showed that the association of antibody responses to S. gallolyticus with CRC in EPIC 
was present already several years prior to diagnosis. This is in concordance with the bacterial-
driver passenger model developed by Harold Tjalsma (1.2) [33], defining S. gallolyticus as a 
passenger bacterium invading adenomatous tissue in the colon. The lag-time in EPIC ranged 
from 0.4 to 8.5 years with a median time of 3.3 years. Since CRC development is a long-term 
process taking several years from an initial polyp to malignant disease, most probably 
incident CRC cases already had a precancerous lesion at time of blood draw. Studies with a 
lag-time of more than ten years would be needed to assess whether antibody responses to S. 
gallolyticus can be detected even prior to development of early precancerous lesions. If so, S. 
gallolyticus could be causally linked to initiation of CRC development being a so-called 
driver bacterium in the driver-passenger model [33] or even an alpha-bac in the alpha-bac 
hypothesis [32], similar to H. pylori in the initiation of GC. However, this cannot be inferred 
from the available data and needs to be further elucidated.  
An additional question, independently of the time-point of infection, arising from the results is 
whether S. gallolyticus may be involved in progression of the tumor. As discussed above 
incident CRC cases most probably already had a precancerous lesion at time of blood draw. 
However, also among controls presence of a certain number of precancerous lesions has to be 
expected. Data from the German screening colonoscopy registry showed that the detection 
rate of non-advanced adenomas was 22.3% among males and 14.9% among females aged 
above 55 years in 2012 [154]. The detection rate for advanced adenomas in the same age 
groups was 9% for males and 5.2% for females. Rough estimates from these numbers would 
suggest that also about 25% of control samples might have had an adenoma at time of blood 
draw. Thus, the question arises which factors make an adenoma further progress to cancer and 
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whether S. gallolyticus might be among these contributing factors. The given data does also 
not answer this question, however, may stimulate further more mechanistic investigations into 
the connection of S. gallolyticus infection and CRC development. 
I performed separate analyses by sex, age at blood draw, country of residence but also case 
characteristics like age at diagnosis, stage and tumor site. I observed an effect of age on the 
estimate in EPIC but not in BliTz-DACHSplus. The youngest age-group at blood draw (37 to 
55 years) showed a null association with CRC risk as opposed to age groups older than 55 
years, where positivity to two or more proteins of the 6-marker panel was significantly 
associated with CRC. This is reflected in the analyses separated by age at diagnosis, since 
with a median lag-time of 3.3 years most individuals from the age group 37 to 55 years at 
blood draw were below 60 years at diagnosis. CRC diagnosed early in life is mostly of 
different etiology than CRC diagnosed later in life and represents a group of patients at 
specific risk for CRC [155]. They might represent a specific group of tumors that is not as 
prone to S. gallolyticus invasion as others. Interestingly, in the published Spanish CRC case-
control study I observed an increased association with prevalent CRC cases younger than 65 
years [81]. Both studies are difficult to compare due to the retrospective and prospective study 
designs but also the different sets of antigens applied. Nevertheless, the observed discordant 
age-effect should be regarded with caution and might also originate from cohort effects.  
Apart from age, I also observed a difference in the estimate between the distinct participating 
countries with CRC cases from Italy/Greece having the strongest association as opposed to 
Germany/Netherlands with a null association. Regional differences in the prevalence of S. 
gallolyticus bacteremia were previously observed and ascribed to cattle farming and fishing 
areas [77]. The underlying reasons here for an increased number of  
S. gallolyticus positive CRC cases in Italy/Greece remain unclear. I observed neither in BliTz-
DACHSplus nor in EPIC an effect of sex or tumor stage on the estimate. However, the 
estimate differed with tumor site with a stronger association in rectal compared to colon cases. 
The number of rectal cancer cases was small (n=53) resulting in wide confidence intervals. 
Whether this difference between colon and rectal cancer cases is true should be assessed in 
studies with larger sample sizes of rectal cancers. 
In a brief exploratory analysis, I wanted to assess whether results from the prospective 
analyses can be inferred to precancerous lesions. Two independent colonoscopy screening 
trials (BliTz and the Irish CRC cohort) included colonoscopy-verified adenoma-negative 
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controls, different types of precancerous lesions as well as CRC cases. Interestingly, 
associations with antibody responses to S. gallolyticus proteins were found already with 
precancerous lesions, especially non-advanced adenomas and polyps indicating that  
S. gallolyticus infection of colorectal tissue may happen very early. The frequency of 
positives to two or more proteins of the 6-marker panel among non-advanced adenoma cases 
(27%) in BliTz and polyp cases (25%) in the Irish cohort thereby resembled the frequency of 
positives found by Garza-Gonzalez et al. (29%) with a Western blot using S. gallolyticus 
whole cell protein [83]. The Irish cohort additionally included serum samples of individuals 
with minor diagnoses in colonoscopy, mainly hemorrhoids and diverticulosis. Also in this 
group the frequency of antibody responses to S. gallolyticus was higher than in colonoscopy-
negative controls. A study by Reynolds et al. from 1983 found that S. bovis (not further 
specified to subspecies)-induced endocarditis was found in patients with diverticulosis [156]. 
A potential association of diverticulosis with CRC is controversially discussed in the literature 
[157], however, it does not seem unlikely that pouches in the intestinal wall increase the 
invading potential for S. gallolyticus . 
4.2.3. Antibody responses to S. gallolyticus and CRC in a case-control study 
nested within a southern US prospective cohort 
Observed associations with the risk of developing CRC in EPIC could not be reproduced in 
SCCS. Neither antibody responses to individual S. gallolyticus proteins nor to established 
protein combinations were significantly associated with CRC risk in this study. Major 
differences between EPIC and SCCS that can be inferred from the given data include the 
geographic area in which the study was conducted, Europe versus US, the ethnicity of the 
majority of study participants, mainly Caucasian versus mainly African-American, as well as 
the mean age at diagnosis, 63 versus 59 years, respectively. Interestingly, the overall CRC 
incidence differs substantially between the Caucasian-American (CA) and African-American 
(AA) population in the US, between 1992 and 2006 with an age-adjusted incidence rate of 
71.0 in males and 54.8 in females per 100,000 among AA and 61.8 and 45.3 per 100,000 
among CA [105]. Age at diagnosis is generally lower in AA compared to CA which is 
reflected by new recommendations for screening of AA already from age 45 years onwards in 
contrast to the usually recommended age of 50 years [158, 159]. With respect to an 
association with S. gallolyticus infection the differences between the ethnicities in CRC 
development might have distinct impacts:  
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i) Differences in biological mechanisms between CRC in CA and AA are unknown, 
however, might impact susceptibility for S. gallolyticus infection.  
ii) Concordant with increased incidences for CRC also the risk for adenoma is 
increased in AA compared to CA, especially below age 50 [160]. The cut-off that 
defines 10% of controls as positive for individual S. gallolyticus proteins was 
higher for many of the antigens (Gallo0272, Gallo0933, Gallo2018, Gallo2178, 
Gallo2179) in the SCCS controls compared to colonoscopy-negative controls in 
BliTz indicating a higher baseline antibody response in the SCCS controls. A 
higher rate of S. gallolyticus positive adenoma or even CRC already in the SCCS 
control group, not yet diagnosed, might result in the lowered difference in S. 
gallolyticus positivity to SCCS CRC cases.  
iii)  Factors potentially underlying the increased risk for CRC in the AA population 
might affect S. gallolyticus colonization of the intestine. Participants of the SCCS 
included in the CRC nested case-control study for example had a high rate of self-
reported obesity-related morbidities like diabetes (27.7% among controls, 35.1% 
among cases) or hypercholesterol (35.8% among controls, 38.3% among cases) 
[134]. In contrast, the prevalence of diabetes in Europe had been much lower with 
7.9% in 2015 [161]. In addition, rates of H. pylori infection, which was itself 
shown to be associated with CRC in this population differed substantially between 
the ethnicities in SCCS (AA: 92%; CA: 68%) [134]. H. pylori was shown to 
reshape the gastric microbiota upon infection [162] and also seems to have an 
influence on the intestinal microbiome [163, 164] Whether obesity-related 
morbidities or underlying factors in diet and lifestyle as well as co-infections with 
other bacteria, like H. pylori, may affect the association with S. gallolyticus needs 
to be further elucidated.  
Analyses of the association of S. gallolyticus with CRC separately by ethnicity in the SCCS 
revealed a higher effect estimate in the CA population than in the AA population, however, 
due to small sample numbers, confidence intervals were strongly overlapping and this 
difference in the effect estimate should be regarded with caution and just as indication for 
above discusses hypotheses for the difference between SCCS and EPIC.  
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4.3. Natural history of F. nucleatum and S. gallolyticus infection 
High antibody responses to proteins of both, F. nucleatum and S. gallolyticus, have been rare 
events in the studies presented here. Both bacteria have in common to be considered as 
opportunists, i.e. commensals with the potential to turn pathogenic under certain 
circumstances. However, F. nucleatum and S. gallolyticus have been identified in different 
sites and diseases in the human body.  
S. gallolyticus is a rare commensal in the intestine: the reported fecal carriage rates for S. 
gallolyticus are low and range from 1 to 11% in healthy individuals [78, 79]. However, 
species of the S.bovis/S. equinus complex, including S. gallolyticus, were also found to be 
inducers of infective endocarditis and accounted for 5 to 15% of infective endocarditis 
patients in the US [165]. It is hypothesized that a colorectal neoplasm in the intestine is the 
entry port for S. gallolyticus to the bloodstream building the connection to a potential 
systemic infection and pathogenicity of the commensal bacterium in the heart valves [90]. 
This hypothesis is supported by the findings in this thesis with high antibody responses being 
a rare event in colonoscopy-negative controls and a significantly larger fraction of individuals 
with high antibody responses in CRC cases. Risk factors for and the time points of intestinal 
colonization but also infection and seroconversion have not been reported so far but would be 
of great importance to further understand the etiology of S. gallolyticus in the development of 
CRC.  
In contrast to the apparently rare colonizer S. gallolyticus, F. nucleatum has been reported to 
be present in the saliva of 91% of infants already at one year of age [166]. A study of the 
subgingival periodontal flora in adults found F. nucleatum in 58% to 71% of all isolates in 
individuals with no or mild gingivitis increasing to 82% to 91% in patients with severe 
gingivitis [35]. Gingivitis is a very frequent disease with a prevalence of more than 50% 
among adults in the US [167]. Thus, F. nucleatum represents a dominant species in the oral 
microflora and was found to be associated with inflammatory disease at this specific site. I 
therefore expected to detect strong F. nucleatum antibody responses in a substantial portion of 
study individuals independent of being a CRC case or control, however, as discussed above 
high antibody responses to the selected F. nucleatum proteins were only rarely detected. Other 
serological studies on F. nucleatum conducted in periodontitis patients found lower antibody 
titers against F. nucleatum whole cell protein compared to those against other oral bacteria, 
although the bacterial load was similar [117, 168].  
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Commensals are usually tolerated by the mucosal immune system, whereas pathogens like  
H. pylori induce a strong immune response also elicited by high antibody responses [143]. A 
pathogen-turned commensal would therefore be expected to induce antibody responses, as 
seen with S. gallolyticus in CRC patients. Indeed, as shown by Tew et al., antibody responses 
to F. nucleatum are almost absent in healthy subjects but higher in patients with severe 
periodontitis, however, still remain lower compared to other bacteria, e.g. Bacteroides 
gingivales, examined in the same study [169]. Unfortunately, attempts to get access to serum 
samples of periodontitis patients failed but would have been interesting for the serological 
validation of F. nucleatum multiplex serology. Why the overall antibody responses to  
F. nucleatum were comparably low, as shown in this thesis but also by others [117, 168, 169], 
remains to be elucidated. Some reviews even discuss whether F. nucleatum is able to actively 
inhibit an adaptive immune response [170, 171], however, this is not proven yet.  
It is important to further elucidate the natural history, epidemiology and seroconversion 
pattern of S. gallolyticus and F. nucleatum to understand differences in the antibody response 
compared to other bacterial infections, like for example H. pylori. The time-point of 
seroconversion might be of special interest to see when antibody responses are first detectable 
and whether this is dependent or independent of diseases like periodontitis or intestinal 
adenoma. One out of two mice inoculated with S. gallolyticus bacterial culture showed 
successful colonization of the intestine and antibody responses of up to 2000 MFI against 
Gallo2179 already two weeks after inoculation (3.2.2). Factors determining infection success 
and whether these can be transferred to human infection with S. gallolyticus remain to be 
elucidated. Furthermore, identification of risk factors for carrier state and infection is 
important to identify individuals at specific risk for the disease. Large cross-sectional studies 
conducted in children and adults of different age with comprehensive questionnaires would be 
of high impact in the general understanding of antibody responses to opportunists  
F. nucleatum and S. gallolyticus. 
4.4. Conclusions and Outlook 
In conclusion, antibody responses detected by F. nucleatum multiplex serology were not 
associated with prevalent and incident CRC in the studies presented here. It could be 
attempted to further improve the assay. An advantage of multiplex serology is the possibility 
to analyze antibody responses to several antigens in one reaction. However, the number of 
antigens that can be analyzed is limited to 100 and recombinant expression of potential 
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antigens with adequate quality controls would not be feasible for very many or the event of all 
of the approximate 2000 open reading frames of F. nucleatum. Screening of protein 
microarrays representing the complete set of proteins potentially expressed by F. nucleatum 
for sero-reactive proteins could circumvent this problem. A technique developed in our 
laboratory by Katrin Hufnagel, Smith Lueong and Tim Waterboer uses in vitro transcription 
and translation of selected genes directly spotted on a Nickel-coated chip. Subsequent 
incubation of expressed proteins with serum of patients of interest may reveal the 
identification of immunogenic proteins and disease-specific antibody pattern. This system was 
already established for Chlamydia trachomatis (unpublished data) and is theoretically 
applicable for all infectious agents with a sequenced genome. However, also for this approach 
it would be necessary to obtain a set of appropriate reference sera. Reference sera should 
either be tested with a gold standard serological assay or retrieved from patients with a 
diagnosed F. nucleatum infection or from negative controls without infection, respectively. So 
far, a gold standard serological assay is not available, however, as described above, other 
studies used whole cell protein of F. nucleatum in ELISA, which could serve as a rather 
unspecific but potentially sensitive comparison assay. A collection of reference sera, e.g. from 
patients with severe periodontitis and diagnosed F. nucleatum involvement could be an 
alternative for an infection-based validation. A collaboration with a dentist clinic would have 
to be established, attempts during my thesis time have failed.  
A different technical improvement could arise from applying secondary antibodies for IgA 
and IgG separately. Application of biotinylated IgA and IgG antibodies in multiplex serology 
would first have to be established and presented studies would have to be reanalyzed. Apart 
from technical improvements of the assay, analysis of studies with more information on 
histology and morphology of the tumor could help assessing whether antibody responses to F. 
nucleatum might serve as specific marker for a subgroup of CRC cases, e.g. tumors of the 
serrated pathway [49]. If all these attempts fail we would have contradictory results to Wang 
et al. [147] and could not verify with the developed F. nucleatum multiplex serology that 
serology is applicable to identify specific F. nucleatum infection markers for CRC. Antibody 
responses resulting from F. nucleatum infection at its natural site, the gingiva, might lead to a 
lack of specificity in the detection of CRC specific antibody responses. More site-specific 
analyses in stool or even tumor tissue as found in the literature is probably advantageous in 
this respect, however, also less cost- and time-effective than multiplex serology in the 
analyses of larger epidemiological studies. 
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In contrast to the absence of a serological association of F. nucleatum with CRC, antibody 
responses to multiple S. gallolyticus proteins were significantly associated with CRC. I 
reproduced and extended earlier findings from Butt et al. [81] by expanding the CRC-specific 
antigen panel from Gallo2178 and Gallo2179 to a 6-marker panel that was associated with 
prevalent and incident CRC in two studies conducted in Europe, however, not in a prospective 
study from southern US with a majority of African-American subjects. The results discussed 
here raised many new open questions in the association of S. gallolyticus with CRC. Positivity 
to two or more proteins of the 6-marker panel was found in 17% of CRC cases in the 
prospective EPIC study, two times more than in controls. However, in the southern US study 
SCCS this association was absent and it remains to be elucidated what the underlying reasons 
for this difference in the association is. Both studies were conducted on different continents 
and in distinct ethnicities bearing differences in lifestyle, environment, diet, microbiota and 
genetics that may have contributed to the differing results. A large cross-sectional study 
specifically addressing potential risk factors, for example red meat consumption as proposed 
by Harald zur Hausen [172], could identify risk factors for colonization of the intestine with  
S. gallolyticus. Additionally, it should be analyzed whether S. gallolyticus infection is 
restricted to a certain morphological or histological subtype of CRC. 
So far, the data obtained with the prospective study EPIC and with the small sample sets of 
polyp and adenoma cases from the BliTz and Irish CRC case-control study follow the 
bacterial-driver passenger model of Harold Tjalsma [33]: Antibody responses to  
S. gallolyticus could be detected in precancerous lesions and in CRC cases prior to diagnosis, 
showing that infection happens already in precursors. However, whether S. gallolyticus is 
involved in progression of tumor development and thus plays a causal role needs to be further 
elucidated. The Bradford Hill criteria for causation include: 1) Strength of the association; 2) 
Consistency; 3) Specificity; 4) Temporality; 5) Biological gradient; 6) Plausibility; 7) 
Coherence; 8) Experiment; 9) Analogy. Points 1) to 4) are addressed by the data and literature 
(1.2.2) presented in this thesis. Plausibility and coherence are given by the analogy to  
H. pylori, which is causally related to the development of gastric cancer by the induction of a 
chronic inflammation. However, a definite causal relation can only be inferred from 
experimental evidence. Abdulamir et al. found S. gallolyticus DNA directly in tumor tissue of 
CRC patients as a first indicator for a direct involvement of the bacterium in tumorigenesis 
[80, 82]. In addition they found pro-inflammatory markers elevated in tumor tissue of  
S. gallolyticus positive adenoma and CRC cases [80, 82] indicating a pro-carcinogenic 
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potential, similar to H. pylori in the gastric mucosa [173]. These findings, however, are 
necessary to be confirmed by independent studies. Additionally, more mechanistic studies 
should be undertaken. It could be studied in vitro whether infection of cell lines with  
S. gallolyticus leads to altered activation of cellular pathways and which proteins of  
S. gallolyticus might interfere with host metabolics. H. pylori, for example, was shown to 
activate MAPK (Mitogen-activated protein kinase), which has pro-inflammatory and pro-
proliferative consequences for the cells [174]. APCmin/+ mice are a frequently applied in vivo 
model to study the influence of environmental factors on CRC development [175]. These 
mice develop, due to a point mutation in the tumor suppressor APC gene, multiple intestinal 
metaplasia. This type of mice was used for studies of the relationship of F. nucleatum and 
CRC and Yang et al. could show that APCmin/+ mice gavaged with F. nucleatum develop more 
colorectal tumors than mice fed with PBS. Additionally, these mice had shorter survival 
times. This mouse model could also be applied to study whether colonization with  
S. gallolyticus promotes tumor progression. The finding of a causal relationship could be 
valuable in prevention of the disease by eradication of the bacterium. However, CRC 
development is considered a multifactorial process [176] and the impact of eradication of one 
specific bacterium remains to be elucidated. 
Independently of a causal relationship, antibody responses to proteins in S. gallolyticus 
multiplex serology, in contrast to F. nucleatum multiplex serology, might serve as an early 
marker for the development of CRC in European populations and could therefore be of 
diagnostic value for a subgroup of CRC cases. The identified 6-marker panel should be 
verified in additional independent prospective studies and analyzed for the diagnostic 
potential in larger studies of colorectal precancerous lesions. 
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II. Alignments of sequenced inserts to reference insert sequences  
(light blue: BamHI restriction site, light green: SalI restriction site, orange: pGEXfor, brown: 
pGEXrev, purple: pGEXs, red: pGEXas) 
Fn0131 (forward sequencing of miniPrep DNA via primer pGEXfor, reverse 
sequencing of PCR product via T3 primer (PCR primer pGEXs+T7 and 
pGEXas+T3)) 
Fn0131_exp      ATAGCATGGCCTTTGCAGGGCTGGCAAGCCACGTTTGGTGGTGGCGACCATCCTCCAAAA 
Fn0131_Seq      --------------------------------------------------ATCCTCCAAA 
                                                                    *  * *** 
 
Fn0131_exp      TCGGATCTGGTTCCGCGTGGATCCTCTTTTAACGAGAACGAGGATGAACGTACCATTCTG 
Fn0131_Seq      TCGGATCTGGTTCCGCGTGGATCCTCTTTTAACGAGAACGAGGATGAACGTACCATTCTG 
                ************************************************************ 
 
Fn0131_exp      AAACAGGAACAACGTTCGGAACAAGAACGTCTGCAGAAAGAATTTCAGAAACGCGAAGAA 
Fn0131_Seq      AAACAGGAACAACGTTCGGAACAAGAACGTCTGCAGAAAGAATTTCAGAAACGCGAAGAA 
                ************************************************************ 
 
Fn0131_exp      ATTTTCAACCAACTGAAAAGCGAGAAAACGGACAAGCAAGAAGTGAGCACCAACGAAATC 
Fn0131_Seq      ATTTTCAACCAACTGAAAAGCGAGAAAACGGACAAGCAAGAAGTGAGCACCAACGAAATC 
                ************************************************************ 
 
Fn0131_exp      AAATTCCACATTTCACAGATCAATCTGGAAGATAATGAACGGCTCCTGAATGAAATCGAA 
Fn0131_Seq      AAATTCCACATTTCACAGATCAATCTGGAAGATAATGAACGGCTCCTGAATGAAATCGAA 
                ************************************************************ 
 
Fn0131_exp      AAGGAGAATATTCTGGGCAAATACATCAATCGCGATTTAGGGTCTACAGACATCACGAAT 
Fn0131_Seq      AAGGAGAATATTCTGGGCAAATACATCAATCGCGATTTAGGGTCTACAGACATCACGAAT 
                ************************************************************ 
 
Fn0131_exp      CTGATTACGGACCTTACCAATCGTCTGATCGCTAAAGGCTATATTACGAGCGTAGCGACC 
Fn0131_Seq      CTGATTACGGACCTTACCAATCGTCTGATCGCTAAAGGCTATATTACGAGCGTAGCGACC 
                ************************************************************ 
 
Fn0131_exp      ATCAGTGAGGATAACGACTTATCTACTAAAACGCTTAATCTCAAAATCATTCCGGGGAAG 
Fn0131_Seq      ATCAGTGAGGATAACGACTTATCTACTAAAACGCTTAATCTCAAAATCATTCCGGGGAAG 
                ************************************************************ 
 
Fn0131_exp      ATCGAGAAAATTATCCTGAACGAAGATAAAACCCTCGACAACCTGAAGAAATATTTTCTG 
Fn0131_Seq      ATCGAGAAAATTATCCTGAACGAAGATAAAACCCTCGACAACCTGAAGAAATATTTTCTG 
                ************************************************************ 
 
Fn0131_exp      GTGGACACTAAAGCCGGCAAGGTGTTAAACATTCGTGATTTGGACACTACGACAGAAAAT 
Fn0131_Seq      GTGGACACTAAAGCCGGCAAGGTGTTAAACATTCGTGATTTGGACACTACGACAGAAAAT 
                ************************************************************ 
 
Fn0131_exp      TTCAATTATCTGGAAGCCAACAACATGACTATGGAGATCATTCCGAGTGAAATCCAAAAC 
Fn0131_Seq      TTCAATTATCTGGAAGCCAACAACATGACTATGGAGATCATTCCGAGTGAAATCCAAAAC 
                ************************************************************ 
 
Fn0131_exp      CATTCCATTGTCAAACTGAAGAACGAAATGAAAGAGAAGTTCACGGTGAGTGTGCTGACC 
Fn0131_Seq      CATTCCATTGTCAAACTGAAGAACGAAATGAAAGGAGAAGGTTCACGGTGGAGTGTGCTG 
                **********************************   *     *   * *     **    
 
Fn0131_exp      AACAACTACGGCGAAGATCGTCAGAATGCTATTTGGCGCGGCGGTGTCTCAATTAACATT 
Fn0131_Seq      ACCAA------------------------------------------------------- 
                * ***                                                        
 
Fn0131_exp      GATTCGCCATTAGGGATCGGTGATCGCGTGTACTTTTCCTATATGACAGTGCACAAGAAA 
Fn0131_Seq      ----------------------------------------------CAGTGCACAAGAAA 
                                                              ************** 
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Fn0131_exp      AAACCGGATCGCAGCTGGAAACGGACAACAGAATCCCTCAAACCTGGCGAAATTGCACCT 
Fn0131_Seq      AAACCGGATCGCAGCTGGAAACGGACAACAGAATCCCTCAAACCTGGCGAAATTGCACCT 
                ************************************************************ 
 
Fn0131_exp      ATTGGTCCGAAAGGCTATGATCCACGCAAAGATACCTTGCCGTATAAACGCGACTTGGAT 
Fn0131_Seq      ATTGGTCCGAAAGGCTATGATCCACGCAAAGATACCTTGCCGTATAAACGCGACTTGGAT 
                ************************************************************ 
 
Fn0131_exp      TTGTACAATTTCCGCTATACACTGAAATTCAATTCCTATACCCTGAGCTTAGGCTCCTCC 
Fn0131_Seq      TTGTACAATTTCCGCTATACACTGAAATTCAATTCCTATACCCTGAGCTTAGGCTCCTCC 
                ************************************************************ 
 
Fn0131_exp      CGCATTGAAAATACGAGTTCGTTTTATACCCCGAATACCGTGTACGACATGGAAACCGTT 
Fn0131_Seq      CGCATTGAAAATACGAGTTCGTTTTATACCCCGAATACCGTGTACGACATGGAAACCGTT 
                ************************************************************ 
 
Fn0131_exp      AGCAATACGTTTTCAGTAAACTTGGATAAAGTCCTGTTACGCAACCAGAAGAATAAACTG 
Fn0131_Seq      AGCAATACGTTTTCAGTAAACTTGGATAAAGTCCTGTTACGCAACCAGAAGAATAAACTG 
                ************************************************************ 
 
Fn0131_exp      ACGTTTGGTATTGGGCTGAAACGGAAACATAATCAGTCGTACATCGAGGAAGCGATTCTG 
Fn0131_Seq      ACGTTTGGTATTGGGCTGAAACGGAAACATAATCAGTCGTACATCGAGGAAGCGATTCTG 
                ************************************************************ 
 
Fn0131_exp      AGTGATCGTGTCTTAACGATTGGAGACATTAGCCTGAACGGCACTACCACCTTTTATGGC 
Fn0131_Seq      AGTGATCGTGTCTTAACGATTGGAGACATTAGCCTGAACGGCACTACCACCTTTTATGGC 
                ************************************************************ 
 
Fn0131_exp      GGACTGCTGGGTGCAAGCCTGGGATACGAACGTGGCATGCGTGCACTGGGTGCGGAACGT 
Fn0131_Seq      GGACTGCTGGGTGCAAGCCTGGGATACGAACGTGGCATGCGTGCACTGGGTGCGGAACGT 
                ************************************************************ 
 
Fn0131_exp      GATAAGAATAAAGGCGTTCGCTCTCCCAAAGCGGAGTTTATGAAGTATACCCTGAACACT 
Fn0131_Seq      GATAAGAATAAAGGCGTTCGCTCTCCCAAAGCGGAGTTTATGAAGTATACCCTGAACACT 
                ************************************************************ 
 
Fn0131_exp      AACTACTACAAACCCCTTACCCAGAAACTGGTATACCGCTTTAACACCAATATCACCTAT 
Fn0131_Seq      AACTACTACAAACCCCTTACCCAGAAACTGGTATACCGCTTTAACACCAATATCACCTAT 
                ************************************************************ 
 
Fn0131_exp      TCGAACGATGTTCTCTATGGGTCGGAGAAACACTCTATTGGTGGTGTCGGCTCAGTTGGT 
Fn0131_Seq      TCGAACGATGTTCTCTATGGGTCGGAGAAACACTCTATTGGTGGTGTCGGCTCAGTTGGT 
                ************************************************************ 
 
Fn0131_exp      GGATATCATCGCACTGGGAATATTCAGGGTGATAAAGCCATCGAGATTGAAAACGAGCTG 
Fn0131_Seq      GGATATCATCGCACTGGGAATATTCAGGGTGATAAAGCCATCGAGATTGAAAACGAGCTG 
                ************************************************************ 
 
Fn0131_exp      AGCTACCGTGTTCTGGACTCTGAAAAGTTCGGCAAAATCACCCCGTATCTTAGCTACTCA 
Fn0131_Seq      AGCTACCGTGTTCTGGACTCTGAAAAGTTCGGCAAAATCACCCCGTATCTTAGCTACTCA 
                ************************************************************ 
 
Fn0131_exp      TATGGTAAAGTTCGCAACAACAAAAACAATAGCAAATACCGCAAAGGTTACATGAGTGGC 
Fn0131_Seq      TATGGTAAAGTTCGCAACAACAAAAACAATAGCAAATACCGCAAAGGTTACATGAGTGGC 
                ************************************************************ 
 
Fn0131_exp      GCGATCCTTGGTTTGCGCTATAACATGAAATATCTCCAGTTGACCGTCGACAAACCTCCC 
Fn0131_Seq      GCGATCCTTGGTTTGCGCTATAACATGAAATATCTCCAGTTGACCGTCGACAAACCTCCC 
                ************************************************************ 
 
Fn0131_exp      ACACCTCCCCCTGAACCTGAAACATAAGCGGCCGCATCGTGACTGACTGACGATCTGCCT 
Fn0131_Seq      ACACCTCCCCCTAAC--------------------------------------------- 
                ************ *                                               
 
Fn0131_exp      CGCGCGTTTCGGTGATGACGGTGAAAACCTCTGACACATGCAGCTC 
Fn0131_Seq      ---------------------------------------------- 
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Fn0253 (sequencing of PCR product via T3 primer (PCR primer pGEXs+T7 and 
pGEXas+T3)) 
Fn0253_exp      ---------------------TCCAAAATCGGATCTGGTTCCGCGTGGATCCAACTTCGA 
Fn0253_Seq      TTAATACGACTCACTATAGGGTCCAAAATCGGATCTGGTTCCGCGTGGATCCAACTTCGA 
                                     *************************************** 
 
Fn0253_exp      CTTTGACAAGTCGAATGTGAAACCGCAGTATTACGATCTGCTGAACAACATCAAGGAGTT 
Fn0253_Seq      CTTTGACAAGTCGAATGTGAAACCGCAGTATTACGATCTGCTGAACAACATCAAGGAGTT 
                ************************************************************ 
 
Fn0253_exp      TGTGGAACAGAACAACTATGAGATCACCATTGTAGGACATACGGATTCAATCGGCTCTAA 
Fn0253_Seq      TGTGGAACAGAACAACTATGAGATCACCATTGTAGGACATACGGATTCAATCGGCTCTAA 
                ************************************************************ 
 
Fn0253_exp      TGCCTACAACTTCAAACTGAGTCGTCGTCGCGCAGAAAGCGTCAAAGCGAAACTCTTGGA 
Fn0253_Seq      TGCCTACAACTTCAAACTGAGTCGTCGTCGCGCAGAAAGCGTCAAAGCGAAACTCTTGGA 
                ************************************************************ 
 
Fn0253_exp      GTTTGGGTTATCCGAAGATCGCATTGTTGGCATTGAAGCGATGGGTGAAGAACAGCCAAT 
Fn0253_Seq      GTTTGGGTTATCCGAAGATCGCATTGTTGGCATTGAAGCGATGGGTGAAGAACAGCCAAT 
                ************************************************************ 
 
Fn0253_exp      TGCCACTAATGCGACCAAAGAAGGTCGGGCTCAAAATCGCGTCGACAAACCTCCCACACC 
Fn0253_Seq      TGCCACTAATGCGACCAAAGAAGGTCGGGCTCAAAATCGCGTCGACAAACCTCCCACACC 
                ************************************************************ 
 
Fn0253_exp      TCCCCCTGAACCTGAAACATAAGCGGCCGCATC 
Fn0253_Seq      TCCCCCT-------------------------- 
                *******                           
 
Fn0264 (sequencing of PCR product via T3 primer (PCR primer pGEXs+T7 and 
pGEXas+T3)) 
Fn0264_exp      -------------------------------TCCAAAATCGGATCTGGTTCCGCGTGGAT 
Fn0264_Seq      ACTGAAGCTTTTAATACGACTCACTATAGGGTCCAAAATCGGATCTGGTTCCGCGTGGAT 
                                               ***************************** 
 
Fn0264_exp      CCGGCGAACTGCAAGCTCTGGATGCCGAGTATCAGAACCTGGCGAATCAGGAAGAAGCCC 
Fn0264_Seq      CCGGCGAACTGCAAGCTCTGGATGCCGAGTATCAGAACCTGGCGAATCAGGAAGAAGCCC 
                ************************************************************ 
 
Fn0264_exp      GGTTTAACGAAGAACGCGCTCAGGCTGATGCAGCACGTCAGGCATTGGCACAGAACGAAC 
Fn0264_Seq      GGTTTAACGAAGAACGCGCTCAGGCTGATGCAGCACGTCAGGCATTGGCACAGAACGAAC 
                ************************************************************ 
 
Fn0264_exp      AGGTGTATAACGAACTGAGTCAACGCGCGCAACGTCTGCAAGCGGAAGCGAATACCCGCT 
Fn0264_Seq      AGGTGTATAACGAACTGAGTCAACGCGCGCAACGTCTGCAAGCGGAAGCGAATACCCGCT 
                ************************************************************ 
 
Fn0264_exp      TCTACAAATCGCAGTATCAGGACCTTGCGAGCAAATACGAAGATGCCCTGAAGAAACTCG 
Fn0264_Seq      TCTACAAATCGCAGTATCAGGACCTTGCGAGCAAATACGAAGATGCCCTGAAGAAACTCG 
                ************************************************************ 
 
Fn0264_exp      AGTCTGAGATGGAACAACAGAAAGCCATTATCTCCGACTTTGAGAAAATTCAGGCCTTAC 
Fn0264_Seq      AGTCTGAGATGGAACAACAGAAAGCCATTATCTCCGACTTTGAGAAAATTCAGGCCTTAC 
                ************************************************************ 
 
Fn0264_exp      GTGCGGGTAATGTCGACAAACCTCCCACACCTCCCCCTGAACCTGAAACATAAGCGGCCG 
Fn0264_Seq      GTGCGGGTAATGTCGACAAACCTCCCACACCTCCCCCTAA-------------------- 
                **************************************.*                     
 
Fn0264_exp      CATC 
Fn0264_Seq      ---- 
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Fn0387 (sequencing of PCR product via T3 primer (PCR primer pGEXs+T7 and 
pGEXas+T3)) 
Fn0387_exp      TCCAAAATCGGATCTGGTTCCGCGTGGATCCTCTAAAGACTCGAACAAAATCAAAGCATT 
Fn0387_Seq      ----AAATTGGATCTGGTTCCGCGTGGATCCTCTAAAGACTCGAACAAAATCAAAGCATT 
                    **** *************************************************** 
 
Fn0387_exp      CGGTGCTCGTGGTGAATACAAGACCAATACTGCTGGTGTGATCGATTACAAGAACTATGC 
Fn0387_Seq      CGGTGCTCGTGGTGAATACAAGACCAATACTGCTGGTGTGATCGATTACAAGAACTATGC 
                ************************************************************ 
 
Fn0387_exp      GTATGGTGTTGCCTATATTCACGAGAATGAAAGTGTAAAACTGGGGAAAGACATCGGCTG 
Fn0387_Seq      GTATGGTGTTGCCTATATTCACGAGAATGAAAGTGTAAAACTGGGGAAAGACATCGGCTG 
                ************************************************************ 
 
Fn0387_exp      GTATACCGGGTTCGTACACAACACGTTTCGCTTTGAGGATATCGGTAAATCCAAAGAGGA 
Fn0387_Seq      GTATACCGGGTTCGTACACAACACGTTTCGCTTTGAGGATATCGGTAAATCCAAAGAGGA 
                ************************************************************ 
 
Fn0387_exp      AATGCTGTTAGGCAAAATCGGAATGTTTAAAAGCATTCCGTTTGATGACGATAATTCACT 
Fn0387_Seq      AATGCTGTTAGGCAAAATCGGAATGTTTAAAAGCATTCCGTTTGATGACGATAATTCACT 
                ************************************************************ 
 
Fn0387_exp      GAACTGGACAGTCAGTGGCAATGTGTTTGTTGGTCGCAACAAAATGCATCGGAAATTCCT 
Fn0387_Seq      GAACTGGACAGTCAGTGGCAATGTGTTTGTTGGTCGCAACAAAATGCATCGGAAATTCCT 
                ************************************************************ 
 
Fn0387_exp      CATTGTGGACGAAATCTTCAACGCGAAAAGCAAGTACTACGCGTATGGCATTGGGGTCAA 
Fn0387_Seq      CATTGTGGACGAAATCTTCAACGCGAAAAGCAAGTACTACGCGTATGGCATTGGGGTCAA 
                ************************************************************ 
 
Fn0387_exp      GAACGAAATTGGCAAAGAATTCCGGCTTTCTGAGGACTTTAGCATTCGTCCATATGGTGC 
Fn0387_Seq      GAACGAAATTGGCAAAGAATTCCGGCTTTCTGAGGACTTTAGCATTCGTCCATATGGTGC 
                ************************************************************ 
 
Fn0387_exp      ACTGAAGCTGGAGTACGGACGCATTTCGAAAATCAAAGAGAAAACGGGCGAAATTCGCCT 
Fn0387_Seq      ACTGAAGCTGGAGTACGGACGCATTTCGAAAATCAAAGAGAAAACGGGCGAAATTCGCCT 
                ************************************************************ 
 
Fn0387_exp      GGAAGTGAAAAGCAACGATTATGTCTCCATTAAACCGGAAATTGGCACGGAACTTAAATA 
Fn0387_Seq      GGAAGTGAAAAGCAACGATTATGTCTCCATTAAACCGGAAATTGGCACGGAACTTAAATA 
                ************************************************************ 
 
Fn0387_exp      CAAATATCTGTTCACCAACCGCAAAACCTTGACCGTTGGTTTGGGCGTTGCGTATGAGAA 
Fn0387_Seq      CAAATATCTGTTCACCAACCGCAAAACCTTGACCGTTGGTTTGGGCGTTGCGTATGAGAA 
                ************************************************************ 
 
Fn0387_exp      TGAACTCGGGAAAGTCGCCAATCCTAAGAACAAAGCCCGCGTAGCGTATACTGCGGCCGA 
Fn0387_Seq      TGAACTCGGGAAAGTCGCCAATCCTAAGAACAAAGCCCGCGTAGCGTATACTGCGGCCGA 
                ************************************************************ 
 
Fn0387_exp      TTGGTACAACTTACGCGGTGAAAAGGAAGATCGTCGTGGCAACATCAAAACGGATCTGAC 
Fn0387_Seq      TTGGTACAACTTACGCGGTGAAAAGGAAGATCGTCGTGGCAACATCAAAACGGATCTGAC 
                ************************************************************ 
 
Fn0387_exp      AATTGGTCTGGAAAATACCCGTTTTGGCGCTACTGCAAATGTGGGATACGATACCAAAGG 
Fn0387_Seq      AATTGGTCTGGAAAATACCCGTTTTGGCGCTACTGCAAATGTGGGATACGATACCAAAGG 
                ************************************************************ 
 
Fn0387_exp      CCATAATGTGGTCGACAAACCTCCCACACCTCCCCCTGAACCTGAAACATAAGCGGCCGC 
Fn0387_Seq      CCATAATGTGGTCGACAAACCTCCCACACCTCCCCCT----------------------- 
                *************************************                        
 
Fn0387_exp      ATC 
Fn0387_Seq      --- 
                    
  
Appendix 
162 
 
Fn1426 (sequencing of PCR product via T3 and T7 primer (PCR primer pGEXs+T7 
and pGEXas+T3)) 
Fn1426_exp      TCCAAAATCGGATCTGGTTCCGCGTGGATCCACCATTCCGACCGAAACCATTTCGTACAA 
Fn1426_Seq      -------------------TCGCGTGGATCCACCATTCCGACCGAAACCATTTCGTACAA 
                                    **************************************** 
 
Fn1426_exp      TGGTAGCACCGTTAAAATCGGTATCCTTGACAGCGACTTTACGGACCCAGTCCGCAAAGC 
Fn1426_Seq      TGGTAGCACCGTTAAAATCGGTATCCTTGACAGCGACTTTACGGACCCAGTCCGCAAAGC 
                ************************************************************ 
 
Fn1426_exp      GCAATTGAGTGCACGTTACCCTGGCATTGAATTCATTCCACGCGTCAATTCGGACACAAG 
Fn1426_Seq      GCAATTGAGTGCACGTTACCCTGGCATTGAATTCATTCCACGCGTCAATTCGGACACAAG 
                ************************************************************ 
 
Fn1426_exp      CACCAGCTCTCACGGGGTGCAAGTACTGGAGGTAATGATGGACACCCTCGAAGATCGCAC 
Fn1426_Seq      CACCAGCTCTCACGGGGTGCAAGTACTGGAGGTAATGATGGACACCCTCGAAGATCGCAC 
                ************************************************************ 
 
Fn1426_exp      GAAAGGGAAGGCGAAATTCAAGGCCATTGCGGCGTCCATCGGGAATGGTGGTGCCAGCGA 
Fn1426_Seq      GAAAGGGAAGGCGAAATTCAAGGCCATTGCGGCGTCCATCGGGAATGGTGGTGCCAGCGA 
                ************************************************************ 
 
Fn1426_exp      AACGAACAAATCGGTGAATCCCAATGTTAAGACGTATGAGAAAGTGTTTGAGCGCTTCAA 
Fn1426_Seq      AACGAACAAATCGGTGAATCCCAATGTTAAGACGTATGAGAAAGTGTTTGAGCGCTTCAA 
                ************************************************************ 
 
Fn1426_exp      CTTCAACCAGAAAGTGAAAGTCGTGAATCAGTCCTTTGGCGCAGACATCACTATCGAGGA 
Fn1426_Seq      CTTCAACCAGAAAGTGAAAGTCGTGAATCAGTCCTTTGGCGCAGACATCACTATCGAGGA 
                ************************************************************ 
 
Fn1426_exp      AGCCCCGTATACCAAGAACAACATTCGCAACTATGTATGGGCAGGCGATTCGAAACCATT 
Fn1426_Seq      AGCCCCGTATACCAAGAACAACATTCGCAACTATGTATGGGCAGGCGATTCGAAACCATT 
                ************************************************************ 
 
Fn1426_exp      TGCCACCTACTTCGAAGAAAAGGTCAACAACGATGGTGGCTTATTTGTTTGGGCCGCAGG 
Fn1426_Seq      TGCCACCTACTTCGAAGAAAAGGTCAACAACGATGGTGGCTTATTTGTTTGGGCCGCAGG 
                ************************************************************ 
 
Fn1426_exp      AAATCGGAAAGGCGCGACAGAAACCAACCCGGGACAGGATATGGATTCAGTTGGCATGGA 
Fn1426_Seq      AAATCGGAAAGGCGCGACAGAAACCAACCCGGGACAGGATATGGATTCAGTTGGCATGGA 
                ************************************************************ 
 
Fn1426_exp      AGCGGGCCTTCCGTATCTGGTGAATGACCTGGAGAAAGGTTGGATTGCAGTTGTTGGCAT 
Fn1426_Seq      AGCGGGCCTTCCGTATCTGGTGAATGACCTGGAGAAAGGTTGGATTGCAGTTGTTGGCAT 
                ************************************************************ 
 
Fn1426_exp      TCAACCCAAAGAAACGGTCCGTGTGGGTACGGCACCTGATGGCACGCCGATTGTGAACAT 
Fn1426_Seq      TCAACCCAAAGAAACGGTCCGTGTGGGTACGGCACCTGATGGCACGCCGATTGTGAACAT 
                ************************************************************ 
 
Fn1426_exp      CAAACCGAATGGGAAACTCAATATTCATCGCACTGGGACTGATCGCCTGGCATATGCTGG 
Fn1426_Seq      CAAACCGAATGGGAAACTCAATATTCATCGCACTGGGACTGATCGCCTGGCATATGCTGG 
                ************************************************************ 
 
Fn1426_exp      CGATAACGCCAAATACTGGAGCATCAGTGCCGATGATTCAGCGATTCCGACTGCTGGTCG 
Fn1426_Seq      CGATAACGCCAAATACTGGAGCATCAGTGCCGATGATTCAGCGATTCCGACTGCTGGTCG 
                ************************************************************ 
 
Fn1426_exp      TGCTGGTATCGGCTCCTCATATGCCGCCCCTCGTGTGTCTCGCGCTGCTGCGTTAGTTGC 
Fn1426_Seq      TGCTGGTATCGGCTCCTCATATGCCGCCCCTCGTGTGTCTCGCGCTGCTGCGTTAGTTGC 
                ************************************************************ 
 
Fn1426_exp      GGAGAAATTTGACTGGATGACCGCTGATCAGGTACGGCAGACCCTGTTTACCACAACTGA 
Fn1426_Seq      GGAGAAATTTGACTGGATGACCGCTGATCAGGTACGGCAGACCCTGTTTACCACAACTGA 
                ************************************************************ 
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Fn1426_exp      CGATACAGAACTGGATGCCTCTTTGGCGGGAAACGCGAATGCGGAAAAGCGCCGTCGTGT 
Fn1426_Seq      CGATACAGAACTGGATGCCTCTTTGGCGGGAAACGCGAATGCGGAAAAGCGCCGTCGTGT 
                ************************************************************ 
 
Fn1426_exp      GAAAACGAGTCCGGATTACAAATATGGTTGGGGCATGCTGAACCAGGAACGTGCGCTGAA 
Fn1426_Seq      GAAAACGAGTCCGGATTACAAATATGGTTGGGGCATGCTGAACCAGGAACGTGCGCTGAA 
                ************************************************************ 
 
Fn1426_exp      AGTCGACAAACCTCCCACACCTCCCCCTGAACCTGAAACATAAGCGGCCGCATC 
Fn1426_Seq      AGTCGACAAACCTCCCACACCTCCCCCT-------------------------- 
                ****************************                           
 
Fn1449 (sequencing of PCR product via T3 primer (PCR primer pGEXs+T7 and 
pGEXas+T3)) 
Fn1449_exp      -----------TCCAAAATCGGATCTGGTTCCGCGTGGATCCAGCAAAGACTCGAACAAG 
Fn1449_Seq      CTCCCTATAGGTCCAAAATCGGATCTGGTTCCGCGTGGATCCAGCAAAGACTCGAACAAG 
                           ************************************************* 
 
Fn1449_exp      GTCAAAACCTTTGGCATGAAAGGGGAATACAAAACCGATACTGCAGGAGTGATTGACTAC 
Fn1449_Seq      GTCAAAACCTTTGGCATGAAAGGGGAATACAAAACCGATACTGCAGGAGTGATTGACTAC 
                ************************************************************ 
 
Fn1449_exp      AAGTATAATGCGTATGGCGTAGCGTATGTCCATGAGAATGAAGATATCAAACTGGGCAAA 
Fn1449_Seq      AAGTATAATGCGTATGGCGTAGCGTATGTCCATGAGAATGAAGATATCAAACTGGGCAAA 
                ************************************************************ 
 
Fn1449_exp      GGTACAGGTTGGTATACCGGTATCGTGCACAACACCTTCAAGTTCAAAGACATCGGCAAT 
Fn1449_Seq      GGTACAGGTTGGTATACCGGTATCGTGCACAACACCTTCAAGTTCAAAGACATCGGCAAT 
                ************************************************************ 
 
Fn1449_exp      TCCAAAGAGAAACAGCTGCAAGCGAAAGTTGGCCTGTTTAAAAGTGTCCCGTTTGACGAA 
Fn1449_Seq      TCCAAAGAGAAACAGCTGCAAGCGAAAGTTGGCCTGTTTAAAAGTGTCCCGTTTGACGAA 
                ************************************************************ 
 
Fn1449_exp      AATAACTCTCTGAACTGGACTATTAGTGGCGACATTTTCATTGGACACAACAAACTCGAA 
Fn1449_Seq      AATAACTCTCTGAACTGGACTATTAGTGGCGACATTTTCATTGGACACAACAAACTCGAA 
                ************************************************************ 
 
Fn1449_exp      CGCAAGTTTCTTGTGGTTGATGAAATCTTTCATGCCAAAAGCAAGTACTACACGTATGGT 
Fn1449_Seq      CGCAAGTTTCTTGTGGTTGATGAAATCTTTCATGCCAAAAGCAAGTACTACACGTATGGT 
                ************************************************************ 
 
Fn1449_exp      ATCGGCATCAAGAACGAAATTGGCAAGGAGTTCCGTTTAAGCGAAGATTTTAGCATTCGC 
Fn1449_Seq      ATCGGCATCAAGAACGAAATTGGCAAGGAGTTCCGTTTAAGCGAAGATTTTAGCATTCGC 
                ************************************************************ 
 
Fn1449_exp      CCATATGGTGCCTTGAAAGTGGAATATGGTCGCGTGTCGAAAATCAAAGAGAAATCTGGG 
Fn1449_Seq      CCATATGGTGCCTTGAAAGTGGAATATGGTCGCGTGTCGAAAATCAAAGAGAAATCTGGG 
                ************************************************************ 
 
Fn1449_exp      GAAATGAAACTGGAGGTAAAAGAAAACGATTACCTCTCCATTCGTCCGGAAATTGGTACG 
Fn1449_Seq      GAAATGAAACTGGAGGTAAAAGAAAACGATTACCTCTCCATTCGTCCGGAAATTGGTACG 
                ************************************************************ 
 
Fn1449_exp      GAACTGGCGTATCGGCATTACTTTGGCACCAAAACCTTGCGTACCTCAGTTGGGGTTGCA 
Fn1449_Seq      GAACTGGCGTATCGGCATTACTTTGGCACCAAAACCTTGCGTACCTCAGTTGGGGTTGCA 
                ************************************************************ 
 
Fn1449_exp      TACGAAAATGAACTGGGTCGTGTGGCTAATGGCAAGAACAAAGCACGCGTTGCTGGTACA 
Fn1449_Seq      TACGAAAATGAACTGGGTCGTGTGGCTAATGGCAAGAACAAAGCACGCGTTGCTGGTACA 
                ************************************************************ 
 
Fn1449_exp      ACTGCCGATTGGTTCAACATTCGTGGGGAGAAAGAGGATCGCAAAGGCAATGTGAAAGTG 
Fn1449_Seq      ACTGCCGATTGGTTCAACATTCGTGGGGAGAAAGAGGATCGCAAAGGCAATGTGAAAGTG 
                ************************************************************ 
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Fn1449_exp      GATCTGAACGTTGGCATTGATAACCAGCGCTTAGGGGTCACGGGTAATGTCGGCTATGAC 
Fn1449_Seq      GATCTGAACGTTGGCATTGATAACCAGCGCTTAGGGGTCACGGGTAATGTCGGCTATGAC 
                ************************************************************ 
 
Fn1449_exp      ACGAAAGGACACAATGTAGTCGACAAACCTCCCACACCTCCCCCTGAACCTGAAACATAA 
Fn1449_Seq      ACGAAAGGACACAATGTAGTCGACAAACCTCCCACACCTCCCCCG--------------- 
                ********************************************                 
 
Fn1449_exp      GCGGCCGCATC 
Fn1449_Seq      ----------- 
                            
 
Fn1526 (sequencing of PCR product via T3 primer (PCR primer pGEXs+T7 and 
pGEXas+T3)) 
Fn1526_exp      TCCAAAATCGGATCTGGTTCCGCGTGGATCCAACGTGAACAAGTTTGGCATCATTTATAC 
Fn1526_Seq      ---------TCGATTGGTTCCGCGTGGATCCAACGTGAACAAGTTTGGCATCATTTATAC 
                              ********************************************** 
 
Fn1526_exp      AGGCGGTGAACACAAAGATAGCACGCTTGGAGTGTCCGGGTATAAATACAAATCGACCGG 
Fn1526_Seq      AGGCGGTGAACACAAAGATAGCACGCTTGGAGTGTCCGGGTATAAATACAAATCGACCGG 
                ************************************************************ 
 
Fn1526_exp      TGTGCTCTATCTGAACGATCGCGAAGCCTTTACGTATGGTGGCAAATACGGCTGGTCAGC 
Fn1526_Seq      TGTGCTCTATCTGAACGATCGCGAAGCCTTTACGTATGGTGGCAAATACGGCTGGTCAGC 
                ************************************************************ 
 
Fn1526_exp      CGGTATTGTCGGGAGCAACTTCGAGTTTAACGGTGATACCAATAAAGGGTCTAAAGAACG 
Fn1526_Seq      CGGTATTGTCGGGAGCAACTTCGAGTTTAACGGTGATACCAATAAAGGGTCTAAAGAACG 
                ************************************************************ 
 
Fn1526_exp      CGTTGTTAGTGGTAAACTGGGCCTGCATTACCAGGCTCCCCTGAATAAAGAAGATGACAA 
Fn1526_Seq      CGTTGTTAGTGGTAAACTGGGCCTGCATTACCAGGCTCCCCTGAATAAAGAAGATGACAA 
                ************************************************************ 
 
Fn1526_exp      TGCGAAACTCAAATGGCTTACTCGCGGTGAAGTTACGGTCAACAACCATCGCACTAATCG 
Fn1526_Seq      TGCGAAACTCAAATGGCTTACTCGCGGTGAAGTTACGGTCAACAACCATCGCACTAATCG 
                ************************************************************ 
 
Fn1526_exp      GTACTCGCAAGTAGGCAAAGATACCTATCAGAACAAAGCCTCGTTTTATTCCACGGAATT 
Fn1526_Seq      GTACTCGCAAGTAGGCAAAGATACCTATCAGAACAAAGCCTCGTTTTATTCCACGGAATT 
                ************************************************************ 
 
Fn1526_exp      GAGCTGGAAGAACATTATCTCCTATGACTACGACATCAATACGAACTGGATGGTTAAACC 
Fn1526_Seq      GAGCTGGAAGAACATTATCTCCTATGACTACGACATCAATACGAACTGGATGGTTAAACC 
                ************************************************************ 
 
Fn1526_exp      GTATACCGGGATTGACATGAGCTATGGTCACATCTTCAACATCAAAGAGAAGAACGAAGG 
Fn1526_Seq      GTATACCGGGATTGACATGAGCTATGGTCACATCTTCAACATCAAAGAGAAGAACGAAGG 
                ************************************************************ 
 
Fn1526_exp      CTTACCGCTGGAAGTGAAAGGCAAAGATTACTTCGTCATTACCCCGAATGTAGGCGTGGA 
Fn1526_Seq      CTTACCGCTGGAAGTGAAAGGCAAAGATTACTTCGTCATTACCCCGAATGTAGGCGTGGA 
                ************************************************************ 
 
Fn1526_exp      AACCAAGTATGTACTGCCATTAGGCGCAACTCACCAGGTGTTTGCGAAAGCGGATACAGA 
Fn1526_Seq      AACCAAGTATGTACTGCCATTAGGCGCAACTCACCAGGTGTTTGCGAAAGCGGATACAGA 
                ************************************************************ 
 
Fn1526_exp      GTTCAGCTATGATGTGGCTAAACTGTACCATGGTGTCAATCAGGCGAAAATGAAGAATGC 
Fn1526_Seq      GTTCAGCTATGATGTGGCTAAACTGTACCATGGTGTCAATCAGGCGAAAATGAAGAATGC 
                ************************************************************ 
 
Fn1526_exp      GAGTTCTGGCTACTACGACCTGAGTAAGCCTGAACGTCGTCGTGCTCGTGTTGCCGTGGG 
Fn1526_Seq      GAGTTCTGGCTACTACGACCTGAGTAAGCCTGAACGTCGTCGTGCTCGTGTTGCCGTGGG 
                ************************************************************ 
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Fn1526_exp      AGCAGAACTGGGTTTGGAGAAAGAGAATGCGTATGGCATTACCTTTCGCGCAGAATATCA 
Fn1526_Seq      AGCAGAACTGGGTTTGGAGAAAGAGAATGCGTATGGCATTACCTTTCGCGCAGAATATCA 
                ************************************************************ 
 
Fn1526_exp      GGGATATAAGAAATCACAACTGAATTACGTCGACAAACCTCCCACACCTCCCCCTGAACC 
Fn1526_Seq      GGGATATAAGAAATCACAACTGAATTACGTCGACAAACCTCCCACACCTCCCCCTAAC-- 
                ******************************************************* *    
 
Fn1526_exp      TGAAACATAAGCGGCCGCATC 
Fn1526_Seq      --------------------- 
                                      
 
Fn1817_1 (sequencing of PCR product via T3 primer (PCR primer pGEXs+T7 and 
pGEXas+T3)) 
Fn1817_1_exp      ---------------------TCCAAAATCGGATCTGGTTCCGCGTGGATCCGTTGTTAC 
Fn1817_1_Seq      TTAATACGACTCACTATAGGGTCCAAAATCGGATCTGGTTCCGCGTGGATCCGTTGTTAC 
                                       *************************************** 
 
Fn1817_1_exp      GAATGACCTGAAAGTGGTAACAGGGAGTAATAGCACCACTTCTACCAACAACATTGCCAT 
Fn1817_1_Seq      GAATGACCTGAAAGTGGTAACAGGGAGTAATAGCACCACTTCTACCAACAACATTGCCAT 
                  ************************************************************ 
 
Fn1817_1_exp      TGATGCCAAAGAGTTAGGTGGCATGTATGCGAATCGTATTCGCATCATTAGCACGGATAA 
Fn1817_1_Seq      TGATGCCAAAGAGTTAGGTGGCATGTATGCGAATCGTATTCGCATCATTAGCACGGATAA 
                  ************************************************************ 
 
Fn1817_1_exp      AGGTGCTGGAGTCAATTCAGACGCGTTTATCGTGTCGAAGAACTCCAAACTGGAAATTAC 
Fn1817_1_Seq      AGGTGCTGGAGTCAATTCAGACGCGTTTATCGTGTCGAAGAACTCCAAACTGGAAATTAC 
                  ************************************************************ 
 
Fn1817_1_exp      CGCAGATGGCAAAATCAAGGTGAACAAAGTCGACAAACCTCCCACACCTCCCCCTGAACC 
Fn1817_1_Seq      CGCAGATGGCAAAATCAAGGTGAACAAAGTCGACAAACCTCCCACACCTCCCCCGAAGT- 
                  ******************************************************  *    
 
Fn1817_1_exp      TGAAACATAAGCGGCCGCATC 
Fn1817_1_Seq      --------------------- 
 
 
Fn1817_2 (sequencing of PCR product via T3 primer (PCR primer pGEXs+T7 and 
pGEXas+T3)) 
Fn1817_2_exp      ---------------------TCCAAAATCGGATCTGGTTCCGCGTGGATCCGCCGCAGC 
Fn1817_2_Seq      TTAATACGACTCACTATAGGGTCCAAAATCGGATCTGGTTCCGCGTGGATCCGCCGCAGC 
                                       *************************************** 
 
Fn1817_2_exp      TGGTGATCTGACCTTAACTGCGACCAATAAGGTCGATAACAAAAGCGGGAAAACGATCTT 
Fn1817_2_Seq      TGGTGATCTGACCTTAACTGCGACCAATAAGGTCGATAACAAAAGCGGGAAAACGATCTT 
                  ************************************************************ 
 
Fn1817_2_exp      TGCAGGCAATAAACTGACGGTAACAGCGAAAGAGATCAAGAACAACAAACGTGCTGAACT 
Fn1817_2_Seq      TGCAGGCAATAAACTGACGGTAACAGCGAAAGAGATCAAGAACAACAAACGTGCTGAACT 
                  ************************************************************ 
 
Fn1817_2_exp      CTTGGGTACGAACATTGAACTGACTGCCGATAAAGTGCGCAATGAAGTTGGCACCATTAA 
Fn1817_2_Seq      CTTGGGTACGAACATTGAACTGACTGCCGATAAAGTGCGCAATGAAGTTGGCACCATTAA 
                  ************************************************************ 
 
Fn1817_2_exp      AGCGTTCAATGACATCACCATTAAAGTCGACAAACCTCCCACACCTCCCCCTGAACCTGA 
Fn1817_2_Seq      AGCGTTCAATGACATCACCATTAAAGTCGACAAACCTCCCACACCTCCCCCTAAC----- 
                  **************************************************** *       
 
Fn1817_2_exp      AACATAAGCGGCCGCATC 
Fn1817_2_Seq      ------------------  
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Fn1859 (sequencing of PCR product via T3 and T7 primer (PCR primer pGEXs+T7 
and pGEXas+T3)) 
Fn1859_exp      TCCAAAATCGGATCTGGTTCCGCGTGGATCCCCGACACCAGCGCCTAAGAAAGTCGTCGA 
Fn1859_Seq      ------------------------------CCCGACACCAGCGCCTAAGAAAGTCGTCGA 
                                              ****************************** 
 
Fn1859_exp      ATACGTGGAGAAACCGGTGATTGTCTATCGTGATCGGGAAGTAGCGCCGGCTTGGCGTCC 
Fn1859_Seq      ATACGTGGAGAAACCGGTGATTGTCTATCGTGATCGGGAAGTAGCGCCGGCTTGGCGTCC 
                ************************************************************ 
 
Fn1859_exp      CAATGGTAGCGTTGATGTTCAGTATCGCTGGTATGGCAATGTGGAGAATCGCACCCCGAA 
Fn1859_Seq      CAATGGTAGCGTTGATGTTCAGTATCGCTGGTATGGCAATGTGGAGAATCGCACCCCGAA 
                ************************************************************ 
 
Fn1859_exp      GAAAGAAGATCCAGCCTCTCCGTGGCTTGGTGATAATGTGAATGCGGGGCGCTTACAGAC 
Fn1859_Seq      GAAAGAAGATCCAGCCTCTCCGTGGCTTGGTGATAATGTGAATGCGGGGCGCTTACAGAC 
                ************************************************************ 
 
Fn1859_exp      GCTCACCAAAGTGAACTTTACCGAGAAACAAACGCTTGAAATTCGCACACGGAATTATCA 
Fn1859_Seq      GCTCACCAAAGTGAACTTTACCGAGAAACAAACGCTTGAAATTCGCACACGGAATTATCA 
                ************************************************************ 
 
Fn1859_exp      TACTCTGATGAACCCCAAGGATTCACAAGCTGCTGATGACCAAGTCCGTGTTCGCCACTT 
Fn1859_Seq      TACTCTGATGAACCCCAAGGATTCACAAGCTGCTGATGACCAAGTCCGTGTTCGCCACTT 
                ************************************************************ 
 
Fn1859_exp      CTACAAATTCGGGAAACTGGGCAGTTCGAAAATCGATGTAACCAGTCGCTTGGAGTATAA 
Fn1859_Seq      CTACAAATTCGGGAAACTGGGCAGTTCGAAAATCGATGTAACCAGTCGCTTGGAGTATAA 
                ************************************************************ 
 
Fn1859_exp      AAAAAACAATGGAGATGCCGGACGCAAACAGGCTGAAGCGTCAGTACTGTTCGATTTTGC 
Fn1859_Seq      AAAAAACAATGGAGATGCCGGACGCAAACAGGCTGAAGCGTCAGTACTGTTCGATTTTGC 
                ************************************************************ 
 
Fn1859_exp      GGACTACATCTATTCTAACAACTTCTTCAAAGCCGACAAATTCGGCTTTCGTCTGGGGTA 
Fn1859_Seq      GGACTACATCTATTCTAACAACTTCTTCAAAGCCGACAAATTCGGCTTTCGTCTGGGGTA 
                ************************************************************ 
 
Fn1859_exp      TCAGCACAAATGGGCGGGTCATAACTCGGGTGTTGTGGGCCAGCCGTTTAACAAAGGTAC 
Fn1859_Seq      TCAGCACAAATGGGCGGGTCATAACTCGGGTGTTGTGGGCCAGCCGTTTAACAAAGGTAC 
                ************************************************************ 
 
Fn1859_exp      TCAGGATAACTACTTTATCAATTTCGAAAGTGAATACACGTTACCTTGGGGCTTTTCGGC 
Fn1859_Seq      TCAGGATAACTACTTTATCAATTTCGAAAGTGAATACACGTTACCTTGGGGCTTTTCGGC 
                ************************************************************ 
 
Fn1859_exp      CGAACTGAACGCCTACAACTATTACAATGTTCACAACAAGAAATTTGCCACCTATAACAA 
Fn1859_Seq      CGAACTGAACGCCTACAACTATTACAATGTTCACAACAAGAAATTTGCCACCTATAACAA 
                ************************************************************ 
 
Fn1859_exp      AGGCAACAAGAAAAGCCAGTTCTATGGCGAAATTGAGGCCTATTTGTACCAGCATACCCC 
Fn1859_Seq      AGGCAACAAGAAAAGCCAGTTCTATGGCGAAATTGAGGCCTATTTGTACCAGCATACCCC 
                ************************************************************ 
 
Fn1859_exp      ACTCTATAAAACAAACAATGTGGAACTGTCCTTTGACTTTGAAGGTGGCTATGATCCGTA 
Fn1859_Seq      ACTCTATAAAACAAACAATGTGGAACTGTCCTTTGACTTTGAAGGTGGCTATGATCCGTA 
                ************************************************************ 
 
Fn1859_exp      TACGTGGCATCAGTACAAAGTCGTTTCCGCAAAAGACAGCAATAAATACGAAGTGTACAT 
Fn1859_Seq      TACGTGGCATCAGTACAAAGTCGTTTCCGCAAAAGACAGCAATAAATACGAAGTGTACAT 
                ************************************************************ 
 
Fn1859_exp      GCTGCCTACGCTGCAAGTTAGCTACAAACCGACCGACTTTGTGAAACTGTATGCAGCGGC 
Fn1859_Seq      GCTGCCTACGCTGCAAGTTAGCTACAAACCGACCGACTTTGTGAAACTGTATGCAGCGGC 
                ************************************************************ 
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Fn1859_exp      AGGCGCGGAATATCGCAATTGGGCAGTAACCGCAGAGAGCAAAGCGAAGAACTGGCGTTG 
Fn1859_Seq      AGGCGCGGAATATCGCAATTGGGCAGTAACCGCAGAGAGCAAAGCGAAGAACTGGCGTTG 
                ************************************************************ 
 
Fn1859_exp      GCAACCGACTGCATGGGCGGGTATGAAGGTGACCTTTGTCGACAAACCTCCCACACCTCC 
Fn1859_Seq      GCAACCGACTGCATGGGCGGGTATGAAGGTGACCTTTGTCGACAAACCTCCCACACCTCC 
                ************************************************************ 
 
Fn1859_exp      CCCTGAACCTGAAACATAAGCGGCCGCATC 
Fn1859_Seq      CCT--------------------------- 
                **                            
 
Fn1893 (sequencing of PCR product via T3 and T7 primer (PCR primer pGEXs+T7 
and pGEXas+T3)) 
Fn1893_exp      --------TCCAAAATCGGATCTGGTTCCGCGTGGATCCAGCAAAGATAGCAACAAAATC 
Fn1893_Seq      CCCTTAGGTCCAAAATCGGATCTGGTTCCGCGTGGATCCAGCAAAGATAGCAACAAAATC 
                        **************************************************** 
 
Fn1893_exp      AAGATTTTCGGTATTAAGGGCGAATACAAAACCGATACTGCAGGCGTGATTGACTATAAG 
Fn1893_Seq      AAGATTTTCGGTATTAAGGGCGAATACAAAACCGATACTGCAGGCGTGATTGACTATAAG 
                ************************************************************ 
 
Fn1893_exp      AATGAAGCCTATGGAATGGCGTATGTGCACGAAAATGAGGACATTAAACTGGGTAAAGGG 
Fn1893_Seq      AATGAAGCCTATGGAATGGCGTATGTGCACGAAAATGAGGACATTAAACTGGGTAAAGGG 
                ************************************************************ 
 
Fn1893_exp      ATTGGCTGGTATACTGGGATTGTGGATAACACCTTTAAATTCAAAGATATCGGTAAATCC 
Fn1893_Seq      ATTGGCTGGTATACTGGGATTGTGGATAACACCTTTAAATTCAAAGATATCGGTAAATCC 
                ************************************************************ 
 
Fn1893_exp      AAAGAGGAACAGATTCAGGCCAAAGTCGGTCTGCTGAAATCAATCCCGTTTGATGACAAC 
Fn1893_Seq      AAAGAGGAACAGATTCAGGCCAAAGTCGGTCTGCTGAAATCAATCCCGTTTGATGACAAC 
                ************************************************************ 
 
Fn1893_exp      AATTCGCTCAATTGGACCATTTCTGGGGACATTTTCGTCGGCTATAACAAAATGCATCGC 
Fn1893_Seq      AATTCGCTCAATTGGACCATTTCTGGGGACATTTTCGTCGGCTATAACAAAATGCATCGC 
                ************************************************************ 
 
Fn1893_exp      AAGTACCTGGTTGTGAACGAAATCTTTAATGCGAAATCGAAGTATTACACGTATGGCATT 
Fn1893_Seq      AAGTACCTGGTTGTGAACGAAATCTTTAATGCGAAATCGAAGTATTACACGTATGGCATT 
                ************************************************************ 
 
Fn1893_exp      GGCATCAAGAATAAAATCAGCAAAGACTTTCGCTTGTCCGAAGATTTTAGTCTGGTACCA 
Fn1893_Seq      GGCATCAAGAATAAAATCAGCAAAGACTTTCGCTTGTCCGAAGATTTTAGTCTGGTACCA 
                ************************************************************ 
 
Fn1893_exp      TACGGCTCTCTGAACTTAGAGTATGGCCGCGTGAACAAAATTAAGGAGAAAGTTGGTGAA 
Fn1893_Seq      TACGGCTCTCTGAACTTAGAGTATGGCCGCGTGAACAAAATTAAGGAGAAAGTTGGTGAA 
                ************************************************************ 
 
Fn1893_exp      ATCCGGTTGGAAGTCAAAGAAAACTACTACGTAAGCGTGAATCCGGAAATCGGAGCGGAA 
Fn1893_Seq      ATCCGGTTGGAAGTCAAAGAAAACTACTACGTAAGCGTGAATCCGGAAATCGGAGCGGAA 
                ************************************************************ 
 
Fn1893_exp      TTAACCTACAAACACCTCCTTGCCAGTCGCAAAACGTTCCGTATGGGTCTGGGAATTGCC 
Fn1893_Seq      TTAACCTACAAACACCTCCTTGCCAGTCGCAAAACGTTCCGTATGGGTCTGGGAATTGCC 
                ************************************************************ 
 
Fn1893_exp      TACGAAAACGAGCTTGGTAAAGTTGCGAATGGCAAGAACAAAGCTCGTGTTGCGTATACC 
Fn1893_Seq      TACGAAAACGAGCTTGGTAAAGTTGCGAATGGCAAGAACAAAGCTCGTGTTGCGTATACC 
                ************************************************************ 
 
Fn1893_exp      AATGCTGACTGGTTTAACATTCGTGGTGAGAAAGAAGATCGCAAAGGCAACATCAAATTC 
Fn1893_Seq      AATGCTGACTGGTTTAACATTCGTGGTGAGAAAGAAGATCGCAAAGGCAACATCAAATTC 
                ************************************************************ 
 
 
Appendix 
168 
 
Fn1893_exp      GATCTGAACATCGGTCTGGATAACCAACGTGTAGGTGTGACAGCAAATGCAGGCTATGAT 
Fn1893_Seq      GATCTGAACATCGGTCTGGATAACCAACGTGTAGGTGTGACAGCAAATGCAGGCTATGAT 
                ************************************************************ 
 
Fn1893_exp      ACGAAAGGGCATAATGTCGTCGACAAACCTCCCACACCTCCCCCTGAACCTGAAACATAA 
Fn1893_Seq      ACGAAAGGGCATAATGTCGTCGACAAACCTCCCACACCTCCCCCTAA------------- 
                ********************************************* *              
 
Fn1893_exp      GCGGCCGCATC 
Fn1893_Seq      ----------- 
                            
 
Gallo0112A (forward sequencing of miniPrep DNA via primer pGEXfor, reverse 
sequencing of PCR product via T3 primer (PCR primer pGEXs+T7 and 
pGEXas+T3)) 
Gallo0112A_exp      ATAGCATGGCCTTTGCAGGGCTGGCAAGCCACGTTTGGTGGTGGCGACCATCCTCCAAAA 
Gallo0112A_Seq      ---------------------------------------------GCGACATCCTCCAAA 
                                                                 *      *  * *** 
 
Gallo0112A_exp      TCGGATCTGGTTCCGCGTGGATCCGATGAAGCTGTGTCTAGTCCGATGGAACTCGTAACG 
Gallo0112A_Seq      TCGGATCTGGTTCCGCGTGGATCCGATGAAGCTGTGTCTAGTCCGATGGAACTCGTAACG 
                    ************************************************************ 
 
Gallo0112A_exp      GTCGCGGATGTTAACGCGGATAACAATACCAATACCGATCAGAAAACCGAGGTGGACCAG 
Gallo0112A_Seq      GTCGCGGATGTTAACGCGGATAACAATACCAATACCGATCAGAAAACCGAGGTGGACCAG 
                    ************************************************************ 
 
Gallo0112A_exp      GAAACGCAGCAGCCTGCGAACCAAGTTGAAACGCCGGAGAACCAGACCCCGATTGAGCAA 
Gallo0112A_Seq      GAAACGCAGCAGCCTGCGAACCAAGTTGAAACGCCGGAGAACCAGACCCCGATTGAGCAA 
                    ************************************************************ 
 
Gallo0112A_exp      GGTGTCGTTGGCGAGCAGAATCAGAAAGTGACGGAGGAAAACCAGGTGACGGAGAACCAA 
Gallo0112A_Seq      GGTGTCGTTGGCGAGCAGAATCAGAAAGTGACGGAGGAAAACCAGGTGACGGAGAACCAA 
                    ************************************************************ 
 
Gallo0112A_exp      GATGTAACCCAACAGAATCAGGTCACCGAAAATCAAGAACCTGCGACCAAAACCCAGGAT 
Gallo0112A_Seq      GATGTAACCCAACAGAATCAGGTCACCGAAAATCAAGAACCTGCGACCAAAACCCAGGAT 
                    ************************************************************ 
 
Gallo0112A_exp      GATGCCCAGAAAACGGAAACGACAGATGCGGAAGAGAAAGTCGAAGTAACGGATAGCCTG 
Gallo0112A_Seq      GATGCCCAGAAAACGGAAACGACAGATGCGGAAGAGAAAGTCGAAGTAACGGATAGCCTG 
                    ************************************************************ 
 
Gallo0112A_exp      AAACAGAAAGCTGATCAGCCAAACGAATCGACCGAGAAAGCGCGTAAGGCTCTGTCAACG 
Gallo0112A_Seq      AAACAGAAAGCTGATCAGCCAAACGAATCGACCGAGAAAGCGCGTAAGGCTCTGTCAACG 
                    ************************************************************ 
 
Gallo0112A_exp      AATCTGACGACGAAGAAGGAATCGTCCTATAATACGAACCTGCAGGGGTTGTCGTATGAC 
Gallo0112A_Seq      AATCTGACGACGAAGAAGGAATCGTCCTATAATACGAACCTGCAGGGGTTGTCGTATGAC 
                    ************************************************************ 
 
Gallo0112A_exp      GCCAACGTTTGGGAGGTCCGGGAGGATGGCCTGTATAGCAATGCGATTGGCGAAGGTGAT 
Gallo0112A_Seq      GCCAACGTTTGGGAGGTCCGGGAGGATGGCCTGTATAGCAATGCGATTGGCGAAGGTGAT 
                    ************************************************************ 
 
Gallo0112A_exp      TCCTTTCTGCTCTCGACATCCGCAGGTAAGAA--TTTTGTGTTCCAGACAGATGTGACGT 
Gallo0112A_Seq      TCCTTTCTGCTCTCGACATCCGCAGGTAAAGAAATTTTGTGTTCCAGACAGATGTGACGT 
                    *****************************  *  ************************** 
 
Gallo0112A_exp      TTCTGCAAAACACCGGTGCAGCCTCACTGGTATTTCGCAGCACTGGGGACGCACAGAACC 
Gallo0112A_Seq      TTCTGCAAAACACCGGTGCAC--------------------------------------- 
                    ********************                                         
 
Gallo0112A_exp    TTAAAGGATACGTGGTGAACCTGGACGGCAATAGCCACAAAATCAAATTCATGCGTTGGGGC 
Gallo0112A_Seq    -------------------------------------------------------------- 
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Gallo0112A_exp      GAGGCTAACCTGATTGACGAAAAGGAAATTGAAGCAACTAGCGATAACAAATACAGTCTG 
Gallo0112A_Seq      ------------------------------------------------------------ 
                                                                                 
 
Gallo0112A_exp      AAAGTTGTTGCAGCGAATGGTTGGATCTCCTATTACATTAACGGGATTTTGGTGGCAAAT 
Gallo0112A_Seq      ------------------------------------------------------------ 
                                                                                 
 
Gallo0112A_exp      CTGTCGGATTATACCATCCAACGCGATGATCGTGGCCAAACGACCTATATTAAGGATGGC 
Gallo0112A_Seq      ------------------------------------------------------------ 
                                                                                 
 
Gallo0112A_exp      AATTTCAGCCTTCTGAACTGGAACGGGGAAATGATTTTCCAGAACACCTTCTATCGCGAA 
Gallo0112A_Seq      ------------------------------------------------------------ 
                                                                                 
 
Gallo0112A_exp      CTTACTGACGCTGAACTGCCAATTCTGAAAGATGTAACCGTGTCGTCAAAGAATGGTCCA 
Gallo0112A_Seq      ------------------------------------------------------------ 
                                                                                 
 
Gallo0112A_exp      GTCGAACCCAAAGGGCAATTCTTTCCGGAGGGTGCGGTTTATATCCAGTATGTCAGTCAC 
Gallo0112A_Seq      ------------------------------------------------------------ 
                                                                                 
 
Gallo0112A_exp      GATGCCTCTACTGTGGACTTGTCGTTCGTTCCGAATAATCAAGACGCAGTCATCAAAGTG 
Gallo0112A_Seq      ------------------------------------------------------------ 
                                                                                 
 
Gallo0112A_exp      ACCGATGACCAAGGCAACGTTTATAGCGACCCGAGCAACATTCCCGTAAGCGTTGGTGCC 
Gallo0112A_Seq      ------------------------------------------------------------ 
                                                                                 
 
Gallo0112A_exp      AATTACCTGACCGTGACCTCTACCTACACAGTTGATGGCTACGAAGTGACATCCACCTAT 
Gallo0112A_Seq      ------------------------------------------------------------ 
                                                                                 
 
Gallo0112A_exp      CGCATCAATGTTCATCGCCGTCAAAGCGCCGAAGTCTACTATAACGAGAACTTTCGCGAT 
Gallo0112A_Seq      ------------------------------------------------------------ 
                                                                                 
 
Gallo0112A_exp      CAGTACCACTATAGTGTGAAAGACGGTTGGGCCAATGATCCGAACGGTTTAGTGTACTAC 
Gallo0112A_Seq      ------------------------------------------------------------ 
                                                                                 
 
Gallo0112A_exp      AATGGCGTATATCACATGTTTTATCAGTTCTATGATGACATTCAATGGGGTCCGATGCAT 
Gallo0112A_Seq      ----------------TGTTTTATCAGTTCTATGATGACATTCAATGGGGTCCGATGCAT 
                                    ******************************************** 
 
Gallo0112A_exp      TGGGCACATGCGACTTCCACTGATCTGATCCATTGGGAGGATCAACCCATCGCGTTTTAT 
Gallo0112A_Seq      TGGGCACATGCGACTTCCACTGATCTGATCCATTGGGAGGATCAACCCATCGCGTTTTAT 
                    ************************************************************ 
 
Gallo0112A_exp      CCGGATTACAACGGAGCCATGTTTAGTGGTTGCATTGTGGCGGACCCCAATAACACCTCT 
Gallo0112A_Seq      CCGGATTACAACGGAGCCATGTTTAGTGGTTGCATTGTGGCGGACCCCAATAACACCTCT 
                    ************************************************************ 
 
Gallo0112A_exp      GGACTGTTCGAAGGCGACAAAGGCGGTCTGGTGGCACTGATTACGGCCGATGGCGAGGGT 
Gallo0112A_Seq      GGACTGTTCGAAGGCGACAAAGGCGGTCTGGTGGCACTGATTACGGCCGATGGCGAGGGT 
                    ************************************************************ 
 
Gallo0112A_exp      CAGCGGATCAAAGTTGCGTACTCTAAGGATGAAGGCAAAACATGGCAGAAATTAGACGAA 
Gallo0112A_Seq      CAGCGGATCAAAGTTGCGTACTCTAAGGATGAAGGCAAAACATGGCAGAAATTAGACGAA 
                    ************************************************************ 
 
Gallo0112A_exp      GTCGCGGCGGACTGGTCTACCGATCCGCTGCAGAATCGCGACTTTCGTGATCCTAAAGTG 
Gallo0112A_Seq      GTCGCGGCGGACTGGTCTACCGATCCGCTGCAGAATCGCGACTTTCGTGATCCTAAAGTG 
                    ************************************************************ 
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Gallo0112A_exp      TTTCGCTGGGAAGGCAAATGGTTCATGGTCCTTGCCGGAGGACCACTGCGCATCTATAGC 
Gallo0112A_Seq      TTTCGCTGGGAAGGCAAATGGTTCATGGTCCTTGCCGGAGGACCACTGCGCATCTATAGC 
                    ************************************************************ 
 
Gallo0112A_exp      TCCGACAACTTACTTGATTGGTCAGTTGAAAGCACCTATCCTGACCTGCATACTGAATGT 
Gallo0112A_Seq      TCCGACAACTTACTTGATTGGTCAGTTGAAAGCACCTATCCTGACCTGCATACTGAATGT 
                    ************************************************************ 
 
Gallo0112A_exp      CCGGACTTGTATCCGATTATGGCCGAAGGAAACACCGTTAAATGGGTCTTGAGTCGTGGT 
Gallo0112A_Seq      CCGGACTTGTATCCGATTATGGCCGAAGGAAACACCGTTAAATGGGTCTTGAGTCGTGGT 
                    ************************************************************ 
 
Gallo0112A_exp      GGGCGTTATTACAAGGTAGGTGACCTGAAACAGGTGGATGGCCATTGGAAATTCGTTGCA 
Gallo0112A_Seq      GGGCGTTATTACAAGGTAGGTGACCTGAAACAGGTGGATGGCCATTGGAAATTCGTTGCA 
                    ************************************************************ 
 
 
Gallo0112A_exp      GATGCCGATTACCAGGAATCAGATGGCATCATGAATTTTGGCAAAGATAGTTATGCCGCT 
Gallo0112A_Seq      GATGCCGATTACCAGGAATCAGATGGCATCATGAATTTTGGCAAAGATAGTTATGCCGCT 
                    ************************************************************ 
 
Gallo0112A_exp      ATGACTTACTATGTGCAAGATTTTGGTACAAAAGACAACCCGACCATTCCGCAGATTATT 
Gallo0112A_Seq      ATGACTTACTATGTGCAAGATTTTGGTACAAAAGACAACCCGACCATTCCGCAGATTATT 
                    ************************************************************ 
 
Gallo0112A_exp      GAACTCAACTGGATGAACACTTGGGATAACTACTGCAATCTCGTAGCTGAACGCACAGGT 
Gallo0112A_Seq      GAACTCAACTGGATGAACACTTGGGATAACTACTGCAATCTCGTAGCTGAACGCACAGGT 
                    ************************************************************ 
 
Gallo0112A_exp      CAGAAATTCAATGGGACCTTTAATCTCAACTTGACGCTGGGCTTAGTGAAAGATGGCGAC 
Gallo0112A_Seq      CAGAAATTCAATGGGACCTTTAATCTCAACTTGACGCTGGGCTTAGTGAAAGATGGCGAC 
                    ************************************************************ 
 
Gallo0112A_exp      AAATATGTGTTAACCCAGACTCCAATCAAGGCGTACGAAAGCTTACGTGATGTAGACCAC 
Gallo0112A_Seq      AAATATGTGTTAACCCAGACTCCAATCAAGGCGTACGAAAGCTTACGTGATGTAGACCAC 
                    ************************************************************ 
 
Gallo0112A_exp      AAGGTTGAATACAAAGACGTCGTGGTCGGCAAAGATAACAATCTGTTTAAAGACTTTTCT 
Gallo0112A_Seq      AAGGTTGAATACAAAGACGTCGTGGTCGGCAAAGATAACAATCTGTTTAAAGACTTTTCT 
                    ************************************************************ 
 
Gallo0112A_exp      GGGGTCGACAAACCTCCCACACCTCCCCCTGAACCTGAAACATAAGCGGCCGCATC 
Gallo0112A_Seq      GGGGTCGACAAACCTCCCACACCTCCCCCT-------------------------- 
                    ******************************                           
 
Gallo0112B (sequencing of PCR product via T3 and T7 primer (PCR primer 
pGEXs+T7 and pGEXas+T3)) 
Gallo0112B_exp      TCCAAAATCGGATCTGGTTCCGCGTGGATCCATCAAAGCGTATGAATCGCTTCGCGATGT 
Gallo0112B_Seq      -----------------GTTCGCGTGGATCCATCAAAGCGTATGAATCGCTTCGCGATGT 
                                      * **************************************** 
 
Gallo0112B_exp      GGATCACAAAGTTGAGTACAAAGACGTCGTAGTGGGCAAAGACAACAACTTGTTCAAAGA 
Gallo0112B_Seq      GGATCACAAAGTTGAGTACAAAGACGTCGTAGTGGGCAAAGACAACAACTTGTTCAAAGA 
                    ************************************************************ 
 
Gallo0112B_exp      CTTTAGTGGTGATACCTATGAAATCGTCGCGCATTTCAAGCCGTCCGATCGTACGACGAA 
Gallo0112B_Seq      CTTTAGTGGTGATACCTATGAAATCGTCGCGCATTTCAAGCCGTCCGATCGTACGACGAA 
                    ************************************************************ 
 
Gallo0112B_exp      AGTGGGTTTTAACCTCCGCGTTGGGCAAGGCGAAGTGACAAAAGTCTACTACGACCTTCA 
Gallo0112B_Seq      AGTGGGTTTTAACCTCCGCGTTGGGCAAGGCGAAGTGACAAAAGTCTACTACGACCTTCA 
                    ************************************************************ 
 
Gallo0112B_exp      GACCGGTCGCATTGCTATCGATCGCAGCCAATCAGGCATTATTCTGACCGAACTCTTTCG 
Gallo0112B_Seq      GACCGGTCGCATTGCTATCGATCGCAGCCAATCAGGCATTATTCTGACCGAACTCTTTCG 
                    ************************************************************ 
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Gallo0112B_exp      CAACGTCGATTCTCAAGCCGTGACGCGCAATGCGGACGGTTCCATTGATCTGCACATCTT 
Gallo0112B_Seq      CAACGTCGATTCTCAAGCCGTGACGCGCAATGCGGACGGTTCCATTGATCTGCACATCTT 
                    ************************************************************ 
 
Gallo0112B_exp      TGTAGATCGTGCGAGCGTTGAAGTGTTCACCAAGGGCGGTACAGTGACGGGTGCCAACCA 
Gallo0112B_Seq      TGTAGATCGTGCGAGCGTTGAAGTGTTCACCAAGGGCGGTACAGTGACGGGTGCCAACCA 
                    ************************************************************ 
 
Gallo0112B_exp      GATTTTCACGAGCCCGCAATCTCTCGGCTTAGGCGTGTTTGCGGAAGGGTATGAAGCAAA 
Gallo0112B_Seq      GATTTTCACGAGCCCGCAATCTCTCGGCTTAGGCGTGTTTGCGGAAGGGTATGAAGCAAA 
                    ************************************************************ 
 
Gallo0112B_exp      AGCTGATATCGCCCTTTATCCGTTAAAATCTATTTGGAAAGATAAAGTTGAAACCACCAA 
Gallo0112B_Seq      AGCTGATATCGCCCTTTATCCGTTAAAATCTATTTGGAAAGATAAAGTTGAAACCACCAA 
                    ************************************************************ 
 
Gallo0112B_exp      ACCCCAGAGTATTGTTCCCGCAAGCGCGAAGAACGTTCGCATGAACGTTGGCGATTCGAC 
Gallo0112B_Seq      ACCCCAGAGTATTGTTCCCGCAAGCGCGAAGAACGTTCGCATGAACGTTGGCGATTCGAC 
                    ************************************************************ 
 
Gallo0112B_exp      CGTAGTAAAAGCGTATGTTTCGCCTGCCGTTGTTAATCAGGATCTGTTGTGGAGCATCCT 
Gallo0112B_Seq      CGTAGTAAAAGCGTATGTTTCGCCTGCCGTTGTTAATCAGGATCTGTTGTGGAGCATCCT 
                    ************************************************************ 
 
Gallo0112B_exp      GAACAATGGGAATGTTAGCACGGAAATTAGCGGTAATCAAGTCTTTGTGAAAGCCCTGAA 
Gallo0112B_Seq      GAACAATGGGAATGTTAGCACGGAAATTAGCGGTAATCAAGTCTTTGTGAAAGCCCTGAA 
                    ************************************************************ 
 
Gallo0112B_exp      GAAGGGTCAGGTCATTGTCCGGGCACAGTCCAAAACAGACCCGTCAGTCTATCAGGACTT 
Gallo0112B_Seq      GAAGGGTCAGGTCATTGTCCGGGCACAGTCCAAAACAGACCCGTCAGTCTATCAGGACTT 
                    ************************************************************ 
 
Gallo0112B_exp      CGTCCTGGATATTCTGGAGGACAATTTTAAAACCAACGTGAAGAACGTAAAAGTGTTTGC 
Gallo0112B_Seq      CGTCCTGGATATTCTGGAGGACAATTTTAAAACCAACGTGAAGAACGTAAAAGTGTTTGC 
                    ************************************************************ 
 
Gallo0112B_exp      TGGGGACTGGCATGCCGATGGTGAATCGCTGAAAGTGGAAAATCACAACAGTAATGACAT 
Gallo0112B_Seq      TGGGGACTGGCATGCCGATGGTGAATCGCTGAAAGTGGAAAATCACAACAGTAATGACAT 
                    ************************************************************ 
 
Gallo0112B_exp      CTATATGGCAGCTGATAAAATGCCGTACGAGAATTACCAGATGGATCTGGATATCAAATA 
Gallo0112B_Seq      CTATATGGCAGCTGATAAAATGCCGTACGAGAATTACCAGATGGATCTGGATATCAAATA 
                    ************************************************************ 
 
Gallo0112B_exp      TGGCCGTGGAGTCGTTAACATTTTCTTTGCTAGTGGCAACCCAGATGCGAACAATGCGTA 
Gallo0112B_Seq      TGGCCGTGGAGTCGTTAACATTTTCTTTGCTAGTGGCAACCCAGATGCGAACAATGCGTA 
                    ************************************************************ 
 
Gallo0112B_exp      CTCAATCCAGTTTGGAGGAGATAATTCGGTGCGTCTGTTTCGGTTTTATAGCGACACCAT 
Gallo0112B_Seq      CTCAATCCAGTTTGGAGGAGATAATTCGGTGCGTCTGTTTCGGTTTTATAGCGACACCAT 
                    ************************************************************ 
 
Gallo0112B_exp      TTCCGAATCTCAAATGACGGCCGCAATCAACGATAACCAATTTCATCATGTGCGTCTGGT 
Gallo0112B_Seq      TTCCGAATCTCAAATGACGGCCGCAATCAACGATAACCAATTTCATCATGTGCGTCTGGT 
                    ************************************************************ 
 
Gallo0112B_exp      AAAGAGCGCCAATGCCATCCAGGTTTTCGTAGACAATCAGCTGGCCATGTCATATACCTT 
Gallo0112B_Seq      AAAGAGCGCCAATGCCATCCAGGTTTTCGTAGACAATCAGCTGGCCATGTCATATACCTT 
                    ************************************************************ 
 
Gallo0112B_exp      TGATCAGGTGGAAGATTTCTTCAACAATCCGTACATTGGCTTAGGCTTATGGGACGGCGA 
Gallo0112B_Seq      TGATCAGGTGGAAGATTTCTTCAACAATCCGTACATTGGCTTAGGCTTATGGGACGGCGA 
                    ************************************************************ 
 
Gallo0112B_exp      ATTGGAGGTGCAGAATTTCTTCGTGGTAGACCTGGACGCAAAGGAACCGACCCAGAACGA 
Gallo0112B_Seq      ATTGGAGGTGCAGAATTTCTTCGTGGTAGACCTGGACGCAAAGGAACCGACCCAGAACGA 
                    ************************************************************ 
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Gallo0112B_exp      AGAGAAAGTGGAAGTCGTTCCGACCGATCCTCAGACTCCGGCTGAACAGGTCGTGACGAC 
Gallo0112B_Seq      AGAGAAAGTGGAAGTCGTTCCGACCGATCCTCAGACTCCGGCTGAACAGGTCGTGACGAC 
                    ************************************************************ 
 
Gallo0112B_exp      CACAACTCTGGCGGCGAAAGCGCCAGCAAAATCTGAGAAAGCGACCGATGCGAAAGCCCC 
Gallo0112B_Seq      CACAACTCTGGCGGCGAAAGCGCCAGCAAAATCTGAGAAAGCGACCGATGCGAAAGCCCC 
                    ************************************************************ 
 
Gallo0112B_exp      AGTAATTCCGAAAACTGCACTGGTGAGTGAGACTGTGTTGCCTCAAACTGGTGAGAAAGA 
Gallo0112B_Seq      AGTAATTCCGAAAACTGCACTGGTGAGTGAGACTGTGTTGCCTCAAACTGGTGAGAAAGA 
                    ************************************************************ 
 
Gallo0112B_exp      TTCCCATGTCGACAAACCTCCCACACCTCCCCCTGAACCTGAAACATAAGCGGCCGCATC 
Gallo0112B_Seq      TTCCCATGTCGACAAACCTCCCACACCTCCCCCTA------------------------- 
                    **********************************                           
 
Gallo0272 (sequencing of PCR product via T3 and T7 primer (PCR primer 
pGEXs+T7 and pGEXas+T3)) 
Gallo0272_exp      TCCAAAATCGGATCTGGTTCCGCGTGGATCCGAAGAGATTATCAATGCGCAGAATAGCGT 
Gallo0272_Seq      ----------------GGGTCGCGTGGATCCGAAGAGATTATCAATGCGCAGAATAGCGT 
                                   *   **************************************** 
 
Gallo0272_exp      GAATAAACAACTGCAAGACCTCATGGCCTCTCTGAATGCGGTTACGCAGACGATTACCGG 
Gallo0272_Seq      GAATAAACAACTGCAAGACCTCATGGCCTCTCTGAATGCGGTTACGCAGACGATTACCGG 
                   ************************************************************ 
 
Gallo0272_exp      CAATAAAGTGACTGTATCTAGTATTGAAGAAGCCAACAAGAAACTGGCCGAAATTAAAGC 
Gallo0272_Seq      CAATAAAGTGACTGTATCTAGTATTGAAGAAGCCAACAAGAAACTGGCCGAAATTAAAGC 
                   ************************************************************ 
 
Gallo0272_exp      AAAGATTCAGGCTGTGGACAAGTTAAACGCACAGCTGAAAGCAGAGTATGACGCTGAAGT 
Gallo0272_Seq      AAAGATTCAGGCTGTGGACAAGTTAAACGCACAGCTGAAAGCAGAGTATGACGCTGAAGT 
                   ************************************************************ 
 
Gallo0272_exp      CCAACGCGTTAATGAGCATAACGCACAACTGAAAGCGGACTACGAAAAGAAACTTGCACA 
Gallo0272_Seq      CCAACGCGTTAATGAGCATAACGCACAACTGAAAGCGGACTACGAAAAGAAACTTGCACA 
                   ************************************************************ 
 
Gallo0272_exp      GTATGAAGCCGATAAAGCCGAATACGATAAGAAACTCGCCGAATACGAAGCCAACAAAGG 
Gallo0272_Seq      GTATGAAGCCGATAAAGCCGAATACGATAAGAAACTCGCCGAATACGAAGCCAACAAAGG 
                   ************************************************************ 
 
Gallo0272_exp      GAAAGATGGTTATCTGAACCAAACGTACGTCCAAGGACTGATCTTTAAATCAGAAGCGGA 
Gallo0272_Seq      GAAAGATGGTTATCTGAACCAAACGTACGTCCAAGGACTGATCTTTAAATCAGAAGCGGA 
                   ************************************************************ 
 
Gallo0272_exp      TGCTCATGTTACCATTGTCAAGTCGGATGGTGCTATCATCGTCAATGACAGTACAGACTC 
Gallo0272_Seq      TGCTCATGTTACCATTGTCAAGTCGGATGGTGCTATCATCGTCAATGACAGTACAGACTC 
                   ************************************************************ 
 
Gallo0272_exp      ACATCGTGTAGTGCTGCATCAGGGCGAATCCGTAACGGTGACCTACACCAATCTGAAGAA 
Gallo0272_Seq      ACATCGTGTAGTGCTGCATCAGGGCGAATCCGTAACGGTGACCTACACCAATCTGAAGAA 
                   ************************************************************ 
 
Gallo0272_exp      TTCGTACTACAACGGTGTGAAAATCGACAAAGTGGTTTACGTATACACGGCTAAGGATGC 
Gallo0272_Seq      TTCGTACTACAACGGTGTGAAAATCGACAAAGTGGTTTACGTATACACGGCTAAGGATGC 
                   ************************************************************ 
 
Gallo0272_exp      GGTCAATGGTTTGCACATCTCTAACAACCCGAACATCACCGTGACCTTTATGAGTTCGGA 
Gallo0272_Seq      GGTCAATGGTTTGCACATCTCTAACAACCCGAACATCACCGTGACCTTTATGAGTTCGGA 
                   ************************************************************ 
 
Gallo0272_exp      CTTCGATACAGATGATAAGAACGGTGAGCAAAATGGGTCACAATCCAGCCATATTGGCAT 
Gallo0272_Seq      CTTCGATACAGATGATAAGAACGGTGAGCAAAATGGGTCACAATCCAGCCATATTGGCAT 
                   ************************************************************ 
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Gallo0272_exp      GTCTATTCAGTTCTTTGACGAGAAAGGACAGGTCATCACATTCAACGAGAAGAATCCGGC 
Gallo0272_Seq      GTCTATTCAGTTCTTTGACGAGAAAGGACAGGTCATCACATTCAACGAGAAGAATCCGGC 
                   ************************************************************ 
 
Gallo0272_exp      GTTAATTGCCTTCAATAGCCTGAACAAAACTGAAGTGTATGCGGGTTCAGGGTATGGCGA 
Gallo0272_Seq      GTTAATTGCCTTCAATAGCCTGAACAAAACTGAAGTGTATGCGGGTTCAGGGTATGGCGA 
                   ************************************************************ 
 
Gallo0272_exp      AAGCATCCACAACCTGAGCTCGAATATCAAAATCGAAACGATTGCGGGTAGTAGTGTCAT 
Gallo0272_Seq      AAGCATCCACAACCTGAGCTCGAATATCAAAATCGAAACGATTGCGGGTAGTAGTGTCAT 
                   ************************************************************ 
 
Gallo0272_exp      CTATAAAGACGGCGTGTTATATGCGGGCAATTACAACGATTATGTTTCCAATGGTAGTCG 
Gallo0272_Seq      CTATAAAGACGGCGTGTTATATGCGGGCAATTACAACGATTATGTTTCCAATGGTAGTCG 
                   ************************************************************ 
 
Gallo0272_exp      CTTTGATGCTAATCCAGCGACAGATCCGAATTCATATTGGGACGGTGATACCCAGGCGAA 
Gallo0272_Seq      CTTTGATGCTAATCCAGCGACAGATCCGAATTCATATTGGGACGGTGATACCCAGGCGAA 
                   ************************************************************ 
 
Gallo0272_exp      TCGCTGGTATGGAGCCGCAGTTGGGGTTGTGAGCTCCGGCGATACCATTAGCTTTGATGT 
Gallo0272_Seq      TCGCTGGTATGGAGCCGCAGTTGGGGTTGTGAGCTCCGGCGATACCATTAGCTTTGATGT 
                   ************************************************************ 
 
Gallo0272_exp      GGTAATGGATGCTGGTGCCGATGCCAAACGTCACGAATACGGCAAATTTTGGTTCGCGTT 
Gallo0272_Seq      GGTAATGGATGCTGGTGCCGATGCCAAACGTCACGAATACGGCAAATTTTGGTTCGCGTT 
                   ************************************************************ 
 
Gallo0272_exp      TTCGAGCGATGTTGCAGCTCCAGTGTTAACCCCGCCGACTCCTCCGGAAGTCCCCAACTA 
Gallo0272_Seq      TTCGAGCGATGTTGCAGCTCCAGTGTTAACCCCGCCGACTCCTCCGGAAGTCCCCAACTA 
                   ************************************************************ 
 
Gallo0272_exp      CAAGAAGGACCCTACGACCCCACCGGATTACCAGAAAGTAAACGTCCCGACTATTCAGAT 
Gallo0272_Seq      CAAGAAGGACCCTACGACCCCACCGGATTACCAGAAAGTAAACGTCCCGACTATTCAGAT 
                   ************************************************************ 
 
Gallo0272_exp      TAAAACCGATGTGCATGAAGTTGGCATTAACAAGACGACCAGTATTGATGTGCAGACCCC 
Gallo0272_Seq      TAAAACCGATGTGCATGAAGTTGGCATTAACAAGACGACCAGTATTGATGTGCAGACCCC 
                   ************************************************************ 
 
Gallo0272_exp      GCAGTTAGAGACAACTGTTCACGAAGTTGGGGTTAACAAAACCACGGAAATGGAAGTTGA 
Gallo0272_Seq      GCAGTTAGAGACAACTGTTCACGAAGTTGGGGTTAACAAAACCACGGAAATGGAAGTTGA 
                   ************************************************************ 
 
Gallo0272_exp      GACTCCCCAACTTGAAACGGATGTACACGAAGTGGGTATCAACAAAACGACGGAGATGAA 
Gallo0272_Seq      GACTCCCCAACTTGAAACGGATGTACACGAAGTGGGTATCAACAAAACGACGGAGATGAA 
                   ************************************************************ 
 
Gallo0272_exp      AGTCGAAACTCCACAGTTGAAAATGGACATGCACACCGTTGCCTATGATAAACCGGCAAC 
Gallo0272_Seq      AGTCGAAACTCCACAGTTGAAAATGGACATGCACACCGTTGCCTATGATAAACCGGCAAC 
                   ************************************************************ 
 
Gallo0272_exp      GCCTCAGGTGGTCAAGTCAAGCATCGTCGACAAACCTCCCACACCTCCCCCTGAACCTGA 
Gallo0272_Seq      GCCTCAGGTGGTCAAGTCAAGCATCGTCGACAAACCTCCCACACCTCCCCCTA------- 
                   ****************************************************         
 
Gallo0272_exp      AACATAAGCGGCCGCATC 
Gallo0272_Seq      ------------------ 
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Gallo0577 (sequencing of PCR product via T3 and T7 primer (PCR primer 
pGEXs+T7 and pGEXas+T3)) 
Gallo0577_exp      TCCAAAATCGGATCTGGTTCCGCGTGGATCCGATACAGTGGACATTACGGTGAGCAATAC 
Gallo0577_Seq      -----------------GGTCGCGTGGATCCGATACAGTGGACATTACGGTGAGCAATAC 
                                       **************************************** 
 
Gallo0577_exp      CTCGTTAAGTACAAATGCTATCAATGGTGGTACGAGTACAGAATTCTCGTTCGATTTTGC 
Gallo0577_Seq      CTCGTTAAGTACAAATGCTATCAATGGTGGTACGAGTACAGAATTCTCGTTCGATTTTGC 
                   ************************************************************ 
 
Gallo0577_exp      CGTTCCGAATAGTGCGAAATCCGGTGATACGACCGTTATCTCGTTGCCGGACGAACTGAA 
Gallo0577_Seq      CGTTCCGAATAGTGCGAAATCCGGTGATACGACCGTTATCTCGTTGCCGGACGAACTGAA 
                   ************************************************************ 
 
Gallo0577_exp      TTTCCAACGCAACCAGACCTTCAACGTGTATGCCTCTGATGGTACAACGGTCGTGGCAAC 
Gallo0577_Seq      TTTCCAACGCAACCAGACCTTCAACGTGTATGCCTCTGATGGTACAACGGTCGTGGCAAC 
                   ************************************************************ 
 
Gallo0577_exp      CGCCGTGATTGACACCACAACTAAAACCCTGACACTGACTTACACGGACTATGTTGATAC 
Gallo0577_Seq      CGCCGTGATTGACACCACAACTAAAACCCTGACACTGACTTACACGGACTATGTTGATAC 
                   ************************************************************ 
 
Gallo0577_exp      GCACGATGATGTCACGGGGCATCTCTCAATGAACGTAGTCGTGGATCGCACCGTTGTGAC 
Gallo0577_Seq      GCACGATGATGTCACGGGGCATCTCTCAATGAACGTAGTCGTGGATCGCACCGTTGTGAC 
                   ************************************************************ 
 
Gallo0577_exp      GGAAGCGACGACTGTTCCAGCCACTGTTACCATTAACGGCACTACCACGATTACGATTTC 
Gallo0577_Seq      GGAAGCGACGACTGTTCCAGCCACTGTTACCATTAACGGCACTACCACGATTACGATTTC 
                   ************************************************************ 
 
Gallo0577_exp      TTCCGGCGGAATTAACTACACCGTTTCTACAGGCGATAGCGATGACATCGATTTCTGGAA 
Gallo0577_Seq      TTCCGGCGGAATTAACTACACCGTTTCTACAGGCGATAGCGATGACATCGATTTCTGGAA 
                   ************************************************************ 
 
Gallo0577_exp      ATACGGCGTAAGCTATTCCGATGATGAAGTCATGTACCTGATTAACGTGAACACTTCCGC 
Gallo0577_Seq      ATACGGCGTAAGCTATTCCGATGATGAAGTCATGTACCTGATTAACGTGAACACTTCCGC 
                   ************************************************************ 
 
Gallo0577_exp      TGCGACGGTATCGAATGTGGTGATCTCAGATACGATCAATTCAACTGGACTGGAGTACGT 
Gallo0577_Seq      TGCGACGGTATCGAATGTGGTGATCTCAGATACGATCAATTCAACTGGACTGGAGTACGT 
                   ************************************************************ 
 
Gallo0577_exp      TGACGGGTCTTTTGAAATCTTTGAGGGTACCTGGTATAAGAATGCGCAGAACTACTGGGC 
Gallo0577_Seq      TGACGGGTCTTTTGAAATCTTTGAGGGTACCTGGTATAAGAATGCGCAGAACTACTGGGC 
                   ************************************************************ 
 
Gallo0577_exp      ATTGGGAGGCAGTACCAACGTGACGTCGAACTACAACATCGAGCTGTCAGCAGACAATAC 
Gallo0577_Seq      ATTGGGAGGCAGTACCAACGTGACGTCGAACTACAACATCGAGCTGTCAGCAGACAATAC 
                   ************************************************************ 
 
Gallo0577_exp      GTCGTTTAGCATTAATCTGGGTACCATTTCGAAAGGCTACATGATTCGGTATCGTGTCAA 
Gallo0577_Seq      GTCGTTTAGCATTAATCTGGGTACCATTTCGAAAGGCTACATGATTCGGTATCGTGTCAA 
                   ************************************************************ 
 
Gallo0577_exp      AGCGAATTACACCCTCATTAATGGCGAACAGCTGTCCAATAGCGCGACTTATTACAGCGA 
Gallo0577_Seq      AGCGAATTACACCCTCATTAATGGCGAACAGCTGTCCAATAGCGCGACTTATTACAGCGA 
                   ************************************************************ 
 
Gallo0577_exp      AAACACCGCCCTGAACAACGCCGACAATACCTTTACGTATCAAGGCGCGAGCGGTACGGC 
Gallo0577_Seq      AAACACCGCCCTGAACAACGCCGACAATACCTTTACGTATCAAGGCGCGAGCGGTACGGC 
                   ************************************************************ 
 
Gallo0577_exp      CAGTGGCTATAATTACTCCCTCACCGTACAGAAAGTGAACGAAGCAGGCGAAGCATTAGC 
Gallo0577_Seq      CAGTGGCTATAATTACTCCCTCACCGTACAGAAAGTGAACGAAGCAGGCGAAGCATTAGC 
                   ************************************************************ 
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Gallo0577_exp      AGGCGCGGAGTTCACCGTTACGCGTGAAAGCACTGGACAAGTGGTCGGGACGATCACGAC 
Gallo0577_Seq      AGGCGCGGAGTT------------------------------------------------ 
                   ************                                                 
 
Gallo0577_exp      CGGCTCAGACGGTACAGCCACCATTTCAGGTTTACTGAAAGACAATTACATCATTACCGA 
Gallo0577_Seq      ------------------------------------------------------------ 
                                                                                
 
Gallo0577_exp      AACGAAAGCTCCTACTGGGTACGCCATTGCCGATCCAGTGACGGCTGAAGCCGATAACAG 
Gallo0577_Seq      ---------------------------------------GACGGCTGAAGCCGATAACAG 
                                                          ********************* 
 
Gallo0577_exp      TACGGTCACCGTTACTGACAAGAAAGCGACCGTGGAAGTAACCGGTACCAAAACGTGGGA 
Gallo0577_Seq      TACGGTCACCGTTACTGACAAGAAAGCGACCGTGGAAGTAACCGGTACCAAAACGTGGGA 
                   ************************************************************ 
 
Gallo0577_exp      TGACAACAACGATCAAGATGGTAAGCGTCCCGATTCCATCACTGTTAATCTGTTAGCGAA 
Gallo0577_Seq      TGACAACAACGATCAAGATGGTAAGCGTCCCGATTCCATCACTGTTAATCTGTTAGCGAA 
                   ************************************************************ 
 
Gallo0577_exp      CGGTACAGTAGTTGATACCAAAACAGTCACAGCGGATGACAATTGGACTTATGCGTTTAG 
Gallo0577_Seq      CGGTACAGTAGTTGATACCAAAACAGTCACAGCGGATGACAATTGGACTTATGCGTTTAG 
                   ************************************************************ 
 
Gallo0577_exp      CGACCTGGATCAGTATGACGCTGATGGTAACGAAATTGCCTACACTGTGTCGGAGGAAAT 
Gallo0577_Seq      CGACCTGGATCAGTATGACGCTGATGGTAACGAAATTGCCTACACTGTGTCGGAGGAAAT 
                   ************************************************************ 
 
Gallo0577_exp      GGTTGATGGGTATACGACAGTCGTCGATGGCTATAACATCACCAATACCCACGCATCAGA 
Gallo0577_Seq      GGTTGATGGGTATACGACAGTCGTCGATGGCTATAACATCACCAATACCCACGCATCAGA 
                   ************************************************************ 
 
Gallo0577_exp      AACCACCGAAGTTTCAGGCACTAAAACATGGGATGATAACGACGACCAAGATGGCAAACG 
Gallo0577_Seq      AACCACCGAAGTTTCAGGCACTAAAACATGGGATGATAACGACGACCAAGATGGCAAACG 
                   ************************************************************ 
 
Gallo0577_exp      CCCGGATTCCATCACGGTGAACCTGCTGGCAAATGGCACGGTCGTGGATACGAAAACGGT 
Gallo0577_Seq      CCCGGATTCCATCACGGTGAACCTGCTGGCAAATGGCACGGTCGTGGATACGAAAACGGT 
                   ************************************************************ 
 
Gallo0577_exp      AACAGCCGATGATAATTGGTCTTATAGCTTTACCGATTTGCCGAAATACGATAATGGAAA 
Gallo0577_Seq      AACAGCCGATGATAATTGGTCTTATAGCTTTACCGATTTGCCGAAATACGATAATGGAAA 
                   ************************************************************ 
 
Gallo0577_exp      CGAGATCACATACACCGTAACCGAAGATACAGTCGCTGACTATACAACTACGTATGACGG 
Gallo0577_Seq      CGAGATCACATACACCGTAACCGAAGATACAGTCGCTGACTATACAACTACGTATGACGG 
                   ************************************************************ 
 
Gallo0577_exp      GTACAACATTACCAACAGTTACACCCCGGGTGAAACCAGTATCACCGTCACCAAAGTGTG 
Gallo0577_Seq      GTACAACATTACCAACAGTTACACCCCGGGTGAAACCAGTATCACCGTCACCAAAGTGTG 
                   ************************************************************ 
 
Gallo0577_exp      GGACGACAATAATGATCAGGACGGTATTCGCCCTGATGCGATTCAGGTGCAGCTGTATGC 
Gallo0577_Seq      GGACGACAATAATGATCAGGACGGTATTCGCCCTGATGCGATTCAGGTGCAGCTGTATGC 
                   ************************************************************ 
 
Gallo0577_exp      GAATGGCGAGAAAAGCGGTGATGTGATCACTCTTACGGTCGCAGACAACTGGACCTATAC 
Gallo0577_Seq      GAATGGCGAGAAAAGCGGTGATGTGATCACTCTTACGGTCGCAGACAACTGGACCTATAC 
                   ************************************************************ 
 
Gallo0577_exp      CTGGACTGGTTTGGCTGAGAAAGCGAACAAGAAAACTATCACTTACACGGTAGAAGAGGT 
Gallo0577_Seq      CTGGACTGGTTTGGCTGAGAAAGCGAACAAGAAAACTATCACTTACACGGTAGAAGAGGT 
                   ************************************************************ 
 
Gallo0577_exp      TAGTGCAGTTGACGGGTATACCGCGACAGTAGGCGAGGTCGAAAATGGCAATGTGACAAT 
Gallo0577_Seq      TAGTGCAGTTGACGGGTATACCGCGACAGTAGGCGAGGTCGAAAATGGCAATGTGACAAT 
                   ************************************************************ 
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Gallo0577_exp      CACCAACACCCATACTCCTACGACCCCAGAAACTCCGAGCAGCGATGAACCGACAACCCC 
Gallo0577_Seq      CACCAACACCCATACTCCTACGACCCCAGAAACTCCGAGCAGCGATGAACCGACAACCCC 
                   ************************************************************ 
 
Gallo0577_exp      GTCGCAAAGCAACAAGAAATCTGATAAAGAGCAGGATAAGAACATTATCGCTGCGCTTGT 
Gallo0577_Seq      GTCGCAAAGCAACAAGAAATCTGATAAAGAGCAGGATAAGAACATTATCGCTGCGCTTGT 
                   ************************************************************ 
 
Gallo0577_exp      CGACAAACCTCCCACACCTCCCCCTGAACCTGAAACATAAGCGGCCGCATC 
Gallo0577_Seq      CGACAAACCTCCCACACCTCCCCCTA------------------------- 
                   *************************                           
 
Gallo0748 (sequencing of PCR product via T3 and T7 primer (PCR primer 
pGEXs+T7 and pGEXas+T3)) 
Gallo0748_exp      TCCAAAATCGGATCTGGTTCCGCGTGGATCCGATGAACTCTCCAAAGCTGCGGGTGTGAG 
Gallo0748_Seq      ----------------------------TCCGATGAACTCTCCAAAGCTGCGGGTGTGAG 
                                               ******************************** 
 
Gallo0748_exp      CCAGACCGATCCGGCGTCGAACATTGAGCAAGTGGTGCAAGCAACCGAATCCTCTAGCAC 
Gallo0748_Seq      CCAGACCGATCCGGCGTCGAACATTGAGCAAGTGGTGCAAGCAACCGAATCCTCTAGCAC 
                   ************************************************************ 
 
Gallo0748_exp      AGCTGATTTTGCCCAGGTGGCATCCGTTGAAGCGACCACAGAAGTGAGCGGAGTGGAAAG 
Gallo0748_Seq      AGCTGATTTTGCCCAGGTGGCATCCGTTGAAGCGACCACAGAAGTGAGCGGAGTGGAAAG 
                   ************************************************************ 
 
Gallo0748_exp      CACAGCTACTGTTTCGGTAACAGCGGACGAAGTTGCTGTGGTAAGCAAAACTCAAGAAAT 
Gallo0748_Seq      CACAGCTACTGTTTCGGTAACAGCGGACGAAGTTGCTGTGGTAAGCAAAACTCAAGAAAT 
                   ************************************************************ 
 
Gallo0748_exp      TGTATCGGAAGAGTTGAGTAGTCCGGCCGCAACGTCTGATGCGACCGCTGTTGGGAACGT 
Gallo0748_Seq      TGTATCGGAAGAGTTGAGTAGTCCGGCCGCAACGTCTGATGCGACCGCTGTTGGGAACGT 
                   ************************************************************ 
 
Gallo0748_exp      AGCTAACGCACAGAATTCGGGCGTTTCTAGTGAAGTCGCGGAAGAGATTGCGCAAGACGT 
Gallo0748_Seq      AGCTAACGCACAGAATTCGGGCGTTTCTAGTGAAGTCGCGGAAGAGATTGCGCAAGACGT 
                   ************************************************************ 
 
Gallo0748_exp      TGAAGCATCTGCCACCAGTGTGAGCTCAGAAGTTGTCACGGAAGTTACGGAGAAAGCCCA 
Gallo0748_Seq      TGAAGCATCTGCCACCAGTGTGAGCTCAGAAGTTGTCACGGAAGTTACGGAGAAAGCCCA 
                   ************************************************************ 
 
Gallo0748_exp      GTCTGAGGAACAGACGTTAGATTCCGCCACCCCGCAGTCTATCGACTCGGACGAATTGAT 
Gallo0748_Seq      GTCTGAGGAACAGACGTTAGATTCCGCCACCCCGCAGTCTATCGACTCGGACGAATTGAT 
                   ************************************************************ 
 
Gallo0748_exp      CACGGTACCGGAAGCGTGGGAATCGGGCTATAAAGGCCAGGGCACCATTGTGGCTATCAT 
Gallo0748_Seq      CACGGTACCGGAAGCGTGGGAATCGGGCTATAAAGGCCAGGGCACCATTGTGGCTATCAT 
                   ************************************************************ 
 
Gallo0748_exp      TGACTCAGGGCTGGATGTAGAACATGATGTGCTGCACATTAGCGACTTAAGTACCGCCAA 
Gallo0748_Seq      TGACTCAGGGCTGGATGTAGAACATGATGTGCTGCACATTAGCGACTTAAGTACCGCCAA 
                   ************************************************************ 
 
Gallo0748_exp      ATATGGGTCGGAGGAAGAAATTGAGGCGGCGAAAGCAGCCGCGGGTATTACGTATGGCAA 
Gallo0748_Seq      ATATGGGTCGGAGGAAGAAATTGAGGCGGCGAAAGCAGCCGCGGGTATTACGTATGGCAA 
                   ************************************************************ 
 
Gallo0748_exp      ATGGTTCAATGATAAAGTCGTGTTTGGTTACAACTACGTGGACGGGAATACCATCCTGAA 
Gallo0748_Seq      ATGGTTCAATGATAAAGTCGTGTTTGGTTACAACTACGTGGACGGGAATACCATCCTGAA 
                   ************************************************************ 
 
Gallo0748_exp      AGAGGGAGAAGAAGCGTCCCATGGCATGCACGTCACCGGGATCGCTACCGGGAATCCGAC 
Gallo0748_Seq      AGAGGGAGAAGAAGCGTCCCATGGCATGCACGTCACCGGGATCGCTACCGGGAATCCGAC 
                   ************************************************************ 
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Gallo0748_exp      CAAAGCATTGGGAGATGAATACATCTACGGTGTAGCGCCGGAGGCACAGGTCATCTTCCT 
Gallo0748_Seq      CAAAGCATTGGGAGATGAATACATCTACGGTGTAGCGCCGGAGGCACAGGTCATCTTCCT 
                   ************************************************************ 
 
Gallo0748_exp      GCGTGTCTTTAGTGATCTGAAATCCTATACCGGCCCTGCGCTGTATGTCCGTGCGATCGA 
Gallo0748_Seq      GCGTGTCTTTAGTGATCTGAAATCCTATACCGGCCCTGCGCTGTATGTCCGTGCGATCGA 
                   ************************************************************ 
 
Gallo0748_exp      GGATGCAGTGAAACTGGGTGCTGACAGCATCAACCTGAGTCTGGGCTCGACAACTGGCAG 
Gallo0748_Seq      GGATGCAGTGAAACTGGGTGCTGACAGCATCAACCTGAGTCTGGGCTCGACAACTGGCAG 
                   ************************************************************ 
 
Gallo0748_exp      CGAGGTCAACATGGATGAAACCTTAATTGCAGCCATCAAAGCAGCACAGAAAGCGGGTGT 
Gallo0748_Seq      CGAGGTCAACATGGATGAAACCTTAATTGCAGCCATCAAAGCAGCACAGAAAG------- 
                   *****************************************************        
 
Gallo0748_exp      AAACGTGGCTATTAGCGCGGGCAATGATGGCGTATTTGGCGATAGCATTAATCCGAGCGC 
Gallo0748_Seq      ------------------------------------------------------------ 
                                                                                
 
Gallo0748_exp      AGAAAATCCCGATTATGGCCTGGTAGGTAACCCCAGCACGACGCAGGATGTTATTAGCGT 
Gallo0748_Seq      ------------------------------------------------------------ 
                                                                                
 
Gallo0748_exp      TGCGTCGTACAATAACTCAATCACTCGCAGCAATGTTGTGACGTTTGTTGGTATGGAAGA 
Gallo0748_Seq      ------------------------------------------------------------ 
                                                                                
 
Gallo0748_exp      TAACGCTGAACTGAACAATGGCAAATCTTCCTTCACCAACCCGGACAAAAGCGACAAGAA 
Gallo0748_Seq      ------------------------------------------------------------ 
                                                                                
 
Gallo0748_exp      ATTCGAAAATGGAAAGGCGTATGATTATGTGTACGTTGGCACGGGGACTGCCGAGGAACT 
Gallo0748_Seq      ------------------------------------------------------------ 
                                                                                
 
Gallo0748_exp      TGAAGGTGTGGACTTGACCGGGAAGCTGGCTCTGATTCAACGCGGTGGTCTTACGTTTTC 
Gallo0748_Seq      ------------------------------------------------------------ 
                                                                                
 
Gallo0748_exp      GGAAAAGATTGCGAACGCGACTGCACATGGCGCCGAGGGTGTGATTATTTTCAACAACGA 
Gallo0748_Seq      ---------------------------TGGCGCCGAGGGTGTGATTATTTTCAACAACGA 
                                              ********************************* 
 
Gallo0748_exp      TCCAGATGGAAGTAATGTTTCTATGGCCATTGACGATACTGCCATTGCAATTCCTTCTGC 
Gallo0748_Seq      TCCAGATGGAAGTAATGTTTCTATGGCCATTGACGATACTGCCATTGCAATTCCTTCTGC 
                   ************************************************************ 
 
Gallo0748_exp      GTTTATCCCGTACAAGTTCGGTATTGAGCTGGCCAAAGGCGGTTACCAGATCAAGTTCTC 
Gallo0748_Seq      GTTTATCCCGTACAAGTTCGGTATTGAGCTGGCCAAAGGCGGTTACCAGATCAAGTTCTC 
                   ************************************************************ 
 
Gallo0748_exp      CGATGTCGCCGAGAAATTCGATAATCCCGGAGCGGGCAAGTTCAGTAGTTTCAGCTCATG 
Gallo0748_Seq      CGATGTCGCCGAGAAATTCGATAATCCCGGAGCGGGCAAGTTCAGTAGTTTCAGCTCATG 
                   ************************************************************ 
 
Gallo0748_exp      GGGACTGACCGCCGATGGCGAACTGAAGCCAGATGTGGCGGCACCAGGCGGGTCAATCTA 
Gallo0748_Seq      GGGACTGACCGCCGATGGCGAACTGAAGCCAGATGTGGCGGCACCAGGCGGGTCAATCTA 
                   ************************************************************ 
 
Gallo0748_exp      TTCGTCTTACAACAACGACAAATACGGCTCTATGTCCGGTACCTCAATGGCCTCACCGCA 
Gallo0748_Seq      TTCGTCTTACAACAACGACAAATACGGCTCTATGTCCGGTACCTCAATGGCCTCACCGCA 
                   ************************************************************ 
 
Gallo0748_exp      TGTTGCCGGTGTGATCGCGCTTGTGAAACAGTACCTGAAAGAGAACTTTCCAGAGAAATC 
Gallo0748_Seq      TGTTGCCGGTGTGATCGCGCTTGTGAAACAGTACCTGAAAGAGAACTTTCCAGAGAAATC 
                   ************************************************************ 
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Gallo0748_exp      CGATGAGGAAGTCGGCTATCTCGTTAAAGCCTTAATTATGAGCACCGCCAAAGCGCACTA 
Gallo0748_Seq      CGATGAGGAAGTCGGCTATCTCGTTAAAGCCTTAATTATGAGCACCGCCAAAGCGCACTA 
                   ************************************************************ 
 
Gallo0748_exp      TGACAAAGAAGCCCAAGCCTATACTAGTCCTCGTCAGCAAGGTGCGGGATTAGTCGATAC 
Gallo0748_Seq      TGACAAAGAAGCCCAAGCCTATACTAGTCCTCGTCAGCAAGGTGCGGGATTAGTCGATAC 
                   ************************************************************ 
 
Gallo0748_exp      TGCGTCAGCTGTCTCAACGGGCCTGTACGTGACGGGTGATGATGGCTACGGTAGTGTCAC 
Gallo0748_Seq      TGCGTCAGCTGTCTCAACGGGCCTGTACGTGACGGGTGATGATGGCTACGGTAGTGTCAC 
                   ************************************************************ 
 
Gallo0748_exp      TCTGGGGAACGTGGGTGATACCTTCACCTTTGACGTCACCATCCACAATATTGGTGACCA 
Gallo0748_Seq      TCTGGGGAACGTGGGTGATACCTTCACCTTTGACGTCACCATCCACAATATTGGTGACCA 
                   ************************************************************ 
 
 
Gallo0748_exp      AGATAAAACTCTGACGTATGAAACGAACTTAGGCACAGACACAGTTGAAAATGGCGAAAT 
Gallo0748_Seq      AGATAAAACTCTGACGTATGAAACGAACTTAGGCACAGACACAGTTGAAAATGGCGAAAT 
                   ************************************************************ 
 
Gallo0748_exp      CACCCTTGCACCTCGGCAGTTGTCCACGACAACCGGTCATACCATTACCGTTAAGGCGAA 
Gallo0748_Seq      CACCCTTGCACCTCGGCAGTTGTCCACGACAACCGGTCATACCATTACCGTTAAGGCGAA 
                   ************************************************************ 
 
Gallo0748_exp      TAGCTCGGAAACCATCACAATTACCGTGGACGCATCCCAGTTTGCGGAACTGCTCAGCAA 
Gallo0748_Seq      TAGCTCGGAAACCATCACAATTACCGTGGACGCATCCCAGTTTGCGGAACTGCTCAGCAA 
                   ************************************************************ 
 
Gallo0748_exp      AGAAATTCCGAATGGCTATTATCTGGAGGGCTTTGTGCGCTTTCTCGATCCGACGGATCT 
Gallo0748_Seq      AGAAATTCCGAATGGCTATTATCTGGAGGGCTTTGTGCGCTTTCTCGATCCGACGGATCT 
                   ************************************************************ 
 
Gallo0748_exp      GGCCGAAGTCATCAGCATTCCGTATGTGGGTTTTCGCGGTGACTTTGTCGACAAACCTCC 
Gallo0748_Seq      GGCCGAAGTCATCAGCATTCCGTATGTGGGTTTTCGCGGTGACTTTGTCGACAAACCTCC 
                   ************************************************************ 
 
Gallo0748_exp      CACACCTCCCCCTGAACCTGAAACATAAGCGGCCGCATC 
Gallo0748_Seq      CACACCTCCCC---------------------------- 
                   ***********                             
 
Gallo0933 (sequencing of PCR product via T3 and T7 primer (PCR primer 
pGEXs+T7 and pGEXas+T3)) 
Gallo0933_exp      TCCAAAATCGGATCTGGTTCCGCGTGGATCCCTGACTGCGTGCAGCAGCTCTTCCAACTC 
Gallo0933_Seq      ----------------TTGTCGCGTGGATCCCTGACTGCGTGCAGCAGCTCTTCCAACTC 
                                    *  **************************************** 
 
Gallo0933_exp      ATCAACTAGCAGCAGTAGTAGTCAGAATACGACAGCGTCAACCAGCTCTTTAAGCAGCGG 
Gallo0933_Seq      ATCAACTAGCAGCAGTAGTAGTCAGAATACGACAGCGTCAACCAGCTCTTTAAGCAGCGG 
                   ************************************************************ 
 
Gallo0933_exp      CGAAGTCTCCACAACCCTGGATAAAGTGGACAACTCTAAATGGCAGTATAATGCGGATGA 
Gallo0933_Seq      CGAAGTCTCCACAACCCTGGATAAAGTGGACAACTCTAAATGGCAGTATAATGCGGATGA 
                   ************************************************************ 
 
Gallo0933_exp      CAATGTGTACTACCAGATCGGGATTTCGTACGCTGCAAACCCGACAGATGCTGAACAGCA 
Gallo0933_Seq      CAATGTGTACTACCAGATCGGGATTTCGTACGCTGCAAACCCGACAGATGCTGAACAGCA 
                   ************************************************************ 
 
Gallo0933_exp      GACGTTATCCATTTTCGTGCCAGGCGATTATATGACCGCGACGGATAACGGTAATGGTAC 
Gallo0933_Seq      GACGTTATCCATTTTCGTGCCAGGCGATTATATGACCGCGACGGATAACGGTAATGGTAC 
                   ************************************************************ 
 
Gallo0933_exp      CTATACGTGCGAAATTAACACGTCGGCCACAGTCGGAAACTACACTAGCGAAACCGCGCC 
Gallo0933_Seq      CTATACGTGCGAAATTAACACGTCGGCCACAGTCGGAAACTACACTAGCGAAACCGCGCC 
                   ************************************************************ 
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Gallo0933_exp      GATTGTGATTCCCATCAACACCCCGGGCTATTCCGCCATGTCGGCCTTAACAGAGTATAC 
Gallo0933_Seq      GATTGTGATTCCCATCAACACCCCGGGCTATTCCGCCATGTCGGCCTTAACAGAGTATAC 
                   ************************************************************ 
 
Gallo0933_exp      CTCAGATGCGACCGACTATACCTCGCAAGGCATGATTTACGTTAGCGCCGGATTACGTGG 
Gallo0933_Seq      CTCAGATGCGACCGACTATACCTCGCAAGGCATGATTTACGTTAGCGCCGGATTACGTGG 
                   ************************************************************ 
 
Gallo0933_exp      ACGCGATAGTGGCGCACCTAGCGGTGTTACCGATGCCAAAGCAGCGATTCGCTATCTCCG 
Gallo0933_Seq      ACGCGATAGTGGCGCACCTAGCGGTGTTACCGATGCCAAAGCAGCGATTCGCTATCTCCG 
                   ************************************************************ 
 
Gallo0933_exp      CTATAATCAGGGTAACATTTCCGGCAATACCGACAGCATCTTCGTGTTCGGCATGAGTGG 
Gallo0933_Seq      CTATAATCAGGGTAACATTTCCGGCAATACCGACAGCATCTTCGTGTTCGGCATGAGTGG 
                   ************************************************************ 
 
Gallo0933_exp      TGGAGGTGCACAATCTGCGATTATTGGCAGCAGTGGGGACAGTTCCTTGTATGACGACTA 
Gallo0933_Seq      TGGAGGTGCACAATCTGCGATTATTGGCAGCAGTGGGGACAGTTCCTTGTATGACGACTA 
                   ************************************************************ 
 
Gallo0933_exp      CCTGACGGAGATCGGGGCTGTTGAGGGCGTTAGCGACAGTGTAGCTGGTGTAATGGCCTG 
Gallo0933_Seq      CCTGACGGAGATCGGGGCTGTTGAGGGCGTTAGCGACAGTGTAGCTGGTGTAATGGCCTG 
                   ************************************************************ 
 
Gallo0933_exp      GTGTCCGATTACTAATCTGGACACGGCCAACGAAGCCTATGAATGGAACATGGGTAGTAC 
Gallo0933_Seq      GTGTCCGATTACTAATCTGGACACGGCCAACGAAGCCTATGAATGGAACATGGGTAGTAC 
                   ************************************************************ 
 
Gallo0933_exp      CCGTTCTGACTTGAGTGACGAGGAACAGACCATCTCAGATGGATTGGCTACCGCCTTTGC 
Gallo0933_Seq      CCGTTCTGACTTGAGTGACGAGGAACAGACCATCTCAGATGGATTGGCTACCGCCTTTGC 
                   ************************************************************ 
 
Gallo0933_exp      CAAATACATCAACAAACTTGGGCTTCAGGATGAAGATGGGAACAAACTGACCCTGAAGAA 
Gallo0933_Seq      CAAATACATCAACAAACTTGGGCTTCAGGATGAAGATGGGAACAAACTGACCCTGAAGAA 
                   ************************************************************ 
 
Gallo0933_exp      ATCGGACGACGGAATCTATCAAGCAGGCTCGTACTACAATTACCTGAAATCCGTGATCGA 
Gallo0933_Seq      ATCGGACGACGGAATCTATCAAGCAGGCTCGTACTACAATTACCTGAAATCCGTGATCGA 
                   ************************************************************ 
 
Gallo0933_exp      ATCGGACGACGGAATCTATCAAGCAGGCTCGTACTACAATTACCTGAAATCCGTGATCGA 
Gallo0933_Seq      ATCGGACGACGGAATCTATCAAGCAGGCTCGTACTACAATTACCTGAAATCCGTGATCGA 
                   ************************************************************ 
 
Gallo0933_exp      AGATAGTCTGAACACCTTTCTCGCGAATACCACCTTTCCGTACGATGCAAGCTCATCAAG 
Gallo0933_Seq      AGATAGTCTGAACACCTTTCTCGCGAATACCACCTTTCCGTACGATGCAAGCTCATCAAG 
                   ************************************************************ 
 
Gallo0933_exp      CCAAGGCGGTCTTGGCGGTGGGGATATGCCAACTGGCGAAGCACCTACGGATCTGGGTAC 
Gallo0933_Seq      CCAAGGCGGTCTTGGCGGTGGGGATATGCCAACTGGCGAAGCACCTACGGATCTGGGTAC 
                   ************************************************************ 
 
Gallo0933_exp      GACGGATGACACGACCTCTATTGAGGACGTTGATGATATCAATCGCACGAGCTCTTCGAG 
Gallo0933_Seq      GACGGATGACACGACCTCTATTGAGGACGTTGATGATATCAATCGCACGAGCTCTTCGAG 
                   ************************************************************ 
 
Gallo0933_exp      CATCACTATTGATCTGTCTGGTACTTACGAGACTGCAGCCGACTACATTGCAGCATTGAA 
Gallo0933_Seq      CATCACTATTGATCTGTCTGGTACTTACGAGACTGCAGCCGACTACATTGCAGCATTGAA 
                   ************************************************************ 
 
Gallo0933_exp      CGCCGATTCCACGTGGGTCACGTATGACGAAGATACCAATACGGCTTCAATTAGCAGCAT 
Gallo0933_Seq      CGCCGATTCCACGTGGGTCACGTATGACGAAGATACCAATACGGCTTCAATTAGCAGCAT 
                   ************************************************************ 
 
Gallo0933_exp      TGCGGATTTCGTGAAGTACATGAAGTCGAGCACGAAATCCCTGGGTGCGTTTGATGCGCT 
Gallo0933_Seq      TGCGGATTTCGTGAAGTACATGAAGTCGAGCACGAAATCCCTGGGTGCGTTTGATGCGCT 
                   ************************************************************ 
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Gallo0933_exp      CGATCTGAGCCAGGGCGAAAACCAACTGTTTGGTTATGGCGATGGCAATTCCGTGCATTG 
Gallo0933_Seq      CGATCTGAGCCAGGGCGAAAACCAACTGTTTGGTTATGGCGATGGCAATTCCGTGCATTG 
                   ************************************************************ 
 
Gallo0933_exp      GGATTCTACCCTGGGCGATCTGTTTAAAGGCACTGATTATGAAGAAGCGTTTACAACAGA 
Gallo0933_Seq      GGATTCTACCCTGGGCGATCTGTTTAAAGGCACTGATTATGAAGAAGCGTTTACAACAGA 
                   ************************************************************ 
 
Gallo0933_exp      CCTCGTTAAGACGGATAGTCTGGGTAATGATTTAACTACCCGCATCAACATGTATACCCC 
Gallo0933_Seq      CCTCGTTAAGACGGATAGTCTGGGTAATGATTTAACTACCCGCATCAACATGTATACCCC 
                   ************************************************************ 
 
Gallo0933_exp      GCTGTATTATCTGACCGATTACTATGGTGGGGAAAATTCCTCGAACGTCGCGTCGTATTG 
Gallo0933_Seq      GCTGTATTATCTGACCGATTACTATGGTGGGGAAAATTCCTCGAACGTCGCGTCGTATTG 
                   ************************************************************ 
 
Gallo0933_exp      GCGGATTCGTACAGGGTTATCCCAAGGCGATACAGCGCTGACCACTGAGGTAAATCTGGC 
Gallo0933_Seq      GCGGATTCGTACAGGGTTATCCCAAGGCGATACAGCGCTGACCACTGAGGTAAATCTGGC 
                   ************************************************************ 
 
Gallo0933_exp      CCTGGCGCTTGAAAACTATGGTGTGAAAGATCTGGATTTCGCTACCGTATGGGGCGAACA 
Gallo0933_Seq      CCTGGCGCTTGAAAACTATGGTGTGAAAGATCTGGATTTCGCTACCGTATGGGGCGAACA 
                   ************************************************************ 
 
Gallo0933_exp      GCACACCGAAGCTGAGATCTCTGGCGACTCAACCTCGAACTTCATCGATTGGGTCAATCA 
Gallo0933_Seq      GCACACCGAAGCTGAGATCTCTGGCGACTCAACCTCGAACTTCATCGATTGGGTCAATCA 
                   ************************************************************ 
 
Gallo0933_exp      GTCTTTGGCGGACAACTCGGTCGACAAACCTCCCACACCTCCCCCTGAACCTGAAACATA 
Gallo0933_Seq      GTCTTTGGCGGACAACTCGGTCGACAAACCTCCCACACCTCCCCCT-------------- 
                   **********************************************               
 
Gallo0933_exp      AGCGGCCGCATC 
Gallo0933_Seq      ------------ 
 
Gallo1570 (forward sequencing of miniPrep DNA via primer pGEXfor, reverse 
sequencing of PCR product via T3 primer (PCR primer pGEXs+T7 and pGEXas+T3)) 
Gallo1570_exp      ATAGCATGGCCTTTGCAGGGCTGGCAAGCCACGTTTGGTGGTGGCGACCATCCTCCAAAA 
Gallo1570_Seq      -------------------------------------------------CATCCTCCAAA 
                                                                       *  * *** 
 
Gallo1570_exp      TCGGATCTGGTTCCGCGTGGATCCAAAGCCGAAGAGGATGTGTACTATACCGGCTATACC 
Gallo1570_Seq      TCGGATCTGGTTCCGCGTGGATCCAAAGCCGAAGAGGATGTGTACTATACCGGCTATACC 
                   ************************************************************ 
 
Gallo1570_exp      TCGGATATTTCCCTGAACAGTAGTTACATCAATCCGGACCCAGGGCCATATGCGATTGAC 
Gallo1570_Seq      TCGGATATTTCCCTGAACAGTAGTTACATCAATCCGGACCCAGGGCCATATGCGATTGAC 
                   ************************************************************ 
 
Gallo1570_exp      GAAGGCGGGGAGTCGAAATTAGCCTATTGCTTTAACCGGAACAAATCGCGTCCTCCTGCA 
Gallo1570_Seq      GAAGGCGGGGAGTCGAAATTAGCCTATTGCTTTAACCGGAACAAATCGCGTCCTCCTGCA 
                   ************************************************************ 
 
Gallo1570_exp      AAGTCAGAACCGGAGGACGGTGAAGCGAAATACCGCAAAATTGCAGATGTGGATTACGTC 
Gallo1570_Seq      AAGTCAGAACCGGAGGACGGTGAAGCGAAATACCGCAAAATTGCAGATGTGGATTACGTC 
                   ************************************************************ 
 
Gallo1570_exp      CGCCTTAAAGAGAACTGTTCGTCTGACATGGAAGGCCGTGAATTGTACGATGCCATCATG 
Gallo1570_Seq      CGCCTTAAAGAGAACTGTTCGTCTGACATGGAAGGCCGTGAATTGTACGATGCCATCATG 
                   ************************************************************ 
 
Gallo1570_exp      AAAGTGATCTACAACGGGTATCCGAACAATTGTAGCGGCATCAATGGCAAATATCGCCTG 
Gallo1570_Seq      AAAGTGATCTACAACGGGTATCCGAACAATTGTAGCGGCATCAATGGCAAATATCGCCTG 
                   ************************************************************ 
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Gallo1570_exp      AAAGACGGCGACTTTTGCGCGATTACCCAGTGGGCTATCTGGCACTTTACGGATGGCGCG 
Gallo1570_Seq      AAAGACGGCGACTTTTGCGCGATTACCCAGTGGGCTATCTGGCACTTTACGGATGGCGCG 
                   ************************************************************ 
 
Gallo1570_exp      GATAGCGATGGTACCGGCAATCTGCCGTATTATGGGAAAGAAAGCATGTGGAACCGCTCA 
Gallo1570_Seq      GATAGCGATGGTACCGGCAATCTGCCGTATTATGGG------------------------ 
                   ************************************                         
 
Gallo1570_exp      GACGTGAAAGAAGCCTATCTCGAGCTCATCGATGTTGCGAACCTGTCTTACCCAGCAGAC 
Gallo1570_Seq      ------------------------------------------------------------ 
                                                                                
 
Gallo1570_exp      GCAAAACTGAACCTGTATATTTACGATCATGGTGCCGAACACGATCGCCAGAATCTGCTT 
Gallo1570_Seq      ------------------------------------------------------------ 
                                                                                
 
Gallo1570_exp      ACCACGGACGTAGGCTATACAAATCTGTCTGTCGAGAAAGTGTGGAATGACAGCGATGAT 
Gallo1570_Seq      ------------------------------------------------------------ 
                                                                                
 
Gallo1570_exp      CAGGATGGTATTCGTCCGGCTTTTATCGATGTACAGCTGTTAGCGAATGGAGTGGAAGTT 
Gallo1570_Seq      ------------------------------------------------------------ 
                                                                                
 
Gallo1570_exp      GAGGGACAGAAAATCGAACTGTCCAAATTTCTGAATTCGAACTGGCAAGGTGTATTCCGT 
Gallo1570_Seq      ------------------------------------------------------------ 
                                                                                
 
Gallo1570_exp      GGTCTTAGTCTCTACGATAGTGACGGTAATCCTATCGAATATTCCGTGAAGGAAGTTGAG 
Gallo1570_Seq      ------AGTCTCTACGATAGTGACGGTAATCCTATCGAATATTCCGTGAAGGAAGTTGAG 
                         ****************************************************** 
 
Gallo1570_exp      AAGTACCGCGGACAGTTGGATGGTTACCAGTCTACTGTGACGAAAAGCGACAGCGGCTAT 
Gallo1570_Seq      AAGTACCGCGGACAGTTGGATGGTTACCAGTCTACTGTGACGAAAAGCGACAGCGGCTAT 
                   ************************************************************ 
 
Gallo1570_exp      TCCTATACCATCACCAATACACACGTTCCGGAAACAACCGAAATTAGCGGTACTAAAACG 
Gallo1570_Seq      TCCTATACCATCACCAATACACACGTTCCGGAAACAACCGAAATTAGCGGTACTAAAACG 
                   ************************************************************ 
 
Gallo1570_exp      TGGGATGATAAAGACGATCAAGACGGGAAACGTCCCTCTAGCATTACGGTGAAATTACTG 
Gallo1570_Seq      TGGGATGATAAAGACGATCAAGACGGGAAACGTCCCTCTAGCATTACGGTGAAATTACTG 
                   ************************************************************ 
 
Gallo1570_exp      GCTGATGATGAGGAAATCGATAGTCAAGAGGTGACGGCAGATACGGACTGGAAGTACAGC 
Gallo1570_Seq      GCTGATGATGAGGAAATCGATAGTCAAGAGGTGACGGCAGATACGGACTGGAAGTACAGC 
                   ************************************************************ 
 
Gallo1570_exp      TTTAAAGATCTGCCGAAATATAAGAACGAAGGCGTCGAAATTAACTATTCAGTCGCCGAA 
Gallo1570_Seq      TTTAAAGATCTGCCGAAATATAAGAACGAAGGCGTCGAAATTAACTATTCAGTCGCCGAA 
                   ************************************************************ 
 
Gallo1570_exp      GAATCAGTGAGCGATTATGAAACCACCATCAGCGGTACGGATATTACGAACACTCATGTC 
Gallo1570_Seq      GAATCAGTGAGCGATTATGAAACCACCATCAGCGGTACGGATATTACGAACACTCATGTC 
                   ************************************************************ 
 
Gallo1570_exp      CCGGAAACAACAGAAATTTCGGGAACTAAAACCTGGGACGATAACGATGACCAAGATGGC 
Gallo1570_Seq      CCGGAAACAACAGAAATTTCGGGAACTAAAACCTGGGACGATAACGATGACCAAGATGGC 
                   ************************************************************ 
 
Gallo1570_exp      AAACGGCCGACGGCGATTACAGTCAACTTGCTGGCTGATGGCGTTAAAGTAGATTCCAAG 
Gallo1570_Seq      AAACGGCCGACGGCGATTACAGTCAACTTGCTGGCTGATGGCGTTAAAGTAGATTCCAAG 
                   ************************************************************ 
 
Gallo1570_exp      AAAGTTACGGCAGCCGACGATTGGAAATATGAATTCAAAGACTTGCCGAAGTACAAGGCG 
Gallo1570_Seq      AAAGTTACGGCAGCCGACGATTGGAAATATGAATTCAAAGACTTGCCGAAGTACAAGGCG 
                   ************************************************************ 
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Gallo1570_exp      GGTCAGGAAATCAAGTATTCTGTAACCGAAGAAGCCGTGAAAGACTATGAGACAAAAGTT 
Gallo1570_Seq      GGTCAGGAAATCAAGTATTCTGTAACCGAAGAAGCCGTGAAAGACTATGAGACAAAAGTT 
                   ************************************************************ 
 
Gallo1570_exp      TCCGGTACTGACATTACCAACATTCATACTCCGGAAACCACCGACATTACCGTTACGAAA 
Gallo1570_Seq      TCCGGTACTGACATTACCAACATTCATACTCCGGAAACCACCGACATTACCGTTACGAAA 
                   ************************************************************ 
 
Gallo1570_exp      ATCTGGGATGATCGCAACGATAAAGAAAAGAAACGCCCCGATAGTATCAAAGTCACCCTG 
Gallo1570_Seq      ATCTGGGATGATCGCAACGATAAAGAAAAGAAACGCCCCGATAGTATCAAAGTCACCCTG 
                   ************************************************************ 
 
Gallo1570_exp      AAAGCGAATGACAAAGATCTGCAAACCGTGACTATTACGGCGGAGGATGATTGGAAATAC 
Gallo1570_Seq      AAAGCGAATGACAAAGATCTGCAAACCGTGACTATTACGGCGGAGGATGATTGGAAATAC 
                   ************************************************************ 
 
Gallo1570_exp      GAGTTCAAAGATCTGCCCAAATACGAAAATGGCAAACAGATTAAGTATTCAGTCACTGAG 
Gallo1570_Seq      GAGTTCAAAGATCTGCCCAAATACGAAAATGGCAAACAGATTAAGTATTCAGTCACTGAG 
                   ************************************************************ 
 
Gallo1570_exp      GAAGAAGTTACGGGGTATACCACCACCATTGAAGAGGACGAGAGCGGCAACTTCGAAATT 
Gallo1570_Seq      GAAGAAGTTACGGGGTATACCACCACCATTGAAGAGGACGAGAGCGGCAACTTCGAAATT 
                   ************************************************************ 
 
Gallo1570_exp      ACCAATAAGATTCCACGTGACTACTTATTCGTCGACAAACCTCCCACACCTCCCCCTGAA 
Gallo1570_Seq      ACCAATAAGATTCCACGTGACTACTTATTCGTCGACAAACCTCCCACACCTCCCCCTA-- 
                   *********************************************************    
 
Gallo1570_exp      CCTGAAACATAAGCGGCCGCATC 
Gallo1570_Seq      ----------------------- 
                                           
 
Gallo1675 (sequencing of PCR product via T3 and T7 primer (PCR primer 
pGEXs+T7 and pGEXas+T3)) 
Gallo1675_exp      TCCAAAATCGGATCTGGTTCCGCGTGGATCCGCCGTGGTTCCGGATGGTACCGACGTACC 
Gallo1675_Seq      ---------------------GCGTGGATCCGCCGTGGTTCCGGATGGTACCGACGTACC 
                                        *************************************** 
 
Gallo1675_exp      AGTCGTGGCGGAAGCAAGTCAGACGATCGTTGAACCAGCGAGCGATGAGTTAAACACAGC 
Gallo1675_Seq      AGTCGTGGCGGAAGCAAGTCAGACGATCGTTGAACCAGCGAGCGATGAGTTAAACACAGC 
                   ************************************************************ 
 
Gallo1675_exp      GATTAGCGATGCGGAAAATGCGGGTGTGACGGTATCTCAAACCACATCTGAAACTGTGGT 
Gallo1675_Seq      GATTAGCGATGCGGAAAATGCGGGTGTGACGGTATCTCAAACCACATCTGAAACTGTGGT 
                   ************************************************************ 
 
Gallo1675_exp      TAACCAGGAAGAAGCTCAAGCAGATTATGCCACCCAGGCAGAATCACTGGAAGCCGTGAC 
Gallo1675_Seq      TAACCAGGAAGAAGCTCAAGCAGATTATGCCACCCAGGCAGAATCACTGGAAGCCGTGAC 
                   ************************************************************ 
 
Gallo1675_exp      TGCCCAGCAGGAGCAGATTAATACGGAAAATGCGCAGATTACCGCCGATAATCAGGCTCT 
Gallo1675_Seq      TGCCCAGCAGGAGCAGATTAATACGGAAAATGCGCAGATTACCGCCGATAATCAGGCTCT 
                   ************************************************************ 
 
Gallo1675_exp      CAACGAAGCTTACGAATCGGCCAAAGCTCAGGCCGAATCCACTAACCAGGCAGTCTCGGA 
Gallo1675_Seq      CAACGAAGCTTACGAATCGGCCAAAGCTCAGGCCGAATCCACTAACCAGGCAGTCTCGGA 
                   ************************************************************ 
 
Gallo1675_exp      AGCCCAAAGCACGTATGGCGCCACGGTGACCGAAACAACGGTGGACTATGGAGATGGTAC 
Gallo1675_Seq      AGCCCAAAGCACGTATGGCGCCACGGTGACCGAAACAACGGTGGACTATGGAGATGGTAC 
                   ************************************************************ 
 
Gallo1675_exp      TCTGACCACTGACTATCAAGCGGGTCAGGCGCAGGCAGAGTCCATTGCTGAAGCTAACGA 
Gallo1675_Seq      TCTGACCACTGACTATCAAGCGGGTCAGGCGCAGGCAGAGTCCATTGCTGAAGCTAACGA 
                   ************************************************************ 
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Gallo1675_exp      GCAGGCAGTCTCAGACTACCTGACGGAGAAAGCGGCAGTAGATGCGTATAACGCGCAAGT 
Gallo1675_Seq      GCAGGCAGTCTCAGACTACCTGACGGAGAAAGCGGCAGTAGATGCGTATAACGCGCAAGT 
                   ************************************************************ 
 
Gallo1675_exp      GAAAGCACGTGAGGATGCACTTAAGAGCAACAACATTGCATCGGATGAAGCGAACTACCT 
Gallo1675_Seq      GAAAGCACGTGAGGATGCACTTAAGAGCAACAACATTGCATCGGATGAAGCGAACTACCT 
                   ************************************************************ 
 
Gallo1675_exp      CTATGTAACTGGCGAGTTTGACACTAACGCGACCGGACTGGCTTACTACCAGAACATCAA 
Gallo1675_Seq      CTATGTAACTGGCGAGTTTGACACTAACGCGACCGGACTGGCTTACTACCAGAACATCAA 
                   ************************************************************ 
 
Gallo1675_exp      AGTAGTTACGCTTGACCCCAATGCGAAAACCGCCCAGTCTCTGGGGTGGCAGGATAACAC 
Gallo1675_Seq      AGTAGTTACGCTTGACCCCAATGCGAAAACCGCCCAGTCTCTGGGGTGGCAGGATAACAC 
                   ************************************************************ 
 
Gallo1675_exp      CACTATTAGCAACGCGAATGGCGTCACGGTAACGAGCCATGATACGGCCAATGACCCTGC 
Gallo1675_Seq      CACTATTAGCAACGCGAATGGCGTCACGGTAACGAGCCATGATACGGCCAATGACCCTGC 
                   ************************************************************ 
 
Gallo1675_exp      CATTTATGGCACCACCTCTGACTTCTTGTACAAAGTCACGGAAGCTACGGTGGGCGATAC 
Gallo1675_Seq      CATTTATGGCACCACCTCTGACTTCTTGTACAAAGTCACGGAAGCTACGGTGGGCGATAC 
                   ************************************************************ 
 
Gallo1675_exp      GTTCACGTTAAACAACATTGGCAAAGCCACCGACGGCACAAACATCAACGCTATCGTGAC 
Gallo1675_Seq      GTTCACGTTAAACAACATTGGCAAAGCCACCGACGGCACAAACATCAACGCTATCGTGAC 
                   ************************************************************ 
 
Gallo1675_exp      CATCACCAAAGCATCAGCGTTAACGGATAAGGAAGATAGCTGGTTCGTTATCGGGAAAAC 
Gallo1675_Seq      CATCACCAAAGCATCAGCGTTAACGGATAAGGAAGATAGCTGGTTCGTTATCGGGAAAAC 
                   ************************************************************ 
 
Gallo1675_exp      CGCGGATAACGGTATTGCCGTTGATTACTGGAACTATGACAATCTGGGCTTGAGCTTCCA 
Gallo1675_Seq      CGCGGATAACGGTATTGCCGTTGATTACTGGAACTATGACAATCTGGGCTTGAGCTTCCA 
                   ************************************************************ 
 
Gallo1675_exp      GTTTGTTGACGATTCGGGCAACGCTGTAAAACTGGTGGTCGCGAGTGTTGTCGGTGATGT 
Gallo1675_Seq      GTTTGTTGACGA------------------------------------------------ 
                   ************                                                 
 
Gallo1675_exp      GGACAACGATCAGACGTCCAAGATTGAATTCGACGGGAATACTCTGAACTACGTGAATCC 
Gallo1675_Seq      ------------------------------------------------------------ 
                                                                                
 
Gallo1675_exp      GGATGGGAGCGGTCTTATCGCCAATGCCGATAAATCACTGACCGGCCTGGGCTTTGCGGT 
Gallo1675_Seq      -----------------------------ATAAATCACTGACCGGCCTGGGCTTTGCGGT 
                                                ******************************* 
 
Gallo1675_exp      TGACGGTTACCAACAAGCGCCACAAGGTACCTATCTGATGGTGGGCTCTTCCACCACGGT 
Gallo1675_Seq      TGACGGTTACCAACAAGCGCCACAAGGTACCTATCTGATGGTGGGCTCTTCCACCACGGT 
                   ************************************************************ 
 
Gallo1675_exp      GAATTATACCCATACGAGTGACGATAATGTCGTGGACGGTAATGGCAATATCGTGAACTA 
Gallo1675_Seq      GAATTATACCCATACGAGTGACGATAATGTCGTGGACGGTAATGGCAATATCGTGAACTA 
                   ************************************************************ 
 
Gallo1675_exp      TATCGAATTCGACCTGTTTGGTACCACCAGTATGGTTACCACAGAAGAATTCAAGTACTT 
Gallo1675_Seq      TATCGAATTCGACCTGTTTGGTACCACCAGTATGGTTACCACAGAAGAATTCAAGTACTT 
                   ************************************************************ 
 
Gallo1675_exp      GCCCGATCCGACCTTAACCCTGACAAGTGTCACACTGCCGACTTCGCCTGTTGAGACACC 
Gallo1675_Seq      GCCCGATCCGACCTTAACCCTGACAAGTGTCACACTGCCGACTTCGCCTGTTGAGACACC 
                   ************************************************************ 
 
Gallo1675_exp      TCTGAAAGACAATTTGACCGCAACCTACCACCTCAATGAGTACGACGTAGCATTAACCAC 
Gallo1675_Seq      TCTGAAAGACAATTTGACCGCAACCTACCACCTCAATGAGTACGACGTAGCATTAACCAC 
                   ************************************************************ 
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Gallo1675_exp      CGTTAAAGACGTACTGAATGATCAGGGTATCAGCATTGACGGTGGAGAGCTCCAAATTGG 
Gallo1675_Seq      CGTTAAAGACGTACTGAATGATCAGGGTATCAGCATTGACGGTGGAGAGCTCCAAATTGG 
                   ************************************************************ 
 
Gallo1675_exp      AGAGACAGGTCACTATACCCTGGAAGGTGCCAAAGTGCTGGCTAATGGAAAAGATACCTT 
Gallo1675_Seq      AGAGACAGGTCACTATACCCTGGAAGGTGCCAAAGTGCTGGCTAATGGAAAAGATACCTT 
                   ************************************************************ 
 
Gallo1675_exp      GGTCAAGTATGACTTCGAAGATTATCTGGATATCGAACATGATGAGTACCAGGGCTATTC 
Gallo1675_Seq      GGTCAAGTATGACTTCGAAGATTATCTGGATATCGAACATGATGAGTACCAGGGCTATTC 
                   ************************************************************ 
 
Gallo1675_exp      GATTTACGCGTTTGTACCGATTACGTTAAAAGATGGCACCGTGATCCAGTCTGGCGAAGA 
Gallo1675_Seq      GATTTACGCGTTTGTACCGATTACGTTAAAAGATGGCACCGTGATCCAGTCTGGCGAAGA 
                   ************************************************************ 
 
Gallo1675_exp      TCTGAAGGCATATGCGCAAGCGGTCTATGATGATGTAACTGGGCACTTTTATGTCAGCCT 
Gallo1675_Seq      TCTGAAGGCATATGCGCAAGCGGTCTATGATGATGTAACTGGGCACTTTTATGTCAGCCT 
                   ************************************************************ 
 
Gallo1675_exp      GAATAGCGATTTTCTTGCTCAGGTTGCGAAAGATTCCGATTTTCAGGCCAAAGTGGACAT 
Gallo1675_Seq      GAATAGCGATTTTCTTGCTCAGGTTGCGAAAGATTCCGATTTTCAGGCCAAAGTGGACAT 
                   ************************************************************ 
 
Gallo1675_exp      TGAATTTGTGCGCATTGCCGCAGGCGATGTCTATAACGACTTTACGAACCATCTGGCCTT 
Gallo1675_Seq      TGAATTTGTGCGCATTGCCGCAGGCGATGTCTATAACGACTTTACGAACCATCTGGCCTT 
                   ************************************************************ 
 
Gallo1675_exp      TGAGGATGAGGATGGGAACGTTACTGAAGTTCCGGTTCCGTCAAATGAAGTCGTGACTCA 
Gallo1675_Seq      TGAGGATGAGGATGGGAACGTTACTGAAGTTCCGGTTCCGTCAAATGAAGTCGTGACTCA 
                   ************************************************************ 
 
Gallo1675_exp      TACAGTGGAACCGCCGGTGGAAGAAGTTCCCGAAGAGCCGCAAGCGCCGACCGATGTGCA 
Gallo1675_Seq      TACAGTGGAACCGCCGGTGGAAGAAGTTCCCGAAGAGCCGCAAGCGCCGACCGATGTGCA 
                   ************************************************************ 
 
Gallo1675_exp      AACCCCGGAAGTCGCGGAGGATGTGCCAGTGGTTTCCCAGAGTGTTGTCGACAAACCTCC 
Gallo1675_Seq      AACCCCGGAAGTCGCGGAGGATGTGCCAGTGGTTTCCCAGAGTGTTGTCGACAAACCTCC 
                   ************************************************************ 
 
Gallo1675_exp      CACACCTCCCCCTGAACCTGAAACATAAGCGGCCGCATC 
Gallo1675_Seq      CACACCTCCCCC--------------------------- 
                   ************                            
 
Gallo2018 (sequencing of PCR product via T3 and T7 primer (PCR primer 
pGEXs+T7 and pGEXas+T3)) 
Gallo2018_exp      TCCAAAATCGGATCTGGTTCCGCGTGGATCCGACGATGAACTGGTTCCAACGACAGAAAC 
Gallo2018_Seq      ----------------------------TCCGACGATGAACTGGTTCCAACGACAGAAAC 
                                               ******************************** 
 
Gallo2018_exp      CACCGAAGTAGTTGATAACGGGGATAACGTGACCAAGAATCTTGCGACTGACATCATTGA 
Gallo2018_Seq      CACCGAAGTAGTTGATAACGGGGATAACGTGACCAAGAATCTTGCGACTGACATCATTGA 
                   ************************************************************ 
 
Gallo2018_exp      ACCGTCCAATGATATCTCCGAATCTCAAAGCGAGAAAACCGAAGAGGAGTCGTCAATCGA 
Gallo2018_Seq      ACCGTCCAATGATATCTCCGAATCTCAAAGCGAGAAAACCGAAGAGGAGTCGTCAATCGA 
                   ************************************************************ 
 
Gallo2018_exp      AACTGCCGATAACAGTTCCGTGATTATGGAGAGCACCGAAGCGACTGAAACGATTGCGAG 
Gallo2018_Seq      AACTGCCGATAACAGTTCCGTGATTATGGAGAGCACCGAAGCGACTGAAACGATTGCGAG 
                   ************************************************************ 
 
Gallo2018_exp      TGACACATCGGATGAACCGGAAGAAGCGGAGGTAACGATCCCGCAGTATGAAGAGAATGT 
Gallo2018_Seq      TGACACATCGGATGAACCGGAAGAAGCGGAGGTAACGATCCCGCAGTATGAAGAGAATGT 
                   ************************************************************ 
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Gallo2018_exp      TGCCGACTTTAACCATGTCCCGATGACCGATGTCTACGTGATGTTCACCGAGGATGGCAA 
Gallo2018_Seq      TGCCGACTTTAACCATGTCCCGATGACCGATGTCTACGTGATGTTCACCGAGGATGGCAA 
                   ************************************************************ 
 
Gallo2018_exp      AGAACACGTTATCTATGTAGGTCGTCCAACGTGCTATTATTGTCGCCAGTTTAGTCCTGC 
Gallo2018_Seq      AGAACACGTTATCTATGTAGGTCGTCCAACGTGCTATTATTGTCGCCAGTTTAGTCCTGC 
                   ************************************************************ 
 
Gallo2018_exp      GTTGAAAGAGTTCAATACGCTGATGGACAATCGCCTCGAATACTACAATACCGATTCACA 
Gallo2018_Seq      GTTGAAAGAGTTCAATACGCTGATGGACAATCGCCTCGAATACTACAATACCGATTCACA 
                   ************************************************************ 
 
Gallo2018_exp      GGACTTTGATGAAGAAGCAGCGAACTTCCTGTTTGGCACAATTGGCATTCCTGGAACACC 
Gallo2018_Seq      GGACTTTGATGAAGAAGCAGCGAACTTCCTGTTTGGCACAATTGGCATTCCTGGAACACC 
                   ************************************************************ 
 
Gallo2018_exp      GACGATTATTCGCTTACAGAATGGCCAAATTGTGTCTGCGTGGATTGGAGGTGGCATCTC 
Gallo2018_Seq      GACGATTATTCGCTTACAGAATGGCCAAATTGTGTCTGCGTGGATTGGAGGTGGCATCTC 
                   ************************************************************ 
 
Gallo2018_exp      TGGTCAGGAGCTGTATGACTACCTGTTCTATGGGAAAATTCCCGTGGCCATGGCTGCAGC 
Gallo2018_Seq      TGGTCAGGAGCTGTATGACTACCTGTTCTATGGGAAAATTCCCGTGGCCATGGCTGCAGC 
                   ************************************************************ 
 
Gallo2018_exp      AATGGCGGAACAGAGCAATGAAGATAACACTGAAACCATTGCCTTTGACGCCAAAGAGAT 
Gallo2018_Seq      AATGGCGGAACAGAGCAATGAAGATAACACTGAAACCATTGCCTTTGACGCCAAAGAGAT 
                   ************************************************************ 
 
Gallo2018_exp      CAAGACCGATAGCAACATCCAGAATGTCGTCTTTCTGCCGCAAAACGATGTGAAAACGGC 
Gallo2018_Seq      CAAGACCGATAGCAACATCCAGAATGTCGTCTTTCTGCCGCAAAACGATGTGAAAACGGC 
                   ************************************************************ 
 
Gallo2018_exp      AGAACGTGCACTGATTGTGCCCGAAAGCCCACAAGCTTTCAGCAAGAACGAAACCAAAAC 
Gallo2018_Seq      AGAACGTGCACTGATTGTGCCCGAAAGCCCACAAGCTTTCAGCAAGAACGAAACCAAAAC 
                   ************************************************************ 
 
Gallo2018_exp      CAACAATTCGAACGCTTTACCGAAATTGGGTATCAAAGCCAACAACGTCGACAAACCTCC 
Gallo2018_Seq      CAACAATTCGAACGCTTTACCGAAATTGGGTATCAAAGCCAACAACGTCGACAAACCTCC 
                   ************************************************************ 
 
Gallo2018_exp      CACACCTCCCCCTGAACCTGAAACATAAGCGGCCGCATC 
Gallo2018_Seq      CACACCTCCCCC--------------------------- 
                   ************                            
 
Gallo2178 (sequencing of PCR product via T3 and T7 primer (PCR primer 
pGEXs+T7 and pGEXas+T3)) 
Gallo2178_exp      TCCAAAATCGGATCTGGTTCCGCGTGGATCCTATGATATTACCGTGGAAAATGGCGGAAG 
Gallo2178_Seq      -------------------TCGCGTGGATCCTATGATATTACCGTGGAAAATGGCGGAAG 
                                       **************************************** 
 
Gallo2178_exp      TGGTACCTACGAGAGCTATCAGATCTTTACTGGGACTTTAAGCGAGGATGGCAAAACCCT 
Gallo2178_Seq      TGGTACCTACGAGAGCTATCAGATCTTTACTGGGACTTTAAGCGAGGATGGCAAAACCCT 
                   ************************************************************ 
 
Gallo2178_exp      GTCCAATATCGAATGGGGTAACGGCATTACGACGGCAGGCCAAACGGCATTACAGGAGAA 
Gallo2178_Seq      GTCCAATATCGAATGGGGTAACGGCATTACGACGGCAGGCCAAACGGCATTACAGGAGAA 
                   ************************************************************ 
 
Gallo2178_exp      ATATGGTGTCAGTTCAGCCGCGGGTCTGGCCGAAGTTTTGGGCGCTGACGATTTTACTGC 
Gallo2178_Seq      ATATGGTGTCAGTTCAGCCGCGGGTCTGGCCGAAGTTTTGGGCGCTGACGATTTTACTGC 
                   ************************************************************ 
 
Gallo2178_exp      GAGTCAAGCCGAGGAATTCGCGAAAGTAGTTGGGCAGTATCTTCAGAATGCGGGTGGTTT 
Gallo2178_Seq      GAGTCAAGCCGAGGAATTCGCGAAAGTAGTTGGGCAGTATCTTCAGAATGCGGGTGGTTT 
                   ************************************************************ 
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Gallo2178_exp      GACCGGATTAGCTGCGGGGTATTACCTGGTCCAGAATGCCTCAGTGGGCAATAACGAAGC 
Gallo2178_Seq      GACCGGATTAGCTGCGGGGTATTACCTGGTCCAGAATGCCTCAGTGGGCAATAACGAAGC 
                   ************************************************************ 
 
Gallo2178_exp      GCATACCAACTATATTCTCCAGGTGGTGAAAGACGTTATTGTGGAACCCAAGACAAGTGT 
Gallo2178_Seq      GCATACCAACTATATTCTCCAGGTGGTGAAAGACGTTATTGTGGAACCCAAGACAAGTGT 
                   ************************************************************ 
 
Gallo2178_exp      ACCAACGGTAGAAAAGAAACTGAAAGACACGAACGATACGACGGGCGAAACGACCGATTG 
Gallo2178_Seq      ACCAACGGTAGAAAAGAAACTGAAAGACACGAACGATACGACGGGCGAAACGACCGATTG 
                   ************************************************************ 
 
Gallo2178_exp      GCAGGATAGCGCCGACTACGATATTAACGATTCAGTGCCTTTCCAACTCACCGCAACTCT 
Gallo2178_Seq      GCAGGATAGCGCCGACTACGATATTAACGATTCAGTGCCTTTCCAACTCACCGCAACTCT 
                   ************************************************************ 
 
Gallo2178_exp      TCCGGATAATCTGGCTTCTTACGACGAATACTATCTGGAGCTGAGTGACACCTTGTCGGC 
Gallo2178_Seq      TCCGGATAATCTGGCTTCTTACGACGAATACTATCTGGAGCTGAGTGACACCTTGTCGGC 
                   ************************************************************ 
 
Gallo2178_exp      TGGTTTGACGTACAACAAAGACGCCAAAGTCTATCTCGTTAATGGCACCACCAAAACCGA 
Gallo2178_Seq      TGGTTTGACGTACAACAAAGACGCCAAAGTCTATCTCGTTAATGGCACCACCAAAACCGA 
                   ************************************************************ 
 
Gallo2178_exp      TGTTACCTCGAGTTTCACCATTGCAGATGATGGCTCGTCTTTCAAAATCAACAACCTGAA 
Gallo2178_Seq      TGTTACCTCGAGTTTCACCATTGCAGATGATGGCTCGTCTTTCAAAATCAACAACCTGAA 
                   ************************************************************ 
 
Gallo2178_exp      AAGCTTAGATGGGGTTACCAGCAGCACCAAAGTTGTGGTCGAGTATACTGCCACACTGAA 
Gallo2178_Seq      AAGCTTAGATGGGGTTACCAGCAGCACCAAAGTTGTGGTCGAGTATACTGCCACACTGAA 
                   ************************************************************ 
 
Gallo2178_exp      CTCTAATGCAGTAATTGGCCTGGAAGGGAACCCGAACACAGTGAAACTGATCTATTCCAA 
Gallo2178_Seq      CTCTAATGCAGTAATTGGCCTGGAAGGGAACCCGAACACAGTGAAACTGATCTATTCCAA 
                   ************************************************************ 
 
Gallo2178_exp      CAACCCGAATTATACAGGTTCCGGCGAAACGTCGCCAACAGGCGAAACACCGGAGGACAA 
Gallo2178_Seq      CAACCCGAATTATACAGGTTCCGGCGAAACGTCGCCAACAGGCGAAACACCGGAGGACAA 
                   ************************************************************ 
 
Gallo2178_exp      AGTCATCGTGTTCACCTACAAAGTAGTGGTAAACAAAGTGGATCAATCCGGCAATGCGCT 
Gallo2178_Seq      AGTCATCGTGTTCACCTACAAAGTAGTGGTAAACAAAGTGGATCAATCCGGCAATGCGCT 
                   ************************************************************ 
 
Gallo2178_exp      TGCAGGAGCCGGTTTTACGCTGTACAAGAAAGATTCCTCTGGCAATTGGAACGCGGTTAG 
Gallo2178_Seq      TGCAGGAGCCGGTTTTACGCTGTACAAGAAAGATTCCTCTGGCAATTGGAACGCGGTTAG 
                   ************************************************************ 
 
Gallo2178_exp      CGACGAAATTACTGGTGTCACCACCTTTACCTTTTCCGGCCTGGATGATGGAGATTACAA 
Gallo2178_Seq      CGACGAAATTACTGGTGTCACCACCTTTACCTTTTCCGGCCTGGATGATGGAGATTACAA 
                   ************************************************************ 
 
Gallo2178_exp      GCTGTCTGAAACCACTACCCCGAATGGGTATAATACCATTGACGATATCACCTTTACGGT 
Gallo2178_Seq      GCTGTCTGAAACCACTACCCCGAATGGGTATAATACCATTGACGATATCACCTTTACGGT 
                   ************************************************************ 
 
Gallo2178_exp      CACTGCGGATCACGACGTGAAAAGCGATTCACCGGCGCTGAATAGCCTGAGCGGTGACGT 
Gallo2178_Seq      CACTGCGGATCACGACGTGAAAAGCGATTCACCGGCGCTGAATAGCCTGAGCGGTGACGT 
                   ************************************************************ 
 
Gallo2178_exp      GACCACCGGTAGCCTGACGTTTGCGTCGAACATCACGGAAGATGACGCATCGCTCACTAC 
Gallo2178_Seq      GACCACCGGTAGCCTGACGTTTGCGTCGAACATCACGGAAGATGACGCATCGCTCACTAC 
                   ************************************************************ 
 
Gallo2178_exp      GAACGTTGTCAACAAGAAGGGTGCTACTCTGCCTTCAACAGTCGACAAACCTCCCACACC 
Gallo2178_Seq      GAACGTTGTCAACAAGAAGGGTGCTACTCTGCCTTCAACAGTCGACAAACCTCCCACACC 
                   ************************************************************ 
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Gallo2178_exp      TCCCCCTGAACCTGAAACATAAGCGGCCGCATC 
Gallo2178_Seq      TCCCCCT-------------------------- 
                   *******                           
 
Gallo2179 (sequencing of miniPrep DNA via primer pGEXfor and pGEXrev) 
Gallo2179_exp      ATAGCATGGCCTTTGCAGGGCTGGCAAGCCACGTTTGGTGGTGGCGACCATCCTCCAAAA 
Gallo2179_Seq      ---------------------------------------------------TCCTCCAAA 
                                                                       *  * *** 
 
Gallo2179_exp      TCGGATCTGGTTCCGCGTGGATCCGCCGATGTATCTAACCGGGTAACCTCACTTACAGTG 
Gallo2179_Seq      TCGGATCTGGTTCCGCGTGGATCCGCCGATGTATCTAACCGGGTAACCTCACTTACAGTG 
                   ************************************************************ 
 
Gallo2179_exp      GCCACAACGGAACTCCAAGACGGTGGTCGTACCACTGTACGTGTCGAGTTTAACGATCGT 
Gallo2179_Seq      GCCACAACGGAACTCCAAGACGGTGGTCGTACCACTGTACGTGTCGAGTTTAACGATCGT 
                   ************************************************************ 
 
Gallo2179_exp      GCAGGCAAAATTCATAGCGGCGATACGATCGAAGTCACCTGGAGTATCTCAAACAGCATT 
Gallo2179_Seq      GCAGGCAAAATTCATAGCGGCGATACGATCGAAGTCACCTGGAGTATCTCAAACAGCATT 
                   ************************************************************ 
 
Gallo2179_exp      TATCTGAACGGTTACACAAAATCGATTCCTCTGACCATCCAGGGTGTGAACGTTGGGACG 
Gallo2179_Seq      TATCTGAACGGTTACACAAAATCGATTCCTCTGACCATCCAGGGTGTGAACGTTGGGACG 
                   ************************************************************ 
 
Gallo2179_exp      TTAGAAGTCACCGAACATAACGCGATCTTCAAATTCAACTCCAATATTGAAACGATGGAA 
Gallo2179_Seq      TTAGAAGTCACCGAACATAACGCGATCTTCAAATTCAACTCCAATATTGAAACGATGGAA 
                   ************************************************************ 
 
Gallo2179_exp      AATGTTTCTGGCTGGGGTGAGTTTGAAGTAATTGGCCGCAATGTGACGAATACTAGCAGC 
Gallo2179_Seq      AATGTTTCTGGCTGGGGTGAGTTTGAAGTAATTGGCCGCAATGTGACGAATACTAGCAGC 
                   ************************************************************ 
 
Gallo2179_exp      GAGAATACGGGAACCGCCGTGGTGCAAGTGGGCGGCTACTCTCAGAACATCTCAATCACT 
Gallo2179_Seq      GAGAATACGGGAACCGCCGTGGTGCAAGTGGGCGGCTACTCTCAGAACATCTCAATCACT 
                   ************************************************************ 
 
Gallo2179_exp      AAACCCCAAAGTGGGACGGGCACCTCAAGCTTCTACTATAAAACTGGGGATATTCAGCCG 
Gallo2179_Seq      AA---------------------------------------------------------- 
                   **                                                           
 
Gallo2179_exp      TCAGATACCAATCGGGTTCGCTGGTTTCTGTTGGTGAATAATAACAAAGAGTATGTCGAA 
Gallo2179_Seq      ------------------------------------------------------------ 
                                                                                
 
Gallo2179_exp      AGTGATGTGACGATCGAAGATGACATCCAAAGCGGGCAAACCCTGGATATGTCCTCGTTC 
Gallo2179_Seq      ------------------------------------------------------------ 
                                                                                
 
Gallo2179_exp      GATATCACCATTTCAGGGTATCAGAACAAGCGCTTTGTTGGCGAATCTGCACTCGAGGAA 
Gallo2179_Seq      ------------------------------------------------------------ 
                                                                                
 
Gallo2179_exp      TTCAAACGTTCGTGCCCAAATTCTAGCATCGAAATTACGCAGAAGAGCGAAGGTGGTCAC 
Gallo2179_Seq      ------------------------------------------------------------ 
                                                                                
 
Gallo2179_exp      ATCTCCATTCGCCTGAGCCGCGACGATGTCATCTTGAACACCATTTCGATCCACTACAAA 
Gallo2179_Seq      ------------------------------------------------------------ 
                                                                                
 
Gallo2179_exp      ACGAAAATTCTGGACTTTGATCAGGAGAAATTTGCGAATAATAGTAATATTACCTACAAA 
Gallo2179_Seq      ------------------------------------------------------------ 
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Gallo2179_exp      CCCTTGTATAAAGACTGGGTAACTAACAAAGAAAGCAACTATGAAGTGGTCAATGTTAAC 
Gallo2179_Seq      ------------------------------------------------------------ 
                                                                                
 
Gallo2179_exp      GCTAACGGTGGCGTCGATGGTTCCCGCTATACGTCGGTTACAGTTAACAAGGTGTGGAAT 
Gallo2179_Seq      ------------------------------------------------------------ 
                                                                                
 
Gallo2179_exp      GATAAAGACAACCAAGATGGCAAACGCTCTGACAAAGTGGTGATTCAGCTTTTGGCGGAT 
Gallo2179_Seq      ------------------------------------------------------------ 
                                                                                
 
Gallo2179_exp      GGTCAGGAGATCAGCGGTAAACAGCTTGAGCTGAGCGAAGAAAACGGTTGGAGTGGTACC 
Gallo2179_Seq      ------------------------------------------------------------ 
                                                                                
 
Gallo2179_exp      TTTGAGAAGCTGAACAAATATCACTCGGATAATACGCTGATTACCTATACTGTGAAAGAA 
Gallo2179_Seq      ------------------------------------------------------------ 
                                                                                
 
Gallo2179_exp      GTCACTGATTTACCGGACTATCAGACGACCGTTTCTGAAAACTCGAAGAACAACTACACC 
Gallo2179_Seq      ------------------------------------------------------------ 
                                                                                
 
Gallo2179_exp      ATTACCAATACCCACATTCCTGAAGTGATTGACCTCTCGGGCAAGAAAATCTGGGATGAC 
Gallo2179_Seq      ------------------------------------------------------------ 
                                                                                
 
Gallo2179_exp      AATAATAATCAAGATGGAATTCGCCCAGAAACCATTACCGTTCATCTGTTAGCTAACGGC 
Gallo2179_Seq      ------------------------------------------------------------ 
                                                                                
 
Gallo2179_exp      GTTGATACCGGACAGGTGAAAACGGTGTCCAAAAGCGACAACTGGGAATACCAGTTTAAA 
Gallo2179_Seq      ------------------------------------------------------------ 
                                                                                
 
Gallo2179_exp      GATCTGCCGAAGTATCAGAATGGCGAAAAGGTTGTGTACACCGTAAGTGAAGATGTTGTA 
Gallo2179_Seq      ------------------------------------------------------------ 
                                                                                
 
Gallo2179_exp      GTGGGGTATGAGATGAGTGTGTCTGGCATGAACCTGACTAATACCCATACACCAGAAGTC 
Gallo2179_Seq      -----------------------TGGCATGAACCTGACTAATACCCATACACCAGAAGTC 
                                          ************************************* 
 
Gallo2179_exp      ACGAATATCCTGATTAGCAAATATTGGGATGACAACGACGACAAGCTGAAGAAACGTCCG 
Gallo2179_Seq      ACGAATATCCTGATTAGCAAATATTGGGATGACAACGACGACAAGCTGAAGAAACGTCCG 
                   ************************************************************ 
 
Gallo2179_exp      GAAAGCATTCAAATCACGCTGCATGCCAACGGAAAAGAGTACCAGACTGTAACCTTAACT 
Gallo2179_Seq      GAAAGCATTCAAATCACGCTGCATGCCAACGGAAAAGAGTACCAGACTGTAACCTTAACT 
                   ************************************************************ 
 
Gallo2179_exp      GCATCCAATCAGTGGCAATATGAGTTCAAAGACCTCCCGAAATACAAAGATGGTGAGAAA 
Gallo2179_Seq      GCATCCAATCAGTGGCAATATGAGTTCAAAGACCTCCCGAAATACAAAGATGGTGAGAAA 
                   ************************************************************ 
 
Gallo2179_exp      ATCGCGTACACAGTCACAGAAGCGGATGTTCCGAACTATCAGCTGATTTCCATTGAAGAA 
Gallo2179_Seq      ATCGCGTACACAGTCACAGAAGCGGATGTTCCGAACTATCAGCTGATTTCCATTGAAGAA 
                   ************************************************************ 
 
Gallo2179_exp      GATGAGTCCGGCAACTGGAAAATTACCAACAAAGTCGAAGAAAGTTACCTGTTTCCGAAT 
Gallo2179_Seq      GATGAGTCCGGCAACTGGAAAATTACCAACAAAGTCGAAGAAAGTTACCTGTTTCCGAAT 
                   ************************************************************ 
 
Gallo2179_exp      ACCGGCGTCGACAAACCTCCCACACCTCCCCCTGAACCTGAAACATAAGCGGCCGCATCG 
Gallo2179_Seq      ACCGGCGTCGACAAACCTCCCACACCTCCCCCTGAACCTGAAACATAAGCGGCCGCATCG 
                   ************************************************************ 
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Gallo2179_exp      TGACTGACTGACGATCTGCCTCGCGCGTTTCGGTGATGACGGTGAAAACCTCTGACACAT 
Gallo2179_Seq      TGACTGACTGACGATCTGCCTCG------------------------------------- 
                   ***********************                                      
 
Gallo2179_exp      GCAGCTC 
Gallo2179_Seq      ------- 
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III. Alignment of S. gallolyticus proteins Gallo0577, Gallo1570 and Gallo2179  
Gallo2179      --------------ADVSNRVTSLTVATTELQDGGRTTVRVEFNDRA------------- 
Gallo0577      ----------DTVDITVS----NTSLSTNAINGGTSTEFSFDFAVPNSAKSGDTTVISLP 
Gallo1570      KAEEDVYYTGYTSDISLNSSYINPDPGPYAIDEGGESKLAYCFNRNKSRPPA----KSEP 
                               :.    .   .   :: *  : .   *                  
 
Gallo2179      -------------------------------------------------GKIHSGDT--- 
Gallo0577      DELNFQRNQTFNVYASDGTTVVATAVIDTTTKTLTLTYTDYVDTHDDVTGHLSMNVVVDR 
Gallo1570      --------------------------EDGEAKYRKIADVDYVRLKENCSSDMEGRELYDA 
                                                                ..:         
 
Gallo2179      --IEVTWSISNSIYLNGYTKSIPLTIQGVNV----------------------------- 
Gallo0577      TVVTEATTVPATVTINGTTTI-TISSGGINYTVSTGDSDDIDFWKYGVSYSDDEVMYLIN 
Gallo1570      IM---------KVIYNGYP----------------------------------------- 
                          .:  **                                            
 
Gallo2179      -GTLEVTEHNAIFKFNSNIETMENVSGWGEFEVIGRNVTNTSSENTGTAVVQVGGYSQNI 
Gallo0577      VNTSAATVSNVVISDTINSTGLEYVD--GSFEIFEGTWYK----NA-QNYWALGGSTNVT 
Gallo1570      -------------------NNCSGIN--GKYRLKDGDFCA----ITQWAIWHFTDGADSD 
                                     . :.  *.:.:            :      . . ::   
 
Gallo2179      SI-TKPQSGTGTSSFYYKTGDIQPS-----DTNRVR--------WFLLVNN-----NKEY 
Gallo0577      SNYNIELSA-DNTSFSINLGTISKGYMI-------RYRVKANYTL---INGEQLSNSATY 
Gallo1570      GTGNLPYYG-KESMW--NRSDVKEAYLELIDVANLSYPADAKLNLYIYDHGAEHDR-QNL 
               .  .    .   : :  : . :. .                        :.          
 
Gallo2179      VESDVTIEDDIQSGQTLDMSSFDITISGYQNKRFVGESALEEFKRSCPNSSIEITQ---- 
Gallo0577      YSENTALNNA-DN--TFTYQGASGTASGYNYSLTV-QK-VNEAGEALAGAEFTVTRE--- 
Gallo1570      LTTDVGYTNL-SV--EKVWN-DSDDQDGIRPAFID-VQ-LLANGVEVEGQKIELSKFLNS 
                  :.   :  .       .  .   .* .       . :        . .: :::     
 
Gallo2179      KSEGGHISIRLSRDDVILNTISIHYKTKILDFDQEKFANNSNITYKPLYKDWVTNKESNY 
Gallo0577      -STGQVVGTITTGSDG----TAT-------------ISG----LLKDNYIITETKAPTGY 
Gallo1570      NWQGVFRGLSLYDSDG----NPIEYSVKEVE----KYRG----Q-LDGYQSTVTKSDSGY 
                  *   .     .*                       .         *    *:  :.* 
 
Gallo2179      EVVNVNA-------NGGVDGSRYTSVTVNKVWNDKDNQDGKRSDKVVIQLLADGQEISGK 
Gallo0577      AIADPVTAEADNSTVTVTDKKATVEVTGTKTWDDNNDQDGKRPDSITVNLLANGTVVDTK 
Gallo1570      S-----------YTITNTHVPETTEISGTKTWDDKDDQDGKRPSSITVKLLADDEEIDSQ 
                                ..    ..:: .*.*:*:::***** ..:.::***:.  :. : 
 
Gallo2179      QLELSEENGWSGTFEKLNKYHSDNTLITYTVKEVTDLPDYQTTVSENSKNNYTITNTHIP 
Gallo0577      T--VTADDNWTYAFSDLDQYDADGNEIAYTVSEEM-VDGYTTV-----VDGYNITNTHAS 
Gallo1570      E--VTADTDWKYSFKDLPKYKNEGVEINYSVAEES-VSDYETT-----ISGTDITNTHVP 
                  :: : .*. :*..* :*. :.  * *:* *   : .* *.      ..  *****   
 
Gallo2179      EVIDLSGKKIWDDNNNQDGIRPETITVHLLANGVDTGQVKTVSKSDNWEYQFKDLPKYQN 
Gallo0577      ETTEVSGTKTWDDNDDQDGKRPDSITVNLLANGTVVD-TKTVTADDNWSYSFTDLPKYDN 
Gallo1570      ETTEISGTKTWDDNDDQDGKRPTAITVNLLADGVKVD-SKKVTAADDWKYEFKDLPKYKA 
               *. ::**.* ****::*** ** :***:***:*. ..  *.*:  *:*.*.*.*****.  
 
Gallo2179      GEKVVYTVSEDVVVGYEMSVSGMNLTNTHTPEVTNILISKYWDDNDDKLKKRPESIQITL 
Gallo0577      GNEITYTVTEDTVADYTTTYDGYNITNSYTPGETSITVTKVWDDNNDQDGIRPDAIQVQL 
Gallo1570      GQEIKYSVTEEAVKDYETKVSGTDITNIHTPETTDITVTKIWDDRNDKEKKRPDSIKVTL 
               *::: *:*:*:.* .*  . .* ::** :**  *.* ::* ***.:*:   **::*:: * 
 
Gallo2179      HANGKE-YQTVTLTASNQWQYEFKDLPKYKDGEKIAYTVTEADVPNYQLISIEEDESGNW 
Gallo0577      YANGEKSGDVITLTVADNWTYTWTGLAEKANKKTITYTVEEVSAVDGYTATVGEVENGNV 
Gallo1570      KANDKD-LQTVTITAEDDWKYEFKDLPKYENGKQIKYSVTEE-EVTGYTTTIEEDESGNF 
                **.:.  :.:*:*. ::* * :..* :  : : * *:* *         :: * *.**  
 
Gallo2179      KITNKVEESYLFPNTG------------------------- 
Gallo0577      TITNTHTPTTPETPSSDEPTTPSQSNKKSDKEQDKNIIAAL 
Gallo1570      EITNKIPRDYLF----------------------------- 
                ***.                                     
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IV. Alignment of F. nucleatum proteins Fn0387, Fn1449 and Fn1893 
Fn0387      SKDSNKIKAFGARGEYKTNTAGVIDYKNYAYGVAYIHENESVKLGKDIGWYTGFVHNTFR 
Fn1449      SKDSNKVKTFGMKGEYKTDTAGVIDYKYNAYGVAYVHENEDIKLGKGTGWYTGIVHNTFK 
Fn1893      SKDSNKIKIFGIKGEYKTDTAGVIDYKNEAYGMAYVHENEDIKLGKGIGWYTGIVDNTFK 
            ******:* ** :*****:********  ***:**:****.:****. *****:*.***: 
 
Fn0387      FEDIGKSKEEMLLGKIGMFKSIPFDDDNSLNWTVSGNVFVGRNKMHRKFLIVDEIFNAKS 
Fn1449      FKDIGNSKEKQLQAKVGLFKSVPFDENNSLNWTISGDIFIGHNKLERKFLVVDEIFHAKS 
Fn1893      FKDIGKSKEEQIQAKVGLLKSIPFDDNNSLNWTISGDIFVGYNKMHRKYLVVNEIFNAKS 
            *:***:***: : .*:*::**:***::******:**::*:* **:.**:*:*:***:*** 
 
Fn0387      KYYAYGIGVKNEIGKEFRLSEDFSIRPYGALKLEYGRISKIKEKTGEIRLEVKSNDYVSI 
Fn1449      KYYTYGIGIKNEIGKEFRLSEDFSIRPYGALKVEYGRVSKIKEKSGEMKLEVKENDYLSI 
Fn1893      KYYTYGIGIKNKISKDFRLSEDFSLVPYGSLNLEYGRVNKIKEKVGEIRLEVKENYYVSV 
            ***:****:**:*.*:********: ***:*::****:.***** **::****.* *:*: 
 
Fn0387      KPEIGTELKYKYLFTNRKTLTVGLGVAYENELGKVANPKNKARVAYTAADWYNLRGEKED 
Fn1449      RPEIGTELAYRHYFGT-KTLRTSVGVAYENELGRVANGKNKARVAGTTADWFNIRGEKED 
Fn1893      NPEIGAELTYKHLLASRKTFRMGLGIAYENELGKVANGKNKARVAYTNADWFNIRGEKED 
            .****:** *:: : . **:  .:*:*******:*** ******* * ***:*:****** 
 
Fn0387      RRGNIKTDLTIGLENTRFGATANVGYDTKGHNV 
Fn1449      RKGNVKVDLNVGIDNQRLGVTGNVGYDTKGHNV 
Fn1893      RKGNIKFDLNIGLDNQRVGVTANAGYDTKGHNV 
            *:**:* **.:*::* *.*.*.*.********* 
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V. Different models for estimating the association of antibody responses to F. nucleatum with CRC in BliTz/DACHSplus, 
SCCS and EPIC 
Supplementary table 1: Antibody responses to F. nucleatum proteins in relation to prevalence of CRC in the DACHSplus study compared 
to BliTz controls 
 Positive n (%) Unadjusted model
1
 Adjusted model 1
2
 Adjusted model 2
3
 
 Controls Cases        
 n=228 n=318 OR 95% CI p-value OR 95% CI p-value OR 95% CI p-value 
Fn0131 22 (10) 36 (11) 1.20 0.68-2.09 0.532 1.14 0.64-2.04 0.658 1.23 0.67-2.26 0.504 
Fn0253 22 (10) 33 (10) 1.08 0.61-1.91 0.782 0.85 0.47-1.54 0.592 0.90 0.49-1.64 0.723 
Fn0264 22 (10) 32 (10) 1.05 0.59-1.86 0.874 0.95 0.53-1.73 0.873 0.90 0.49-1.64 0.719 
Fn0387 22 (10) 31 (10) 1.01 0.57-1.80 0.969 0.95 0.52-1.74 0.878 0.91 0.50-1.68 0.770 
Fn1426 22 (10) 25 (8) 0.80 0.44-1.46 0.463 0.70 0.37-1.31 0.262 0.73 0.38-1.40 0.345 
Fn1449 22 (10) 27 (8) 0.87 0.48-1.57 0.641 0.82 0.45-1.53 0.539 0.77 0.41-1.43 0.404 
Fn1526 19 (8) 35 (11) 1.36 0.76-2.45 0.304 1.28 0.70-2.36 0.420 1.43 0.76-2.70 0.271 
Fn1817_1 22 (10) 26 (8) 0.83 0.46-1.51 0.549 0.86 0.46-1.61 0.643 0.94 0.50-1.77 0.845 
Fn1817_2 22 (10) 25 (8) 0.80 0.44-1.46 0.463 0.69 0.37-1.29 0.240 0.76 0.40-1.44 0.394 
Fn1859 22 (10) 21 (7) 0.66 0.36-1.24 0.196 0.58 0.30-1.11 0.100 0.53 0.27-1.04 0.064 
Fn1893 22 (10) 31 (10) 1.01 0.57-1.80 0.969 0.94 0.52-1.72 0.844 0.92 0.49-1.71 0.785 
Any F. nucleatum protein 129 (57) 175 (55) 0.94 0.67-1.32 0.720 0.81 0.56-1.16 0.254 0.86 0.59-1.25 0.436 
1
Logistic regression model without further adjustment; 
2
Logistic regression model with adjustment for age (continuous variable) and sex; 
3
Logistic 
regression model with adjustment for age (continuous variable), sex, BMI, education and smoking with exclusion of samples with missing baseline 
information in any of these variables (n(controls)=218, n(CRC)=303); Significant associations are marked in bold font
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Supplementary table 2: Antibody responses to F. nculeatum proteins in relation to CRC risk in a nested case-control study within SCCS 
 Positive n (%) Unadjusted model
1
 Adjusted model 1
2
 Adjusted model 2
3
 
 Controls Cases        
 n=348 n=181 OR 95% CI p-value OR 95% CI p-value OR 95% CI p-value 
Fn0131 34 (10) 15 (8) 0.82 0.42-1.58 0.551 0.89 0.45-1.77 0.741 0.86 0.44-1.70 0.664 
Fn0253 34 (10) 15 (8) 0.81 0.42-1.55 0.520 0.89 0.45-1.78 0.743 0.92 0.47-1.82 0.819 
Fn0264 34 (10) 18 (10) 1.05 0.57-1.92 0.877 0.86 0.45-1.62 0.636 0.92 0.49-1.71 0.788 
Fn0387 34 (10) 17 (9) 0.97 0.53-1.77 0.919 1.04 0.55-1.95 0.913 1.06 0.56-1.98 0.864 
Fn1426 34 (10) 30 (17) 1.92 1.11-3.31 0.019 1.85 1.04-3.28 0.037 1.85 1.04-3.29 0.035 
Fn1449 34 (10) 12 (7) 0.67 0.34-1.31 0.240 0.69 0.34-1.43 0.323 0.77 0.38-1.55 0.457 
Fn1526 34 (10) 15 (8) 0.80 0.41-1.56 0.510 0.80 0.40-1.61 0.534 0.82 0.41-1.64 0.579 
Fn1817_1 34 (10) 19 (11) 1.09 0.61-1.96 0.763 1.21 0.65-2.24 0.554 1.13 0.61-2.08 0.700 
Fn1817_2 34 (10) 16 (9) 0.91 0.48-1.75 0.785 1.06 0.54-2.05 0.872 1.02 0.53-1.97 0.951 
Fn1859 34 (10) 12 (7) 0.64 0.32-1.28 0.209 0.65 0.32-1.32 0.234 0.65 0.32-1.31 0.227 
Fn1893 34 (10) 19 (11) 1.11 0.62-2.01 0.721 1.19 0.64-2.20 0.586 1.21 0.66-2.23 0.545 
Any F. nucleatum protein 205 (59) 99 (55) 0.85 0.59-1.21 0.358 0.85 0.57-1.25 0.398 0.87 0.59-1.27 0.460 
1
Conditional logistic regression model; 
2
Conditional logistic regression model with adjustment for BMI, education and smoking status as categorical 
variables, missings in the variables are excluded from the analyses; 
3
Conditional logistic regression model with adjustment for BMI, education and 
smoking status as categorical variables, missings in the variables are considered as individual category; Significant associations are marked in bold 
font
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Supplementary table 3: Antibody responses to F. nucleatum proteins in relation to CRC risk in a nested case-control study within SCCS in 
cases diagnosed after more than two years from blood draw 
 Positive n (%) Unadjusted model
1
 Adjusted model 1
2
 Adjusted model 2
3
 
 Controls Cases        
 n=239 n=124 OR 95% CI p-value OR 95% CI p-value OR 95% CI p-value 
Fn0131 18 (8) 12 (10) 1.31 0.60-2.85 0.499 1.40 0.61-3.21 0.426 1.39 0.61-3.17 0.431 
Fn0253 24 (10) 11 (9) 0.84 0.39-1.81 0.658 0.85 0.37-1.95 0.699 0.88 0.39-1.99 0.758 
Fn0264 26 (11) 8 (6) 0.58 0.25-1.31 0.188 0.56 0.24-1.30 0.177 0.56 0.24-1.30 0.177 
Fn0387 25 (10) 14 (11) 1.08 0.55-2.13 0.817 1.11 0.53-2.30 0.787 1.12 0.55-2.30 0.756 
Fn1426 27 (11) 22 (18) 1.76 0.94-3.28 0.076 1.70 0.88-3.29 0.114 1.71 0.89-3.30 0.109 
Fn1449 27 (11) 11 (9) 0.77 0.37-1.59 0.476 0.73 0.33-1.63 0.446 0.83 0.39-1.80 0.641 
Fn1526 24 (10) 11 (9) 0.83 0.37-1.84 0.641 0.80 0.34-1.89 0.616 0.84 0.36-1.94 0.681 
Fn1817_1 27 (11) 11 (9) 0.78 0.37-1.64 0.507 0.82 0.37-1.82 0.626 0.74 0.34-1.64 0.463 
Fn1817_2 21 (9) 7 (6) 0.62 0.24-1.56 0.306 0.68 0.26-1.76 0.424 0.67 0.26-1.73 0.410 
Fn1859 21 (9) 10 (8) 0.92 0.40-2.08 0.836 0.88 0.37-2.08 0.776 0.91 0.39-2.13 0.830 
Fn1893 24 (10) 16 (13) 1.35 0.69-2.65 0.379 1.27 0.62-2.59 0.517 1.29 0.64-2.63 0.475 
Any F. nucleatum protein 139 (58) 68 (55) 0.88 0.57-1.36 0.550 0.94 0.58-1.53 0.816 0.96 0.60-1.54 0.868 
1
Conditional logistic regression model; 
2
Conditional logistic regression model with adjustment for BMI, education, smoking and alcohol status as 
categorical variables, missings in the variables are excluded from the analyses; 
3
Conditional logistic regression model with adjustment for BMI, 
education, smoking and alcohol status as categorical variables, missings in the variables are considered as individual category; Significant 
associations are marked in bold font
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Supplementary table 4: Antibody responses to F. nculeatum proteins in relation to CRC risk in a nested case-control study within EPIC 
 Positive n (%) Unadjusted model
1
 Adjusted model 1
2
 Adjusted model 2
3
 
 Controls Cases        
 n=485 n=485 OR 95% CI p-value OR 95% CI p-value OR 95% CI p-value 
Fn0131 46 (9) 31 (6) 0.66 0.41-1.05 0.081 0.65 0.39-1.10 0.107 0.59 0.36-0.95 0.030 
Fn0253 15 (3) 10 (2) 0.67 0.30-2.48 0.321 0.58 0.24-1.43 0.240 0.69 0.30-1.60 0.391 
Fn0264 24 (5) 32 (7) 1.36 0.79-2.36 0.269 0.97 0.51-1.84 0.928 1.37 0.78-2.43 0.276 
Fn0387 38 (8) 42 (9) 1.11 0.71-1.76 0.642 1.16 0.70-1.91 0.562 1.05 0.66-1.69 0.828 
Fn1426 49 (10) 53 (11) 1.10 0.72-1.65 0.673 0.90 0.56-1.43 0.651 1.04 0.68-1.61 0.844 
Fn1449 47 (10) 41 (8) 0.86 0.55-1.34 0.503 0.86 0.53-1.40 0.547 0.83 0.52-1.30 0.414 
Fn1526 20 (4) 15 (3) 0.74 0.37-1.47 0.386 0.72 0.34-1.52 0.395 0.71 0.35-1.44 0.337 
Fn1817_1 49 (10) 40 (8) 0.80 0.51-1.24 0.312 0.87 0.54-1.40 0.565 0.77 0.49-1.23 0.276 
Fn1817_2 48 (10) 46 (9) 0.96 0.64-1.44 0.835 0.92 0.58-1.44 0.705 0.96 0.63-1.47 0.864 
Fn1859 46 (9) 34 (7) 0.71 0.45-1.14 0.159 0.56 0.34-0.94 0.029 0.69 0.43-1.12 0.134 
Fn1893 47 (10) 45 (9) 0.95 0.62-1.47 0.825 1.01 0.63-1.63 0.966 0.91 0.58-1.43 0.692 
Any F. nucleatum protein 255 (53) 230 (47) 0.81 0.62-1.04 0.101 0.73 0.54-0.99 0.040 0.79 0.60-1.04 0.087 
1
Conditional logistic regression model; 
2
Conditional logistic regression model with adjustment for BMI, education, smoking and alcohol status as 
categorical variables, missings in the variables are excluded from the analyses; 
3
Conditional logistic regression model with adjustment for BMI, 
education, smoking and alcohol status as categorical variables, missings in the variables are considered as individual category; Significant 
associations are marked in bold font
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Supplementary table 5: Antibody responses to F. nucleatum proteins in relation to CRC risk in a nested case-control study within EPIC in 
cases diagnosed after more than two years from blood draw 
 Positive n (%) Unadjusted model
1
 Adjusted model 1
2
 Adjusted model 2
3
 
 Controls Cases        
 n=355 n=355 OR 95% CI p-value OR 95% CI p-value OR 95% CI p-value 
Fn0131 33 (9) 21 (6) 0.61 0.35-1.09 0.093 0.67 0.36-1.27 0.222 0.60 0.33-1.08 0.086 
Fn0253 12 (3) 8 (2) 0.67 0.27-1.63 0.374 0.57 0.21-1.59 0.283 0.71 0.28-1.80 0.468 
Fn0264 19 (5) 25 (7) 1.33 0.72-2.46 0.356 1.08 0.54-2.19 0.826 1.42 0.75-2.68 0.279 
Fn0387 28 (8) 25 (7) 0.89 0.51-1.55 0.668 0.91 0.49-1.68 0.752 0.86 0.48-1.53 0.596 
Fn1426 34 (10) 42 (12) 1.28 0.79-2.07 0.326 1.09 0.63-1.89 0.764 1.27 0.76-2.11 0.359 
Fn1449 35 (10) 25 (7) 0.70 0.41-1.19 0.184 0.66 0.36-1.20 0.171 0.68 0.39-1.19 0.174 
Fn1526 16 (5) 11 (3) 0.67 0.30-1.48 0.321 0.66 0.28-1.55 0.337 0.69 0.30-1.56 0.370 
Fn1817_1 32 (9) 29 (8) 0.89 0.51-1.54 0.675 1.03 0.57-1.87 0.914 0.88 0.50-1.54 0.642 
Fn1817_2 34 (10) 34 (10) 1.00 0.62-1.61 1.000 0.95 0.56-1.62 0.843 1.01 0.62-1.66 0.966 
Fn1859 38 (11) 27 (8) 0.69 0.41-1.15 0.155 0.57 0.32-1.01 0.053 0.67 0.40-1.15 0.147 
Fn1893 36 (10) 30 (8) 0.82 0.49-1.36 0.439 0.86 0.49-1.52 0.608 0.79 0.47-1.34 0.386 
Any F. nucleatum protein 184 (52) 173 (49) 0.88 0.65-1.19 0.395 0.80 0.56-1.13 0.197 0.88 0.64-1.21 0.426 
1
Conditional logistic regression model; 
2
Conditional logistic regression model with adjustment for BMI, education, smoking and alcohol status as 
categorical variables, missings in the variables are excluded from the analyses; 
3
Conditional logistic regression model with adjustment for BMI, 
education, smoking and alcohol status as categorical variables, missings in the variables are considered as individual category; Significant 
associations are marked in bold font
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VI. Different models for estimating the association of antibody responses to S. gallolyticus with CRC in BliTz/DACHSplus, 
SCCS and EPIC 
Supplementary table 6: Antibody responses to S. gallolyticus proteins and protein combinations in relation to prevalence of CRC in the 
DACHSplus study compared to BliTz controls 
 Positive n (%) Unadjusted model
1
 Adjusted model 1
2
 Adjusted model 2
3
 
 Controls Cases        
 n=228 n=318 OR 95% CI p-value OR 95% CI p-value OR 95% CI p-value 
Gallo0112A 22 (10) 31 (10) 1.01 0.57-1.80 0.969 0.89 0.49-1.63 0.714 0.89 0.48-1.64 0.702 
Gallo0112B 22 (10) 28 (9) 0.90 0.50-1.63 0.736 0.82 0.45-1.51 0.531 0.84 0.45-1.56 0.583 
Gallo0272 22 (10) 39 (12) 1.31 0.75-2.28 0.340 1.14 0.64-2.02 0.658 1.13 0.63-2.04 0.686 
Gallo0577 22 (10) 32 (10) 1.05 0.59-1.86 0.874 1.03 0.57-1.88 0.915 1.18 0.64-2.18 0.602 
Gallo0748 22 (10) 37 (12) 1.23 0.71-2.15 0.462 1.18 0.66-2.11 0.569 1.32 0.72-2.41 0.373 
Gallo0933 22 (10) 40 (13) 1.35 0.78-2.34 0.289 1.59 0.89-2.85 0.117 1.56 0.86-2.84 0.148 
Gallo1570 22 (10) 16 (5) 0.50 0.25-0.97 0.040 0.45 0.22-0.91 0.027 0.51 0.25-1.06 0.069 
Gallo1675 22 (10) 33 (10) 1.08 0.61-1.91 0.782 0.96 0.54-1.74 0.904 1.12 0.60-2.10 0.725 
Gallo2018 22 (10) 38 (12) 1.27 0.73-2.21 0.398 1.17 0.65-2.08 0.602 1.23 0.68-2.23 0.491 
Gallo2178 11 (5) 55 (17) 4.13 2.11-8.08 <0.0001 4.30 2.14-8.65 <0.0001 4.50 2.22-9.11 <0.0001 
Gallo2179 22 (10) 34 (11) 1.12 0.64-1.97 0.692 1.22 0.68-2.19 0.512 1.35 0.73-2.51 0.342 
Any S. gallolyticus protein 131 (57) 213 (67) 1.50 1.06-2.14 0.023 1.47 1.02-2.12 0.039 1.65 1.13-2.41 0.010 
Gallo2178-Gallo2179 DP 0 (0) 14 (4) - - 0.001 - - - - - - 
≥ 2 of 6-marker panel4 24 (11) 60 (19) 1.98 1.19-3.28 0.009 1.81 1.07-3.06 0.028 1.99 1.15-3.45 0.014 
1
Logistic regression model without further adjustment; 
2
Logistic regression model with adjustment for age (continuous variable) and sex; 
3
Logistic 
regression model with adjustment for age (continuous variable), sex, BMI, education and smoking with exclusion of samples with missing baseline 
information in any of these variables (n(controls) = 218, n(CRC) = 303); 
4
Gallo0272, Gallo0748, Gallo1675, Gallo2018, Gallo2178, Gallo2179; DP 
= double-positive; Significant associations are marked in bold font; Significant associations with Bonferroni-correction (p<0.0036) are underlined
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Supplementary table 7: Antibody responses to S. gallolyticus proteins and protein combinations in relation to CRC risk in a nested case-
control study within SCCS 
 Positive n (%) Unadjusted model
1
 Adjusted model 1
2
 Adjusted model 2
3
 
 Controls Cases        
 n=348 n=181 OR 95% CI p-value OR 95% CI p-value OR 95% CI p-value 
Gallo0112A 34 (10) 20 (11) 1.14 0.62-2.08 0.679 1.26 0.66-2.40 0.480 1.33 0.71-2.52 0.373 
Gallo0112B 34 (10) 21 (12) 1.20 0.67-2.14 0.547 1.32 0.72-2.44 0.372 1.25 0.68-2.29 0.473 
Gallo0272 34 (10) 19 (11) 1.08 0.60-1.95 0.799 0.95 0.51-1.80 0.881 1.04 0.56-1.95 0.895 
Gallo0577 34 (10) 26 (14) 1.50 0.88-2.56 0.135 1.25 0.72-2.18 0.437 1.33 0.77-2.31 0.309 
Gallo0748 34 (10) 20 (11) 1.09 0.61-1.95 0.766 1.12 0.61-2.04 0.713 1.11 0.61-2.02 0.729 
Gallo0933 34 (10) 13 (7) 0.71 0.37-1.38 0.315 0.78 0.38-1.57 0.478 0.81 0.41-1.61 0.547 
Gallo1570 34 (10) 19 (11) 1.08 0.60-1.95 0.799 0.90 0.48-1.70 0.749 0.91 0.48-1.71 0.769 
Gallo1675 34 (10) 19 (11) 1.10 0.61-1.97 0.763 1.11 0.60-2.06 0.741 1.07 0.58-1.97 0.826 
Gallo2018 34 (10) 20 (11) 1.12 0.63-2.00 0.691 1.18 0.65-2.14 0.598 1.13 0.63-2.05 0.681 
Gallo2178 34 (10) 24 (13) 1.40 0.82-2.41 0.218 1.31 0.74-2.29 0.355 1.31 0.74-2.29 0.352 
Gallo2179 34 (10) 16 (9) 0.89 0.48-1.65 0.719 0.83 0.43-1.58 0.565 0.81 0.42-1.54 0.516 
Any S. gallolyticus protein 206 (59) 112 (62) 1.11 0.77-1.58 0.584 1.13 0.77-1.65 0.534 1.11 0.76-1.60 0.599 
Gallo2178-Gallo2179 DP 5 (1) 4 (2) 1.60 0.43-5.96 0.484 1.17 0.27-5.04 0.837 1.18 0.27-5.11 0.823 
≥ 2 of 6-marker panel4 41 (12) 25 (14) 1.19 0.70-2.04 0.517 1.11 0.63-1.95 0.716 1.12 0.64-1.97 0.692 
1
Conditional logistic regression model; 
2
Conditional logistic regression model with adjustment for BMI, education and smoking status as 
categorical variables, missings in the variables are excluded from the analyses; 
3
 Conditional logistic regression model with adjustment for BMI, 
education and smoking status as categorical variables, missings in the variables are considered as individual category; 
4
Gallo0272, Gallo0748, 
Gallo1675, Gallo2018, Gallo2178, Gallo2179; DP = double-positive; Significant associations are marked in bold font
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Supplementary table 8: Antibody responses to S. gallolyticus proteins and protein combinations in relation to CRC risk in a nested case-
control study within SCCS in cases diagnosed after more than two years from blood draw 
 Positive n (%) Unadjusted model
1
 Adjusted model 1
2
 Adjusted model 2
3
 
 Controls Cases        
 n=239 n=124 OR 95% CI p-value OR 95% CI p-value OR 95% CI p-value 
Gallo0112A 23 (9) 17 (14) 1.48 0.75-2.92 0.261 1.78 0.85-3.74 0.126 1.88 0.91-3.90 0.091 
Gallo0112B 24 (10) 13 (10) 1.02 0.49-2.12 0.951 1.14 0.52-2.49 0.744 1.03 0.48-2.23 0.935 
Gallo0272 23 (10) 13 (10) 1.12 0.54-2.32 0.755 0.91 0.41-2.03 0.825 1.08 0.49-2.35 0.854 
Gallo0577 22 (9) 18 (15) 1.59 0.82-3.06 0.169 1.24 0.62-2.47 0.544 1.38 0.70-2.72 0.358 
Gallo0748 27 (11) 12 (10) 0.79 0.38-1.62 0.516 0.78 0.37-1.66 0.515 0.77 0.36-1.64 0.498 
Gallo0933 22 (9) 6 (5) 0.51 0.20-1.29 0.153 0.48 0.17-1.36 0.164 0.56 0.21-1.49 0.245 
Gallo1570 22 (9) 10 (8) 0.87 0.41-1.84 0.709 0.78 0.35-1.73 0.536 0.79 0.35-1.74 0.552 
Gallo1675 24 (10) 13 (10) 1.04 0.52-2.09 0.905 0.92 0.44-1.92 0.817 0.92 0.44-1.91 0.823 
Gallo2018 23 (10) 13 (10) 1.07 0.53-2.16 0.857 1.09 0.52-2.29 0.811 1.09 0.52-2.27 0.819 
Gallo2178 23 (10) 16 (13) 1.38 0.72-2.64 0.332 1.36 0.69-2.68 0.381 1.35 0.69-2.66 0.386 
Gallo2179 21 (9) 13 (10) 1.17 0.57-2.40 0.664 1.01 0.47-2.17 0.974 1.03 0.48-2.20 0.943 
Any S. gallolyticus protein 142 (59) 74 (60) 1.00 0.65-1.53 1.000 0.97 0.61-1.53 0.886 1.00 0.64-1.56 0.985 
Gallo2178-Gallo2179 DP 4 (2) 4 (3) 2.00 0.50-8.00 0.327 1.48 0.32-6.81 0.614 1.50 0.33-6.88 0.604 
≥ 2 of 6-marker panel4 29 (12) 17 (14) 1.13 0.60-2.15 0.700 0.97 0.49-1.91 0.921 0.98 0.50-1.93 0.952 
1
Conditional logistic regression model; 
2
Conditional logistic regression model with adjustment for BMI, education and smoking status as categorical 
variables, missings in the variables are excluded from the analyses; 
3
 Conditional logistic regression model with adjustment for BMI, education and 
smoking status as categorical variables, missings in the variables are considered as individual category; 
4
Gallo0272, Gallo0748, Gallo1675, 
Gallo2018, Gallo2178, Gallo2179; DP = double-positive; Significant associations are marked in bold font
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Supplementary table 9: Antibody responses to S. gallolyticus proteins and protein combinations in relation to CRC risk in a nested case-
control study within EPIC 
 Positive n (%) Unadjusted model
1
 Adjusted model 1
2
 Adjusted model 2
3
 
 Controls Cases        
 n=485 n=485 OR 95% CI p-value OR 95% CI p-value OR 95% CI p-value 
Gallo0112A 33 (7) 37 (8) 1.14 0.69-1.90 0.606 1.26 0.71-2.24 0.426 1.08 0.63-1.82 0.788 
Gallo0112B 28 (6) 26 (5) 0.93 0.54-1.60 0.782 0.90 0.49-1.21 0.730 0.95 0.55-1.66 0.861 
Gallo0272 47 (10) 67 (14) 1.49 1.00-2.21 0.049 1.45 0.93-2.26 0.100 1.52 1.01-2.29 0.044 
Gallo0577 47 (10) 49 (10) 1.05 0.69-1.59 0.831 1.10 0.67-1.21 0.715 1.04 0.68-1.61 0.844 
Gallo0748 50 (10) 74 (15) 1.51 1.05-2.18 0.028 1.60 1.06-2.42 0.025 1.49 1.02-2.17 0.039 
Gallo0933 49 (10) 44 (9) 0.89 0.58-1.36 0.583 0.99 0.62-1.58 0.971 0.91 0.59-1.43 0.689 
Gallo1570 47 (10) 52 (11) 1.13 0.73-1.74 0.583 1.07 0.65-1.78 0.781 1.17 0.75-1.84 0.491 
Gallo1675 48 (10) 51 (11) 1.07 0.70-1.63 0.748 1.21 0.75-1.94 0.435 1.12 0.72-1.72 0.618 
Gallo2018 47 (10) 54 (11) 1.16 0.77-1.74 0.473 1.44 0.91-2.28 0.118 1.24 0.81-1.88 0.325 
Gallo2178 12 (2) 31 (6) 2.58 1.33-5.03 0.005 2.78 1.33-5.80 0.007 2.74 1.39-5.40 0.004 
Gallo2179 47 (10) 64 (13) 1.43 0.95-2.14 0.086 1.50 0.95-2.37 0.085 1.44 0.95-2.19 0.090 
Any S. gallolyticus protein 273 (56) 306 (63) 1.32 1.02-1.71 0.033 1.43 1.07-1.89 0.015 1.36 1.05-1.78 0.022 
Gallo2178-Gallo2179 DP 2 (0) 12 (2) 6.00 1.34-26.81 0.019 4.72 1.01-22.13 0.049 7.02 1.52-32.51 0.013 
≥ 2 of 6-marker panel4 45 (9) 83 (17) 2.03 1.37-3.01 0.0004 2.34 1.50-3.65 0.0002 2.10 1.40-3.14 0.0004 
1
Conditional logistic regression model; 
2
Conditional logistic regression model with adjustment for BMI, education, smoking and alcohol status as 
categorical variables, missings in the variables are excluded from the analyses; 
3
 Conditional logistic regression model with adjustment for BMI, 
education, smoking and alcohol status as categorical variables, missings in the variables are considered as individual category; 
4
Gallo0272, Gallo0748, 
Gallo1675, Gallo2018, Gallo2178, Gallo2179; DP = double-positive; Significant associations are marked in bold font; Significant associations with 
Bonferroni-correction (p<0.0036) are underlined
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Supplementary table 10: Antibody responses to S. gallolyticus proteins and protein combinations in relation to CRC risk in a nested case-
control study within EPIC in cases diagnosed after more than two years from blood draw. 
 Positive n (%) Unadjusted model
1
 adjusted model 1
2
 adjusted model 2
3
 
 Controls Cases        
 n=355 n=355 OR 95% CI p-value OR 95% CI p-value OR 95% CI p-value 
Gallo0112A 22 (6) 23 (6) 1.06 0.55-2.01 0.869 1.21 0.58-2.55 0.615 1.10 0.56-2.16 0.785 
Gallo0112B 15 (4) 16 (5) 1.07 0.53-2.16 0.858 1.02 0.48-2.15 0.963 1.17 0.57-2.42 0.668 
Gallo0272 32 (9) 51 (14) 1.68 1.05-2.68 0.030 1.72 1.01-2.91 0.045 1.74 1.07-2.82 0.026 
Gallo0577 34 (10) 36 (10) 1.06 0.66-1.72 0.806 1.21 0.69-2.12 0.499 1.10 0.67-1.81 0.713 
Gallo0748 37 (10) 51 (14) 1.40 0.91-2.16 0.128 1.50 0.92-2.44 0.103 1.38 0.89-2.15 0.151 
Gallo0933 37 (10) 38 (11) 1.03 0.63-1.68 0.901 1.10 0.65-1.85 0.729 1.08 0.65-1.78 0.772 
Gallo1570 36 (10) 41 (12) 1.17 0.72-1.90 0.536 1.18 0.66-2.10 0.581 1.25 0.75-2.07 0.391 
Gallo1675 38 (11) 39 (11) 1.03 0.64-1.65 0.904 1.23 0.72-2.10 0.443 1.06 0.65-1.72 0.813 
Gallo2018 38 (11) 43 (12) 1.14 0.73-1.78 0.569 1.34 0.81-2.23 0.255 1.19 0.75-1.89 0.466 
Gallo2178 7 (2) 17 (5) 2.43 1.01-5.86 0.048 2.93 1.04-8.30 0.043 2.64 1.07-6.51 0.035 
Gallo2179 34 (10) 44 (12) 1.33 0.83-2.14 0.234 1.46 0.85-2.51 0.171 1.46 0.89-2.39 0.132 
Any S. gallolyticus protein 201 (57) 224 (63) 1.30 0.96-1.74 0.087 1.41 1.01-1.95 0.041 1.37 1.01-1.86 0.043 
Gallo2178-Gallo2179 DP 1 (0) 7 (2) 7.00 0.86-56.89 0.069 4.45 0.48-41.55 0.191 9.92 1.03-77.45 0.047 
≥ 2 of 6-marker panel4 36 (10) 60 (17) 1.80 1.15-2.81 0.010 2.24 1.34-3.74 0.002 1.91 1.21-3.03 0.006 
1
Conditional logistic regression model; 
2
Conditional logistic regression model with adjustment for BMI, education, smoking and alcohol status as 
categorical variables, missings in the variables are excluded from the analyses; 
3
 Conditional logistic regression model with adjustment for BMI, 
education, smoking and alcohol status as categorical variables, missings in the variables are considered as individual category; 
4
Gallo0272, Gallo0748, 
Gallo1675, Gallo2018, Gallo2178, Gallo2179; DP = double-positive; Significant associations are marked in bold font; Significant associations with 
Bonferroni-correction (p<0.0036) are underlined
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VII. Abbreviations 
°C Degrees Celsius 
%CV Coefficient of variation 
amp ampicillin 
APC Adenomatous polyposis coli 
APS Ammoniumperoxodisulfate 
ASR Age-standardized incidence rate 
ATCC American type culture collection 
BliTz “Begleitende Evaluierung innovativer Testverfahren 
zur Darmkrebs-Früherkennung” 
BMI Body mass index 
bp Base pairs 
BSA Bovine serum albumin 
CagA Cytotoxin-associated antigen A 
CBS-K Superchemiblock 
CD3 Cluster of differentiation 3 
CHC Community health care centers 
CI Confidence interval 
CIMP CpG island methylator phenotype 
cm centimeter 
CRC Colorectal cancer 
C-terminus Carboxy-terminus 
CW Cell wall 
DACHSplus “Darmkrebs: Chancen der Verhütung durch 
Screening” 
ddH2O Double-distilled water 
DMSO Dimethylsulfoxide 
DNA Deoxyribonucleic acid 
DP Double-positive 
DTT 1,4-Dithiothreitol 
EC extracellular 
E. coli Escherichia coli 
EDTA Ethylenediaminetetraacetate 
e.g. Exempli gratia 
ELISA Enzyme-linked immunosorbent assay 
EPIC European prospective investigation into cancer and 
nutrition 
et al. Et alii 
FIT Fecal immunochemical test 
F. nucleatum Fusobacterium nucleatum 
g gramm 
GC Gastric cancer 
gFOBT Guaiac-based fecal occult blood test 
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GST Glutathione-S-transferase 
HC Healthy control 
HNPCC Hereditary non-polyposis colorectal cancer 
H. pylori Helicobacter pylori 
HRP Horse radish peroxidase 
IBD Inflammatory bowel disease 
ICD-O International classification of diseases for oncology 
i.e. Id est 
Ig Immunoglobulin 
inHg Inch Hg 
IPTG Isopropyl β-D-1-thiogalactopyranoside 
kD kilo Dalton 
KRAS Kirsten rat sarcoma 
kV kilovolt 
LB Lysogeny broth 
µF microfarad 
µl microliter 
M Marker 
MAPK Mitogen-activated protein kinase 
MFI Median fluorescence intensity 
min minute 
ml milliliter 
mm millimeter 
mM millimolar 
MSI-H Microsatellite instability-high 
n Number 
neg Negative 
NFκB Nuclear factor kappa B 
nm nanometer 
NSAID Non-steroidal anti-inflammatory drugs 
nt nucleotide 
N-terminus Amino-terminus 
OD Optical density 
OM Outer membrane 
Omp Outer membrane protein 
OR Odds ratio 
PAGE Polyacrylamide gel electrophoresis 
PBS Phosphate-buffered saline 
PBS-T PBS-Tween 
PCR Polymerase chain reaction 
pos Positive 
PVA Polyvinylalcohol 
PVP Polyvinylpyrrolidone 
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PVX Synonym for PVA plus PVP  
qPCR Quantitative PCR 
R2 R-square correlation coefficient 
ref reference 
RNA Ribonucleic acid 
rpm Rounds per minute 
S. bovis Streptococcus bovis 
SCCS Southern community cohort study 
SDS Sodium dodecyl sulfate 
sec seconds 
SEER Surveillance, epidemiology, and end results program 
S. equinus Streptococcus equinus 
S. gallolyticus Streptococcus gallolyticus subsp. gallolyticus 
SGG-pos S. gallolyticus positive 
SGMB S. gallolyticus member bacteria 
S. infantarius Streptococcus infantarius subsp. infantarius 
S. macedonicus Streptococcus gallolyticus subsp. macedonicus 
S. pasteurianus Streptococcus gallolyticus subsp. pasteurianus 
Strep-PE Streptavidin-R-Phycoerythrin 
subsp. Subspecies 
SV40 Simian virus 40 
TEMED N,N,N’,N’-Tetramethylethylendiamin 
TMB Tetramethylbencidine 
UICC “Union international contre le cancer” 
UK United Kingdom 
US United States of America 
VacA Vacuolating cytotxin A 
WHO World Health Organization 
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